Unnamed: 0 stringlengths 3 8 | Date stringlengths 23 23 | Article_title stringlengths 1 250 | Stock_symbol stringlengths 1 5 | Url stringlengths 44 135 | Publisher stringclasses 1 value | Author stringclasses 1 value | Article stringlengths 1 343k | Lsa_summary stringlengths 3 53.9k | Luhn_summary stringlengths 1 53.9k | Textrank_summary stringlengths 1 53.9k | Lexrank_summary stringlengths 1 53.9k |
|---|---|---|---|---|---|---|---|---|---|---|---|
36200.0 | 2016-06-06 00:00:00 UTC | Notable ETF Inflow Detected - XBI, ACAD, ANAC, MDVN | ACAD | https://www.nasdaq.com/articles/notable-etf-inflow-detected-xbi-acad-anac-mdvn-2016-06-06 | nan | nan | Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel , one standout is the SPDR S&P Biotech ETF (Symbol: XBI) where we have detected an approximate $116.0 million dollar inflow -- that's a 6.1% increase week over week in outstanding units (from 33,050,000 to 35,050,000). Among the largest underlying components of XBI, in trading today Acadia Pharmaceuticals Inc (Symbol: ACAD) is up about 4.4%, Anacor Pharmaceuticals Inc (Symbol: ANAC) is up about 0.2%, and Medivation Inc (Symbol: MDVN) is lower by about 0.8%. For a complete list of holdings, visit the XBI Holdings page » The chart below shows the one year price performance of XBI, versus its 200 day moving average:
Looking at the chart above, XBI's low point in its 52 week range is $44.16 per share, with $91.11 as the 52 week high point - that compares with a last trade of $58.23. Comparing the most recent share price to the 200 day moving average can also be a useful technical analysis technique -- learn more about the 200 day moving average » .
Exchange traded funds (ETFs) trade just like stocks, but instead of ''shares'' investors are actually buying and selling ''units''. These ''units'' can be traded back and forth just like stocks, but can also be created or destroyed to accommodate investor demand. Each week we monitor the week-over-week change in shares outstanding data, to keep a lookout for those ETFs experiencing notable inflows (many new units created) or outflows (many old units destroyed). Creation of new units will mean the underlying holdings of the ETF need to be purchased, while destruction of units involves selling underlying holdings, so large flows can also impact the individual components held within ETFs.
Click here to find out which 9 other ETFs had notable inflows »
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Among the largest underlying components of XBI, in trading today Acadia Pharmaceuticals Inc (Symbol: ACAD) is up about 4.4%, Anacor Pharmaceuticals Inc (Symbol: ANAC) is up about 0.2%, and Medivation Inc (Symbol: MDVN) is lower by about 0.8%. For a complete list of holdings, visit the XBI Holdings page » The chart below shows the one year price performance of XBI, versus its 200 day moving average: Looking at the chart above, XBI's low point in its 52 week range is $44.16 per share, with $91.11 as the 52 week high point - that compares with a last trade of $58.23. These ''units'' can be traded back and forth just like stocks, but can also be created or destroyed to accommodate investor demand. | Among the largest underlying components of XBI, in trading today Acadia Pharmaceuticals Inc (Symbol: ACAD) is up about 4.4%, Anacor Pharmaceuticals Inc (Symbol: ANAC) is up about 0.2%, and Medivation Inc (Symbol: MDVN) is lower by about 0.8%. For a complete list of holdings, visit the XBI Holdings page » The chart below shows the one year price performance of XBI, versus its 200 day moving average: Looking at the chart above, XBI's low point in its 52 week range is $44.16 per share, with $91.11 as the 52 week high point - that compares with a last trade of $58.23. Click here to find out which 9 other ETFs had notable inflows » The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Among the largest underlying components of XBI, in trading today Acadia Pharmaceuticals Inc (Symbol: ACAD) is up about 4.4%, Anacor Pharmaceuticals Inc (Symbol: ANAC) is up about 0.2%, and Medivation Inc (Symbol: MDVN) is lower by about 0.8%. Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel , one standout is the SPDR S&P Biotech ETF (Symbol: XBI) where we have detected an approximate $116.0 million dollar inflow -- that's a 6.1% increase week over week in outstanding units (from 33,050,000 to 35,050,000). For a complete list of holdings, visit the XBI Holdings page » The chart below shows the one year price performance of XBI, versus its 200 day moving average: Looking at the chart above, XBI's low point in its 52 week range is $44.16 per share, with $91.11 as the 52 week high point - that compares with a last trade of $58.23. | Among the largest underlying components of XBI, in trading today Acadia Pharmaceuticals Inc (Symbol: ACAD) is up about 4.4%, Anacor Pharmaceuticals Inc (Symbol: ANAC) is up about 0.2%, and Medivation Inc (Symbol: MDVN) is lower by about 0.8%. Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel , one standout is the SPDR S&P Biotech ETF (Symbol: XBI) where we have detected an approximate $116.0 million dollar inflow -- that's a 6.1% increase week over week in outstanding units (from 33,050,000 to 35,050,000). For a complete list of holdings, visit the XBI Holdings page » The chart below shows the one year price performance of XBI, versus its 200 day moving average: Looking at the chart above, XBI's low point in its 52 week range is $44.16 per share, with $91.11 as the 52 week high point - that compares with a last trade of $58.23. |
36201.0 | 2016-06-06 00:00:00 UTC | Why Shares of ACADIA Pharmaceuticals Inc. Jumped Today | ACAD | https://www.nasdaq.com/articles/why-shares-acadia-pharmaceuticals-inc-jumped-today-2016-06-06 | nan | nan | ACAD Short Interest data by YCharts .
Now what: AstraZeneca does have a recent history of buying small biopharma companies in an effort to reignite its top-line growth. Just last year it spent $2.7 billion to acquire ZS Pharma, a company developing a treatment for hyperkalemia. Unfortunately, that treatment's future recently came into question , so I'd be surprised if AstraZeneca was already hunting for its next target given its recent acquisition success rate.
Regardless, while the idea of a buyout is always exciting, ACADIA's investors should do their best to stay focused on how well the company's new Parkinson's psychosis drug, Nuplazid, performs on the market.
I think that ACADIA bulls have plenty of reasons to believe that Nuplazid has a real shot at being a winner. In clinical trials, Nuplazid was able to help reduce many of the symptoms of Parkinson's psychosis. In addition, patients who took Nuplazid did not experience problems with their motor control, which is a common side effect of antipsychotics. That could greatly help to reduce the burden placed on patients' caregivers, which is one of the biggest challenges in treating the disease.
Image source: ACADIA presentations.
It is estimated that 40% of patients who have Parkinson's develop psychosis, and with 1 million patients in the U.S. alone suffering from the disease, Nuplazid has a big market opportunity ahead of it. That's especially true when you consider there are no other approved therapies available, so Nuplazid has the market all to itself.
Nuplazid was just launched for sale on May 31, so investors will get their first look at how well the drug is performing out of the gate during the company's second-quarter earnings report.
Until we get confirmation otherwise, investors should do their best to ignore today's move and stay focused on the long-term potential of Nuplazid.
A secret billion-dollar stock opportunity
The world's biggest tech company forgot to show you something, but a few Wall Street analysts and the Fool didn't miss a beat: There's a small company that's powering their brand-new gadgets and the coming revolution in technology. And we think its stock price has nearly unlimited room to run for early in-the-know investors! To be one of them, just click here .
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Regardless, while the idea of a buyout is always exciting, ACADIA's investors should do their best to stay focused on how well the company's new Parkinson's psychosis drug, Nuplazid, performs on the market. ACAD Short Interest data by YCharts . I think that ACADIA bulls have plenty of reasons to believe that Nuplazid has a real shot at being a winner. | Regardless, while the idea of a buyout is always exciting, ACADIA's investors should do their best to stay focused on how well the company's new Parkinson's psychosis drug, Nuplazid, performs on the market. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. ACAD Short Interest data by YCharts . | Regardless, while the idea of a buyout is always exciting, ACADIA's investors should do their best to stay focused on how well the company's new Parkinson's psychosis drug, Nuplazid, performs on the market. ACAD Short Interest data by YCharts . I think that ACADIA bulls have plenty of reasons to believe that Nuplazid has a real shot at being a winner. | ACAD Short Interest data by YCharts . Regardless, while the idea of a buyout is always exciting, ACADIA's investors should do their best to stay focused on how well the company's new Parkinson's psychosis drug, Nuplazid, performs on the market. I think that ACADIA bulls have plenty of reasons to believe that Nuplazid has a real shot at being a winner. |
36202.0 | 2016-06-06 00:00:00 UTC | Noteworthy Monday Option Activity: EAT, ACAD, LNKD | ACAD | https://www.nasdaq.com/articles/noteworthy-monday-option-activity-eat-acad-lnkd-2016-06-06 | nan | nan | Looking at options trading activity among components of the Russell 3000 index, there is noteworthy activity today in Brinker International, Inc. (Symbol: EAT), where a total volume of 6,861 contracts has been traded thus far today, a contract volume which is representative of approximately 686,100 underlying shares (given that every 1 contract represents 100 underlying shares). That number works out to 64.4% of EAT's average daily trading volume over the past month, of 1.1 million shares. Particularly high volume was seen for the $45 strike put option expiring June 17, 2016 , with 3,563 contracts trading so far today, representing approximately 356,300 underlying shares of EAT. Below is a chart showing EAT's trailing twelve month trading history, with the $45 strike highlighted in orange:
Acadia Pharmaceuticals Inc (Symbol: ACAD) options are showing a volume of 15,957 contracts thus far today. That number of contracts represents approximately 1.6 million underlying shares, working out to a sizeable 64.2% of ACAD's average daily trading volume over the past month, of 2.5 million shares. Especially high volume was seen for the $40 strike call option expiring June 17, 2016 , with 2,236 contracts trading so far today, representing approximately 223,600 underlying shares of ACAD. Below is a chart showing ACAD's trailing twelve month trading history, with the $40 strike highlighted in orange:
And LinkedIn Corp (Symbol: LNKD) saw options trading volume of 10,177 contracts, representing approximately 1.0 million underlying shares or approximately 53.6% of LNKD's average daily trading volume over the past month, of 1.9 million shares. Especially high volume was seen for the $139 strike call option expiring June 10, 2016 , with 528 contracts trading so far today, representing approximately 52,800 underlying shares of LNKD. Below is a chart showing LNKD's trailing twelve month trading history, with the $139 strike highlighted in orange:
For the various different available expirations for EAT options , ACAD options , or LNKD options , visit StockOptionsChannel.com.
Today's Most Active Call & Put Options of the S&P 500 »
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Especially high volume was seen for the $40 strike call option expiring June 17, 2016 , with 2,236 contracts trading so far today, representing approximately 223,600 underlying shares of ACAD. Below is a chart showing EAT's trailing twelve month trading history, with the $45 strike highlighted in orange: Acadia Pharmaceuticals Inc (Symbol: ACAD) options are showing a volume of 15,957 contracts thus far today. That number of contracts represents approximately 1.6 million underlying shares, working out to a sizeable 64.2% of ACAD's average daily trading volume over the past month, of 2.5 million shares. | Below is a chart showing EAT's trailing twelve month trading history, with the $45 strike highlighted in orange: Acadia Pharmaceuticals Inc (Symbol: ACAD) options are showing a volume of 15,957 contracts thus far today. Below is a chart showing ACAD's trailing twelve month trading history, with the $40 strike highlighted in orange: And LinkedIn Corp (Symbol: LNKD) saw options trading volume of 10,177 contracts, representing approximately 1.0 million underlying shares or approximately 53.6% of LNKD's average daily trading volume over the past month, of 1.9 million shares. That number of contracts represents approximately 1.6 million underlying shares, working out to a sizeable 64.2% of ACAD's average daily trading volume over the past month, of 2.5 million shares. | Especially high volume was seen for the $40 strike call option expiring June 17, 2016 , with 2,236 contracts trading so far today, representing approximately 223,600 underlying shares of ACAD. Below is a chart showing ACAD's trailing twelve month trading history, with the $40 strike highlighted in orange: And LinkedIn Corp (Symbol: LNKD) saw options trading volume of 10,177 contracts, representing approximately 1.0 million underlying shares or approximately 53.6% of LNKD's average daily trading volume over the past month, of 1.9 million shares. Below is a chart showing EAT's trailing twelve month trading history, with the $45 strike highlighted in orange: Acadia Pharmaceuticals Inc (Symbol: ACAD) options are showing a volume of 15,957 contracts thus far today. | Below is a chart showing ACAD's trailing twelve month trading history, with the $40 strike highlighted in orange: And LinkedIn Corp (Symbol: LNKD) saw options trading volume of 10,177 contracts, representing approximately 1.0 million underlying shares or approximately 53.6% of LNKD's average daily trading volume over the past month, of 1.9 million shares. Below is a chart showing EAT's trailing twelve month trading history, with the $45 strike highlighted in orange: Acadia Pharmaceuticals Inc (Symbol: ACAD) options are showing a volume of 15,957 contracts thus far today. That number of contracts represents approximately 1.6 million underlying shares, working out to a sizeable 64.2% of ACAD's average daily trading volume over the past month, of 2.5 million shares. |
36203.0 | 2016-05-31 00:00:00 UTC | How The Parts Add Up: IYY Headed For $115 | ACAD | https://www.nasdaq.com/articles/how-parts-add-iyy-headed-115-2016-05-31 | nan | nan | Looking at the underlying holdings of the ETFs in our coverage universe at ETF Channel , we have compared the trading price of each holding against the average analyst 12-month forward target price, and computed the weighted average implied analyst target price for the ETF itself. For the iShares Dow Jones U.S. ETF (Symbol: IYY), we found that the implied analyst target price for the ETF based upon its underlying holdings is $115.25 per unit.
With IYY trading at a recent price near $104.83 per unit, that means that analysts see 9.94% upside for this ETF looking through to the average analyst targets of the underlying holdings. Three of IYY's underlying holdings with notable upside to their analyst target prices are Ultragenyx Pharmaceutical Inc (Symbol: RARE), Advisory Board Company (Symbol: ABCO), and Acadia Pharmaceuticals Inc (Symbol: ACAD). Although RARE has traded at a recent price of $68.57/share, the average analyst target is 49.15% higher at $102.27/share. Similarly, ABCO has 30.90% upside from the recent share price of $32.34 if the average analyst target price of $42.33/share is reached, and analysts on average are expecting ACAD to reach a target price of $46.44/share, which is 30.42% above the recent price of $35.61. Below is a twelve month price history chart comparing the stock performance of RARE, ABCO, and ACAD:
Below is a summary table of the current analyst target prices discussed above:
Are analysts justified in these targets, or overly optimistic about where these stocks will be trading 12 months from now? Do the analysts have a valid justification for their targets, or are they behind the curve on recent company and industry developments? A high price target relative to a stock's trading price can reflect optimism about the future, but can also be a precursor to target price downgrades if the targets were a relic of the past. These are questions that require further investor research.
10 ETFs With Most Upside To Analyst Targets »
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Below is a twelve month price history chart comparing the stock performance of RARE, ABCO, and ACAD: Below is a summary table of the current analyst target prices discussed above: Are analysts justified in these targets, or overly optimistic about where these stocks will be trading 12 months from now? Three of IYY's underlying holdings with notable upside to their analyst target prices are Ultragenyx Pharmaceutical Inc (Symbol: RARE), Advisory Board Company (Symbol: ABCO), and Acadia Pharmaceuticals Inc (Symbol: ACAD). Similarly, ABCO has 30.90% upside from the recent share price of $32.34 if the average analyst target price of $42.33/share is reached, and analysts on average are expecting ACAD to reach a target price of $46.44/share, which is 30.42% above the recent price of $35.61. | Three of IYY's underlying holdings with notable upside to their analyst target prices are Ultragenyx Pharmaceutical Inc (Symbol: RARE), Advisory Board Company (Symbol: ABCO), and Acadia Pharmaceuticals Inc (Symbol: ACAD). Similarly, ABCO has 30.90% upside from the recent share price of $32.34 if the average analyst target price of $42.33/share is reached, and analysts on average are expecting ACAD to reach a target price of $46.44/share, which is 30.42% above the recent price of $35.61. Below is a twelve month price history chart comparing the stock performance of RARE, ABCO, and ACAD: Below is a summary table of the current analyst target prices discussed above: Are analysts justified in these targets, or overly optimistic about where these stocks will be trading 12 months from now? | Similarly, ABCO has 30.90% upside from the recent share price of $32.34 if the average analyst target price of $42.33/share is reached, and analysts on average are expecting ACAD to reach a target price of $46.44/share, which is 30.42% above the recent price of $35.61. Below is a twelve month price history chart comparing the stock performance of RARE, ABCO, and ACAD: Below is a summary table of the current analyst target prices discussed above: Are analysts justified in these targets, or overly optimistic about where these stocks will be trading 12 months from now? Three of IYY's underlying holdings with notable upside to their analyst target prices are Ultragenyx Pharmaceutical Inc (Symbol: RARE), Advisory Board Company (Symbol: ABCO), and Acadia Pharmaceuticals Inc (Symbol: ACAD). | Below is a twelve month price history chart comparing the stock performance of RARE, ABCO, and ACAD: Below is a summary table of the current analyst target prices discussed above: Are analysts justified in these targets, or overly optimistic about where these stocks will be trading 12 months from now? Three of IYY's underlying holdings with notable upside to their analyst target prices are Ultragenyx Pharmaceutical Inc (Symbol: RARE), Advisory Board Company (Symbol: ABCO), and Acadia Pharmaceuticals Inc (Symbol: ACAD). Similarly, ABCO has 30.90% upside from the recent share price of $32.34 if the average analyst target price of $42.33/share is reached, and analysts on average are expecting ACAD to reach a target price of $46.44/share, which is 30.42% above the recent price of $35.61. |
36204.0 | 2016-05-26 00:00:00 UTC | XBI, ACAD, MDVN, ANAC: Large Inflows Detected at ETF | ACAD | https://www.nasdaq.com/articles/xbi-acad-mdvn-anac-large-inflows-detected-etf-2016-05-26 | nan | nan | Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel , one standout is the SPDR S&P Biotech ETF (Symbol: XBI) where we have detected an approximate $39.2 million dollar inflow -- that's a 2.1% increase week over week in outstanding units (from 32,900,000 to 33,600,000). Among the largest underlying components of XBI, in trading today Acadia Pharmaceuticals Inc (Symbol: ACAD) is off about 1.3%, Medivation Inc (Symbol: MDVN) is down about 0.8%, and Anacor Pharmaceuticals Inc (Symbol: ANAC) is up by about 0.1%. For a complete list of holdings, visit the XBI Holdings page » The chart below shows the one year price performance of XBI, versus its 200 day moving average:
Looking at the chart above, XBI's low point in its 52 week range is $44.16 per share, with $91.11 as the 52 week high point - that compares with a last trade of $56.14. Comparing the most recent share price to the 200 day moving average can also be a useful technical analysis technique -- learn more about the 200 day moving average » .
Exchange traded funds (ETFs) trade just like stocks, but instead of ''shares'' investors are actually buying and selling ''units''. These ''units'' can be traded back and forth just like stocks, but can also be created or destroyed to accommodate investor demand. Each week we monitor the week-over-week change in shares outstanding data, to keep a lookout for those ETFs experiencing notable inflows (many new units created) or outflows (many old units destroyed). Creation of new units will mean the underlying holdings of the ETF need to be purchased, while destruction of units involves selling underlying holdings, so large flows can also impact the individual components held within ETFs.
Click here to find out which 9 other ETFs had notable inflows »
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Among the largest underlying components of XBI, in trading today Acadia Pharmaceuticals Inc (Symbol: ACAD) is off about 1.3%, Medivation Inc (Symbol: MDVN) is down about 0.8%, and Anacor Pharmaceuticals Inc (Symbol: ANAC) is up by about 0.1%. For a complete list of holdings, visit the XBI Holdings page » The chart below shows the one year price performance of XBI, versus its 200 day moving average: Looking at the chart above, XBI's low point in its 52 week range is $44.16 per share, with $91.11 as the 52 week high point - that compares with a last trade of $56.14. These ''units'' can be traded back and forth just like stocks, but can also be created or destroyed to accommodate investor demand. | Among the largest underlying components of XBI, in trading today Acadia Pharmaceuticals Inc (Symbol: ACAD) is off about 1.3%, Medivation Inc (Symbol: MDVN) is down about 0.8%, and Anacor Pharmaceuticals Inc (Symbol: ANAC) is up by about 0.1%. For a complete list of holdings, visit the XBI Holdings page » The chart below shows the one year price performance of XBI, versus its 200 day moving average: Looking at the chart above, XBI's low point in its 52 week range is $44.16 per share, with $91.11 as the 52 week high point - that compares with a last trade of $56.14. Click here to find out which 9 other ETFs had notable inflows » The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Among the largest underlying components of XBI, in trading today Acadia Pharmaceuticals Inc (Symbol: ACAD) is off about 1.3%, Medivation Inc (Symbol: MDVN) is down about 0.8%, and Anacor Pharmaceuticals Inc (Symbol: ANAC) is up by about 0.1%. Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel , one standout is the SPDR S&P Biotech ETF (Symbol: XBI) where we have detected an approximate $39.2 million dollar inflow -- that's a 2.1% increase week over week in outstanding units (from 32,900,000 to 33,600,000). For a complete list of holdings, visit the XBI Holdings page » The chart below shows the one year price performance of XBI, versus its 200 day moving average: Looking at the chart above, XBI's low point in its 52 week range is $44.16 per share, with $91.11 as the 52 week high point - that compares with a last trade of $56.14. | Among the largest underlying components of XBI, in trading today Acadia Pharmaceuticals Inc (Symbol: ACAD) is off about 1.3%, Medivation Inc (Symbol: MDVN) is down about 0.8%, and Anacor Pharmaceuticals Inc (Symbol: ANAC) is up by about 0.1%. Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel , one standout is the SPDR S&P Biotech ETF (Symbol: XBI) where we have detected an approximate $39.2 million dollar inflow -- that's a 2.1% increase week over week in outstanding units (from 32,900,000 to 33,600,000). For a complete list of holdings, visit the XBI Holdings page » The chart below shows the one year price performance of XBI, versus its 200 day moving average: Looking at the chart above, XBI's low point in its 52 week range is $44.16 per share, with $91.11 as the 52 week high point - that compares with a last trade of $56.14. |
36205.0 | 2016-05-24 00:00:00 UTC | The 10 Best Healthcare Stocks to Buy Now | ACAD | https://www.nasdaq.com/articles/the-10-best-healthcare-stocks-to-buy-now-2016-05-24 | nan | nan | InvestorPlaceInvestorPlace - Stock Market News, Stock Advice & Trading Tips
Biotechnology and healthcare stocks are by no means taking the market by storm, with both groups down big over the last year. The broad Health Care SPDR (ETF) ( XLV ) is off 6% versus just 2% for the broader S&P 500 , and the iShares NASDAQ Biotechnology Index (ETF) ( IBB ) is down a whopping 26%.
Source: Will Thomas via Flickr (Modified)
However, the iShares NASDAQ Biotechnology Index (ETF) ( IBB ) is up 8% in just the past couple of weeks, and the XLV is still recovering from its February lows.
Fact is there are a handful of biotech and healthcare stocks that are getting too cheap to ignore - maybe not by normal market standards, of course, but most certainly when you consider growth prospects and recent stock loss.
The Top 10 S&P 500 Dividend Stocks to Buy Now
Let's take a look at 10 such healthcare stocks with near-term catalysts that should spark significant gains, thereby performing much better in the back half of 2016.
10 Best Healthcare Stocks to Buy: Walgreens Boots Alliance (WBA)
Walgreens Boots Alliance Inc ( WBA ) is down 10% this year, and much of that relates to a considerable amount of uncertainty with how to value the company.
After its acquisition of Alliance Boots, Walgreens' look has certainly changed, and it's about to get an even bigger makeover after Rite Aid Corporation's ( RAD ) retail pharmacies and pharmacy benefit management business is absorbed.
Nevertheless, the Rite Aid acquisition later this year is certainly a catalyst. WBA is already forecasting up to $4.55 per share in earnings for this fiscal year, meaning it trades at less than 17 times this year's EPS. With Walgreens' U.S. retail pharmacy, wholesale and international retail pharmacy business all achieving mid-single digit comparable sales growth, WBA is a stock that should certainly find favor with the market during the latter half of 2016.
Not to mention, Rite Aid is going to add 20% top-line growth to WBA, and Walgreens could very well achieve 20%-plus EPS growth next year.
When you consider this likely outlook, W BA stock becomes even more attractive.
10 Best Healthcare Stocks to Buy: Regeneron Pharmaceuticals (REGN)
Regeneron Pharmaceuticals Inc ( REGN ) stock is down almost 30% this year, although its main drug Eylea is expected to see worldwide sales growth upwards of 25% this year and surpass the $5 billion mark.
However, that's not necessarily the catalyst that will send REGN flying.
Instead, data from its Odyssey Outcomes trial will be unveiled later this year. If successful, REGN will effectively prove that its bad-cholesterol-lowering drug Praluent can also save lives, and insurers who have been resistant to cover the drug's high price will have no choice.
At that point, Praluent will be well on its way to realizing the billions in annual sales that analysts expected prior to FDA approval.
The 10 Best Index Funds to Buy Right Now
Given that REGN has turned everything it touches to gold for the last decade, I tend to give its Odyssey Outcomes trial the benefit of doubt.
10 Best Healthcare Stocks to Buy: Acadia Pharmaceuticals (ACAD)
After years of waiting, Acadia Pharmaceuticals Inc. ( ACAD ) Nuplazid is finally FDA-approved and will begin marketing distribution next month.
With more than 1 million who suffer from Parkinson's disease, and with Acadia offering a breakthrough-designated anti-psychotic that is effective without the harsh side effects, the stage is set for Nuplazid sales to be quite remarkable.
Plus, Acadia is pricing Nuplazid twice as high as shareholders expected, so ACAD stock has set the stake for big gains.
While ACAD is up more than 80% during the past three months, the stock is still down more than 25% from its 52-week high. Thus, it has some ground to make up for investors who want to buy ahead of the drug launch.
10 Best Healthcare Stocks to Buy: Celldex Therapeutics (CLDX)
Celldex Therapeutics, Inc. ( CLDX ) stock is down 85% over the past year, and has gone from a near $4 billion company to just $440 million during that time.
Yes, its breakthrough brain cancer drug Rintega shocked investors when it failed in its Phase 3 trial , and now CLDX has lost its favor with the market. However, investors must not forget that back in early 2012, CLDX began a two-year march from $3 to more than $30 based solely on the clinical performance of its other late-stage drug, Glembatumumab vedotin, which treats a mutated late-stage form of breast cancer.
Investors have seemingly forgotten this performance due to the disappointment of Rintega.
The 10 Best Dividend Stocks in Tech
Thankfully, CLDX will present data later this year from an ongoing trial, and when that happens, investors should quickly forget this more recent disappointment.
10 Best Healthcare Stocks to Buy: Relypsa Inc (RLYP)
Relypsa Inc ( RLYP ) is down 44% this year, and most of that loss is a result of the M&A rumors and speculation that surrounds RLYP.
Fact is that most investors thought RLYP would have been acquired by now. The company has a recently approved drug that treats excessive potassium in the blood. Last year, AstraZeneca plc (ADR) ( AZN ) bought ZS Pharma for $2.7 billion to gain rights to its competing drug .
Considering that RLYP's market capitalization is now down to $770 million, and it already has an approved drug , it is just a matter of time before someone buys Relypsa.
If not, it should rally with biotech stocks as investors realize the discount to what AstraZeneca paid for a competing, not-yet-approved drug.
10 Best Healthcare Stocks to Buy: Juno Therapeutics (JUNO)
Juno Therapeutics Inc ( JUNO ) has fallen 27% over the last six months, and while still expensive with a market capitalization of $4 billion, investors must remember that Juno is the future of treating cancer.
JUNO has a partnership with CelgeneCorporation ( CELG ) and is the face of CAR-T. Much like anti-PD1s about five years ago, CAR-T is the latest, transcendent treatment approach for fighting cancer, and Juno is leading the way.
While $4 billion is a lot to pay for a company that is still four, maybe five years from commercializing one of its products, this is a company that might very well have $10 billion to $15 billion of peak worldwide revenue in its pipeline right now.
7 A-Rated Small Caps to Pocket and Run With
Given that Juno has Celgene to help with the development and worldwide commercialization of drugs, and considering that JUNO is about 35% off its high, investors should feel good about both the entry point and the stock's long-term prospects.
10 Best Healthcare Stocks to Buy: Allergan (AGN)
Allergan plc Ordinary Shares ( AGN ) is not a company that most investors think of as must-buys with the potential for great appreciation.
However, it is a company that has high-single-digit, low-double-digit revenue growth, has fallen 26% over the last six months and trades at just 13 times next year's EPS.
Allergan - which boasts products such as Botox, Enablex and Restasis - is a classic example of a solid company's stock falling because of the industry in which it operates.
Therefore, if the IBB continues to trade higher, and if markets continue to recover, AGN stock should thereby be one of the biggest beneficiaries.
10 Best Healthcare Stocks to Buy: Gilead Sciences (GILD)
The market wants Gilead Sciences, Inc. ( GILD ) to put its money to work and acquire the next Pharmacyclics .
While many biotechnology companies grow from pipeline development, GILD has always been more about identifying value, and acquiring growth. The fact that Gilead has chosen to return capital in the form of share buybacks versus big acquisitions, however, suggests that the biotech does not see a great deal of value for M&A.
Regardless, GILD stock is not going to trade at big multiples without a multibillion-dollar acquisition. However, it is not realistic to assume that Gilead stock is worth 7x forward earnings, or that it will stay at these levels.
9 Low-Risk, High-Yield Dividend Stocks to Buy
Hence, if the industry as a whole starts to appreciate, expect GILD stock to lead the charge as bargain hunters are drawn to its valuation.
10 Best Healthcare Stocks to Buy: Amgen (AMGN)
Amgen, Inc. ( AMGN ) is a company and stock that is much like AGN. It trades at a similar multiple, is a similar size and has similar growth.
However, one thing that separates AMGN from most other biotechs is that it is not driven by one single product, or category of products. Yes, Enbrel is its biggest and fastest-growing drug, but it accounted for just 25% of total sales last quarter. Most biotechs get 75% of their revenue from a single product.
AMGN relies on about a dozen products and has a robust pipeline that should allow it to grow at a mid-single-digit growth for many years to come.
When you can get this degree of diversity and growth at 13x forward earnings, you take it!
10 Best Healthcare Stocks to Buy: Valeant Pharmaceuticals (VRX)
Valeant Pharmaceuticals, Inc. ( VRX ) is down 90% over the last year, and while shares are still hovering near 52-week lows, there are quite a few reasons to think its bad fortunes will soon change.
First, short interest has decreased by 4 million shares over the last month - a reflection that even shorts don't see the value in betting on additional downside.
The reason is because of its valuation.
VRX now trades at just 2.5x this year's expected EPS. Even if you don't buy Valeant's EPS outlook, the company will still top $2 billion in free cash flow this year. That means it trades at 5x FCF!
9 Hot Stocks That Could Jump 30% and Still Be Cheap
At the end of the day, VRX is cheap, and despite all it has gone through, it is still a growing business that earns enough profit to repay its debt over time.
Therefore, it looks like a good time to bet on Valeant.
As of this writing, Brian Nichols was long ACAD, REGN, VRX and WBA.
The post The 10 Best Healthcare Stocks to Buy Now appeared first on InvestorPlace .
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | 10 Best Healthcare Stocks to Buy: Acadia Pharmaceuticals (ACAD) After years of waiting, Acadia Pharmaceuticals Inc. ( ACAD ) Nuplazid is finally FDA-approved and will begin marketing distribution next month. With more than 1 million who suffer from Parkinson's disease, and with Acadia offering a breakthrough-designated anti-psychotic that is effective without the harsh side effects, the stage is set for Nuplazid sales to be quite remarkable. Plus, Acadia is pricing Nuplazid twice as high as shareholders expected, so ACAD stock has set the stake for big gains. | 10 Best Healthcare Stocks to Buy: Acadia Pharmaceuticals (ACAD) After years of waiting, Acadia Pharmaceuticals Inc. ( ACAD ) Nuplazid is finally FDA-approved and will begin marketing distribution next month. With more than 1 million who suffer from Parkinson's disease, and with Acadia offering a breakthrough-designated anti-psychotic that is effective without the harsh side effects, the stage is set for Nuplazid sales to be quite remarkable. Plus, Acadia is pricing Nuplazid twice as high as shareholders expected, so ACAD stock has set the stake for big gains. | 10 Best Healthcare Stocks to Buy: Acadia Pharmaceuticals (ACAD) After years of waiting, Acadia Pharmaceuticals Inc. ( ACAD ) Nuplazid is finally FDA-approved and will begin marketing distribution next month. With more than 1 million who suffer from Parkinson's disease, and with Acadia offering a breakthrough-designated anti-psychotic that is effective without the harsh side effects, the stage is set for Nuplazid sales to be quite remarkable. Plus, Acadia is pricing Nuplazid twice as high as shareholders expected, so ACAD stock has set the stake for big gains. | 10 Best Healthcare Stocks to Buy: Acadia Pharmaceuticals (ACAD) After years of waiting, Acadia Pharmaceuticals Inc. ( ACAD ) Nuplazid is finally FDA-approved and will begin marketing distribution next month. With more than 1 million who suffer from Parkinson's disease, and with Acadia offering a breakthrough-designated anti-psychotic that is effective without the harsh side effects, the stage is set for Nuplazid sales to be quite remarkable. Plus, Acadia is pricing Nuplazid twice as high as shareholders expected, so ACAD stock has set the stake for big gains. |
36206.0 | 2016-05-11 00:00:00 UTC | Notable ETF Outflow Detected - VTI, VIS, ACAD, CPHD | ACAD | https://www.nasdaq.com/articles/notable-etf-outflow-detected-vti-vis-acad-cphd-2016-05-11 | nan | nan | Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel , one standout is the Vanguard Total Stock Market ETF (Symbol: VTI) where we have detected an approximate $82.4 million dollar outflow -- that's a 0.1% decrease week over week (from 562,998,249 to 562,223,660). Among the largest underlying components of VTI, in trading today Vanguard Sector Index Funds - Vanguard Industrials ETF (Symbol: VIS) is trading flat, Acadia Pharmaceuticals Inc (Symbol: ACAD) is down about 1%, and Cepheid (Symbol: CPHD) is up by about 2.1%. For a complete list of holdings, visit the VTI Holdings page » The chart below shows the one year price performance of VTI, versus its 200 day moving average:
Looking at the chart above, VTI's low point in its 52 week range is $91.58 per share, with $110.90 as the 52 week high point - that compares with a last trade of $106.15. Comparing the most recent share price to the 200 day moving average can also be a useful technical analysis technique -- learn more about the 200 day moving average » .
Exchange traded funds (ETFs) trade just like stocks, but instead of ''shares'' investors are actually buying and selling ''units''. These ''units'' can be traded back and forth just like stocks, but can also be created or destroyed to accommodate investor demand. Each week we monitor the week-over-week change in shares outstanding data, to keep a lookout for those ETFs experiencing notable inflows (many new units created) or outflows (many old units destroyed). Creation of new units will mean the underlying holdings of the ETF need to be purchased, while destruction of units involves selling underlying holdings, so large flows can also impact the individual components held within ETFs.
Click here to find out which 9 other ETFs experienced notable outflows »
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Among the largest underlying components of VTI, in trading today Vanguard Sector Index Funds - Vanguard Industrials ETF (Symbol: VIS) is trading flat, Acadia Pharmaceuticals Inc (Symbol: ACAD) is down about 1%, and Cepheid (Symbol: CPHD) is up by about 2.1%. For a complete list of holdings, visit the VTI Holdings page » The chart below shows the one year price performance of VTI, versus its 200 day moving average: Looking at the chart above, VTI's low point in its 52 week range is $91.58 per share, with $110.90 as the 52 week high point - that compares with a last trade of $106.15. These ''units'' can be traded back and forth just like stocks, but can also be created or destroyed to accommodate investor demand. | Among the largest underlying components of VTI, in trading today Vanguard Sector Index Funds - Vanguard Industrials ETF (Symbol: VIS) is trading flat, Acadia Pharmaceuticals Inc (Symbol: ACAD) is down about 1%, and Cepheid (Symbol: CPHD) is up by about 2.1%. For a complete list of holdings, visit the VTI Holdings page » The chart below shows the one year price performance of VTI, versus its 200 day moving average: Looking at the chart above, VTI's low point in its 52 week range is $91.58 per share, with $110.90 as the 52 week high point - that compares with a last trade of $106.15. Click here to find out which 9 other ETFs experienced notable outflows » The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Among the largest underlying components of VTI, in trading today Vanguard Sector Index Funds - Vanguard Industrials ETF (Symbol: VIS) is trading flat, Acadia Pharmaceuticals Inc (Symbol: ACAD) is down about 1%, and Cepheid (Symbol: CPHD) is up by about 2.1%. Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel , one standout is the Vanguard Total Stock Market ETF (Symbol: VTI) where we have detected an approximate $82.4 million dollar outflow -- that's a 0.1% decrease week over week (from 562,998,249 to 562,223,660). For a complete list of holdings, visit the VTI Holdings page » The chart below shows the one year price performance of VTI, versus its 200 day moving average: Looking at the chart above, VTI's low point in its 52 week range is $91.58 per share, with $110.90 as the 52 week high point - that compares with a last trade of $106.15. | Among the largest underlying components of VTI, in trading today Vanguard Sector Index Funds - Vanguard Industrials ETF (Symbol: VIS) is trading flat, Acadia Pharmaceuticals Inc (Symbol: ACAD) is down about 1%, and Cepheid (Symbol: CPHD) is up by about 2.1%. For a complete list of holdings, visit the VTI Holdings page » The chart below shows the one year price performance of VTI, versus its 200 day moving average: Looking at the chart above, VTI's low point in its 52 week range is $91.58 per share, with $110.90 as the 52 week high point - that compares with a last trade of $106.15. Exchange traded funds (ETFs) trade just like stocks, but instead of ''shares'' investors are actually buying and selling ''units''. |
36207.0 | 2016-05-04 00:00:00 UTC | Why ACADIA Pharmaceuticals Inc Jumped 12.7% in April | ACAD | https://www.nasdaq.com/articles/why-acadia-pharmaceuticals-inc-jumped-127-april-2016-05-04 | nan | nan | So what: Traders continued to bid up shares throughout the month as Nuplazid's May 1st PDUFA inched closer.
In addition, the company stated they will be submitting Nuplazid for regulatory review in Europe in the first half of this year. Management has not yet decided if they want to find a partner to help them commercialize the drug internationally.
Receiving regulatory approval for their lead compound was a transformative step for Acadia. However, there is still plenty of risk here. The company still has to educate the marketplace about Nuplazid's benefits and secure nationwide reimbursement.
Still, given that there is a huge unmet medical need for patients with PDP, I think the medical community will welcome Nuplazid with open arms. Acadia also has about $490 million in cash on its balance sheet, so it has ample liquidity to launch the drug successfully.
Will Acadia be able to successfully transition from a clinical-stage company into a commercial enterprise? Investors will have to wait a few more quarters before they will have an answer.
This iSecret stock could make this pop look tiny
The world's biggest tech company forgot to show you something, but a few Wall Street analysts and the Fool didn't miss a beat: There's a small company that's powering their brand-new gadgets and the coming revolution in technology. And we think its stock price has nearly unlimited room to run for early-in-the-know investors! To be one of them, just click here .
The article Why ACADIA Pharmaceuticals Inc Jumped 12.7% in April originally appeared on Fool.com.
Brian Feroldihas no position in any stocks mentioned. Like this article? Follow him on Twitter where he goes by the handle@Longtermmind-set or connect with him onLinkedInto see more articles like this.The Motley Fool has no position in any of the stocks mentioned. Try any of our Foolish newsletter services free for 30 days . We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy .
Copyright © 1995 - 2016 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy .
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Receiving regulatory approval for their lead compound was a transformative step for Acadia. Acadia also has about $490 million in cash on its balance sheet, so it has ample liquidity to launch the drug successfully. Will Acadia be able to successfully transition from a clinical-stage company into a commercial enterprise? | The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. Receiving regulatory approval for their lead compound was a transformative step for Acadia. Acadia also has about $490 million in cash on its balance sheet, so it has ample liquidity to launch the drug successfully. | Receiving regulatory approval for their lead compound was a transformative step for Acadia. Acadia also has about $490 million in cash on its balance sheet, so it has ample liquidity to launch the drug successfully. Will Acadia be able to successfully transition from a clinical-stage company into a commercial enterprise? | Will Acadia be able to successfully transition from a clinical-stage company into a commercial enterprise? Receiving regulatory approval for their lead compound was a transformative step for Acadia. Acadia also has about $490 million in cash on its balance sheet, so it has ample liquidity to launch the drug successfully. |
36208.0 | 2016-05-02 00:00:00 UTC | SPDR S&P Biotech ETF Experiences Big Outflow | ACAD | https://www.nasdaq.com/articles/spdr-sp-biotech-etf-experiences-big-outflow-2016-05-02 | nan | nan | Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel , one standout is the SPDR S&P Biotech ETF (Symbol: XBI) where we have detected an approximate $43.1 million dollar outflow -- that's a 2.4% decrease week over week (from 33,900,000 to 33,100,000). Among the largest underlying components of XBI, in trading today Acadia Pharmaceuticals Inc (Symbol: ACAD) is off about 0.3%, Neurocrine Biosciences, Inc. (Symbol: NBIX) is off about 0.6%, and Medivation Inc (Symbol: MDVN) is lower by about 0.8%. For a complete list of holdings, visit the XBI Holdings page » The chart below shows the one year price performance of XBI, versus its 200 day moving average:
Looking at the chart above, XBI's low point in its 52 week range is $44.16 per share, with $91.11 as the 52 week high point - that compares with a last trade of $53.93. Comparing the most recent share price to the 200 day moving average can also be a useful technical analysis technique -- learn more about the 200 day moving average » .
Exchange traded funds (ETFs) trade just like stocks, but instead of ''shares'' investors are actually buying and selling ''units''. These ''units'' can be traded back and forth just like stocks, but can also be created or destroyed to accommodate investor demand. Each week we monitor the week-over-week change in shares outstanding data, to keep a lookout for those ETFs experiencing notable inflows (many new units created) or outflows (many old units destroyed). Creation of new units will mean the underlying holdings of the ETF need to be purchased, while destruction of units involves selling underlying holdings, so large flows can also impact the individual components held within ETFs.
Click here to find out which 9 other ETFs experienced notable outflows »
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Among the largest underlying components of XBI, in trading today Acadia Pharmaceuticals Inc (Symbol: ACAD) is off about 0.3%, Neurocrine Biosciences, Inc. (Symbol: NBIX) is off about 0.6%, and Medivation Inc (Symbol: MDVN) is lower by about 0.8%. For a complete list of holdings, visit the XBI Holdings page » The chart below shows the one year price performance of XBI, versus its 200 day moving average: Looking at the chart above, XBI's low point in its 52 week range is $44.16 per share, with $91.11 as the 52 week high point - that compares with a last trade of $53.93. These ''units'' can be traded back and forth just like stocks, but can also be created or destroyed to accommodate investor demand. | Among the largest underlying components of XBI, in trading today Acadia Pharmaceuticals Inc (Symbol: ACAD) is off about 0.3%, Neurocrine Biosciences, Inc. (Symbol: NBIX) is off about 0.6%, and Medivation Inc (Symbol: MDVN) is lower by about 0.8%. For a complete list of holdings, visit the XBI Holdings page » The chart below shows the one year price performance of XBI, versus its 200 day moving average: Looking at the chart above, XBI's low point in its 52 week range is $44.16 per share, with $91.11 as the 52 week high point - that compares with a last trade of $53.93. Each week we monitor the week-over-week change in shares outstanding data, to keep a lookout for those ETFs experiencing notable inflows (many new units created) or outflows (many old units destroyed). | Among the largest underlying components of XBI, in trading today Acadia Pharmaceuticals Inc (Symbol: ACAD) is off about 0.3%, Neurocrine Biosciences, Inc. (Symbol: NBIX) is off about 0.6%, and Medivation Inc (Symbol: MDVN) is lower by about 0.8%. Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel , one standout is the SPDR S&P Biotech ETF (Symbol: XBI) where we have detected an approximate $43.1 million dollar outflow -- that's a 2.4% decrease week over week (from 33,900,000 to 33,100,000). For a complete list of holdings, visit the XBI Holdings page » The chart below shows the one year price performance of XBI, versus its 200 day moving average: Looking at the chart above, XBI's low point in its 52 week range is $44.16 per share, with $91.11 as the 52 week high point - that compares with a last trade of $53.93. | Among the largest underlying components of XBI, in trading today Acadia Pharmaceuticals Inc (Symbol: ACAD) is off about 0.3%, Neurocrine Biosciences, Inc. (Symbol: NBIX) is off about 0.6%, and Medivation Inc (Symbol: MDVN) is lower by about 0.8%. For a complete list of holdings, visit the XBI Holdings page » The chart below shows the one year price performance of XBI, versus its 200 day moving average: Looking at the chart above, XBI's low point in its 52 week range is $44.16 per share, with $91.11 as the 52 week high point - that compares with a last trade of $53.93. Each week we monitor the week-over-week change in shares outstanding data, to keep a lookout for those ETFs experiencing notable inflows (many new units created) or outflows (many old units destroyed). |
36209.0 | 2016-05-02 00:00:00 UTC | Pre-Market Most Active for May 2, 2016 : TLK, TVIX, ACAD, OPWR, FCX, BIDU, ABX, BCRX, AUY, QQQ, SDRL, AAPL | ACAD | https://www.nasdaq.com/articles/pre-market-most-active-may-2-2016-tlk-tvix-acad-opwr-fcx-bidu-abx-bcrx-auy-qqq-sdrl-aapl | nan | nan | The NASDAQ 100 Pre-Market Indicator is up 8.52 to 4,349.82. The total Pre-Market volume is currently 6,765,987 shares traded.
The following are the most active stocks for the pre-market session :
PT Telekomunikasi Indonesia, Tbk ( TLK ) is +0.0105 at $53.38, with 1,800,000 shares traded.
region ( TVIX ) is -0.09 at $3.74, with 296,929 shares traded. This represents a 18.73% increase from its 52 Week Low.
ACADIA Pharmaceuticals Inc. ( ACAD ) is +2.16 at $34.46, with 288,750 shares traded.ACAD is scheduled to provide an earnings report on 5/5/2016, for the fiscal quarter ending Mar2016. The consensus earnings per share forecast is -0.4 per share, which represents a -40 percent increase over the EPS one Year Ago
Opower, Inc. ( OPWR ) is +2.4 at $10.30, with 277,427 shares traded.OPWR is scheduled to provide an earnings report on 5/9/2016, for the fiscal quarter ending Mar2016. The consensus earnings per share forecast is -0.27 per share, which represents a -22 percent increase over the EPS one Year Ago
Freeport-McMoran, Inc. ( FCX ) is +0.18 at $14.18, with 267,491 shares traded. Over the last four weeks they have had 4 up revisions for the earnings forecast, for the fiscal quarter ending Sep 2016. The consensus EPS forecast is $0.16. FCX's current last sale is 141.8% of the target price of $10.
Baidu, Inc. ( BIDU ) is -7.12 at $187.18, with 235,748 shares traded. As reported by Zacks, the current mean recommendation for BIDU is in the "buy range".
Barrick Gold Corporation ( ABX ) is +0.33 at $19.70, with 221,171 shares traded. Over the last four weeks they have had 3 up revisions for the earnings forecast, for the fiscal quarter ending Jun 2016. The consensus EPS forecast is $0.13. , following a 52-week high recorded in prior regular session.
BioCryst Pharmaceuticals, Inc. ( BCRX ) is unchanged at $3.26, with 210,358 shares traded.BCRX is scheduled to provide an earnings report on 5/5/2016, for the fiscal quarter ending Mar2016. The consensus earnings per share forecast is -0.23 per share, which represents a -21 percent increase over the EPS one Year Ago
Yamana Gold Inc. ( AUY ) is +0.22 at $5.17, with 165,202 shares traded. Over the last four weeks they have had 3 up revisions for the earnings forecast, for the fiscal quarter ending Jun 2016. The consensus EPS forecast is $0.03. AUY is scheduled to provide an earnings report on 5/4/2016, for the fiscal quarter ending Mar2016. The consensus earnings per share forecast is 0 per share, which represents a -4 percent increase over the EPS one Year Ago
PowerShares QQQ Trust, Series 1 ( QQQ ) is +0.18 at $105.90, with 152,608 shares traded. This represents a 24.97% increase from its 52 Week Low.
Seadrill Limited ( SDRL ) is -0.16 at $4.62, with 150,204 shares traded. SDRL's current last sale is 154% of the target price of $3.
Apple Inc. ( AAPL ) is +0.31 at $94.05, with 130,197 shares traded. Over the last four weeks they have had 3 up revisions for the earnings forecast, for the fiscal quarter ending Mar 2017. The consensus EPS forecast is $2.23. As reported by Zacks, the current mean recommendation for AAPL is in the "buy range".
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | ACADIA Pharmaceuticals Inc. ( ACAD ) is +2.16 at $34.46, with 288,750 shares traded.ACAD is scheduled to provide an earnings report on 5/5/2016, for the fiscal quarter ending Mar2016. The following are the most active stocks for the pre-market session : PT Telekomunikasi Indonesia, Tbk ( TLK ) is +0.0105 at $53.38, with 1,800,000 shares traded. BioCryst Pharmaceuticals, Inc. ( BCRX ) is unchanged at $3.26, with 210,358 shares traded.BCRX is scheduled to provide an earnings report on 5/5/2016, for the fiscal quarter ending Mar2016. | ACADIA Pharmaceuticals Inc. ( ACAD ) is +2.16 at $34.46, with 288,750 shares traded.ACAD is scheduled to provide an earnings report on 5/5/2016, for the fiscal quarter ending Mar2016. The consensus earnings per share forecast is -0.27 per share, which represents a -22 percent increase over the EPS one Year Ago Freeport-McMoran, Inc. ( FCX ) is +0.18 at $14.18, with 267,491 shares traded. The consensus earnings per share forecast is -0.23 per share, which represents a -21 percent increase over the EPS one Year Ago Yamana Gold Inc. ( AUY ) is +0.22 at $5.17, with 165,202 shares traded. | ACADIA Pharmaceuticals Inc. ( ACAD ) is +2.16 at $34.46, with 288,750 shares traded.ACAD is scheduled to provide an earnings report on 5/5/2016, for the fiscal quarter ending Mar2016. The consensus earnings per share forecast is -0.4 per share, which represents a -40 percent increase over the EPS one Year Ago Opower, Inc. ( OPWR ) is +2.4 at $10.30, with 277,427 shares traded.OPWR is scheduled to provide an earnings report on 5/9/2016, for the fiscal quarter ending Mar2016. The consensus earnings per share forecast is -0.27 per share, which represents a -22 percent increase over the EPS one Year Ago Freeport-McMoran, Inc. ( FCX ) is +0.18 at $14.18, with 267,491 shares traded. | ACADIA Pharmaceuticals Inc. ( ACAD ) is +2.16 at $34.46, with 288,750 shares traded.ACAD is scheduled to provide an earnings report on 5/5/2016, for the fiscal quarter ending Mar2016. The consensus earnings per share forecast is -0.4 per share, which represents a -40 percent increase over the EPS one Year Ago Opower, Inc. ( OPWR ) is +2.4 at $10.30, with 277,427 shares traded.OPWR is scheduled to provide an earnings report on 5/9/2016, for the fiscal quarter ending Mar2016. The consensus earnings per share forecast is -0.27 per share, which represents a -22 percent increase over the EPS one Year Ago Freeport-McMoran, Inc. ( FCX ) is +0.18 at $14.18, with 267,491 shares traded. |
36210.0 | 2016-05-02 00:00:00 UTC | 3 Stocks to Watch on Monday: Acadia Pharmaceuticals Inc. (ACAD), Caterpillar Inc. (CAT) and Tesla Motors Inc (TSLA) | ACAD | https://www.nasdaq.com/articles/3-stocks-to-watch-on-monday%3A-acadia-pharmaceuticals-inc.-acad-caterpillar-inc.-cat-and | nan | nan | InvestorPlace InvestorPlace - Stock Market News, Stock Advice & Trading Tips
A floundering week in U.S. stocks ended on a low note, with the S&P 500 finishing Friday's yo-yo trading down 0.5%, while the Dow Jones Industrial Average slid 0.3%.
We take a break from the busy earnings season on Monday to look at some of the companies making noise with other news. Acadia Pharmaceuticals Inc. (NASDAQ: ACAD ), Caterpillar Inc. (NYSE: CAT ) and Tesla Motors Inc (NASDAQ: TSLA ) are all stocks worth watching as the calendar turns to May.
Here's what could have these three companies on the move today:
Acadia Pharmaceuticals Inc. (ACAD)
Acadia on Friday received a green light on a treatment for psychosis associated with Parkinson's disease.
Nuplazid, a once-a-day oral drug, was given U.S. Food and Drug Administration approval seven months after Acadia filed a New Drug Application, setting up a June launch for the drug. This is the "first and only medicine to be approved by the FDA for this indication," treating hallucinations and delusions without impairing motor function - a typical negative side effect of other current Parkinson's psychosis treatments.
10 Stocks to Sell in May and Go Away
The company will provide more details today at an 8:30 a.m. call. As of early Monday premarket trading , however, the news had ACAD shares up some 5%.
Caterpillar Inc. (CAT)
Caterpillar is narrowing its focus by closing down five plants .
The construction equipment manufacturer has been suffering a decrease in demand that has given the company no choice but to consolidate its operations and cut down its workforce.
Over the next year and a half, Caterpillar will no longer have its plants in Oxford, Miss., Newberry, S.C., Ridgeway, S.C., Jacksonville, Fla. and Morganton, N.C.
A total of 820 employees will part ways with the company over this period, increasing the total number of workers laid off by Caterpillar since September north of 6,000.
Despite this, CAT stock itself is actually doing quite well. Shares are up more than 14% year-to-date, and the stock last month scrawled out a golden cross - a bullish technical pattern that sees the shorter-term 50-day moving average climb above the 200-day MA.
Tesla Motors Inc (TSLA)
TSLA shares could get a love today after the company revealed a new element of the Model 3.
The Model already is a highly anticipated vehicle that could be the automaker's most important piece of machinery, as it should put TSLA in the hands of the masses thanks to its quite affordable price compared to its other offerings.
While Tesla's flagship Model S starts at $70,000, the base Model 3 will sell for half that price ($35,000), and it will also diminish your carbon footprint significantly.
And now, Model 3s will have Ludicrous Mode available.
In the Model S, this feature can take the car from 0 to 60 in 2.8 seconds, though analysts aren't quite sure exactly how quickly the mode will get the Model 3 up to speed.
Tesla already has 400,000 pre-orders registered for the Model 3, which won't even be produced until next year, so Ludicrous Mode is far from a game-changer. Still, it's yet another example of Tesla's ability to generate buzz - something that TSLA is often able to turn into positive momentum.
TSLA shares are set to open Monday's trading slightly higher.
As of this writing, Karl Utermohlen did not hold a position in any of the aforementioned securities.
More From InvestorPlace
7 Wealth-Building REITs You Should Buy Now
The 10 Best Growth Stocks to Buy for Retirement
Berkshire Hathaway: A Great Buy for All Seasons (BRK.A, BRK.B)
The post 3 Stocks to Watch on Monday: Acadia Pharmaceuticals Inc. (ACAD), Caterpillar Inc. (CAT) and Tesla Motors Inc (TSLA) appeared first on InvestorPlace .
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Acadia Pharmaceuticals Inc. (NASDAQ: ACAD ), Caterpillar Inc. (NYSE: CAT ) and Tesla Motors Inc (NASDAQ: TSLA ) are all stocks worth watching as the calendar turns to May. Here's what could have these three companies on the move today: Acadia Pharmaceuticals Inc. (ACAD) Acadia on Friday received a green light on a treatment for psychosis associated with Parkinson's disease. Nuplazid, a once-a-day oral drug, was given U.S. Food and Drug Administration approval seven months after Acadia filed a New Drug Application, setting up a June launch for the drug. | Acadia Pharmaceuticals Inc. (NASDAQ: ACAD ), Caterpillar Inc. (NYSE: CAT ) and Tesla Motors Inc (NASDAQ: TSLA ) are all stocks worth watching as the calendar turns to May. Here's what could have these three companies on the move today: Acadia Pharmaceuticals Inc. (ACAD) Acadia on Friday received a green light on a treatment for psychosis associated with Parkinson's disease. More From InvestorPlace 7 Wealth-Building REITs You Should Buy Now The 10 Best Growth Stocks to Buy for Retirement Berkshire Hathaway: A Great Buy for All Seasons (BRK.A, BRK.B) The post 3 Stocks to Watch on Monday: Acadia Pharmaceuticals Inc. (ACAD), Caterpillar Inc. (CAT) and Tesla Motors Inc (TSLA) appeared first on InvestorPlace . | Acadia Pharmaceuticals Inc. (NASDAQ: ACAD ), Caterpillar Inc. (NYSE: CAT ) and Tesla Motors Inc (NASDAQ: TSLA ) are all stocks worth watching as the calendar turns to May. More From InvestorPlace 7 Wealth-Building REITs You Should Buy Now The 10 Best Growth Stocks to Buy for Retirement Berkshire Hathaway: A Great Buy for All Seasons (BRK.A, BRK.B) The post 3 Stocks to Watch on Monday: Acadia Pharmaceuticals Inc. (ACAD), Caterpillar Inc. (CAT) and Tesla Motors Inc (TSLA) appeared first on InvestorPlace . Here's what could have these three companies on the move today: Acadia Pharmaceuticals Inc. (ACAD) Acadia on Friday received a green light on a treatment for psychosis associated with Parkinson's disease. | Acadia Pharmaceuticals Inc. (NASDAQ: ACAD ), Caterpillar Inc. (NYSE: CAT ) and Tesla Motors Inc (NASDAQ: TSLA ) are all stocks worth watching as the calendar turns to May. Here's what could have these three companies on the move today: Acadia Pharmaceuticals Inc. (ACAD) Acadia on Friday received a green light on a treatment for psychosis associated with Parkinson's disease. As of early Monday premarket trading , however, the news had ACAD shares up some 5%. |
36211.0 | 2016-04-30 00:00:00 UTC | 3 All-or-Nothing Stocks To Watch Closely | ACAD | https://www.nasdaq.com/articles/3-all-or-nothing-stocks-watch-closely-2016-04-30 | nan | nan | Image source: Pixabay .
Some companies are pretty easy to understand because their entire future is predicated on one thing happening. These all-or-nothing stocks can be very lucrative investments if that one thing goes the right way for them, but can also spell doom if the winds blow in the other direction. So if you are an investor in this type of stock, you need to know what that catalyst is and why it's important for the company's future.
We asked three of our contributors to highlight a stock in their respective sectors that fits this all-or-nothing description and what catalyst you should be watching to determine whether each will be a success or not. Here's what they had to say.
It doesn't get more "all-or-nothing" than a clinical-stage biotech whose entire value is tied up in the success or failure of a single drug. For that reason I've been keeping a close eye on ACADIA Pharmaceuticals , a red-hot biopharma based out of San Diego, as this company is only days away from the FDA ruling on whether or not it will approve the company's lead drug, Nuplazid.
Nuplazid was submitted for review last year as a new treatment option for Parkinson's disease psychosis, or PDP, which affects about 40% of patients who develop Parkinson's. Caring for patients with PDP can be a huge burden as the disease often causes patients to hallucinate and have delusions, which makes it very hard for them to care for themselves.
In clinical trials, Nuplazid was shown to be an effective treatment for alleviating some of the symptoms caused by PDP. If Nuplazid wins approval, then it could offer real hope to the roughly 400,000 patients in the U.S. alone who currently have PDP, as there are currently no approved treatment options available.
So what are the odds of success here? I'd argue they are quite good, as a panel of advisors to the FDA recently voted 12 to 2 in favor of giving Nuplazid the green light. That suggests that the FDA is likely to approve the drug on its May 1 PDUFA date.
With peak sales estimates for Nuplazid running in excess of $3 billion, I think the company stands a decent chance at continuing to climb from here. It's also possible that another big pharma company could make a bid to acquire ACADIA at some point if Nuplazid proves to be the real deal. This is one company I plan on watching closely.
This might be sort of a stretch for "all-or-nothing," but I'm going with Tesla Motors . Let's be clear that as an overall company, Tesla does not rely entirely on a single product. The electric automaker has had quite a journey so far with the three vehicles that it has launched to date: Roadster, Model S, and Model X.
But Tesla's incredibly high valuation is absolutely predicated on a single product: the forthcoming Model 3. The Model 3 unit volumes that Tesla hopes to deliver are the underpinning of its valuation. There's no other way that the market could justify Tesla's current market cap of over $30 billion when the company made just 50,000 vehicles last year. Model 3 has always been the end goal: a mainstream affordable EV with sufficient performance. If Model 3 fails or falls short in any way, Tesla shares would be punished badly. Whether or not Tesla can pull it off is an active debate and precisely why the company is such a battleground stock right now.
Tesla is also going all-in financially on Model 3. The majority of cash flow over the next couple of years will be primarily allocated to investing in the Model 3 production ramp-up. The company closed out last year with $1.2 billion in cash, much of which will be needed for the $1.5 billion in capital expenditures planned for 2016. With the launch at least 18 months out at a minimum, this is a stock to keep a close eye on.
Any oil and gas company that focuses just on the exploration and production side of the business is pretty much living off the possibility of decent commodity prices. Most of them do diversify by virtue of producing oil, natural gas, and natural gas liquids from a well. Because of the technique that Denbury Resources uses for production, though, it is almost exclusively an oil producer, which makes it pretty much an all-or-nothing bet on oil prices .
Underground reservoirs will have a mix of oil and gas, and when freshly drilled, the pressure of the natural gas and oil will push both out of the ground. Denbury, though, produces its oil from a technique known as enhanced oil recovery. This involves going to older wells that are no longer pressurized with gas and injecting them with CO2 to get some of the last drops of oil from the reservoir. This also means that Denbury's production is overwhelmingly oil. During its last earnings report, Denbury said that oil made up 95% of total production.
Considering the precarious position that oil and gas producers have been in over the past couple of years, Denbury Resources has done surprisingly well. The company has used futures contracts to protect its sales prices, and despite some challenging debt renegotiations, the company has a rather modest debt load compared to other independent oil and gas producers. Still, for this company's stock to truly succeed, it needs better oil prices and only oil prices. You'll be hard pressed to find a company so singularly dependent on oil prices as Denbury is.
A secret billion-dollar stock opportunity
The world's biggest tech company forgot to show you something, but a few Wall Street analysts and the Fool didn't miss a beat: There's a small company that's powering their brand-new gadgets and the coming revolution in technology. And we think its stock price has nearly unlimited room to run for early in-the-know investors! To be one of them, just click here .
The article 3 All-or-Nothing Stocks To Watch Closely originally appeared on Fool.com.
Brian Feroldi owns shares of Tesla Motors. Evan Niu, CFA , owns shares of Tesla Motors and has the following options: long January 2018 $180 calls on Tesla Motors. Tyler Crowe has no position in any stocks mentioned. The Motley Fool owns shares of and recommends Tesla Motors. The Motley Fool owns shares of Denbury Resources. Try any of our Foolish newsletter services free for 30 days . We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy .
Copyright © 1995 - 2016 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy .
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | It's also possible that another big pharma company could make a bid to acquire ACADIA at some point if Nuplazid proves to be the real deal. For that reason I've been keeping a close eye on ACADIA Pharmaceuticals , a red-hot biopharma based out of San Diego, as this company is only days away from the FDA ruling on whether or not it will approve the company's lead drug, Nuplazid. We asked three of our contributors to highlight a stock in their respective sectors that fits this all-or-nothing description and what catalyst you should be watching to determine whether each will be a success or not. | For that reason I've been keeping a close eye on ACADIA Pharmaceuticals , a red-hot biopharma based out of San Diego, as this company is only days away from the FDA ruling on whether or not it will approve the company's lead drug, Nuplazid. It's also possible that another big pharma company could make a bid to acquire ACADIA at some point if Nuplazid proves to be the real deal. Most of them do diversify by virtue of producing oil, natural gas, and natural gas liquids from a well. | For that reason I've been keeping a close eye on ACADIA Pharmaceuticals , a red-hot biopharma based out of San Diego, as this company is only days away from the FDA ruling on whether or not it will approve the company's lead drug, Nuplazid. It's also possible that another big pharma company could make a bid to acquire ACADIA at some point if Nuplazid proves to be the real deal. Because of the technique that Denbury Resources uses for production, though, it is almost exclusively an oil producer, which makes it pretty much an all-or-nothing bet on oil prices . | For that reason I've been keeping a close eye on ACADIA Pharmaceuticals , a red-hot biopharma based out of San Diego, as this company is only days away from the FDA ruling on whether or not it will approve the company's lead drug, Nuplazid. It's also possible that another big pharma company could make a bid to acquire ACADIA at some point if Nuplazid proves to be the real deal. If Nuplazid wins approval, then it could offer real hope to the roughly 400,000 patients in the U.S. alone who currently have PDP, as there are currently no approved treatment options available. |
36212.0 | 2016-04-23 00:00:00 UTC | Billionaires Love These 3 Stocks -- But Are They Right for You? | ACAD | https://www.nasdaq.com/articles/billionaires-love-these-3-stocks-are-they-right-you-2016-04-23 | nan | nan | The reasons why billionaire investors like Warren Buffett, Carl Icahn, and George Soros buy a stock can seem alien to retail investors like you or me. After all, the capital allocation strategies of most billionaires are generally far more complex than those of retail investors due to the sheer size of their portfolios. As such, it's probably never a good idea to simply mimic so-called 'super-investors' when building a portfolio of your own.
Source: Flickr via user thetaxhaven
Armed with this insight, our Foolish contributors discuss whether or not they think investors should take a page from the billionaires when it comes to Acadia Pharmaceuticals , Kinder Morgan , and International Business Machines .
(Acadia Pharmaceuticals) The biotech gurus Felix and Julian Baker that run the investing firm Baker Bros. Advisors, have reportedly been gobbling up even more shares of Acadia Pharmaceuticals. According to recently filed Form 4s with the SEC, for instance, Baker Bros. Advisors made three indirect stock acquisitions in the last thirty days. These buys are noteworthy because Acadia is currently waiting for the final word from the FDA about its lead product candidate Nuplazid, an experimental drug indicated for Parkinson's disease psychosis.
Should retail investors follow in the Baker Bros. footsteps? My tentative answer is a 'yes', with the caveat that this stock is best-suited for investors with a healthy appetite for risk. The low down is that Nuplazid could enter a market in desperate need of new treatment options. And with nearly 1 million Americans already afflicted with Parkinson's disease, Nuplazid stands a good chance at eventually reaching blockbuster status if it's approved.
Having said that, I wouldn't expect Nuplazid to get off to a roaring start in light of Acadia's limited sales infrastructure and experience, meaning that investors may need to remain patient with this stock as the drug's commercial launch unfolds. Then again, Acadia's management may decide to put the company up for sale, following an approval for Nuplazid, for these very reasons.
Matt DiLallo
(Kinder Morgan) Beaten down pipeline giant Kinder Morgan has gotten a lot of love from billionaires over the past few months. Not only did the company's own billionaire founder Richard Kinder snap up shares as the stock dropped last year, but so did some of the world's top billionaire investors including David Tepper, George Soros, and Warren Buffett.
A number of investors initially piled into the stock after it was disclosed that Buffett's Berkshire Hathaway bought a $400 million stake in the company only to find out that Buffett himself didn't direct that purchase, which was instead initiated by one of his two portfolio managers. While the company certainly has a number of the characteristics Buffett looks for in one of his own stock picks, it does show that sometimes investors blindly follow a billionaire into a company, which can cause problems down the road. Especially if the billionaire is making a risky bet, which is something the rest of us can't as easily afford to make.
That being said, in this case the reason Buffett's investment manager, as well as other well-known investors like Tepper and Soros started buying Kinder Morgan's stock last year really boiled down to value. Kinder Morgan's stock price cratered last year due to concerns that its credit would start to deteriorate after the energy market took a turn for the worse. However, unlike most others in the energy sector, Kinder Morgan's cash flow is relatively unaffected by changes in oil and gas prices. So, the sell-off enabled these investors to buy that cash flow stream at a pretty compelling price.
While the stock isn't quite the extreme value it was when these billionaires bought their stake, it's still selling for much less than it was this time last year, despite the fact that its cash flow hasn't really budged. That makes it a pretty compelling buy, even if you don't have billions to invest.
( International Business Machines) One of largest positions in Berkshire-Hathaway's stock portfolio is International Business Machines. Berkshire CEO Warren Buffett began accumulating the stake in 2011, and as of the end of 2015, Berkshire owned just over $11 billion worth of IBM. The company is in the middle of a multi-year transition, investing in high-growth areas like cloud computing. This transition, along with currency fluctuations, have driven IBM's revenue and profits lower in recent years.
In February, the billionaire admitted that buying IBM could turn out to be a mistake if he's ultimately wrong about the company. However, Buffett continues to believe that his investment in IBM will work out well in the long run. Technology is generally outside of Buffett's circle of competence, and he's bought few tech stocks throughout the years. That tendency made Buffett's investment in IBM all the more surprising.
IBM was late to the cloud computing party, but the company is now aggressively going after opportunities as some of its legacy businesses shrink. Acquisitions have been part of the strategy, with IBM buying a handful of companies during the first quarter, including Ustream, a provider of live video streaming services, and Truven Health Analytics, a provider of cloud-based healthcare data and insights. Healthcare is a major opportunity for the company, and its Watson cognitive computing business has engaged in a slew of partnerships aimed at leveraging the technology to improve diagnoses and patient outcomes.
IBM ten years from now will look very different from the IBM of ten years ago, and the transition will continue to be messy. The company continues to generate plenty of profits, with free cash flow expected to be around $12 billion this year, despite all of the issues facing the company. Things are changing at IBM, but Buffett still thinks the company will be just fine in the long run.
A secret billion-dollar stock opportunity
The world's biggest tech company forgot to show you something, but a few Wall Street analysts and the Fool didn't miss a beat: There's a small company that's powering their brand-new gadgets and the coming revolution in technology. And we think its stock price has nearly unlimited room to run for early in-the-know investors! To be one of them, just click here .
The article Billionaires Love These 3 Stocks -- But Are They Right for You? originally appeared on Fool.com.
George Budwell owns shares of Berkshire Hathaway. Matt DiLallo owns shares of Berkshire Hathaway and Kinder Morgan. Matt DiLallo has the following options: short January 2018 $30 puts on Kinder Morgan, long January 2018 $30 calls on Kinder Morgan, long January 2017 $135 calls on Berkshire Hathaway, and short January 2017 $145 calls on Berkshire Hathaway. Timothy Green owns shares of Berkshire Hathaway and International Business Machines. The Motley Fool owns shares of and recommends Berkshire Hathaway and Kinder Morgan. The Motley Fool has the following options: short June 2016 $12 puts on Kinder Morgan. Try any of our Foolish newsletter services free for 30 days . We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy .
Copyright © 1995 - 2016 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy .
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Source: Flickr via user thetaxhaven Armed with this insight, our Foolish contributors discuss whether or not they think investors should take a page from the billionaires when it comes to Acadia Pharmaceuticals , Kinder Morgan , and International Business Machines . Having said that, I wouldn't expect Nuplazid to get off to a roaring start in light of Acadia's limited sales infrastructure and experience, meaning that investors may need to remain patient with this stock as the drug's commercial launch unfolds. (Acadia Pharmaceuticals) The biotech gurus Felix and Julian Baker that run the investing firm Baker Bros. Advisors, have reportedly been gobbling up even more shares of Acadia Pharmaceuticals. | Source: Flickr via user thetaxhaven Armed with this insight, our Foolish contributors discuss whether or not they think investors should take a page from the billionaires when it comes to Acadia Pharmaceuticals , Kinder Morgan , and International Business Machines . (Acadia Pharmaceuticals) The biotech gurus Felix and Julian Baker that run the investing firm Baker Bros. Advisors, have reportedly been gobbling up even more shares of Acadia Pharmaceuticals. These buys are noteworthy because Acadia is currently waiting for the final word from the FDA about its lead product candidate Nuplazid, an experimental drug indicated for Parkinson's disease psychosis. | Source: Flickr via user thetaxhaven Armed with this insight, our Foolish contributors discuss whether or not they think investors should take a page from the billionaires when it comes to Acadia Pharmaceuticals , Kinder Morgan , and International Business Machines . (Acadia Pharmaceuticals) The biotech gurus Felix and Julian Baker that run the investing firm Baker Bros. Advisors, have reportedly been gobbling up even more shares of Acadia Pharmaceuticals. These buys are noteworthy because Acadia is currently waiting for the final word from the FDA about its lead product candidate Nuplazid, an experimental drug indicated for Parkinson's disease psychosis. | Source: Flickr via user thetaxhaven Armed with this insight, our Foolish contributors discuss whether or not they think investors should take a page from the billionaires when it comes to Acadia Pharmaceuticals , Kinder Morgan , and International Business Machines . (Acadia Pharmaceuticals) The biotech gurus Felix and Julian Baker that run the investing firm Baker Bros. Advisors, have reportedly been gobbling up even more shares of Acadia Pharmaceuticals. These buys are noteworthy because Acadia is currently waiting for the final word from the FDA about its lead product candidate Nuplazid, an experimental drug indicated for Parkinson's disease psychosis. |
36213.0 | 2016-04-18 00:00:00 UTC | 3 Stocks That Could Double Your Money | ACAD | https://www.nasdaq.com/articles/3-stocks-could-double-your-money-2016-04-18 | nan | nan | ACAD data by YCharts
The long and short of it is that Nuplazid offers a jaw-dropping long-term value proposition for shareholders. While considerable debate exists over Nuplazid's peak sales potential, the fact remains that the Parkinson's disease market is enormous, with over 1 million Americans currently afflicted with the disease and another 9 million patients in ex-U.S. territories. As PDP occurs in approximately 20% of Parkinson's patients, according to industry experts, Nuplazid clearly has a sizable target market, implying that this experimental drug does indeed harbor megablockbuster potential.
Perhaps the best part is that Nuplazid could end up facing little competition for an extended period of time. If this drug is approved by the FDA and gets a relatively clean label in the process, analysts estimate that Nuplazid could dominate the PDP market for at least the next seven years -- given both the lack of experimental stage drugs under development for this particular indication and the black boxed warnings that come with some of the drugs presently used to treat PDP.
Looking ahead, investors will want to keep an eye out for the FDA's final decision on Nuplazid that's expected no later than May 1, along with the drug's label if approved. But barring any unforeseen even events on the regulatory front, I'm cautiously optimistic that Acadia's shares could surge higher due to the need for new treatment options for PDP and Nuplazid's potential to gobble up a nice chunk of this already large and growing market.
Celator is poised to bring a new treatment foracute myeloid leukemia to market
Celator's stock has been on absolute fire ever since the company announced positive late-stage results for its experimental treatment for secondary acute myeloid leukemia (AML) called Vyxeos last month:
CPXX data by YCharts
The key issue to understand is that Vyxeos stands to become the first major advancement in the treatment for AML in nearly three decades -- a disease that claims over 95% of lives of afflicted patients aged 65 or older. Although AML is a relatively rare form of cancer, industry experts estimate that the market for this orphan indication will grow to nearly $900 million in sales by 2020. So, with a market cap of less than $550 million at the time of writing, Celator would only need to capture perhaps a third of this growing market for Vyxeos to be a major value driver for the company moving forward.
Celator is in the process of putting together a regulatory filing for Vyxeos in the U.S., which could come as early as the third quarter of this year. The company is then expected to file for the drug's approval in Europe sometime in 2017. Based on the top-line data released thus far and the dire need for new therapeutic options for AML, Vyxeos seems to stand a fairly good chance at getting a green light from the FDA -- assuming there isn't a black swan hiding in the full data package that's to be presented to the FDA for approval.
The main downside risk with this stock thus appears to be the possible entry of game-changing adoptive cell therapies for blood-based cancers like AML down the road. That said, the earliest any of these competing therapies would hit the market would be late 2017, and that's a generous estimate -- meaning that Vyxeos should face little competition, if approved, in the near-term.
TransEnterix's stock is soaring on SurgiBot's regulatory filing
TransEnterix's shares have been going ballistic this year due to its regulatory application for SurgiBot -- a minimally invasive surgical platform that is expected to directly compete with Intuitive Surgical 's blockbuster product, the da Vinci Surgical system, in the United States.
TRXC data by YCharts
TransEnterix is hoping that a lower pricing point and more user-friendly features will allow it to rapidly capture market share from Intuitive's market-leading product.
The real thrust behind TransEnterix's recent surge, though, is the rampant speculation about the company being bought out by either Johnson & Johnson or Opko Health following SurgiBot's expected clearance by the FDA sometime in the next few days or weeks. The main impetus behind these rumors is the fact that the robotic surgery space is forecast to grow to a staggering $20 billion by 2021 .
Adding fuel to the fire, J&J recently announced that it plans on restructuring its medical device business to focus on higher growth areas of the market like robotic surgery, implying that it could be interested in fast-tracking this process by acquiring an up and coming company like TransEnterix.
Opko, for its part, has been linked to a possible buyout of TransEnterix primarily through its CEO Phillip Frost -- who also happens to be a major shareholder and former director of TransEnterix, and has a well-documented history of going the M&A route to create shareholder value.
Because a substantial amount of TransEnterix's current value seems to be predicated on a buyout, I find this stock to be somewhat risky for my taste. After all, TransEnterix may have a tough time beating out Intuitive for market share due to the underlying dynamics of the robotic surgery market (high upfront and maintenance costs for hospitals making it hard to switch to another system) -- not to mention TransEnterix's need to raise a highly skilled sales force with limited resources .
Are any of these stocks worth buying right now?
I think both Acadia and Celator easily have more room to run in light of the commercial potential of their lead product candidates relative to their respective market caps. TransEnterix, on the other hand, is probably going to need a buyout to drive its shares much higher as a result of the immense demands of commercializing a robotic surgery product. Furthermore, I'm not entirely sold on the idea that either J&J or Opko are waiting in the wings to buy TransEnterix. After all, J&J has formed a joint venture in order to develop its own line of robotic surgery products, and Opko may not have the resources available after its New Drug Application for Rayaldee was recently bounced back by the FDA.
A secret billion-dollar stock opportunity
The world's biggest tech company forgot to show you something, but a few Wall Street analysts and the Fool didn't miss a beat: There's a small company that's powering their brand-new gadgets and the coming revolution in technology. And we think its stock price has nearly unlimited room to run for early in-the-know investors! To be one of them, just click here .
The article 3 Stocks That Could Double Your Money originally appeared on Fool.com.
George Budwell has no position in any stocks mentioned. The Motley Fool owns shares of and recommends Intuitive Surgical and Johnson & Johnson. Try any of our Foolish newsletter services free for 30 days . We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy .
Copyright © 1995 - 2016 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy .
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | But barring any unforeseen even events on the regulatory front, I'm cautiously optimistic that Acadia's shares could surge higher due to the need for new treatment options for PDP and Nuplazid's potential to gobble up a nice chunk of this already large and growing market. ACAD data by YCharts The long and short of it is that Nuplazid offers a jaw-dropping long-term value proposition for shareholders. I think both Acadia and Celator easily have more room to run in light of the commercial potential of their lead product candidates relative to their respective market caps. | ACAD data by YCharts The long and short of it is that Nuplazid offers a jaw-dropping long-term value proposition for shareholders. But barring any unforeseen even events on the regulatory front, I'm cautiously optimistic that Acadia's shares could surge higher due to the need for new treatment options for PDP and Nuplazid's potential to gobble up a nice chunk of this already large and growing market. I think both Acadia and Celator easily have more room to run in light of the commercial potential of their lead product candidates relative to their respective market caps. | ACAD data by YCharts The long and short of it is that Nuplazid offers a jaw-dropping long-term value proposition for shareholders. But barring any unforeseen even events on the regulatory front, I'm cautiously optimistic that Acadia's shares could surge higher due to the need for new treatment options for PDP and Nuplazid's potential to gobble up a nice chunk of this already large and growing market. I think both Acadia and Celator easily have more room to run in light of the commercial potential of their lead product candidates relative to their respective market caps. | ACAD data by YCharts The long and short of it is that Nuplazid offers a jaw-dropping long-term value proposition for shareholders. But barring any unforeseen even events on the regulatory front, I'm cautiously optimistic that Acadia's shares could surge higher due to the need for new treatment options for PDP and Nuplazid's potential to gobble up a nice chunk of this already large and growing market. I think both Acadia and Celator easily have more room to run in light of the commercial potential of their lead product candidates relative to their respective market caps. |
36214.0 | 2016-04-13 00:00:00 UTC | SPDR S&P Biotech ETF Experiences Big Inflow | ACAD | https://www.nasdaq.com/articles/spdr-sp-biotech-etf-experiences-big-inflow-2016-04-13 | nan | nan | Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel , one standout is the SPDR S&P Biotech ETF (Symbol: XBI) where we have detected an approximate $76.9 million dollar inflow -- that's a 3.9% increase week over week in outstanding units (from 35,750,000 to 37,150,000). Among the largest underlying components of XBI, in trading today Acadia Pharmaceuticals Inc (Symbol: ACAD) is up about 2%, Intercept Pharmaceuticals Inc (Symbol: ICPT) is down about 1%, and Neurocrine Biosciences, Inc. (Symbol: NBIX) is higher by about 1.4%. For a complete list of holdings, visit the XBI Holdings page » The chart below shows the one year price performance of XBI, versus its 200 day moving average:
Looking at the chart above, XBI's low point in its 52 week range is $44.16 per share, with $91.11 as the 52 week high point - that compares with a last trade of $55.64. Comparing the most recent share price to the 200 day moving average can also be a useful technical analysis technique -- learn more about the 200 day moving average » .
Exchange traded funds (ETFs) trade just like stocks, but instead of ''shares'' investors are actually buying and selling ''units''. These ''units'' can be traded back and forth just like stocks, but can also be created or destroyed to accommodate investor demand. Each week we monitor the week-over-week change in shares outstanding data, to keep a lookout for those ETFs experiencing notable inflows (many new units created) or outflows (many old units destroyed). Creation of new units will mean the underlying holdings of the ETF need to be purchased, while destruction of units involves selling underlying holdings, so large flows can also impact the individual components held within ETFs.
Click here to find out which 9 other ETFs had notable inflows »
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Among the largest underlying components of XBI, in trading today Acadia Pharmaceuticals Inc (Symbol: ACAD) is up about 2%, Intercept Pharmaceuticals Inc (Symbol: ICPT) is down about 1%, and Neurocrine Biosciences, Inc. (Symbol: NBIX) is higher by about 1.4%. For a complete list of holdings, visit the XBI Holdings page » The chart below shows the one year price performance of XBI, versus its 200 day moving average: Looking at the chart above, XBI's low point in its 52 week range is $44.16 per share, with $91.11 as the 52 week high point - that compares with a last trade of $55.64. These ''units'' can be traded back and forth just like stocks, but can also be created or destroyed to accommodate investor demand. | Among the largest underlying components of XBI, in trading today Acadia Pharmaceuticals Inc (Symbol: ACAD) is up about 2%, Intercept Pharmaceuticals Inc (Symbol: ICPT) is down about 1%, and Neurocrine Biosciences, Inc. (Symbol: NBIX) is higher by about 1.4%. For a complete list of holdings, visit the XBI Holdings page » The chart below shows the one year price performance of XBI, versus its 200 day moving average: Looking at the chart above, XBI's low point in its 52 week range is $44.16 per share, with $91.11 as the 52 week high point - that compares with a last trade of $55.64. Click here to find out which 9 other ETFs had notable inflows » The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Among the largest underlying components of XBI, in trading today Acadia Pharmaceuticals Inc (Symbol: ACAD) is up about 2%, Intercept Pharmaceuticals Inc (Symbol: ICPT) is down about 1%, and Neurocrine Biosciences, Inc. (Symbol: NBIX) is higher by about 1.4%. Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel , one standout is the SPDR S&P Biotech ETF (Symbol: XBI) where we have detected an approximate $76.9 million dollar inflow -- that's a 3.9% increase week over week in outstanding units (from 35,750,000 to 37,150,000). For a complete list of holdings, visit the XBI Holdings page » The chart below shows the one year price performance of XBI, versus its 200 day moving average: Looking at the chart above, XBI's low point in its 52 week range is $44.16 per share, with $91.11 as the 52 week high point - that compares with a last trade of $55.64. | Among the largest underlying components of XBI, in trading today Acadia Pharmaceuticals Inc (Symbol: ACAD) is up about 2%, Intercept Pharmaceuticals Inc (Symbol: ICPT) is down about 1%, and Neurocrine Biosciences, Inc. (Symbol: NBIX) is higher by about 1.4%. Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel , one standout is the SPDR S&P Biotech ETF (Symbol: XBI) where we have detected an approximate $76.9 million dollar inflow -- that's a 3.9% increase week over week in outstanding units (from 35,750,000 to 37,150,000). For a complete list of holdings, visit the XBI Holdings page » The chart below shows the one year price performance of XBI, versus its 200 day moving average: Looking at the chart above, XBI's low point in its 52 week range is $44.16 per share, with $91.11 as the 52 week high point - that compares with a last trade of $55.64. |
36215.0 | 2016-04-10 00:00:00 UTC | 3 Charts That Explain Acadia Pharmaceuticals Inc Stock | ACAD | https://www.nasdaq.com/articles/3-charts-explain-acadia-pharmaceuticals-inc-stock-2016-04-10 | nan | nan | Of equal importance was that patients who used Nuplazid did not have their motor control comprised, which is a typical side effect of many antipsychotics.
Naturally, when these results become available, shares skyrocketed, making Acadia the best-performing biotech stock of 2013. Peak sales estimates for Nuplazid currently run in excess of $3 billion.
2. Pipeline
Right now, all eyes on are the Nuplazid opportunity in treating PDP, but there may be other uses for the drug, too. Acadia is currently running trials testing its ability to treat Alzheimer's disease Psychosis and Schizophrenia.
Beyond that, the company has two other compounds that are in early and mid-stage clinical trials at the moment. Way back in 2003, the company signed a collaboration deal with pharma giant Allergan with the goal of developing new therapies. So far, that deal hasn't turned into much, but the two companies are currently advancing a drug that's aimed at treating chronic pain down the regulatory pathway. The compound, called Adrenergic, is currently just in Phase 2 development, but it could prove to be a growth driver down the road.
Having a deep-pocketed (and highly acquisitive) company like Allergan helping to foot the bills of clinical trials isn't a bad thing.
3. Market cap
With the company's share price in the stratosphere, management hasn't been shy about selling equity to raise additional funds. That's likely a smart more considering that successfully commercializing a drug doesn't come cheap.
Still, all the secondary share offerings have caused the number of shares outstanding to rise quickly over the past few years. Mix that with the company's share price, and its market cap is currently hovering around $3.6 billion.
Thankfully, all of these share offerings have put the company on solid financial footing. After selling an additional 10 million shares in January 2016, the company now has about $496 million worth of cash of its books. That should give it plenty of firepower to commercialize Nuplazid and fund the rest of its pipeline for at least a couple of years.
What now?
So, there you have it -- bulls think Nuplazid is going to be approved and revolutionize the way we treat PDP. That might not be that far-fetched of an assumption since a few days ago, a FDA panel of outside experts voted 12 to two in favor of approving Nuplazid, stating that the potential benefits of using the drug outweigh its risks. That's a great sign, and it bodes well for the drug's chances when the FDA issues its final ruling, which is currently scheduled for May 1st.
For that reason, it might not be so crazy to buy a few shares -- even way up here. Pharmaceutical buyouts often occur at two to three times peak sales estimates, and with Acadia currently trading around one times peak sales, there could still be room for substantial upside from here.
That is, of course, if everything goes according to plan.
A secret billion-dollar stock opportunity
The world's biggest tech company forgot to show you something, but a few Wall Street analysts and the Fool didn't miss a beat: There's a small company that's powering their brand-new gadgets and the coming revolution in technology. And we think its stock price has nearly unlimited room to run for early, in-the-know investors! To be one of them, just click here .
The article 3 Charts That Explain Acadia Pharmaceuticals Inc Stock originally appeared on Fool.com.
Brian Feroldi has no position in any stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. Try any of our Foolish newsletter services free for 30 days . We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy .
Copyright © 1995 - 2016 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy .
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Naturally, when these results become available, shares skyrocketed, making Acadia the best-performing biotech stock of 2013. Acadia is currently running trials testing its ability to treat Alzheimer's disease Psychosis and Schizophrenia. Pharmaceutical buyouts often occur at two to three times peak sales estimates, and with Acadia currently trading around one times peak sales, there could still be room for substantial upside from here. | The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. Naturally, when these results become available, shares skyrocketed, making Acadia the best-performing biotech stock of 2013. Acadia is currently running trials testing its ability to treat Alzheimer's disease Psychosis and Schizophrenia. | Naturally, when these results become available, shares skyrocketed, making Acadia the best-performing biotech stock of 2013. Acadia is currently running trials testing its ability to treat Alzheimer's disease Psychosis and Schizophrenia. Pharmaceutical buyouts often occur at two to three times peak sales estimates, and with Acadia currently trading around one times peak sales, there could still be room for substantial upside from here. | Naturally, when these results become available, shares skyrocketed, making Acadia the best-performing biotech stock of 2013. Acadia is currently running trials testing its ability to treat Alzheimer's disease Psychosis and Schizophrenia. Pharmaceutical buyouts often occur at two to three times peak sales estimates, and with Acadia currently trading around one times peak sales, there could still be room for substantial upside from here. |
36216.0 | 2016-04-09 00:00:00 UTC | 3 Stocks the Smartest Investors Are Buying Now | ACAD | https://www.nasdaq.com/articles/3-stocks-smartest-investors-are-buying-now-2016-04-09 | nan | nan | ACAD data by YCharts
The interesting part is that the Baker Bros. have stuck with this volatile biotech stock ever since the fourth quarter of 2010, despite a steep mid-year pull back in 2015, according to the latest 13F filings with the SEC. And that decision looks like it's about to payoff in a big way. Specifically, an advisory committee for the FDA voted 12 to 2 in favor of approving Nuplazid last month, causing the company's shares to bounce off their 52-week lows in a hurry.
Even so, the best may be yet to come. After all, some analysts see this drug as having the potential to generate close to $3 billion in peak sales if approved, meaning that Acadia's stock could be in for a long-lived bull run moving forward.
A secret billion-dollar stock opportunity
The world's biggest tech company forgot to show you something, but a few Wall Street analysts and the Fool didn't miss a beat: There's a small company that's powering their brand-new gadgets and the coming revolution in technology. And we think its stock price has nearly unlimited room to run for early in-the-know investors! To be one of them, just click here .
The article 3 Stocks the Smartest Investors Are Buying Now originally appeared on Fool.com.
Steve Symington has no position in any stocks mentioned. The Motley Fool owns shares of and recommends Amazon.com and Kinder Morgan. The Motley Fool has the following options: short June 2016 $12 puts on Kinder Morgan. Try any of our Foolish newsletter services free for 30 days . We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy .
Copyright © 1995 - 2016 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy .
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | ACAD data by YCharts The interesting part is that the Baker Bros. have stuck with this volatile biotech stock ever since the fourth quarter of 2010, despite a steep mid-year pull back in 2015, according to the latest 13F filings with the SEC. After all, some analysts see this drug as having the potential to generate close to $3 billion in peak sales if approved, meaning that Acadia's stock could be in for a long-lived bull run moving forward. Specifically, an advisory committee for the FDA voted 12 to 2 in favor of approving Nuplazid last month, causing the company's shares to bounce off their 52-week lows in a hurry. | The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. ACAD data by YCharts The interesting part is that the Baker Bros. have stuck with this volatile biotech stock ever since the fourth quarter of 2010, despite a steep mid-year pull back in 2015, according to the latest 13F filings with the SEC. After all, some analysts see this drug as having the potential to generate close to $3 billion in peak sales if approved, meaning that Acadia's stock could be in for a long-lived bull run moving forward. | The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. ACAD data by YCharts The interesting part is that the Baker Bros. have stuck with this volatile biotech stock ever since the fourth quarter of 2010, despite a steep mid-year pull back in 2015, according to the latest 13F filings with the SEC. After all, some analysts see this drug as having the potential to generate close to $3 billion in peak sales if approved, meaning that Acadia's stock could be in for a long-lived bull run moving forward. | ACAD data by YCharts The interesting part is that the Baker Bros. have stuck with this volatile biotech stock ever since the fourth quarter of 2010, despite a steep mid-year pull back in 2015, according to the latest 13F filings with the SEC. After all, some analysts see this drug as having the potential to generate close to $3 billion in peak sales if approved, meaning that Acadia's stock could be in for a long-lived bull run moving forward. The Motley Fool owns shares of and recommends Amazon.com and Kinder Morgan. |
36217.0 | 2016-04-08 00:00:00 UTC | Why ACADIA Pharmaceuticals Inc Skyrocketed 46% Higher in March | ACAD | https://www.nasdaq.com/articles/why-acadia-pharmaceuticals-inc-skyrocketed-46-higher-march-2016-04-08 | nan | nan | So what:
The news was so huge that trading on the company's stock was temporarily halted. When it resumed, shares immediately jumped more than 21% in a single day. Shares have even continued to rally into April as investors digested the news.
Now what: Even though Acadia's stock was able to roar higher during the month, it still hasn't fully recovered from the drubbing that it took to start the year. Just like the iShares Nasdaq Biotechnology ETF , shares plunged when the calendar turned to January 1st.
That large drop is likely owed to the fact that short interest in the company jumped from 13 million shares on December 31st to more than 17 million by mid-March. These traders seem to believe that regulators would reject Nuplazid since its clinical data wasn't perfect. When news broke that the panel of FDA advisers had recommended the drug's approval, many short-sellers were forced to cover at the same time, creating a short squeeze which sent shares screaming higher.
The next catalyst that investors can look forward to is Nuplazid's PDUFA date which is scheduled for May 1. While the FDA is not obligated to follow the recommendation of its external panel of experts, more often than not it does.
With analysts predicting peak sales as high as $3 billion for Nuplazid, even after March's monster move there still could be plenty of room left for Acadia's stock to run -- assuming, of course, that everything goes according to plan.
A secret billion-dollar stock opportunity
The world's biggest tech company forgot to show you something, but a few Wall Street analysts and the Fool didn't miss a beat: There's a small company that's powering their brand-new gadgets and the coming revolution in technology. And we think its stock price has nearly unlimited room to run for early in-the-know investors! To be one of them, just click here .
The article Why ACADIA Pharmaceuticals Inc Skyrocketed 46% Higher in March originally appeared on Fool.com.
Brian Feroldi has no position in any stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. Try any of our Foolish newsletter services free for 30 days . We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy .
Copyright © 1995 - 2016 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy .
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Now what: Even though Acadia's stock was able to roar higher during the month, it still hasn't fully recovered from the drubbing that it took to start the year. With analysts predicting peak sales as high as $3 billion for Nuplazid, even after March's monster move there still could be plenty of room left for Acadia's stock to run -- assuming, of course, that everything goes according to plan. The article Why ACADIA Pharmaceuticals Inc Skyrocketed 46% Higher in March originally appeared on Fool.com. | The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. Now what: Even though Acadia's stock was able to roar higher during the month, it still hasn't fully recovered from the drubbing that it took to start the year. With analysts predicting peak sales as high as $3 billion for Nuplazid, even after March's monster move there still could be plenty of room left for Acadia's stock to run -- assuming, of course, that everything goes according to plan. | Now what: Even though Acadia's stock was able to roar higher during the month, it still hasn't fully recovered from the drubbing that it took to start the year. With analysts predicting peak sales as high as $3 billion for Nuplazid, even after March's monster move there still could be plenty of room left for Acadia's stock to run -- assuming, of course, that everything goes according to plan. The article Why ACADIA Pharmaceuticals Inc Skyrocketed 46% Higher in March originally appeared on Fool.com. | Now what: Even though Acadia's stock was able to roar higher during the month, it still hasn't fully recovered from the drubbing that it took to start the year. With analysts predicting peak sales as high as $3 billion for Nuplazid, even after March's monster move there still could be plenty of room left for Acadia's stock to run -- assuming, of course, that everything goes according to plan. The article Why ACADIA Pharmaceuticals Inc Skyrocketed 46% Higher in March originally appeared on Fool.com. |
36218.0 | 2016-04-06 00:00:00 UTC | Here's Why Sarepta Therapeutics Jumped Today | ACAD | https://www.nasdaq.com/articles/heres-why-sarepta-therapeutics-jumped-today-2016-04-06 | nan | nan | IMAGE SOURCE: SAREPTA
What: Shares of Sarepta Therapeutics , a clinical-stage biopharmaceutical company, jumped by more than 15% as of 3:00 p.m. EST Wednesday after an analyst raised his price target and issued a bullish forecast for the company.
So what: Oppenheimer released a note today stating that the firm believes the FDA panel will issue a positive ruling on Sarepta's Duchenne muscular dystrophy, or DMD, drug etepliresen later this month, which they think will cause the share price to spike. The firm raised the company's price target up to $60 -- just shy of a triple from today's market price -- and gave the shares an 'outperform' rating.
Oppenheimer believes that the agency will end up giving etepliresen the green light since there are currently no approved treatment options available for patients with DMD. The thesis rests in part on the fact that ACADIA Pharmaceuticals drug Nuplazid also did not have perfect data but the FDA's advisory committee still recommended approving the drug in a 12 to two vote .
Now what: It's also worth noting that Sarepta has received a huge amount of support from the DMD community as a letter was recently posted to the website of the University of California's Los Angeles website that urged the FDA to approve eteplirsen. The letter was signed by 34 healthcare providers from around the world that specialize in DMD research who believe that the potential benefits of using etepliresen outweigh its downsides.
Oppenheimer may end up looking like it made a great call if everything works out for Sarepta, but recommending the stock ahead of the meeting is quite risky. I understand their confidence as ACADIA Pharmaceutical's drug didn't have anywhere near that kind of support from the medical community as Sarepta does and yet it still managed to come out of its FDA panel meeting looking good.
Still, it's hard to guess at what kind of response the FDA will have have for eteplirsen and if the news isn't good then Sarepta's shares could easily get crushed. For that reason I'm content to watch this story play out from the sidelines.
A secret billion-dollar stock opportunity
The world's biggest tech company forgot to show you something, but a few Wall Street analysts and the Fool didn't miss a beat: There's a small company that's powering their brand-new gadgets and the coming revolution in technology. And we think its stock price has nearly unlimited room to run for early in-the-know investors! To be one of them, just click here .
The article Here's Why Sarepta Therapeutics Jumped Today originally appeared on Fool.com.
Brian Feroldi has no position in any stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. Try any of our Foolish newsletter services free for 30 days . We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy .
Copyright © 1995 - 2016 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy .
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | I understand their confidence as ACADIA Pharmaceutical's drug didn't have anywhere near that kind of support from the medical community as Sarepta does and yet it still managed to come out of its FDA panel meeting looking good. The thesis rests in part on the fact that ACADIA Pharmaceuticals drug Nuplazid also did not have perfect data but the FDA's advisory committee still recommended approving the drug in a 12 to two vote . So what: Oppenheimer released a note today stating that the firm believes the FDA panel will issue a positive ruling on Sarepta's Duchenne muscular dystrophy, or DMD, drug etepliresen later this month, which they think will cause the share price to spike. | The thesis rests in part on the fact that ACADIA Pharmaceuticals drug Nuplazid also did not have perfect data but the FDA's advisory committee still recommended approving the drug in a 12 to two vote . I understand their confidence as ACADIA Pharmaceutical's drug didn't have anywhere near that kind of support from the medical community as Sarepta does and yet it still managed to come out of its FDA panel meeting looking good. So what: Oppenheimer released a note today stating that the firm believes the FDA panel will issue a positive ruling on Sarepta's Duchenne muscular dystrophy, or DMD, drug etepliresen later this month, which they think will cause the share price to spike. | The thesis rests in part on the fact that ACADIA Pharmaceuticals drug Nuplazid also did not have perfect data but the FDA's advisory committee still recommended approving the drug in a 12 to two vote . I understand their confidence as ACADIA Pharmaceutical's drug didn't have anywhere near that kind of support from the medical community as Sarepta does and yet it still managed to come out of its FDA panel meeting looking good. What: Shares of Sarepta Therapeutics , a clinical-stage biopharmaceutical company, jumped by more than 15% as of 3:00 p.m. EST Wednesday after an analyst raised his price target and issued a bullish forecast for the company. | I understand their confidence as ACADIA Pharmaceutical's drug didn't have anywhere near that kind of support from the medical community as Sarepta does and yet it still managed to come out of its FDA panel meeting looking good. The thesis rests in part on the fact that ACADIA Pharmaceuticals drug Nuplazid also did not have perfect data but the FDA's advisory committee still recommended approving the drug in a 12 to two vote . What: Shares of Sarepta Therapeutics , a clinical-stage biopharmaceutical company, jumped by more than 15% as of 3:00 p.m. EST Wednesday after an analyst raised his price target and issued a bullish forecast for the company. |
36219.0 | 2016-04-05 00:00:00 UTC | SPDR S&P Biotech ETF Experiences Big Outflow | ACAD | https://www.nasdaq.com/articles/spdr-sp-biotech-etf-experiences-big-outflow-2016-04-05 | nan | nan | Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel , one standout is the SPDR S&P Biotech ETF (Symbol: XBI) where we have detected an approximate $83.5 million dollar outflow -- that's a 4.2% decrease week over week (from 37,300,000 to 35,750,000). Among the largest underlying components of XBI, in trading today Acadia Pharmaceuticals Inc (Symbol: ACAD) is up about 2.8%, Novavax, Inc. (Symbol: NVAX) is up about 2.7%, and Intercept Pharmaceuticals Inc (Symbol: ICPT) is up by about 18.5%. For a complete list of holdings, visit the XBI Holdings page » The chart below shows the one year price performance of XBI, versus its 200 day moving average:
Looking at the chart above, XBI's low point in its 52 week range is $44.16 per share, with $91.11 as the 52 week high point - that compares with a last trade of $54.74. Comparing the most recent share price to the 200 day moving average can also be a useful technical analysis technique -- learn more about the 200 day moving average » .
Exchange traded funds (ETFs) trade just like stocks, but instead of ''shares'' investors are actually buying and selling ''units''. These ''units'' can be traded back and forth just like stocks, but can also be created or destroyed to accommodate investor demand. Each week we monitor the week-over-week change in shares outstanding data, to keep a lookout for those ETFs experiencing notable inflows (many new units created) or outflows (many old units destroyed). Creation of new units will mean the underlying holdings of the ETF need to be purchased, while destruction of units involves selling underlying holdings, so large flows can also impact the individual components held within ETFs.
Click here to find out which 9 other ETFs experienced notable outflows »
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Among the largest underlying components of XBI, in trading today Acadia Pharmaceuticals Inc (Symbol: ACAD) is up about 2.8%, Novavax, Inc. (Symbol: NVAX) is up about 2.7%, and Intercept Pharmaceuticals Inc (Symbol: ICPT) is up by about 18.5%. For a complete list of holdings, visit the XBI Holdings page » The chart below shows the one year price performance of XBI, versus its 200 day moving average: Looking at the chart above, XBI's low point in its 52 week range is $44.16 per share, with $91.11 as the 52 week high point - that compares with a last trade of $54.74. These ''units'' can be traded back and forth just like stocks, but can also be created or destroyed to accommodate investor demand. | Among the largest underlying components of XBI, in trading today Acadia Pharmaceuticals Inc (Symbol: ACAD) is up about 2.8%, Novavax, Inc. (Symbol: NVAX) is up about 2.7%, and Intercept Pharmaceuticals Inc (Symbol: ICPT) is up by about 18.5%. For a complete list of holdings, visit the XBI Holdings page » The chart below shows the one year price performance of XBI, versus its 200 day moving average: Looking at the chart above, XBI's low point in its 52 week range is $44.16 per share, with $91.11 as the 52 week high point - that compares with a last trade of $54.74. Each week we monitor the week-over-week change in shares outstanding data, to keep a lookout for those ETFs experiencing notable inflows (many new units created) or outflows (many old units destroyed). | Among the largest underlying components of XBI, in trading today Acadia Pharmaceuticals Inc (Symbol: ACAD) is up about 2.8%, Novavax, Inc. (Symbol: NVAX) is up about 2.7%, and Intercept Pharmaceuticals Inc (Symbol: ICPT) is up by about 18.5%. Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel , one standout is the SPDR S&P Biotech ETF (Symbol: XBI) where we have detected an approximate $83.5 million dollar outflow -- that's a 4.2% decrease week over week (from 37,300,000 to 35,750,000). For a complete list of holdings, visit the XBI Holdings page » The chart below shows the one year price performance of XBI, versus its 200 day moving average: Looking at the chart above, XBI's low point in its 52 week range is $44.16 per share, with $91.11 as the 52 week high point - that compares with a last trade of $54.74. | Among the largest underlying components of XBI, in trading today Acadia Pharmaceuticals Inc (Symbol: ACAD) is up about 2.8%, Novavax, Inc. (Symbol: NVAX) is up about 2.7%, and Intercept Pharmaceuticals Inc (Symbol: ICPT) is up by about 18.5%. Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel , one standout is the SPDR S&P Biotech ETF (Symbol: XBI) where we have detected an approximate $83.5 million dollar outflow -- that's a 4.2% decrease week over week (from 37,300,000 to 35,750,000). For a complete list of holdings, visit the XBI Holdings page » The chart below shows the one year price performance of XBI, versus its 200 day moving average: Looking at the chart above, XBI's low point in its 52 week range is $44.16 per share, with $91.11 as the 52 week high point - that compares with a last trade of $54.74. |
36220.0 | 2016-04-03 00:00:00 UTC | This Could Be the Next Big Pharma Buyout | ACAD | https://www.nasdaq.com/articles/could-be-next-big-pharma-buyout-2016-04-03 | nan | nan | Sales of Jazz's top product, Xyrem, for treatment of narcolepsy symptoms grew about 23% to $955 million last year. Before we hear of any offers, one important event needs to play out.
While Xyrem has been a spectacular growth driver, it's also the subject of ongoing patent legislation. Jazz holds 20 Xyrem patents, but not the almighty composition-of-matter patent.Smelling an opportunity, seven different drugmakers have filed applications for approval of generic versions, although Jazz insists its patents will stand up for the drug that made up about 73% of the company's total sales last year. Potential suitors are right to be concerned.
Last summer, the Patent Trial and Appeal Board began proceedings involving six Jazz patents regarding distribution of Xyrem. The company expects a decision in mid-July. If the judge rules strongly in favor of letting Jazz maintain Xyrem exclusivity, expect acquisition offers to pop up like dandelions.
If judges rule unfavorably for Jazz, and Xyrem begins facing generic competition, there's still a chance some suitors could come calling later in the year. Jazz is awaiting phase 3 results for JZP-110, a candidate for both narcolepsy and the much wider obstructive sleep apnea indication. If approved for both, it could top Xyrem's success. Results from this trial aren't expected until the end of the year, so we'll have to wait a bit longer to see how it plays out.
Cheryl Swanson : Big pharma companies, like all of us, enjoy bargains. And gene therapy company Bluebird Bio is flashing blue-plate special pricing right now, making this company a much more enticing takeover target. While the clinical-stage biotech is no stranger to takeover speculation, no one could call Bluebird a bargain last year. Inflated expectations sent the stock up 750% in less than two years, to reach an all-time high last summer.
Bluebird has since fallen out of favor with Wall Street, however. In November, a somewhat disappointing update on Bluebird's Lenti-D phase 2/3 trial had analysts slashing price targets to the bone. The question now is whether the clinical-stage biotech could bounce back, especially since more definitive data is due on the Lenti-D program in a few weeks at the American Academy of Neurology conference.
Whatever that data shows -- or analysts assume it to show -- Bluebird has another asset much more important to big pharma buyers. Along with Kite Pharma and Juno Therapeutics , Bluebird is a leader in CAR-T therapies, often touted as the next big thing in cancer treatment. Late last year, preliminary studies from the National Cancer Institute showed selective data on Bluebird's CAR-T cancer program that was impressive. One advanced cancer patient with multiple myeloma experienced a complete remission eight weeks after treatment. Celgene has already opted into Bluebird's first CAR-T clinical trial, handing over $10 million to jump in, which could end up a "try before you buy" deal. There's no guarantee Bluebird is on the right track with its curative drugs. But the well-funded company is now trading at less than twice its cash level, making it the kind of bargain not often seen in smaller biotechs with a highly promising pipeline.
Todd Campbell : I think Cheryl is on to something with her theory that formerly white-hot stocks working on next-generation CAR-T cancer therapies could be the focus of future M&A, but I think that it's Kite Pharma that's the more likely buyout candidate.
Kite Pharma is conducting a pivotal phase 2 trial of KTE-C19, a CAR-T therapy targeting diffuse large B-cell lymphoma (DLBCL), and interim results are expected this year. Kite Pharma thinks that solid interim data could allow it to file for FDA approval ahead of final data in 2017. If so, then Kite Pharma could conceivably have its first CAR-T on the market next year.
That accelerated timeline could be very attractive to a large biopharma, such as Gilead Sciences or Amgen -- two companies that might otherwise balk at forking out big money to buy an early stage cancer company.
Adding conviction to my thinking is that Kite Pharma's C-suite is packed with people who have been previously associated with M&A. CEO Belldegrun was at Cougar Biotechnology when J&J bought it. CFO Butitta was CFO of NextWave when Pfizer bought it in 2012. and, Chief Commercial Officer Shawn Cline Tomasello worked for Pharmacyclics when AbbVie bought it. The list goes on and on.
Who might acquire Kite Pharma is anyone's guess, but Amgen is already collaborating with the company, and Kite Pharma's chief medical officer, David Chang, is the former head of oncology at Amgen.
Sean Williams : The air has been let out of a number majority of biotech stock valuations in 2016, which is beginning to make this industry quite attractive from a possible takeover standpoint. One company that I suspect could begin to draw some interest, and a possible buyout, is Radius Health .
The lynchpin of Radius Health's portfolio is abaloparatide, a once-daily injectable therapy designed to treat osteoporosis. Wall Street and Radius' shareholders had anxiously been waiting for Amgen and its partner UCB to report late-stage data on romosozumab, a once-monthly injectable solution for osteoporosis that was viewed as abaloparatide's greatest competitor. In February Amgen and UCB delivered. Their late-stage trial hit both co-primary endpoint of reducing the relative risk of vertebral fractures through 12- and 24-months by 73% and 75%, respectively. However, romosozumab did not reach clinical significance in a secondary endpoint of reducing relative risk of non-vertebral fractures in the 12- or 24-month periods examined.
On the other hand, abaloparatide reduced vertebral fractures by 86% in the ACTIVE study at the 18-montn mark, and it did lead to a statistically significant reduction in non-vertebral fractures of 43%. In other words, Radius Health's lead drug looks as if it has a clear path to superiority. This could very well make it an attractive asset for a larger drugmaker to acquire.
Additionally, Radius Health is more than likely looking for a partner in Europe that'll help market abaloparatide. In effect, it's actively seeking a world-renowned drug giant to for assistance, or perhaps a buyout. While nothing is written in stone, I'd keep a close eye on Radius as a buyout candidate within the industry.
A secret billion-dollar stock opportunity
The world's biggest tech company forgot to show you something, but a few Wall Street analysts and the Fool didn't miss a beat: There's a small company that's powering their brand-new gadgets and the coming revolution in technology. And we think its stock price has nearly unlimited room to run for early in-the-know investors! To be one of them, just click here .
The article This Could Be the Next Big Pharma Buyout originally appeared on Fool.com.
Brian Feroldi has no position in any stocks mentioned. Cheryl Swanson owns shares of Amgen and Johnson & Johnson. Cory Renauer owns shares of Johnson & Johnson. Kristine Harjes owns shares of Johnson & Johnson. Sean Williams has no position in any stocks mentioned. Todd Campbell has no position in any stocks mentioned. The Motley Fool recommends Bluebird Bio, Johnson & Johnson, and Juno Therapeutics. Try any of our Foolish newsletter services free for 30 days . We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy .
Copyright © 1995 - 2016 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy .
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | The question now is whether the clinical-stage biotech could bounce back, especially since more definitive data is due on the Lenti-D program in a few weeks at the American Academy of Neurology conference. Kite Pharma is conducting a pivotal phase 2 trial of KTE-C19, a CAR-T therapy targeting diffuse large B-cell lymphoma (DLBCL), and interim results are expected this year. Sean Williams : The air has been let out of a number majority of biotech stock valuations in 2016, which is beginning to make this industry quite attractive from a possible takeover standpoint. | The question now is whether the clinical-stage biotech could bounce back, especially since more definitive data is due on the Lenti-D program in a few weeks at the American Academy of Neurology conference. In November, a somewhat disappointing update on Bluebird's Lenti-D phase 2/3 trial had analysts slashing price targets to the bone. However, romosozumab did not reach clinical significance in a secondary endpoint of reducing relative risk of non-vertebral fractures in the 12- or 24-month periods examined. | The question now is whether the clinical-stage biotech could bounce back, especially since more definitive data is due on the Lenti-D program in a few weeks at the American Academy of Neurology conference. Jazz holds 20 Xyrem patents, but not the almighty composition-of-matter patent.Smelling an opportunity, seven different drugmakers have filed applications for approval of generic versions, although Jazz insists its patents will stand up for the drug that made up about 73% of the company's total sales last year. Todd Campbell : I think Cheryl is on to something with her theory that formerly white-hot stocks working on next-generation CAR-T cancer therapies could be the focus of future M&A, but I think that it's Kite Pharma that's the more likely buyout candidate. | The question now is whether the clinical-stage biotech could bounce back, especially since more definitive data is due on the Lenti-D program in a few weeks at the American Academy of Neurology conference. Whatever that data shows -- or analysts assume it to show -- Bluebird has another asset much more important to big pharma buyers. Along with Kite Pharma and Juno Therapeutics , Bluebird is a leader in CAR-T therapies, often touted as the next big thing in cancer treatment. |
36221.0 | 2016-03-31 00:00:00 UTC | 10 Biotech Stocks With Big Catalysts Coming This Quarter | ACAD | https://www.nasdaq.com/articles/10-biotech-stocks-with-big-catalysts-coming-this-quarter-2016-03-31 | nan | nan | InvestorPlaceInvestorPlace - Stock Market News, Stock Advice & Trading Tips
To say biotech stocks suffered a rough second half of 2015 would be an understatement. It was awful. The first quarter of 2016 wasn't exactly stellar either, even with the group testing the bullish waters a few times in March.
Source: Flickr
While Valeant Pharmaceuticals Intl Inc ( VRX ) and a couple of other specialty drugmakers have been specifically targeted, traders have wondered if the entire industry is about to hit a regulatory headwind.
The dust cloud is starting to settle, however, and while plenty of biotech stocks still have trouble ahead, some are ready to rebound.
10 Cheap Stocks to Buy for $10 or Less
With that as the backdrop, here's a closer look at ten biotech stocks that have catalysts in the queue for the second quarter that may well shake them out of their ruts … or put them back in one.
Biotech Stocks to Watch in Q2: Acadia Pharmaceuticals Inc. (ACAD)
Despite the dire need, there just aren't any game-changing drugs that treat Parkinson's disease.
That's why the FDA has given priority review to Nuplazid (pimavanserin), from Acadia Pharmaceuticals Inc. ( ACAD ), for Parkinson's disease psychosis. The scheduled decision date from the administration is May 1st .
Nuplazid is a selective serotonin inverse agonist that targets 5-HT2A receptors. In plain English, HT2A receptors may regulate the brain's chemistry in a way that it's not being regulated in PDP patients . Nuplazid met all of its targeted endpoints in Phase 3 of its trial, and Acadia Pharmaceuticals says those results were statistically significant.
If the drug is approved - and between the priority review, its breakthrough designation and a yes recommendation from an advisory panel , the odds look good - it would be the first viable therapy for Parkinson's disease psychosis, making ACAD one of the hottest biotech stocks of 2016. Though not all Parkinson's patients have PDP, an estimated 40% of them do.
The underserved Parkinson's disease market, in total, is estimated to be worth roughly $2.6 billion per year.
Biotech Stocks to Watch in Q2: Exelixis, Inc. (EXEL)
A priority review from the Food & Drug Administration is never a guarantee of an approval. On the other hand, an accelerated approval effort from the FDA has worked in favor of more biotech stocks than it has worked against; there's a reason the FDA sees the urgency.
That bodes well for Exelixis, Inc. ( EXEL ), which has a June 22nd priority Prescription Drug User Fee Act date for Cabozantinib as a therapy for metastatic renal cell cancer.
10 Best Stocks In the S&P 500 So Far
Cabozantinib is a small-molecule tyrosine kinase inhibitor that takes aim as the vascular endothelial growth factor receptor. In clinical trials it was 42% more effective as an RCC therapy than the current standard of care, everolimus.
Biotech Stocks to Watch in Q2: Tesaro Inc (TSRO)
While several biotech stocks could heat up or cool off very quickly in Q2, by a sheer calendar-based coincidence, Clovis Oncology Inc ( CLVS ) is going to take traders on a roller-coaster ride over the course of the next three months.
That's because an FDA advisory panel is slated to make a recommendation to the regulator on Rociletinib - as a therapy for lung cancer - on April 12th, and the administration will either take or reject that advice (by approving or not approving the drug) on June 28th.
Rociletinib is a treatment for mutant epidermal growth factor receptor (EFGR)-positive non-small cell lung cancer in patients who develop a T790M mutation. The therapy has demonstrated impressive efficacy, with an overall response rate of 67% and a disease-control rate of 89%.
9 Hot Stocks to Toss in the Trash Before Q2
The fact that Rociletinib was also given a breakthrough therapy designation bolsters the odds of an approval, though obviously there are no guarantees.
Biotech Stocks to Watch in Q2: GW Pharmaceuticals PLC- ADR (GWPH)
If the name GW Pharmaceuticals PLC- ADR ( GWPH ) rings a bell, but you're not sure why, it's one of several biotechs working on cannabinoid-based prescription drugs.
Unlike most of the other biotech companies working on ways to convert cannabis to medicine, however, GWPH is one of the few cannabinoid-centric biotech stocks that traders can afford to take seriously.
In any case, the company has two research and development updates expected sometime in the second quarter of 2016. One of those updates will tell the market how the phase 2 trial of GWP-42004 as a therapy for type 2 diabetes is proceeding. GWP-42004 appears to be an oral GLP-1 (glucagon-like peptide-1) secretagogue , and has shown promise thus far.
We may also get a phase 3 trial update on Epidiolex as a treatment for Lennox-Gastaut syndrome during Q2 .
Epidiolex has already shown strong efficacy as a treatment for Dravet syndrome, and if approved, Epidiolex would be the first FDA approved treatment specifically for the disease.
Biotech Stocks to Watch in Q2: GlobeImmune Inc (GBIM)
While the biopharma industry has made hepatitis C public enemy No.1 over the past year or so, it has mostly taken its eye off of hepatitis B. Not GlobeImmune Inc ( GBIM ) though.
GlobeImmune is in the midst of phase 2 trials of GS-4774 as a therapy for chronic HBV. Another round of results for that trial are due sometime in Q2.
10 Stellar Dow Jones Stocks to Buy for Q2
Hepatitis B isn't a massive market. It's only expected to be worth $3.5 billion by 2021 . It's another underserved market though, and if GBIM can come up with something even modestly impressive, it could be a big win.
Biotech Stocks to Watch in Q2: Achillion Pharmaceuticals, Inc. (ACHN)
As was noted, if there has been one overarching theme within the world of biotech stock, hepatitis C would be it … with most of that attention devoted to Harvoni and Sovaldi, from Gilead Sciences, Inc. ( GILD ). If the news in the lineup for Achillion Pharmaceuticals, Inc. ( ACHN ) this quarter pans out, though, ACHN could steal some of Gilead's thunder.
Sometime during Q2, the company is supposed to update the market on its phase 2 trial of odalasvir, AL-335, and simeprevir - in combination - as a treatment of HCV.
Actually, Johnson & Johnson ( JNJ ) is leading the charge, having licensed part of the therapy from Achillion Pharmaceuticals . The deal, however, could be very lucrative for ACHN if JNJ sees the expected efficacy.
Biotech Stocks to Watch in Q2: Kite Pharma Inc (KITE)
There are several non-Hodgkin Lymphoma drugs on the market, and in development. None of them are wildly impressive, however. It remains to be seen if KTE-C19, from Kite Pharma Inc ( KITE ), will be that game-changer, but we may get a better idea of its potential sometime in the second quarter.
That's because KITE is going to offer an interim update on its phase 2 trial of the treatment sometime within the next three months . Though no firm date has been set, the company will likely announce a release date ahead of time.
7 A-Rated Stocks to Buy and Hold for Q2 and Beyond!
KTE-C19 is one of a handful of CAR T cell therapies . CARs, or chimeric antigen receptors, are proteins that allow immune cells called T cells to recognize a specific protein, or antigen, on tumor cells . A patient's own T cells can be collected and engineered to develop CARs on their surface, cultivated and then reinjected into a cancer patient's body where they can more effectively combat cancer.
Biotech Stocks to Watch in Q2: Array Biopharma Inc (ARRY)
The second quarter is going to be an especially busy one for Array Biopharma Inc ( ARRY ). It has two phase 3 trial updates in the hopper, plus - if all goes as planned - an NDA filing. There are no firm dates for any of the potential catalysts, though Array should give pre-announcement warnings for the phase 3 reports.
The new drug application in the lineup is for Binimetinib (MEK162), as a therapy for melanoma . One of the trial updates will look at the results for Selumetinib as a treatment for thyroid cancer.
The likely mover and shaker in the bunch, however, is going to be the look at how MEK162 is faring as a treatment for BRAF-mutated melanoma.
Biotech Stocks to Watch in Q2: Ultragenyx Pharmaceutical Inc (RARE)
Ultragenyx Pharmaceutical Inc ( RARE ) doesn't have just one big announcement in the hopper for the second quarter of 2016, but two: rhGUS and KRN23.
RhGUS is currently in phase 3 trials as a therapy for Mucopolysaccharidosis 7 (or Sly syndrome), which is a an enzyme-deficiency disease that can cause skeletal defects and tissue and organ problems. It's not a big market, but it's a worthy market without a ton of competition.
KRN23 is a monoclonal antibody being tested as a treatment for a couple of different indications, but the drug's efficacy as a therapy for tumor-induced osteomalacia (TIO) is in sharper focus right now. In simplest terms, TIO causes a vitamin D deficiency, which can create a variety of health problems.
8 High-Quality, High-Dividend Stocks to Buy for Q2
Note that there's no firm date (yet) for these updates. The company has only said it expected to post news on rhGUS sometime in mid-2016, and news about KRN23 during the first half of the year. It will likely give the market a "heads up" beforehand, however.
As of this writing, James Brumley did not hold a position in any of the aforementioned securities.
The post 10 Biotech Stocks With Big Catalysts Coming This Quarter appeared first on InvestorPlace .
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | If the drug is approved - and between the priority review, its breakthrough designation and a yes recommendation from an advisory panel , the odds look good - it would be the first viable therapy for Parkinson's disease psychosis, making ACAD one of the hottest biotech stocks of 2016. Biotech Stocks to Watch in Q2: Acadia Pharmaceuticals Inc. (ACAD) Despite the dire need, there just aren't any game-changing drugs that treat Parkinson's disease. That's why the FDA has given priority review to Nuplazid (pimavanserin), from Acadia Pharmaceuticals Inc. ( ACAD ), for Parkinson's disease psychosis. | That's why the FDA has given priority review to Nuplazid (pimavanserin), from Acadia Pharmaceuticals Inc. ( ACAD ), for Parkinson's disease psychosis. Biotech Stocks to Watch in Q2: Acadia Pharmaceuticals Inc. (ACAD) Despite the dire need, there just aren't any game-changing drugs that treat Parkinson's disease. Nuplazid met all of its targeted endpoints in Phase 3 of its trial, and Acadia Pharmaceuticals says those results were statistically significant. | Biotech Stocks to Watch in Q2: Acadia Pharmaceuticals Inc. (ACAD) Despite the dire need, there just aren't any game-changing drugs that treat Parkinson's disease. That's why the FDA has given priority review to Nuplazid (pimavanserin), from Acadia Pharmaceuticals Inc. ( ACAD ), for Parkinson's disease psychosis. Nuplazid met all of its targeted endpoints in Phase 3 of its trial, and Acadia Pharmaceuticals says those results were statistically significant. | Biotech Stocks to Watch in Q2: Acadia Pharmaceuticals Inc. (ACAD) Despite the dire need, there just aren't any game-changing drugs that treat Parkinson's disease. That's why the FDA has given priority review to Nuplazid (pimavanserin), from Acadia Pharmaceuticals Inc. ( ACAD ), for Parkinson's disease psychosis. Nuplazid met all of its targeted endpoints in Phase 3 of its trial, and Acadia Pharmaceuticals says those results were statistically significant. |
36222.0 | 2016-03-30 00:00:00 UTC | Midday Update: Wall Street Still Building on Post-Yellen Gains; Dow Hits New High for 2016 | ACAD | https://www.nasdaq.com/articles/midday-update-wall-street-still-building-post-yellen-gains-dow-hits-new-high-2016-2016-03 | nan | nan | Wall Street was continuing to produce more mileage from dovish remarks by Federal Reserve Chair Janet Yellen on Tuesday before the Economic Club of New York. The Dow Jones Industrial Average has risen to its highest level so far this year, although the blue-chip index stall and then retreated after running into resistance at its 17,800 level. All 10 sectors of the S&P 500 also were in the plus column today, led by gains for financial and technology stocks.
Compounding the bullish tone across global financial markets is today's rebound in oil, fueled by a weaker dollar as well as increase in stockpiles and falling production following the Energy Information Administration report that showed a seventh straight weekly increase in crude oil supply.
Chicago Fed President Charles Evans also echoed Yellen's sentiments in a television interview on CNBC this morning, saying monetary accommodation remained appropriate and that an April rate hike would be a hard sell. Yellen and Evans' remarks have eclipsed statements last week from other Fed officials that appeared to suggest the central bank would raise interest rates in April.
Wednesday'seconomic calendarwas very light, with Automated Data Processing reporting a 200,000 increase in private payrolls in March, trailing estimates looking for a 203,000 gain. February hiring also was revised downward to 205,000 new workers from the 214,000 originally reported.
European markets played catch-up to the post-Yellen rally in the U.S. and posting significant gains across the continent. Demand for equities is also being supported by the upcoming launch of the European Central Bank's expanded quantitative easing program on Friday, which is pushing down EU-zone bond yields and luring investors into equity assets.
Crude oil was up 61 cents to $38.88 per barrel. Natural gas was down a penny to $1.98 per 1 million BTU. Gold was down $10.20 to $1,227.40 per ounce, while silver was down 1 cent to $15.22 per ounce. Copper was down 3 cents to $2.19 per pound.
Among energy ETFs, the United States Oil Fund was down 0.20% to $9.78 with the United States Natural Gas Fund was down 0.20% to $6.71. Among precious-metal funds, the Market Vectors Gold Miners ETF was down 2.97% to 19.92 while SPDR Gold Shares were down 1.35% to $117.18. The iShares Silver Trust was down 0.82% to $14.49.
Here's where the U.S. markets stood at mid-day:
NYSE Composite Index up 51.95 (+0.51%) to 10,242.36
Dow Jones Industrial Average up 67.84 (+0.38%) to 17,700.95
S&P 500 up 7.27 (+0.35%) to 2,062.28
Nasdaq Composite Index up 16.42 (+0.34%) to 4,863.04
GLOBAL SENTIMENT
Nikkei 225 Index down 1.31%
Hang Seng Index up 2.15%
Shanghai China Composite Index up 2.77%
FTSE 100 Index up 1.59%
CAC 40 up 1.78%
DAX up 1.60%
NYSE SECTOR INDICES
NYSE Energy Sector Index up 0.86%
NYSE Financial Sector Index up 0.77%
NYSE Healthcare Sector Index up 0.12%
UPSIDE MOVERS
(+) VICL (+10.36%) Gets FDA fast track status for invasive aspergillosis drug
(+) ACAD (+9.45%) FDA rules that treatment with pimavanserin for psychosis associated with Parkinson's outweighed the risks
(+) ATNM (+3.45%) FDA granted orphan drug status to Iomab-B for acute myloid leukemia
(+) SYMX (+4.76%) Yima joint venture plant received performance test certificate, exceeding performance targets
DOWNSIDE MOVERS
(-) LODE (-14.73%) Prices sale of 10 million shares at $0.35 each
(-) VRNT (-12.36%) Q4 results miss views
(-) OPK (-7.64%) Gets complete response letter from FDA on NDA for secondary hyperparathyroidism drug
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
Copyright (C) 2016 MTNewswires.com. All rights reserved. Unauthorized reproduction is strictly prohibited.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | (+) VICL (+10.36%) Gets FDA fast track status for invasive aspergillosis drug (+) ACAD (+9.45%) FDA rules that treatment with pimavanserin for psychosis associated with Parkinson's outweighed the risks (+) ATNM (+3.45%) FDA granted orphan drug status to Iomab-B for acute myloid leukemia (+) SYMX (+4.76%) Yima joint venture plant received performance test certificate, exceeding performance targets Wall Street was continuing to produce more mileage from dovish remarks by Federal Reserve Chair Janet Yellen on Tuesday before the Economic Club of New York. Chicago Fed President Charles Evans also echoed Yellen's sentiments in a television interview on CNBC this morning, saying monetary accommodation remained appropriate and that an April rate hike would be a hard sell. | (+) VICL (+10.36%) Gets FDA fast track status for invasive aspergillosis drug (+) ACAD (+9.45%) FDA rules that treatment with pimavanserin for psychosis associated with Parkinson's outweighed the risks (+) ATNM (+3.45%) FDA granted orphan drug status to Iomab-B for acute myloid leukemia (+) SYMX (+4.76%) Yima joint venture plant received performance test certificate, exceeding performance targets Among energy ETFs, the United States Oil Fund was down 0.20% to $9.78 with the United States Natural Gas Fund was down 0.20% to $6.71. Here's where the U.S. markets stood at mid-day: NYSE Composite Index up 51.95 (+0.51%) to 10,242.36 Dow Jones Industrial Average up 67.84 (+0.38%) to 17,700.95 S&P 500 up 7.27 (+0.35%) to 2,062.28 Nasdaq Composite Index up 16.42 (+0.34%) to 4,863.04 | (+) VICL (+10.36%) Gets FDA fast track status for invasive aspergillosis drug (+) ACAD (+9.45%) FDA rules that treatment with pimavanserin for psychosis associated with Parkinson's outweighed the risks (+) ATNM (+3.45%) FDA granted orphan drug status to Iomab-B for acute myloid leukemia (+) SYMX (+4.76%) Yima joint venture plant received performance test certificate, exceeding performance targets Compounding the bullish tone across global financial markets is today's rebound in oil, fueled by a weaker dollar as well as increase in stockpiles and falling production following the Energy Information Administration report that showed a seventh straight weekly increase in crude oil supply. NYSE Energy Sector Index up 0.86% NYSE Financial Sector Index up 0.77% NYSE Healthcare Sector Index up 0.12% | (+) VICL (+10.36%) Gets FDA fast track status for invasive aspergillosis drug (+) ACAD (+9.45%) FDA rules that treatment with pimavanserin for psychosis associated with Parkinson's outweighed the risks (+) ATNM (+3.45%) FDA granted orphan drug status to Iomab-B for acute myloid leukemia (+) SYMX (+4.76%) Yima joint venture plant received performance test certificate, exceeding performance targets Gold was down $10.20 to $1,227.40 per ounce, while silver was down 1 cent to $15.22 per ounce. Among energy ETFs, the United States Oil Fund was down 0.20% to $9.78 with the United States Natural Gas Fund was down 0.20% to $6.71. |
36223.0 | 2016-03-30 00:00:00 UTC | Mid-Day Market Update: ACADIA Pharmaceuticals Rises Following FDA Panel Vote; Verint Systems Shares Slide | ACAD | https://www.nasdaq.com/articles/mid-day-market-update-acadia-pharmaceuticals-rises-following-fda-panel-vote-verint-systems | nan | nan | Midway through trading Wednesday, the Dow traded up 0.55 percent to 17,729.78 while the NASDAQ gained 0.54 percent to 4,872.85. The S&P also rose, gaining 0.52 percent to 2,065.63.
Leading and Lagging Sectors
On Wednesday, energy shares jumped by 1.08 percent. Meanwhile, top gainers in the sector included Isramco, Inc. (NASDAQ: ISRL ), up 8 percent, and InterOil Corporation ( USA ) (NYSE: IOC ), up 14 percent.
In trading on Wednesday, healthcare shares rose by just 0.2 percent. Meanwhile, top losers in the sector included Opko Health Inc. (NYSE: OPK ), down 8 percent, and Athersys, Inc. (NASDAQ: ATHX ), down 7 percent.
Top Headline
Lululemon Athletica inc. (NASDAQ: LULU ) reported better-than-expected results for its fourth quarter on Wednesday.
Lululemon posted quarterly earnings of $0.85 per share on revenue of $704.3 million. However, analysts were expecting earnings of $0.80 per share on revenue of $693.4 million.
Lululemon expects FY 2016 earnings of $2.05 to $2.15 per share, and revenue of $2.285 billion to $2.335 billion. Analysts projected earnings of $2.15 per share and revenue of $2.33 billion.
Equities Trading UP
Xtant Medical Holdings Inc (NYSE: XTNT ) shares shot up 16 percent to $2.85 after the company reported the FDA clearance of the Xspan laminoplasty fixation system.
Shares of Argos Therapeutics Inc (NASDAQ: ARGS ) got a boost, shooting up 16 percent to $7.90 on Q4 results. Argos Therapeutics reported a Q4 loss of $(0.84) per share on revenue of $74,000.
ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD ) shares were also up, gaining 10 percent to $26.22. A U.S. Food and Drug Administration panel voted 12-2 on Tuesday that Acadia's drug pimavanserin, a treatment for psychosis associated with Parkinson's disease, outweighed the risks of treatment.
Equities Trading DOWN
ContraVir Pharmaceuticals Inc (NASDAQ: CTRV ) shares dropped 25 percent to $1.25 after the company reported a proposed stock and warrant offering to purchase stock.
Shares of Verint Systems Inc. (NASDAQ: VRNT ) were down 12 percent to $30.88 after the company reported downbeat earnings for its fourth quarter and issued a weak forecast. The company also reported a $150 million buyback program.
FormFactor, Inc. (NASDAQ: FORM ) was down, falling around 9 percent to $7.18 after the company lowered its outlook for the first quarter.
Commodities
In commodity news, oil traded up 0.44 percent to $38.45, while gold traded down 0.81 percent to $1,227.50.
Silver traded down 0.09 percent Wednesday to $15.22, while copper fell 1.11 percent to $2.19.
Eurozone
European shares were higher today. The eurozone's STOXX 600 rose 1.30 percent, the Spanish Ibex Index gained 0.27 percent, while Italy's FTSE MIB Index surged 1.12 percent. Meanwhile, the German DAX gained 1.60 percent, and the French CAC 40 gained 1.78 percent, while U.K. shares rose 1.59 percent.
Economics
The private sector added 200,000 jobs in March, according to ADP. However, economists were expecting a gain of 194,000 jobs.
Crude oil supplies gained 2.3 million barrels for the week ended March 25, the U.S. Energy Information Administration reported. However, analysts were expecting an increase of 2 million barrels. Gasoline supplies slipped 2.5 million barrels, while distillate stockpiles declined 1.1 million barrels last week.
© 2016 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Free Trading Education - Check out the free events taking place on Marketfy this week. Spaces are limited. Sign up today.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD ) shares were also up, gaining 10 percent to $26.22. A U.S. Food and Drug Administration panel voted 12-2 on Tuesday that Acadia's drug pimavanserin, a treatment for psychosis associated with Parkinson's disease, outweighed the risks of treatment. Equities Trading UP Xtant Medical Holdings Inc (NYSE: XTNT ) shares shot up 16 percent to $2.85 after the company reported the FDA clearance of the Xspan laminoplasty fixation system. | ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD ) shares were also up, gaining 10 percent to $26.22. A U.S. Food and Drug Administration panel voted 12-2 on Tuesday that Acadia's drug pimavanserin, a treatment for psychosis associated with Parkinson's disease, outweighed the risks of treatment. Top Headline Lululemon Athletica inc. (NASDAQ: LULU ) reported better-than-expected results for its fourth quarter on Wednesday. | ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD ) shares were also up, gaining 10 percent to $26.22. A U.S. Food and Drug Administration panel voted 12-2 on Tuesday that Acadia's drug pimavanserin, a treatment for psychosis associated with Parkinson's disease, outweighed the risks of treatment. Midway through trading Wednesday, the Dow traded up 0.55 percent to 17,729.78 while the NASDAQ gained 0.54 percent to 4,872.85. | ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD ) shares were also up, gaining 10 percent to $26.22. A U.S. Food and Drug Administration panel voted 12-2 on Tuesday that Acadia's drug pimavanserin, a treatment for psychosis associated with Parkinson's disease, outweighed the risks of treatment. Midway through trading Wednesday, the Dow traded up 0.55 percent to 17,729.78 while the NASDAQ gained 0.54 percent to 4,872.85. |
36224.0 | 2016-03-30 00:00:00 UTC | Why Acadia Pharmaceuticals' Stock Is Rocketing Higher Today | ACAD | https://www.nasdaq.com/articles/why-acadia-pharmaceuticals-stock-rocketing-higher-today-2016-03-30 | nan | nan | ACAD data by YCharts .
Now what : The FDA is expected to hand down its final decision on Nuplazid by May 1. While the agency doesn't have to follow the recommendation of this external panel of experts, the FDA has typically approved drugs that garner favorable opinions from an advisory committee. In short, the chances of Nuplazid getting the green light from the FDA look fairly strong following this overwhelmingly positive vote.
As such, I would expect short-sellers to start to hit the exits over the next few weeks, especially since some analysts are forecasting that the drug could generate peak sales in excess of $3 billion. Acadia's stock appears primed for a huge short squeeze after this positive regulatory development. Stay tuned.
This iSecret stock could make this pop look tiny
The world's biggest tech company forgot to show you something, but a few Wall Street analysts and the Fool didn't miss a beat: There's a small company that's powering their brand-new gadgets and the coming revolution in technology. And we think its stock price has nearly unlimited room to run for early in-the-know investors! To be one of them, just click here .
The article Why Acadia Pharmaceuticals' Stock Is Rocketing Higher Today originally appeared on Fool.com.
George Budwell has no position in any stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. Try any of our Foolish newsletter services free for 30 days . We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy .
Copyright © 1995 - 2016 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy .
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | ACAD data by YCharts . Acadia's stock appears primed for a huge short squeeze after this positive regulatory development. The article Why Acadia Pharmaceuticals' Stock Is Rocketing Higher Today originally appeared on Fool.com. | Acadia's stock appears primed for a huge short squeeze after this positive regulatory development. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. ACAD data by YCharts . | ACAD data by YCharts . Acadia's stock appears primed for a huge short squeeze after this positive regulatory development. The article Why Acadia Pharmaceuticals' Stock Is Rocketing Higher Today originally appeared on Fool.com. | Acadia's stock appears primed for a huge short squeeze after this positive regulatory development. ACAD data by YCharts . The article Why Acadia Pharmaceuticals' Stock Is Rocketing Higher Today originally appeared on Fool.com. |
36225.0 | 2016-03-30 00:00:00 UTC | US Stocks Eye Higher Open on Yellen Remarks; ADP Report Shows 200,000 Jobs Added in March | ACAD | https://www.nasdaq.com/articles/us-stocks-eye-higher-open-yellen-remarks-adp-report-shows-200000-jobs-added-march-2016-03 | nan | nan | U.S. stocks were set to extend gains Wednesday in the wake of Federal Reserve Chair Janet Yellen's remarks Tuesday while the ADP employment report showed a solid increase in private payrolls ahead of the Bureau of Labor Statistics' report on Friday.
Yellen poured some cold water on other Fed officials' recent statements that have implied that monetary policy makers might be inclined to raise rates again as soon as April.
Meanwhile, alternate Federal Open Market Committee member, Chicago Fed Charles Evans said Wednesday that the threshold is high for an April hike but that the rate could move again in June if the labor market continues to show strength, according to CNBC.
In economic data, the ADP employment report showed private payrolls increased 200,000 in March compared to the expected 203,000 increase. For February, it was revised down to 205,000 from 214,000. The report is not always an indicator of the government's employment report. That is out Friday and is expected to show 210,000 non-farm payrolls jobs were added in the March.
At 10:30 a.m., the Energy Information Administration's petroleum status report is expected to show a 9.4 million increase in crude oil inventories in the week to March 25, according to data compiled by Econoday.
In equities, Acadia Pharmaceuticals ( ACAD ) was higher 21% in recent pre-market trade after saying the U.S. Food and Drug Administration's Psychopharmacologic Drugs Advisory Committee voted 12 to 2 that the benefits of NUPLAZID (pimavanserin) for the treatment of psychosis associated with Parkinson's disease outweigh the risks of treatment.
U.S. PRE-MARKET INDICATORS
-Dow Jones Industrial up 0.54%
-S&P 500 futures up 0.46%
-Nasdaq 100 futures up 0.65%
-Nasdaq 100 pre-market indicator up 0.39%
GLOBAL SENTIMENT
Nikkei down 1.31%
Hang Seng up 2.15%
Shanghai Composite up 2.77%
FTSE-100 up 1.62%
DAX-30 up 1.57%
PRE-MARKET SECTOR WATCH
(+) Large cap tech: unchanged to higher
(+/-) Chip stocks: unchanged
(+) Software stocks: unchanged to higher
(+) Hardware stocks: unchanged to higher
(+) Internet stocks: higher
(+) Oil stocks: unchanged to higher
(+/-) Biotech: unchanged
(+/-) Drug stocks: mixed
(+) Financial stocks: unchanged to higher
(+/-) Retail stocks: unchanged
(+) Industrial stocks: unchanged to higher
(+) Airlines: unchanged to higher
(+) Autos: unchanged to higher
UPSIDE MOVERS
(+) AAPL (+1.3%) Cowen upgrades to outperform vs market perform, raises PT to $135 vs $125
(+) VICL (+15.8%) Gets FDA fast track status for invasive aspergillosis drug
(+) VRX (+4.2%) Starts process to obtain amendment, waiver to credit facilty
(+) LULU (+5.9%) Q4 results beat views
(+) GALE (+5.7%) Extends gains made Tuesday on NeuVax vaccine trial results
(+) QIHU (+0.7%) Shareholders OK merger deal
(+) PYPL (+1.8%) Bernstein initiates with market perform
(+) SHAK (+4.0%) Longbow upgrades to buy from neutral
(+) ICPT (+2.6%) Credit Suisse initiates with outperform, $200 PT
DOWNSIDE MOVERS
(-) STOR (-2.2%) Prices secondary share sale at 3% discount
(-) OPK (-9.0%) Gets complete response letter from FDA on NDA for secondary hyperparathyroidism drug
(-) LODE (-18.6%) Prices sale of 10 million shares at $0.35 each
(-) VRNT (-13.3%) Q4 results miss views
(-) SPKE (-5.0%) Shareholder to sell 1.5 million shares in secondary offering
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
Copyright (C) 2016 MTNewswires.com. All rights reserved. Unauthorized reproduction is strictly prohibited.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | In equities, Acadia Pharmaceuticals ( ACAD ) was higher 21% in recent pre-market trade after saying the U.S. Food and Drug Administration's Psychopharmacologic Drugs Advisory Committee voted 12 to 2 that the benefits of NUPLAZID (pimavanserin) for the treatment of psychosis associated with Parkinson's disease outweigh the risks of treatment. Yellen poured some cold water on other Fed officials' recent statements that have implied that monetary policy makers might be inclined to raise rates again as soon as April. At 10:30 a.m., the Energy Information Administration's petroleum status report is expected to show a 9.4 million increase in crude oil inventories in the week to March 25, according to data compiled by Econoday. | In equities, Acadia Pharmaceuticals ( ACAD ) was higher 21% in recent pre-market trade after saying the U.S. Food and Drug Administration's Psychopharmacologic Drugs Advisory Committee voted 12 to 2 that the benefits of NUPLAZID (pimavanserin) for the treatment of psychosis associated with Parkinson's disease outweigh the risks of treatment. In economic data, the ADP employment report showed private payrolls increased 200,000 in March compared to the expected 203,000 increase. (+) Large cap tech: unchanged to higher (+/-) Chip stocks: unchanged (+) Software stocks: unchanged to higher (+) Hardware stocks: unchanged to higher (+) Internet stocks: higher (+) Oil stocks: unchanged to higher (+/-) Biotech: unchanged (+/-) Drug stocks: mixed (+) Financial stocks: unchanged to higher (+/-) Retail stocks: unchanged (+) Industrial stocks: unchanged to higher (+) Airlines: unchanged to higher (+) Autos: unchanged to higher | In equities, Acadia Pharmaceuticals ( ACAD ) was higher 21% in recent pre-market trade after saying the U.S. Food and Drug Administration's Psychopharmacologic Drugs Advisory Committee voted 12 to 2 that the benefits of NUPLAZID (pimavanserin) for the treatment of psychosis associated with Parkinson's disease outweigh the risks of treatment. U.S. stocks were set to extend gains Wednesday in the wake of Federal Reserve Chair Janet Yellen's remarks Tuesday while the ADP employment report showed a solid increase in private payrolls ahead of the Bureau of Labor Statistics' report on Friday. (+) Large cap tech: unchanged to higher (+/-) Chip stocks: unchanged (+) Software stocks: unchanged to higher (+) Hardware stocks: unchanged to higher (+) Internet stocks: higher (+) Oil stocks: unchanged to higher (+/-) Biotech: unchanged (+/-) Drug stocks: mixed (+) Financial stocks: unchanged to higher (+/-) Retail stocks: unchanged (+) Industrial stocks: unchanged to higher (+) Airlines: unchanged to higher (+) Autos: unchanged to higher | In equities, Acadia Pharmaceuticals ( ACAD ) was higher 21% in recent pre-market trade after saying the U.S. Food and Drug Administration's Psychopharmacologic Drugs Advisory Committee voted 12 to 2 that the benefits of NUPLAZID (pimavanserin) for the treatment of psychosis associated with Parkinson's disease outweigh the risks of treatment. U.S. stocks were set to extend gains Wednesday in the wake of Federal Reserve Chair Janet Yellen's remarks Tuesday while the ADP employment report showed a solid increase in private payrolls ahead of the Bureau of Labor Statistics' report on Friday. In economic data, the ADP employment report showed private payrolls increased 200,000 in March compared to the expected 203,000 increase. |
36226.0 | 2016-03-30 00:00:00 UTC | Pre-Market Most Active for Mar 30, 2016 : STOR, ETE, FCAU, BAC, NOK, RIG, ACAD, TVIX, AAPL, YHOO, VOD, FB | ACAD | https://www.nasdaq.com/articles/pre-market-most-active-mar-30-2016-stor-ete-fcau-bac-nok-rig-acad-tvix-aapl-yhoo-vod-fb | nan | nan | The NASDAQ 100 Pre-Market Indicator is up 17.48 to 4,485.2. The total Pre-Market volume is currently 14,405,438 shares traded.
The following are the most active stocks for the pre-market session :
STORE Capital Corporation ( STOR ) is -0.7 at $25.28, with 1,439,251 shares traded. As reported by Zacks, the current mean recommendation for STOR is in the "buy range".
Energy Transfer Equity, L.P. ( ETE ) is +0.17 at $6.99, with 1,436,045 shares traded. ETE's current last sale is 58.25% of the target price of $12.
Fiat Chrysler Automobiles N.V. ( FCAU ) is +0.25 at $8.07, with 1,269,854 shares traded. As reported in the last short interest update the days to cover for FCAU is 15.952519; this calculation is based on the average trading volume of the stock.
Bank of America Corporation ( BAC ) is +0.09 at $13.51, with 867,542 shares traded. As reported by Zacks, the current mean recommendation for BAC is in the "buy range".
Nokia Corporation ( NOK ) is +0.14 at $6.03, with 857,714 shares traded. NOK's current last sale is 86.14% of the target price of $7.
Transocean Ltd. ( RIG ) is -0.15 at $8.73, with 722,064 shares traded. Over the last four weeks they have had 3 up revisions for the earnings forecast, for the fiscal quarter ending Mar 2016. The consensus EPS forecast is $0.27. RIG's current last sale is 109.13% of the target price of $8.
ACADIA Pharmaceuticals Inc. ( ACAD ) is +5.12 at $28.93, with 646,845 shares traded. As reported in the last short interest update the days to cover for ACAD is 8.197547; this calculation is based on the average trading volume of the stock.
region ( TVIX ) is -0.165 at $4.44, with 461,622 shares traded., following a 52-week high recorded in prior regular session.
Apple Inc. ( AAPL ) is +1.43 at $109.11, with 415,490 shares traded. As reported by Zacks, the current mean recommendation for AAPL is in the "buy range".
Yahoo! Inc. ( YHOO ) is +0.28 at $36.60, with 260,685 shares traded. As reported by Zacks, the current mean recommendation for YHOO is in the "buy range".
Vodafone Group Plc ( VOD ) is +0.33 at $32.11, with 217,974 shares traded. As reported by Zacks, the current mean recommendation for VOD is in the "buy range".
Facebook, Inc. ( FB ) is +0.5 at $116.64, with 194,528 shares traded. As reported by Zacks, the current mean recommendation for FB is in the "buy range".
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | As reported in the last short interest update the days to cover for ACAD is 8.197547; this calculation is based on the average trading volume of the stock. ACADIA Pharmaceuticals Inc. ( ACAD ) is +5.12 at $28.93, with 646,845 shares traded. The following are the most active stocks for the pre-market session : STORE Capital Corporation ( STOR ) is -0.7 at $25.28, with 1,439,251 shares traded. | As reported in the last short interest update the days to cover for ACAD is 8.197547; this calculation is based on the average trading volume of the stock. ACADIA Pharmaceuticals Inc. ( ACAD ) is +5.12 at $28.93, with 646,845 shares traded. The total Pre-Market volume is currently 14,405,438 shares traded. | ACADIA Pharmaceuticals Inc. ( ACAD ) is +5.12 at $28.93, with 646,845 shares traded. As reported in the last short interest update the days to cover for ACAD is 8.197547; this calculation is based on the average trading volume of the stock. The following are the most active stocks for the pre-market session : STORE Capital Corporation ( STOR ) is -0.7 at $25.28, with 1,439,251 shares traded. | ACADIA Pharmaceuticals Inc. ( ACAD ) is +5.12 at $28.93, with 646,845 shares traded. As reported in the last short interest update the days to cover for ACAD is 8.197547; this calculation is based on the average trading volume of the stock. The following are the most active stocks for the pre-market session : STORE Capital Corporation ( STOR ) is -0.7 at $25.28, with 1,439,251 shares traded. |
36227.0 | 2016-03-30 00:00:00 UTC | US Futures Continue Higher After Yellen Suggests Caution on Rate Increase | ACAD | https://www.nasdaq.com/articles/us-futures-continue-higher-after-yellen-suggests-caution-rate-increase-2016-03-30 | nan | nan | U.S. equities futures pointed to a higher open Wednesday, building on gains made Tuesday after Federal Reserve Chair Janet Yellen called for caution in raising rates further in the current economic environment.
Yellen's remarks poured some cold water on other Fed officials' recent statements that have implied that monetary policy makers might be inclined to raise rates again as soon as April. Alternate Federal Open Market Committee member, Chicago Fed Charles Evans, will speak in New York at 1 p.m. E.T.
At: 8:15 a.m. the ADP employment report is expected to show the private sector added 203,000 jobs in March, up from 214,000 in February and in the consensus range between 165,000 and 225,000, according to data compiled by Econoday.
At 10:30 a.m., the Energy Information Administration's petroleum status report is expected to show a 9.4 million increase in crude oil inventories in the week to March 25.
In equities, Acadia Pharmaceuticals ( ACAD ) surged nearly 25% in recent pre-market trade after saying the U.S. Food and Drug Administration's Psychopharmacologic Drugs Advisory Committee voted 12 to 2 that the
benefits of NUPLAZID (pimavanserin) for the treatment of psychosis associated with Parkinson's disease outweigh the risks of treatment.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
Copyright (C) 2016 MTNewswires.com. All rights reserved. Unauthorized reproduction is strictly prohibited.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | In equities, Acadia Pharmaceuticals ( ACAD ) surged nearly 25% in recent pre-market trade after saying the U.S. Food and Drug Administration's Psychopharmacologic Drugs Advisory Committee voted 12 to 2 that the benefits of NUPLAZID (pimavanserin) for the treatment of psychosis associated with Parkinson's disease outweigh the risks of treatment. U.S. equities futures pointed to a higher open Wednesday, building on gains made Tuesday after Federal Reserve Chair Janet Yellen called for caution in raising rates further in the current economic environment. Yellen's remarks poured some cold water on other Fed officials' recent statements that have implied that monetary policy makers might be inclined to raise rates again as soon as April. | In equities, Acadia Pharmaceuticals ( ACAD ) surged nearly 25% in recent pre-market trade after saying the U.S. Food and Drug Administration's Psychopharmacologic Drugs Advisory Committee voted 12 to 2 that the benefits of NUPLAZID (pimavanserin) for the treatment of psychosis associated with Parkinson's disease outweigh the risks of treatment. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | In equities, Acadia Pharmaceuticals ( ACAD ) surged nearly 25% in recent pre-market trade after saying the U.S. Food and Drug Administration's Psychopharmacologic Drugs Advisory Committee voted 12 to 2 that the benefits of NUPLAZID (pimavanserin) for the treatment of psychosis associated with Parkinson's disease outweigh the risks of treatment. U.S. equities futures pointed to a higher open Wednesday, building on gains made Tuesday after Federal Reserve Chair Janet Yellen called for caution in raising rates further in the current economic environment. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | In equities, Acadia Pharmaceuticals ( ACAD ) surged nearly 25% in recent pre-market trade after saying the U.S. Food and Drug Administration's Psychopharmacologic Drugs Advisory Committee voted 12 to 2 that the benefits of NUPLAZID (pimavanserin) for the treatment of psychosis associated with Parkinson's disease outweigh the risks of treatment. U.S. equities futures pointed to a higher open Wednesday, building on gains made Tuesday after Federal Reserve Chair Janet Yellen called for caution in raising rates further in the current economic environment. Alternate Federal Open Market Committee member, Chicago Fed Charles Evans, will speak in New York at 1 p.m. E.T. |
36228.0 | 2016-03-28 00:00:00 UTC | Midday Update: Stocks Inching Higher After Mixed Data, Sliding Oil Price Encourages Caution | ACAD | https://www.nasdaq.com/articles/midday-update-stocks-inching-higher-after-mixed-data-sliding-oil-price-encourages-caution | nan | nan | Stocks were struggling to erase losses on Monday tied to another down day for oil prices as Wall Street weighs mixed economic data against the possibility for the Federal Reserve raising interest rates next month following hawkish comments from Federal Reserve officials last week and an upward revision to Q4 GDP on Friday. The 10 industry sectors in the S&P 500 were split equally between winners and losers this afternoon, with energy stocks being the laggard and the consumer sector maintaining a modest gain.
Theeconomic calendarkicked off this week with an above-consensus gain in February personal income of 0.2% and in-line 0.1% increase in spending. And although January personal income was left unchanged with a 0.5% rise, personal spending was revised lower to a 0.1% advance from original reports of a 0.5% gain.
The price component of the data also was disappointing as the core price index increased 0.1%, compared with estimates looking for a 0.2% gain while the year-over-year index dropped to 1.7% from 1.8%, slipping farther away from the Fed target of a 2.0% rise.
Meanwhile, pending home sales improved dramatically last month with the index climbing 3.5% to a 109.1 readomg, more than twice expectations for a gain of 1.5%, and more than offsetting a downward revised 3.0% decline in January.
Other data today included the U.S. trade deficit in goods widening to $62.86 billion from a $62.23 billion deficit, and a better-than-expected improvement in the Dallas Fed manufacturing index to negative 13.6 in March from negative 31.8 reading during the prior month, beating estimates of a negative 26.0 score.
European markets are closed for the Easter holiday.
Crude oil was down 34 cents to $39.12 per barrel. Natural gas was down 1 cents to $1.87 per 1 million BTU. Gold was down $1.90 to $1,219.70 per ounce, while silver was up 5 cents to $15.25 per ounce. Copper was up 2 cents to $2.25 per pound.
Among energy ETFs, the United States Oil Fund was down 1.09% to $9.95 with the United States Natural Gas Fund was up 0.16% to $6.41. Among precious-metal funds, the Market Vectors Gold Miners ETF was down 1.39% to 19.19 while SPDR Gold Shares were up 0.21% to $116.58. The iShares Silver Trust was up 0.49% to $14.50.
Here's where the U.S. markets stood at mid-day:
NYSE Composite Index up 17.29 (+0.17%) to 10,103.90
Dow Jones Industrial Average up 47.05 (+0.27%) to 17,562.78
S&P 500 up 4.31 (+0.21%) to 2,040.25
Nasdaq Composite Index up 3.84 (+0.08%) to 4,777.35
GLOBAL SENTIMENT
Nikkei 225 Index up 0.77%
Hang Seng Index down 1.31%
Shanghai China Composite Index down 0.73%
FTSE 100 Index down 1.49%
CAC 40 down 2.13%
DAX down 1.71%
NYSE SECTOR INDICES
NYSE Energy Sector Index down 0.51%
NYSE Financial Sector Index up 0.34%
NYSE Healthcare Sector Index down 0.15%
UPSIDE MOVERS
(+) ALDR (+47.08%) Phase 2 trial of migraine meets primary and secondary endpoints
(+) ACAD (+22.01%) Meeting with FDA on Tuesday regarding UPLAZID treatment for Parkinson's disease-related psychosis
(+) LEU (+8.41%) Signed a $2.3 million contract for uranium centrifuge work at Oak Ridge National Lab
DOWNSIDE MOVERS
(-) VSCP (-10.49%) Biotelemetry ( BEAT ) to buy VirtualScopics for $15.5 million
(-) P (-9.74%) CEO Brian McAndrews to be replaced by founder Tim Westergren, Mike Herring named CFO and Sara Clemens as COO
(-) EGRX (-4.45%) Bendeka failed to gain seven-year orphan-drug exclusivity status from FDA
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
Copyright (C) 2016 MTNewswires.com. All rights reserved. Unauthorized reproduction is strictly prohibited.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | (+) ALDR (+47.08%) Phase 2 trial of migraine meets primary and secondary endpoints (+) ACAD (+22.01%) Meeting with FDA on Tuesday regarding UPLAZID treatment for Parkinson's disease-related psychosis (+) LEU (+8.41%) Signed a $2.3 million contract for uranium centrifuge work at Oak Ridge National Lab Stocks were struggling to erase losses on Monday tied to another down day for oil prices as Wall Street weighs mixed economic data against the possibility for the Federal Reserve raising interest rates next month following hawkish comments from Federal Reserve officials last week and an upward revision to Q4 GDP on Friday. Meanwhile, pending home sales improved dramatically last month with the index climbing 3.5% to a 109.1 readomg, more than twice expectations for a gain of 1.5%, and more than offsetting a downward revised 3.0% decline in January. | (+) ALDR (+47.08%) Phase 2 trial of migraine meets primary and secondary endpoints (+) ACAD (+22.01%) Meeting with FDA on Tuesday regarding UPLAZID treatment for Parkinson's disease-related psychosis (+) LEU (+8.41%) Signed a $2.3 million contract for uranium centrifuge work at Oak Ridge National Lab Among energy ETFs, the United States Oil Fund was down 1.09% to $9.95 with the United States Natural Gas Fund was up 0.16% to $6.41. NYSE Energy Sector Index down 0.51% NYSE Financial Sector Index up 0.34% NYSE Healthcare Sector Index down 0.15% | (+) ALDR (+47.08%) Phase 2 trial of migraine meets primary and secondary endpoints (+) ACAD (+22.01%) Meeting with FDA on Tuesday regarding UPLAZID treatment for Parkinson's disease-related psychosis (+) LEU (+8.41%) Signed a $2.3 million contract for uranium centrifuge work at Oak Ridge National Lab Nikkei 225 Index up 0.77% Hang Seng Index down 1.31% Shanghai China Composite Index down 0.73% FTSE 100 Index down 1.49% CAC 40 down 2.13% DAX down 1.71% NYSE Energy Sector Index down 0.51% NYSE Financial Sector Index up 0.34% NYSE Healthcare Sector Index down 0.15% | (+) ALDR (+47.08%) Phase 2 trial of migraine meets primary and secondary endpoints (+) ACAD (+22.01%) Meeting with FDA on Tuesday regarding UPLAZID treatment for Parkinson's disease-related psychosis (+) LEU (+8.41%) Signed a $2.3 million contract for uranium centrifuge work at Oak Ridge National Lab And although January personal income was left unchanged with a 0.5% rise, personal spending was revised lower to a 0.1% advance from original reports of a 0.5% gain. Gold was down $1.90 to $1,219.70 per ounce, while silver was up 5 cents to $15.25 per ounce. |
36229.0 | 2016-03-28 00:00:00 UTC | Here's Why Acadia Pharmaceuticals' Stock Is Soaring Today | ACAD | https://www.nasdaq.com/articles/heres-why-acadia-pharmaceuticals-stock-soaring-today-2016-03-28 | nan | nan | Image source: Flickr via user jonel hanopol.
What : Shares of Acadia Pharmaceuticals gained more than 20% in early morning trading today on exceptionally high volume. The apparent catalyst behind this move upward was a positive note in the FDA's briefing documents for the company's experimental Parkinson's disease psychosis (PDP) drug called Nuplazid (pimavanserin), which is scheduled to be reviewed by a panel of outside experts tomorrow. Specifically, the agency noted in its internal review:
So what : Short-sellers have been piling into Acadia ahead of Nuplazid's regulatory review, presumably because the drug has failed to meet its primary endpoint in three of its clinical trials and only hit the mark in a single late-stage study.
ACAD data by YCharts .
Now what : The FDA is expected to hand down Nuplazid's regulatory decision by May 1. As there are no approved treatments for PDP at the moment, some analysts think Nuplazid could generate peak sales in excess of $3 billion if approved. So, Acadia's shareholders will clearly want to pay close attention to tomorrow's review.
This iSecret stock could make this pop look tiny
The world's biggest tech company forgot to show you something, but a few Wall Street analysts and the Fool didn't miss a beat: There's a small company that's powering their brand-new gadgets and the coming revolution in technology. And we think its stock price has nearly unlimited room to run for early in-the-know investors! To be one of them, just click here .
The article Here's Why Acadia Pharmaceuticals' Stock Is Soaring Today originally appeared on Fool.com.
George Budwell has no position in any stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. Try any of our Foolish newsletter services free for 30 days . We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy .
Copyright © 1995 - 2016 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy .
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | What : Shares of Acadia Pharmaceuticals gained more than 20% in early morning trading today on exceptionally high volume. Specifically, the agency noted in its internal review: So what : Short-sellers have been piling into Acadia ahead of Nuplazid's regulatory review, presumably because the drug has failed to meet its primary endpoint in three of its clinical trials and only hit the mark in a single late-stage study. ACAD data by YCharts . | The article Here's Why Acadia Pharmaceuticals' Stock Is Soaring Today originally appeared on Fool.com. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. What : Shares of Acadia Pharmaceuticals gained more than 20% in early morning trading today on exceptionally high volume. | Specifically, the agency noted in its internal review: So what : Short-sellers have been piling into Acadia ahead of Nuplazid's regulatory review, presumably because the drug has failed to meet its primary endpoint in three of its clinical trials and only hit the mark in a single late-stage study. What : Shares of Acadia Pharmaceuticals gained more than 20% in early morning trading today on exceptionally high volume. ACAD data by YCharts . | What : Shares of Acadia Pharmaceuticals gained more than 20% in early morning trading today on exceptionally high volume. Specifically, the agency noted in its internal review: So what : Short-sellers have been piling into Acadia ahead of Nuplazid's regulatory review, presumably because the drug has failed to meet its primary endpoint in three of its clinical trials and only hit the mark in a single late-stage study. ACAD data by YCharts . |
36230.0 | 2016-03-28 00:00:00 UTC | Pre-Market Most Active for Mar 28, 2016 : ACAD, SPIL, TVIX, FCX, XIV, FB, BAC, VRX, YHOO, TWTR, PBR, CHK | ACAD | https://www.nasdaq.com/articles/pre-market-most-active-mar-28-2016-acad-spil-tvix-fcx-xiv-fb-bac-vrx-yhoo-twtr-pbr-chk | nan | nan | The NASDAQ 100 Pre-Market Indicator is up 6.5 to 4,412.03. The total Pre-Market volume is currently 1,246,613 shares traded.
The following are the most active stocks for the pre-market session :
ACADIA Pharmaceuticals Inc. ( ACAD ) is +3.12 at $23.43, with 476,906 shares traded. As reported in the last short interest update the days to cover for ACAD is 8.197547; this calculation is based on the average trading volume of the stock.
Siliconware Precision Industries Company, Ltd. ( SPIL ) is -0.1783 at $7.99, with 375,000 shares traded. SPIL's current last sale is 109.18% of the target price of $7.32.
region ( TVIX ) is -0.155 at $5.06, with 347,251 shares traded. This represents a 6.42% increase from its 52 Week Low.
Freeport-McMoran, Inc. ( FCX ) is +0.16 at $10.27, with 108,009 shares traded. FCX's current last sale is 146.71% of the target price of $7.
region ( XIV ) is +0.425 at $24.12, with 103,930 shares traded. This represents a 57% increase from its 52 Week Low.
Facebook, Inc. ( FB ) is +0.55 at $113.60, with 84,259 shares traded. As reported by Zacks, the current mean recommendation for FB is in the "buy range".
Bank of America Corporation ( BAC ) is +0.04 at $13.72, with 76,608 shares traded. As reported by Zacks, the current mean recommendation for BAC is in the "buy range".
Valeant Pharmaceuticals International, Inc. ( VRX ) is +0.1 at $31.19, with 69,075 shares traded. VRX's current last sale is 58.85% of the target price of $53.
Yahoo! Inc. ( YHOO ) is +0.54 at $35.40, with 66,087 shares traded. As reported by Zacks, the current mean recommendation for YHOO is in the "buy range".
Twitter, Inc. ( TWTR ) is +0.08 at $15.99, with 36,691 shares traded. TWTR's current last sale is 74.37% of the target price of $21.5.
Petroleo Brasileiro S.A.- Petrobras ( PBR ) is +0.22 at $5.62, with 35,297 shares traded. PBR's current last sale is 117.08% of the target price of $4.8.
Chesapeake Energy Corporation ( CHK ) is +0.05 at $4.30, with 30,826 shares traded. CHK's current last sale is 107.5% of the target price of $4.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | The following are the most active stocks for the pre-market session : ACADIA Pharmaceuticals Inc. ( ACAD ) is +3.12 at $23.43, with 476,906 shares traded. As reported in the last short interest update the days to cover for ACAD is 8.197547; this calculation is based on the average trading volume of the stock. Siliconware Precision Industries Company, Ltd. ( SPIL ) is -0.1783 at $7.99, with 375,000 shares traded. | The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. The following are the most active stocks for the pre-market session : ACADIA Pharmaceuticals Inc. ( ACAD ) is +3.12 at $23.43, with 476,906 shares traded. As reported in the last short interest update the days to cover for ACAD is 8.197547; this calculation is based on the average trading volume of the stock. | The following are the most active stocks for the pre-market session : ACADIA Pharmaceuticals Inc. ( ACAD ) is +3.12 at $23.43, with 476,906 shares traded. As reported in the last short interest update the days to cover for ACAD is 8.197547; this calculation is based on the average trading volume of the stock. The total Pre-Market volume is currently 1,246,613 shares traded. | The following are the most active stocks for the pre-market session : ACADIA Pharmaceuticals Inc. ( ACAD ) is +3.12 at $23.43, with 476,906 shares traded. As reported in the last short interest update the days to cover for ACAD is 8.197547; this calculation is based on the average trading volume of the stock. SPIL's current last sale is 109.18% of the target price of $7.32. |
36231.0 | 2016-03-28 00:00:00 UTC | Why did Acadia Pharma (ACAD) Gained 17% on the Day? | ACAD | https://www.nasdaq.com/articles/why-did-acadia-pharma-acad-gained-17-day-2016-03-28 | nan | nan | Acadia Pharmaceuticals Inc. (ACAD) closed on the day 17% up, even reaching highs of over 22% during afternoon trading. During pre-market trading hours today, the company's stock gained over 15%.
Acadia Pharmaceuticals Inc. (ACAD) Stock Price | FindTheCompany
The primary reason for this active and positive trading day is that the Food and Drug Administration (FDA) briefed the upcoming Psychopharmacologic Drugs Advisory Committee (PDAC), meeting tomorrow, about a priority review of Nuplazid, an Acadia Pharmaceutical product.
The document showed positive signs for the drug's future conduct, as the FDA emphasized the benefits compared to a placebo. According to Acadia's website , Nuplazid is a "new chemical entity that we discovered and that has the potential to be the first drug approved in the United States for psychosis associated with Parkinson's disease. "
The FDA highlighted that the company has submitted a New Drug Application (NDA) on the back of just one trial meeting primary endpoint, along with three other trials as supportive information. None of the three supportive trials showed statistical significance on primary endpoint.
According to multiple reports , the Division of Psychiatry Products (DPP) requires efficacy evidence from more than one trial. However, the FDA does have the authority to approve a drug based on one robustly positive trial.
Back in September of last year, Acadia submitted a NDA seeking approval for Nuplazid. The company provided positive results from its phase 3 pivotal study, which evaluated efficacy, tolerability, and safety of Nuplazid in patients suffering from Parkinson's, to aid in the application's acceptance.
Acadia Pharmaceuticals has a Zacks Rank #3 (Hold) and as of 3:42 PM ET, its stock is up over 18%.
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days . Click to get this free report >>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
ACADIA PHARMA (ACAD): Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Acadia Pharmaceuticals Inc. (ACAD) Stock Price | FindTheCompany The primary reason for this active and positive trading day is that the Food and Drug Administration (FDA) briefed the upcoming Psychopharmacologic Drugs Advisory Committee (PDAC), meeting tomorrow, about a priority review of Nuplazid, an Acadia Pharmaceutical product. According to Acadia's website , Nuplazid is a "new chemical entity that we discovered and that has the potential to be the first drug approved in the United States for psychosis associated with Parkinson's disease. " Acadia Pharmaceuticals Inc. (ACAD) closed on the day 17% up, even reaching highs of over 22% during afternoon trading. | Click to get this free report ACADIA PHARMA (ACAD): Free Stock Analysis Report To read this article on Zacks.com click here. Acadia Pharmaceuticals Inc. (ACAD) closed on the day 17% up, even reaching highs of over 22% during afternoon trading. Acadia Pharmaceuticals Inc. (ACAD) Stock Price | FindTheCompany The primary reason for this active and positive trading day is that the Food and Drug Administration (FDA) briefed the upcoming Psychopharmacologic Drugs Advisory Committee (PDAC), meeting tomorrow, about a priority review of Nuplazid, an Acadia Pharmaceutical product. | Acadia Pharmaceuticals Inc. (ACAD) Stock Price | FindTheCompany The primary reason for this active and positive trading day is that the Food and Drug Administration (FDA) briefed the upcoming Psychopharmacologic Drugs Advisory Committee (PDAC), meeting tomorrow, about a priority review of Nuplazid, an Acadia Pharmaceutical product. Click to get this free report ACADIA PHARMA (ACAD): Free Stock Analysis Report To read this article on Zacks.com click here. Acadia Pharmaceuticals Inc. (ACAD) closed on the day 17% up, even reaching highs of over 22% during afternoon trading. | Acadia Pharmaceuticals Inc. (ACAD) closed on the day 17% up, even reaching highs of over 22% during afternoon trading. Acadia Pharmaceuticals Inc. (ACAD) Stock Price | FindTheCompany The primary reason for this active and positive trading day is that the Food and Drug Administration (FDA) briefed the upcoming Psychopharmacologic Drugs Advisory Committee (PDAC), meeting tomorrow, about a priority review of Nuplazid, an Acadia Pharmaceutical product. According to Acadia's website , Nuplazid is a "new chemical entity that we discovered and that has the potential to be the first drug approved in the United States for psychosis associated with Parkinson's disease. " |
36232.0 | 2016-03-28 00:00:00 UTC | Mid-Afternoon Market Update: Dow Jumps 50 Points; Pandora Shares Slide | ACAD | https://www.nasdaq.com/articles/mid-afternoon-market-update-dow-jumps-50-points-pandora-shares-slide-2016-03-28 | nan | nan | Toward the end of trading Monday, the Dow traded up 0.29 percent to 17,566.31 while the NASDAQ gained 0.09 percent to 4,777.83. The S&P also rose, gaining 0.24 percent to 2,040.89.
Leading and Lagging Sectors
On Monday, cyclical consumer goods & services shares gained by 0.87 percent. Meanwhile, top gainers in the sector included New York & Company, Inc. (NYSE: NWY ), up 7 percent, and Finish Line Inc (NASDAQ: FINL ), up 14 percent.
In trading on Monday, technology shares dipped by 0.14 percent. Meanwhile, top losers in the sector included ChinaCache Internatnl Hldgs Ltd (ADR) (NASDAQ: CCIH ), down 7 percent, and Glu Mobile Inc. (NASDAQ: GLUU ), down 7 percent.
Top Headline
Cal-Maine Foods Inc (NASDAQ: CALM ) reported better-than-expected earnings for its third quarter on Monday.
Cal-Maine reported Q3 earnings of $1.33 per share on revenue of $449.8 million. However, analysts were expecting earnings of $0.99 per share on revenue of 463.6 million.
Equities Trading UP
Alder Biopharmaceuticals Inc (NASDAQ: ALDR ) shares shot up 48 percent to $25.49. Alder Biopharmaceuticals announced earlier in the morning positive top-line data from 2 clinical trials which studied its ALD403 product, an antibody product candidate for the treatment of migraine headaches.
Shares of ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD ) got a boost, shooting up 22 percent to $24.75 after the FDA released briefing documents for the company's drug called Nuplazid (pimavanserin). According to Fierce Biotech, Acadia Pharmaceuticals will face "some tough questions" on Tuesday when the U.S. Food and Drug Administration's advisory committee will review the company's antipshotic drug pimavanserin. However, the publication suggested the FDA's internal review document suggests that the "door is still open to a possible approval." Fierce Biotech noted that while the FDA recognized that Acadia Pharmaceuticals' 34-mg dose of pimavanserin significantly improved symptoms of Parkinson's, there was also a "distinct" increase in the numbers of deaths and adverse events among patients.
Synthesis Energy Systems, Inc. (NASDAQ: SYMX ) shares were also up, gaining 27 percent to $1.08. Synthesis Energy Systems detailed earlier in the morning a new strategic joint project development and investment agreement with China Environment State Investment Co (CESI). As part of the agreement, Synthesis Energy Systems will develop at least 20 projects using SES Gasification Technology (SGT) over the next five years.
Equities Trading DOWN
Apricus Biosciences Inc (NASDAQ: APRI ) shares dropped 47 percent to $0.715 after the company disclosed "disappointing" Phase 2b data. Apricus Biosciences stated that a proof-of-concept study of fispemifene in men with secondary hypogonadism and sexual dysfunction failed to achieve statistical significance in key clinical benefit endpoints despite an increase in testosterone levels.
Shares of VirtualScopics Inc (NASDAQ: VSCP ) were down 10 percent to $4.03 after the company agreed to be acquired by BioTelemetry, Inc. (NASDAQ: BEAT ) for a total purchase of around $15.5 million.
Pandora Media Inc (NYSE: P ) was down, falling around 11 percent to $9.72 after the company announced a new lineup of senior executives. Pandora named Tim Westergren as CEO and appointed Mike Herring as President and CFO. Westergren will replace Pandora's outgoing CEO, Brian McAndrews following a more than two-year stint as CEO. Pandora reaffirmed its FY16 sales and adjusted EBITDA outlook.
Commodities
In commodity news, oil traded down 0.53 percent to $39.25, while gold traded down 0.16 percent to $1,221.60.
Silver traded up 0.01 percent Monday to $15.20, while copper rose 0.56 percent to $2.24.
Eurozone
European markets were closed Monday for the Easter holiday.
Economics
U.S. consumer spending rose 0.10 percent for February, versus economists' expectations for a 0.10 percent growth.
The pending home sales index gained 3.5 percent to 109.1 in February, versus a downwardly-revised 105.4 in January. However, economists were projecting a 1 percent growth.
The Dallas Fed manufacturing business index rose to -13.60 for March, versus a prior reading of -31.80.
© 2016 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Free Trading Education - Check out the free events taking place on Marketfy this week. Spaces are limited. Sign up today.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Shares of ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD ) got a boost, shooting up 22 percent to $24.75 after the FDA released briefing documents for the company's drug called Nuplazid (pimavanserin). Fierce Biotech noted that while the FDA recognized that Acadia Pharmaceuticals' 34-mg dose of pimavanserin significantly improved symptoms of Parkinson's, there was also a "distinct" increase in the numbers of deaths and adverse events among patients. According to Fierce Biotech, Acadia Pharmaceuticals will face "some tough questions" on Tuesday when the U.S. Food and Drug Administration's advisory committee will review the company's antipshotic drug pimavanserin. | Shares of ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD ) got a boost, shooting up 22 percent to $24.75 after the FDA released briefing documents for the company's drug called Nuplazid (pimavanserin). According to Fierce Biotech, Acadia Pharmaceuticals will face "some tough questions" on Tuesday when the U.S. Food and Drug Administration's advisory committee will review the company's antipshotic drug pimavanserin. Fierce Biotech noted that while the FDA recognized that Acadia Pharmaceuticals' 34-mg dose of pimavanserin significantly improved symptoms of Parkinson's, there was also a "distinct" increase in the numbers of deaths and adverse events among patients. | Shares of ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD ) got a boost, shooting up 22 percent to $24.75 after the FDA released briefing documents for the company's drug called Nuplazid (pimavanserin). According to Fierce Biotech, Acadia Pharmaceuticals will face "some tough questions" on Tuesday when the U.S. Food and Drug Administration's advisory committee will review the company's antipshotic drug pimavanserin. Fierce Biotech noted that while the FDA recognized that Acadia Pharmaceuticals' 34-mg dose of pimavanserin significantly improved symptoms of Parkinson's, there was also a "distinct" increase in the numbers of deaths and adverse events among patients. | Shares of ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD ) got a boost, shooting up 22 percent to $24.75 after the FDA released briefing documents for the company's drug called Nuplazid (pimavanserin). According to Fierce Biotech, Acadia Pharmaceuticals will face "some tough questions" on Tuesday when the U.S. Food and Drug Administration's advisory committee will review the company's antipshotic drug pimavanserin. Fierce Biotech noted that while the FDA recognized that Acadia Pharmaceuticals' 34-mg dose of pimavanserin significantly improved symptoms of Parkinson's, there was also a "distinct" increase in the numbers of deaths and adverse events among patients. |
36233.0 | 2016-03-21 00:00:00 UTC | Mid-Afternoon Market Update: US Stocks Gain; Markit Shares Surge | ACAD | https://www.nasdaq.com/articles/mid-afternoon-market-update-us-stocks-gain-markit-shares-surge-2016-03-21 | nan | nan | Toward the end of trading Monday, the Dow traded up 0.24 percent to 17,643.73 while the NASDAQ climbed 0.35 percent to 4,812.29. The S&P also rose, gaining 0.18 percent to 2,053.31.
Leading and Lagging Sectors
On Monday, healthcare shares rose by 0.59 percent. Top gainers in the sector included Sarepta Therapeutics Inc (NASDAQ: SRPT ), Valeant Pharmaceuticals Intl Inc (NYSE: VRX ), and ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD ).
In trading on Monday, energy shares dipped by 0.65 percent. Meanwhile, top losers in the sector included Teekay Offshore Partners L.P. (NYSE: TOO ), down 9 percent, and Basic Energy Services, Inc (NYSE: BAS ), down 8 percent.
Top Headline
Sherwin-Williams Co (NYSE: SHW ) agreed to acquire Valspar for an enterprise value of around $11.3 billion.
Sherwin-Williams will pay $113 per share to buy Valspar.
Equities Trading UP
Markit Ltd (NASDAQ: MRKT ) shares shot up 12 percent to $32.98 as IHS Inc. (NYSE: IHS ) agreed to buy Markit.
Shares of The Valspar Corp (NYSE: VAL ) got a boost, shooting up 24 percent to $103.96 after Sherwin-Williams agreed to acquire Valspar for $113 per share.
Valeant Pharmaceuticals Intl Inc (NYSE: VRX ) shares were also up, gaining 9 percent to $29.31 as the company announced a search for a new CEO, Bill Ackman as a new member of the board and other internal matters such as the 10-K filing delay. Katharine B. Stevenson stepped down from the board to make a place for Pershing Square's Bill Ackman. In addition to this move, the board made a request for Howard Schiller, former CFO, to resign; however, that has not happened at this time.
Equities Trading DOWN
CombiMatrix Corp (NASDAQ: CBMX ) shares dropped 18 percent to $4.40 as the company priced $8.0 million underwritten public offering.
Shares of Affymetrix, Inc. (NASDAQ: AFFX ) were down 10 percent to $14.45. Affymetrix executives, announced Friday, that it submitted a proposal to acquire Affymetrix, Inc. for $16.10 per share in cash. The transaction is valued at approximately $1.5 billion. However, Affymetrix announced Sunday, that it was rejecting the Origin offer in the belief that this newly formed entity would be unable to close the deal.
Trinseo S.A. (NYSE: TSE ) was down, falling around 6 percent to $35.79 as the company reported a 9.6 million share offering by selling shareholders.
Commodities
In commodity news, oil traded up 1.72 percent to $40.12, while gold traded down 0.73 percent to $1,245.20.
Silver traded up 0.37 percent Monday to $15.87, while copper rose 0.39 percent to $2.29.
Eurozone
European shares closed mostly lower today. The eurozone's STOXX 600 dropped 0.26 percent, the Spanish Ibex Index fell 0.33 percent, while Italy's FTSE MIB Index surged 0.46 percent. Meanwhile, the German DAX declined 0.02 percent, and the French CAC 40 declined 0.78 percent, while U.K. shares fell 0.08 percent.
Economics
The Chicago Fed National Activity Index slipped to -0.29 in February, versus a prior reading of 0.41.
US existing-home sales declined 7.1 percent to an annual rate of 5.08 million in February, the National Association of Realtors reported. However, economists were expecting a rate of 5.34 million.
© 2016 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Free Trading Education - Check out the free events taking place on Marketfy this week. Spaces are limited. Sign up today.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Top gainers in the sector included Sarepta Therapeutics Inc (NASDAQ: SRPT ), Valeant Pharmaceuticals Intl Inc (NYSE: VRX ), and ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD ). Valeant Pharmaceuticals Intl Inc (NYSE: VRX ) shares were also up, gaining 9 percent to $29.31 as the company announced a search for a new CEO, Bill Ackman as a new member of the board and other internal matters such as the 10-K filing delay. Equities Trading DOWN CombiMatrix Corp (NASDAQ: CBMX ) shares dropped 18 percent to $4.40 as the company priced $8.0 million underwritten public offering. | Top gainers in the sector included Sarepta Therapeutics Inc (NASDAQ: SRPT ), Valeant Pharmaceuticals Intl Inc (NYSE: VRX ), and ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD ). Equities Trading UP Markit Ltd (NASDAQ: MRKT ) shares shot up 12 percent to $32.98 as IHS Inc. (NYSE: IHS ) agreed to buy Markit. Valeant Pharmaceuticals Intl Inc (NYSE: VRX ) shares were also up, gaining 9 percent to $29.31 as the company announced a search for a new CEO, Bill Ackman as a new member of the board and other internal matters such as the 10-K filing delay. | Top gainers in the sector included Sarepta Therapeutics Inc (NASDAQ: SRPT ), Valeant Pharmaceuticals Intl Inc (NYSE: VRX ), and ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD ). Toward the end of trading Monday, the Dow traded up 0.24 percent to 17,643.73 while the NASDAQ climbed 0.35 percent to 4,812.29. The eurozone's STOXX 600 dropped 0.26 percent, the Spanish Ibex Index fell 0.33 percent, while Italy's FTSE MIB Index surged 0.46 percent. | Top gainers in the sector included Sarepta Therapeutics Inc (NASDAQ: SRPT ), Valeant Pharmaceuticals Intl Inc (NYSE: VRX ), and ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD ). Toward the end of trading Monday, the Dow traded up 0.24 percent to 17,643.73 while the NASDAQ climbed 0.35 percent to 4,812.29. Top Headline Sherwin-Williams Co (NYSE: SHW ) agreed to acquire Valspar for an enterprise value of around $11.3 billion. |
36234.0 | 2016-03-07 00:00:00 UTC | Surprising Analyst 12-Month Target For IYH | ACAD | https://www.nasdaq.com/articles/surprising-analyst-12-month-target-iyh-2016-03-07 | nan | nan | Looking at the underlying holdings of the ETFs in our coverage universe at ETF Channel , we have compared the trading price of each holding against the average analyst 12-month forward target price, and computed the weighted average implied analyst target price for the ETF itself. For the iShares U.S. Healthcare ETF (Symbol: IYH), we found that the implied analyst target price for the ETF based upon its underlying holdings is $171.09 per unit.
With IYH trading at a recent price near $139.40 per unit, that means that analysts see 22.73% upside for this ETF looking through to the average analyst targets of the underlying holdings. Three of IYH's underlying holdings with notable upside to their analyst target prices are Acadia Pharmaceuticals Inc (Symbol: ACAD), Anacor Pharmaceuticals Inc (Symbol: ANAC), and Radius Health Inc (Symbol: RDUS). Although ACAD has traded at a recent price of $21.20/share, the average analyst target is 115.41% higher at $45.67/share. Similarly, ANAC has 114.20% upside from the recent share price of $59.99 if the average analyst target price of $128.50/share is reached, and analysts on average are expecting RDUS to reach a target price of $63.25/share, which is 98.90% above the recent price of $31.80. Below is a twelve month price history chart comparing the stock performance of ACAD, ANAC, and RDUS:
Below is a summary table of the current analyst target prices discussed above:
Are analysts justified in these targets, or overly optimistic about where these stocks will be trading 12 months from now? Do the analysts have a valid justification for their targets, or are they behind the curve on recent company and industry developments? A high price target relative to a stock's trading price can reflect optimism about the future, but can also be a precursor to target price downgrades if the targets were a relic of the past. These are questions that require further investor research.
10 ETFs With Most Upside To Analyst Targets »
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Although ACAD has traded at a recent price of $21.20/share, the average analyst target is 115.41% higher at $45.67/share. Below is a twelve month price history chart comparing the stock performance of ACAD, ANAC, and RDUS: Below is a summary table of the current analyst target prices discussed above: Are analysts justified in these targets, or overly optimistic about where these stocks will be trading 12 months from now? Three of IYH's underlying holdings with notable upside to their analyst target prices are Acadia Pharmaceuticals Inc (Symbol: ACAD), Anacor Pharmaceuticals Inc (Symbol: ANAC), and Radius Health Inc (Symbol: RDUS). | Three of IYH's underlying holdings with notable upside to their analyst target prices are Acadia Pharmaceuticals Inc (Symbol: ACAD), Anacor Pharmaceuticals Inc (Symbol: ANAC), and Radius Health Inc (Symbol: RDUS). Although ACAD has traded at a recent price of $21.20/share, the average analyst target is 115.41% higher at $45.67/share. Below is a twelve month price history chart comparing the stock performance of ACAD, ANAC, and RDUS: Below is a summary table of the current analyst target prices discussed above: Are analysts justified in these targets, or overly optimistic about where these stocks will be trading 12 months from now? | Below is a twelve month price history chart comparing the stock performance of ACAD, ANAC, and RDUS: Below is a summary table of the current analyst target prices discussed above: Are analysts justified in these targets, or overly optimistic about where these stocks will be trading 12 months from now? Three of IYH's underlying holdings with notable upside to their analyst target prices are Acadia Pharmaceuticals Inc (Symbol: ACAD), Anacor Pharmaceuticals Inc (Symbol: ANAC), and Radius Health Inc (Symbol: RDUS). Although ACAD has traded at a recent price of $21.20/share, the average analyst target is 115.41% higher at $45.67/share. | Below is a twelve month price history chart comparing the stock performance of ACAD, ANAC, and RDUS: Below is a summary table of the current analyst target prices discussed above: Are analysts justified in these targets, or overly optimistic about where these stocks will be trading 12 months from now? Three of IYH's underlying holdings with notable upside to their analyst target prices are Acadia Pharmaceuticals Inc (Symbol: ACAD), Anacor Pharmaceuticals Inc (Symbol: ANAC), and Radius Health Inc (Symbol: RDUS). Although ACAD has traded at a recent price of $21.20/share, the average analyst target is 115.41% higher at $45.67/share. |
36235.0 | 2016-02-26 00:00:00 UTC | Pre-Market Earnings Report for February 29, 2016 : VRX, ENDP, IEP, NRG, HZNP, TRCO, VGR, ACAD, GRFS, BCPC, FI, SJI | ACAD | https://www.nasdaq.com/articles/pre-market-earnings-report-february-29-2016-vrx-endp-iep-nrg-hznp-trco-vgr-acad-grfs-bcpc | nan | nan | The following companies are expected to report earnings prior to market open on 02/29/2016. Visit our Earnings Calendar for a full list of expected earnings releases.
Valeant Pharmaceuticals International, Inc. ( VRX ) is reporting for the quarter ending December 31, 2015. The drug company's consensus earnings per share forecast from the 8 analysts that follow the stock is $2.59. This value represents a no change for the same quarter last year. In the past year VRX has met analyst expectations once and beat the expectations the other three quarters. Zacks Investment Research reports that the 2015 Price to Earnings ratio for VRX is 8.22 vs. an industry ratio of -10.10, implying that they will have a higher earnings growth than their competitors in the same industry.
Endo International plc ( ENDP ) is reporting for the quarter ending December 31, 2015. The drug company's consensus earnings per share forecast from the 9 analysts that follow the stock is $1.26. This value represents a 8.62% increase compared to the same quarter last year. ENDP missed the consensus earnings per share in the 1st calendar quarter of 2015 by -10.28%. Zacks Investment Research reports that the 2015 Price to Earnings ratio for ENDP is 11.53 vs. an industry ratio of -10.10, implying that they will have a higher earnings growth than their competitors in the same industry.
Icahn Enterprises L.P. ( IEP ) is reporting for the quarter ending December 31, 2015. The diversified operations company's consensus earnings per share forecast from the 1 analyst that follows the stock is $1.50. This value represents a 60.94% decrease compared to the same quarter last year. The last two quarters IEP had negative earnings surprises; the latest report they missed by -230.98%. Zacks Investment Research reports that the 2015 Price to Earnings ratio for IEP is 5.97 vs. an industry ratio of 13.60.
NRG Energy, Inc. ( NRG ) is reporting for the quarter ending December 31, 2015. The electric power utilities company's consensus earnings per share forecast from the 4 analysts that follow the stock is $0.38. This value represents a 80.95% increase compared to the same quarter last year. Zacks Investment Research reports that the 2015 Price to Earnings ratio for NRG is 16.03 vs. an industry ratio of 6.20, implying that they will have a higher earnings growth than their competitors in the same industry.
Horizon Pharma plc ( HZNP ) is reporting for the quarter ending December 31, 2015. The biomedical (gene) company's consensus earnings per share forecast from the 3 analysts that follow the stock is $0.65. This value represents a 140.74% increase compared to the same quarter last year. HZNP missed the consensus earnings per share in the 1st calendar quarter of 2015 by -27.27%. Zacks Investment Research reports that the 2015 Price to Earnings ratio for HZNP is 11.82 vs. an industry ratio of -30.30, implying that they will have a higher earnings growth than their competitors in the same industry.
Tribune Media Company ( TRCO ) is reporting for the quarter ending December 31, 2015. The broadcast (radio/tv) company's consensus earnings per share forecast from the 4 analysts that follow the stock is $0.56. This value represents a 23.29% decrease compared to the same quarter last year. The last two quarters TRCO had negative earnings surprises; the latest report they missed by -6.45%. Zacks Investment Research reports that the 2015 Price to Earnings ratio for TRCO is 26.64 vs. an industry ratio of 20.80, implying that they will have a higher earnings growth than their competitors in the same industry.
Vector Group Ltd. ( VGR ) is reporting for the quarter ending December 31, 2015. The tobacco company's consensus earnings per share forecast from the 1 analyst that follows the stock is $0.18. This value represents a 80.00% increase compared to the same quarter last year. VGR missed the consensus earnings per share in the 3rd calendar quarter of 2015 by -38.89%. The "days to cover" for this stock exceeds 10 days. Zacks Investment Research reports that the 2015 Price to Earnings ratio for VGR is 36.27 vs. an industry ratio of 22.10, implying that they will have a higher earnings growth than their competitors in the same industry.
ACADIA Pharmaceuticals Inc. ( ACAD ) is reporting for the quarter ending December 31, 2015. The biomedical (gene) company's consensus earnings per share forecast from the 6 analysts that follow the stock is $-0.37. This value represents a 32.14% decrease compared to the same quarter last year. Zacks Investment Research reports that the 2015 Price to Earnings ratio for ACAD is -12.08 vs. an industry ratio of -30.30, implying that they will have a higher earnings growth than their competitors in the same industry.
Grifols, S.A. ( GRFS ) is reporting for the quarter ending December 31, 2015. The drug company's consensus earnings per share forecast from the 1 analyst that follows the stock is $0.27. This value represents a 3.85% increase compared to the same quarter last year. GRFS missed the consensus earnings per share in the 4th calendar quarter of 2014 by -10.34%. Zacks Investment Research reports that the 2015 Price to Earnings ratio for GRFS is 15.64 vs. an industry ratio of -10.10, implying that they will have a higher earnings growth than their competitors in the same industry.
Balchem Corporation ( BCPC ) is reporting for the quarter ending December 31, 2015. The chemical company's consensus earnings per share forecast from the 1 analyst that follows the stock is $0.58. This value represents a 13.43% decrease compared to the same quarter last year. In the past year BCPC and beat the expectations the other quarter. Zacks Investment Research reports that the 2015 Price to Earnings ratio for BCPC is 25.72 vs. an industry ratio of 16.00, implying that they will have a higher earnings growth than their competitors in the same industry.
Frank's International N.V. ( FI ) is reporting for the quarter ending December 31, 2015. The oil (production/pipeline) company's consensus earnings per share forecast from the 7 analysts that follow the stock is $0.10. This value represents a 64.29% decrease compared to the same quarter last year. The "days to cover" for this stock exceeds 10 days. Zacks Investment Research reports that the 2015 Price to Earnings ratio for FI is 20.13 vs. an industry ratio of 133.20.
South Jersey Industries, Inc. ( SJI ) is reporting for the quarter ending December 31, 2015. The gas distribution company's consensus earnings per share forecast from the 2 analysts that follow the stock is $0.61. This value represents a 29.79% increase compared to the same quarter last year. Zacks Investment Research reports that the 2015 Price to Earnings ratio for SJI is 17.39 vs. an industry ratio of 18.30.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | ACADIA Pharmaceuticals Inc. ( ACAD ) is reporting for the quarter ending December 31, 2015. Zacks Investment Research reports that the 2015 Price to Earnings ratio for ACAD is -12.08 vs. an industry ratio of -30.30, implying that they will have a higher earnings growth than their competitors in the same industry. The electric power utilities company's consensus earnings per share forecast from the 4 analysts that follow the stock is $0.38. | ACADIA Pharmaceuticals Inc. ( ACAD ) is reporting for the quarter ending December 31, 2015. Zacks Investment Research reports that the 2015 Price to Earnings ratio for ACAD is -12.08 vs. an industry ratio of -30.30, implying that they will have a higher earnings growth than their competitors in the same industry. Zacks Investment Research reports that the 2015 Price to Earnings ratio for VRX is 8.22 vs. an industry ratio of -10.10, implying that they will have a higher earnings growth than their competitors in the same industry. | ACADIA Pharmaceuticals Inc. ( ACAD ) is reporting for the quarter ending December 31, 2015. Zacks Investment Research reports that the 2015 Price to Earnings ratio for ACAD is -12.08 vs. an industry ratio of -30.30, implying that they will have a higher earnings growth than their competitors in the same industry. Zacks Investment Research reports that the 2015 Price to Earnings ratio for VRX is 8.22 vs. an industry ratio of -10.10, implying that they will have a higher earnings growth than their competitors in the same industry. | ACADIA Pharmaceuticals Inc. ( ACAD ) is reporting for the quarter ending December 31, 2015. Zacks Investment Research reports that the 2015 Price to Earnings ratio for ACAD is -12.08 vs. an industry ratio of -30.30, implying that they will have a higher earnings growth than their competitors in the same industry. ENDP missed the consensus earnings per share in the 1st calendar quarter of 2015 by -10.28%. |
36236.0 | 2016-02-20 00:00:00 UTC | 3 All-or-Nothing Biotech Stocks We're Closely Watching | ACAD | https://www.nasdaq.com/articles/3-all-or-nothing-biotech-stocks-were-closely-watching-2016-02-20 | nan | nan | Every small-cap biotechnology investor knows the industry is prone to binary events. Whether it's receiving updates from an important clinical trial or hearing from regulators about an approval decision, some biotech stocks can face all-or-nothing moments that can either send the stock soaring or cause it to crash.
Knowing that, we asked three of our Motley Fool contributors to highlight a biotech stock that will be facing a binary event in the not-to-distant future that they think is worth keeping an eye on. Read below to see if any of the companies they highlighted look worthy of your (speculative!) investment dollar.
Todd Campbell : Neratinib is being developed by Puma Biotechnology for use in breast cancer patients with a specific genetic makeup that have undergone prior treatment.
Recently, Puma Biotechnology's management presented clinical trial data for the use of neratinib in the extended adjuvant setting. After breast cancer surgery, patients received standard of care, including one year of Herceptin, and then they were randomized to either receive neratinib or placebo. At year three, disease-free survival was about 2% to 3% better in the neratinib arm than it was in the placebo arm of the study.
However, roughly 40% of neratinib patients suffered from grade 3 diarrhea, and that raises doubt that patients would stick with neratinib therapy if the drug passes muster with the FDA.
To address that concern, Puma Biotechnology is studying the use of Imodium alongside neratinib, and interim data reported in December shows that Imodium co-therapy reduced the rate of grade 3 diarrhea to below 20%.
Puma Biotechnology expects to file for FDA approval of neratinib this year, and that filing will include efficacy data and Imodium safety data, when it's available.
Overall, given that the improvement in efficacy offered by neratinib is arguably small, the Imodium trial is still ongoing, and the market opportunity in breast cancer is conceivably north of $1 billion annually, Puma Biotechnology is one all-or-nothing biotech company I'm watching like a hawk in 2016.
Brian Feroldi : One all-or-nothing biotech stock I have my eye on right now is Acadia Pharmaceuticals , a company that focuses on diseases of the central nervous system. Acadia's future is currently almost entirely dependent on Nuplazid, its lead compound that is currently pending regulatory approval as a treatment option for Parkinson's Disease Psychosis, or PDP.
In phase 3 clinical trials, Nuplazid helped patients with PDP better control the symptoms of their diseases when compared to placebo. Nuplazid also helped to improve patients' sleep cycles, and it reduced the burden of care placed on their caregivers -- all while demonstrating placebo-like safety.
Currently there are no approved drugs on the market today that treat PDP, so the FDA has designated Nuplazid as breakthrough therapy and given the drug priority review. The FDA has set a target PDUFA decision date of May 1st, but an advisory committee meeting to discuss the drug has been scheduled for March 29th. The outcome of that meeting should give investors a good idea of which way the agency is leaning.
Acadia Pharmaceuticals' stock isn't for the faint of heart -- nearly all of its market value is riding on the success of Nuplazid. If the FDA gives the drug the green light, it's likely Acadia's stock will soar, but if the FDA decides to reject the drug, the company's stock will be crushed.
Sean Williams: It pretty much doesn't get more "all-or-nothing" than Geron , a small-cap drug developer that has just one drug (albeit a promising one) in its pipeline.
Imetelstat is a cancer drug being studied as a treatment for myelofibrosis (a rare cancerous disease of the bone marrow that leads to scarring and an inability to produce normal blood cells) as well as myelodysplastic syndromes and essential thrombocythemia.
What makes Geron's drug so intriguing, and what caught the attention of Johnson & Johnson , which subsequently partnered with Geron, is its success in treating myelofibrosis.
Right now, there's just one drug approved by the Food and Drug Administration for myelofibrosis patients: Incyte 's Jakafi. Jakafi is a JAK inhibitor that works by alleviating symptoms associated with myelofibrosis, such as an enlarged spleen or anemia. Incyte has ridden this approval to $601 million in total sales in 2015. But, in terms of efficacy, Jakafi does nothing to slow or reverse myelofibrosis. In phase 1 clinical trials, we did witness partial and complete responses in myelofibrosis patients taking imetelstat. This was something the medical community had never before seen, and it's a direct threat to Incyte's revenue stream.
The downside? Imetelstat was at one time on clinical hold because of liver function test abnormalities in some patients. This hold was eventually removed by the FDA, but there are still lingering concerns about the drug's long-term safety.
Also, the fact that Geron has just one product in development makes it inherently risky. Johnson & Johnson's $35 million upfront payment does help pad Geron's pockets for now, and the company could earn another $900 million in development, regulatory, and sales-based milestones. However, the fact that losses will continue for the near term is something investors should come to terms with. Additionally, if imetelstat doesn't gain approval, Geron has nothing to fall back on save for its remaining cash.
If imetelstat succeeds in gaining FDA approval, it could very well become a blockbuster drug. The big question is whether or not you believe its results and safety record would pass muster with the FDA.
The next billion-dollar iSecret
The world's biggest tech company forgot to show you something at its recent event, but a few Wall Street analysts and the Fool didn't miss a beat: There's a small company that's powering their brand-new gadgets and the coming revolution in technology. And we think its stock price has nearly unlimited room to run for early, in-the-know investors! To be one of them, just click here .
The article 3 All-or-Nothing Biotech Stocks We're Closely Watching originally appeared on Fool.com.
Brian Feroldi has no position in any stocks mentioned. Sean Williams has no position in any stocks mentioned. Todd Campbell has no position in any stocks mentioned. The Motley Fool recommends Johnson & Johnson. Try any of our Foolish newsletter services free for 30 days . We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy .
Copyright © 1995 - 2016 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy .
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Brian Feroldi : One all-or-nothing biotech stock I have my eye on right now is Acadia Pharmaceuticals , a company that focuses on diseases of the central nervous system. Acadia's future is currently almost entirely dependent on Nuplazid, its lead compound that is currently pending regulatory approval as a treatment option for Parkinson's Disease Psychosis, or PDP. Acadia Pharmaceuticals' stock isn't for the faint of heart -- nearly all of its market value is riding on the success of Nuplazid. | Brian Feroldi : One all-or-nothing biotech stock I have my eye on right now is Acadia Pharmaceuticals , a company that focuses on diseases of the central nervous system. Acadia's future is currently almost entirely dependent on Nuplazid, its lead compound that is currently pending regulatory approval as a treatment option for Parkinson's Disease Psychosis, or PDP. Acadia Pharmaceuticals' stock isn't for the faint of heart -- nearly all of its market value is riding on the success of Nuplazid. | If the FDA gives the drug the green light, it's likely Acadia's stock will soar, but if the FDA decides to reject the drug, the company's stock will be crushed. Brian Feroldi : One all-or-nothing biotech stock I have my eye on right now is Acadia Pharmaceuticals , a company that focuses on diseases of the central nervous system. Acadia's future is currently almost entirely dependent on Nuplazid, its lead compound that is currently pending regulatory approval as a treatment option for Parkinson's Disease Psychosis, or PDP. | If the FDA gives the drug the green light, it's likely Acadia's stock will soar, but if the FDA decides to reject the drug, the company's stock will be crushed. Brian Feroldi : One all-or-nothing biotech stock I have my eye on right now is Acadia Pharmaceuticals , a company that focuses on diseases of the central nervous system. Acadia's future is currently almost entirely dependent on Nuplazid, its lead compound that is currently pending regulatory approval as a treatment option for Parkinson's Disease Psychosis, or PDP. |
36237.0 | 2016-02-13 00:00:00 UTC | 3 Upcoming FDA Decisions We're Most Excited About | ACAD | https://www.nasdaq.com/articles/3-upcoming-fda-decisions-were-most-excited-about-2016-02-13 | nan | nan | Photo source: flickr.com .
Interested in what biotechs might soon bag an important new drug approval? Then the Motley Fool has a treat for you today.
Below, three of our contributors share their picks for biotechs on the cusp of a make-or-break FDA decision. The upside of a green light is huge considering how much the odds are stacked against an investigational compound making it all the way to approval.
It takes about 12 years for an experimental drug to travel from the laboratory to your medicine cabinet, and the chances it will make it are a meager one in 5,000. According to Forbes , the overall cost of creating a new drug averages $5 billion. Of course, that takes into account all the failures; companies don't spend that on each drug.
The good news is that about 80% of drugs that made it through the gauntlet of clinical testing to Phase III gain FDA approval. So, when a drug gets close to receiving a regulatory decision, investors should be on high alert.
Brian Feroldi : One upcoming FDA decision that I'm especially excited to hear about is for ACADIA Pharmaceuticals ' Nuplazid, which was submitted last last year as a potential treatment for psychosis associated with Parkinson's disease, or PDP.
The National Parkinson Foundation estimates that roughly 400,000 Americans suffer from PDP, which can cause hallucinations and delusions and places a huge burden on caregivers. In phase 3 trials, Nuplazid was shown to lower the impact that PDP had on patients' lives when compared to placebo, and it also helped improved patients' sleep cycles. Nuplazid helped to reduce the burden placed on caregivers, and the results were seen regardless of the patient's age, sex, or race.
With no other approved drugs on the market to treat PDP, the FDA granted Nuplazid with breakthrough therapy designation and has given it a priority review. The target PDUFA decision date is May 1, 2016 .
This date should be exciting for investors, as well, as peak sales for Nuplazid are currently running around $2 billion. That number could grow considerably in the future, too, since Nuplazid is also being studied as a treatment for Alzheimer's Disease Psychosis and Schizophrenia. If Nuplazid gets the green light on May 1st, then it bodes well for the drug's chances with future conditions. I, for one, am excited to see what will happen.
Sean Williams : The PDUFA decision I'm most looking forward to is Intercept Pharmaceuticals ' obeticholic acid as a treatment for primary biliary cirrhosis, or PBC, an autoimmune disease that causes bile acids to build up and destroy the liver.
Originally, obeticholic acid, also known as OCA, was slated to be approved (or given a complete response letter detailing what would need to be corrected for approval) in February. However, additional data requests from the Food and Drug Administration wound up pushing the PDUFA date back three months, to May 29, 2016. The FDA also set up a panel review for April 7, 2016.
Even though Intercept was clear that the extension was merely a formality of the FDA asking for more data, it's unnerving to investors considering the potential safety concerns surrounding OCA following the midstage FLINT study for nonalcoholic steatohepatitis, or NASH. Following FLINT, some OCA patients exhibited a rise in LDL-cholesterol (the bad kind) and had other adverse reactions. The delay in OCA's PDUFA decision may have only exacerbated these worries among shareholders.
On the flip side, OCA was wildly successful in treating PBC. As noted in the late-stage POISE trial, 47% and 46% of patients in the 10 mg OCA and 5-10 mg OCA cohorts met the primary endpoint, respectively, whereas just 10% of patients in the placebo cohort met the primary endpoint. The adverse events noted were also similar between OCA and the placebo.
This first approval could be a big one for OCA and Intercept because it would presumably give OCA a clearer path to approval in NASH if late-stage study data proves encouraging. NASH could be a multi-billion indication for Intercept's OCA; this is the reason why the May 29 PDUFA date is so exciting in my book.
Cheryl Swanson : There aren't many bargains left in biotech, but I see a potential big one coming in Clovis Oncology .
Wall Street lost confidence in Clovis' management last November, when the FDA delayed review of its fast-tracked drug rociletinib.The stock promptly crashed 70% and has gone nowhere since. Why?
While the FDA ended up pushing review back only three months (until June 28, 2016), that gave AstraZeneca 's competing lung cancer treatment a chance to leap ahead. AstraZeneca's drug Tagrisso will now be an established treatment before rociletinib reaches commercialization. And that is not what the market expected.
So where's the value in Clovis? The market is acting as if rociletinib is dead, but the FDA saw enough in the clinical data to delay, not kill, the review. At this point, it's likely rociletinib will eventually get approved.
And even if something does go wrong -- which is always possible with drug approvals -- Clovis has another highly promising drug, rucaparib, a PARP inhibitor for ovarian cancer in late-stage trials. Rucaparib clocks in with a $1 billion peak sales forecast.
Rociletinib is also under accelerated assessment in the EU, with a decision expected in mid-2016, and it's being tested in tandem with a Roche checkpoint inhibitor to see if it could have a positive add-on effect. Clovis is a high-risk stock, but it's worth remembering that the pendulum swings both ways in biotech. If rociletinib gets the FDA nod, that will do a lot to restore faith in Clovis' management, and this stock could head skyward again.
The next billion-dollar iSecret
The world's biggest tech company forgot to show you something at its recent event, but a few Wall Street analysts and the Fool didn't miss a beat: There's a small company that's powering their brand-new gadgets and the coming revolution in technology. And we think its stock price has nearly unlimited room to run for early in-the-know investors! To be one of them, just click here .
The article 3 Upcoming FDA Decisions We're Most Excited About originally appeared on Fool.com.
Brian Feroldi has no position in any stocks mentioned. Cheryl Swanson has no position in any stocks mentioned. Sean Williams has no position in any stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. Try any of our Foolish newsletter services free for 30 days . We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy .
Copyright © 1995 - 2016 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy .
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Brian Feroldi : One upcoming FDA decision that I'm especially excited to hear about is for ACADIA Pharmaceuticals ' Nuplazid, which was submitted last last year as a potential treatment for psychosis associated with Parkinson's disease, or PDP. Even though Intercept was clear that the extension was merely a formality of the FDA asking for more data, it's unnerving to investors considering the potential safety concerns surrounding OCA following the midstage FLINT study for nonalcoholic steatohepatitis, or NASH. While the FDA ended up pushing review back only three months (until June 28, 2016), that gave AstraZeneca 's competing lung cancer treatment a chance to leap ahead. | Brian Feroldi : One upcoming FDA decision that I'm especially excited to hear about is for ACADIA Pharmaceuticals ' Nuplazid, which was submitted last last year as a potential treatment for psychosis associated with Parkinson's disease, or PDP. With no other approved drugs on the market to treat PDP, the FDA granted Nuplazid with breakthrough therapy designation and has given it a priority review. As noted in the late-stage POISE trial, 47% and 46% of patients in the 10 mg OCA and 5-10 mg OCA cohorts met the primary endpoint, respectively, whereas just 10% of patients in the placebo cohort met the primary endpoint. | Brian Feroldi : One upcoming FDA decision that I'm especially excited to hear about is for ACADIA Pharmaceuticals ' Nuplazid, which was submitted last last year as a potential treatment for psychosis associated with Parkinson's disease, or PDP. With no other approved drugs on the market to treat PDP, the FDA granted Nuplazid with breakthrough therapy designation and has given it a priority review. This first approval could be a big one for OCA and Intercept because it would presumably give OCA a clearer path to approval in NASH if late-stage study data proves encouraging. | Brian Feroldi : One upcoming FDA decision that I'm especially excited to hear about is for ACADIA Pharmaceuticals ' Nuplazid, which was submitted last last year as a potential treatment for psychosis associated with Parkinson's disease, or PDP. This date should be exciting for investors, as well, as peak sales for Nuplazid are currently running around $2 billion. The market is acting as if rociletinib is dead, but the FDA saw enough in the clinical data to delay, not kill, the review. |
36238.0 | 2016-02-04 00:00:00 UTC | How The Pieces Add Up: IYH Targets $175 | ACAD | https://www.nasdaq.com/articles/how-pieces-add-iyh-targets-175-2016-02-04 | nan | nan | Looking at the underlying holdings of the ETFs in our coverage universe at ETF Channel , we have compared the trading price of each holding against the average analyst 12-month forward target price, and computed the weighted average implied analyst target price for the ETF itself. For the iShares U.S. Healthcare ETF (Symbol: IYH), we found that the implied analyst target price for the ETF based upon its underlying holdings is $175.37 per unit.
With IYH trading at a recent price near $136.23 per unit, that means that analysts see 28.73% upside for this ETF looking through to the average analyst targets of the underlying holdings. Three of IYH's underlying holdings with notable upside to their analyst target prices are Novavax, Inc. (Symbol: NVAX), Acadia Pharmaceuticals Inc (Symbol: ACAD), and Halozyme Therapeutics Inc (Symbol: HALO). Although NVAX has traded at a recent price of $4.59/share, the average analyst target is 209.17% higher at $14.19/share. Similarly, ACAD has 154.76% upside from the recent share price of $18.89 if the average analyst target price of $48.12/share is reached, and analysts on average are expecting HALO to reach a target price of $20.00/share, which is 146.61% above the recent price of $8.11. Below is a twelve month price history chart comparing the stock performance of NVAX, ACAD, and HALO:
Below is a summary table of the current analyst target prices discussed above:
Are analysts justified in these targets, or overly optimistic about where these stocks will be trading 12 months from now? Do the analysts have a valid justification for their targets, or are they behind the curve on recent company and industry developments? A high price target relative to a stock's trading price can reflect optimism about the future, but can also be a precursor to target price downgrades if the targets were a relic of the past. These are questions that require further investor research.
10 ETFs With Most Upside To Analyst Targets »
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Below is a twelve month price history chart comparing the stock performance of NVAX, ACAD, and HALO: Below is a summary table of the current analyst target prices discussed above: Are analysts justified in these targets, or overly optimistic about where these stocks will be trading 12 months from now? Three of IYH's underlying holdings with notable upside to their analyst target prices are Novavax, Inc. (Symbol: NVAX), Acadia Pharmaceuticals Inc (Symbol: ACAD), and Halozyme Therapeutics Inc (Symbol: HALO). Similarly, ACAD has 154.76% upside from the recent share price of $18.89 if the average analyst target price of $48.12/share is reached, and analysts on average are expecting HALO to reach a target price of $20.00/share, which is 146.61% above the recent price of $8.11. | Three of IYH's underlying holdings with notable upside to their analyst target prices are Novavax, Inc. (Symbol: NVAX), Acadia Pharmaceuticals Inc (Symbol: ACAD), and Halozyme Therapeutics Inc (Symbol: HALO). Similarly, ACAD has 154.76% upside from the recent share price of $18.89 if the average analyst target price of $48.12/share is reached, and analysts on average are expecting HALO to reach a target price of $20.00/share, which is 146.61% above the recent price of $8.11. Below is a twelve month price history chart comparing the stock performance of NVAX, ACAD, and HALO: Below is a summary table of the current analyst target prices discussed above: Are analysts justified in these targets, or overly optimistic about where these stocks will be trading 12 months from now? | Similarly, ACAD has 154.76% upside from the recent share price of $18.89 if the average analyst target price of $48.12/share is reached, and analysts on average are expecting HALO to reach a target price of $20.00/share, which is 146.61% above the recent price of $8.11. Below is a twelve month price history chart comparing the stock performance of NVAX, ACAD, and HALO: Below is a summary table of the current analyst target prices discussed above: Are analysts justified in these targets, or overly optimistic about where these stocks will be trading 12 months from now? Three of IYH's underlying holdings with notable upside to their analyst target prices are Novavax, Inc. (Symbol: NVAX), Acadia Pharmaceuticals Inc (Symbol: ACAD), and Halozyme Therapeutics Inc (Symbol: HALO). | Below is a twelve month price history chart comparing the stock performance of NVAX, ACAD, and HALO: Below is a summary table of the current analyst target prices discussed above: Are analysts justified in these targets, or overly optimistic about where these stocks will be trading 12 months from now? Three of IYH's underlying holdings with notable upside to their analyst target prices are Novavax, Inc. (Symbol: NVAX), Acadia Pharmaceuticals Inc (Symbol: ACAD), and Halozyme Therapeutics Inc (Symbol: HALO). Similarly, ACAD has 154.76% upside from the recent share price of $18.89 if the average analyst target price of $48.12/share is reached, and analysts on average are expecting HALO to reach a target price of $20.00/share, which is 146.61% above the recent price of $8.11. |
36239.0 | 2016-01-25 00:00:00 UTC | April 15th Options Now Available For Acadia Pharmaceuticals ACAD) | ACAD | https://www.nasdaq.com/articles/april-15th-options-now-available-acadia-pharmaceuticals-acad-2016-01-25 | nan | nan | Investors in Acadia Pharmaceuticals Inc (Symbol: ACAD) saw new options become available today, for the April 15th expiration. One of the key data points that goes into the price an option buyer is willing to pay, is the time value, so with 81 days until expiration the newly available contracts represent a possible opportunity for sellers of puts or calls to achieve a higher premium than would be available for the contracts with a closer expiration. At Stock Options Channel , our YieldBoost formula has looked up and down the ACAD options chain for the new April 15th contracts and identified one put and one call contract of particular interest.
The put contract at the $24.00 strike price has a current bid of $3.00. If an investor was to sell-to-open that put contract, they are committing to purchase the stock at $24.00, but will also collect the premium, putting the cost basis of the shares at $21.00 (before broker commissions). To an investor already interested in purchasing shares of ACAD, that could represent an attractive alternative to paying $24.82/share today.
Because the $24.00 strike represents an approximate 3% discount to the current trading price of the stock (in other words it is out-of-the-money by that percentage), there is also the possibility that the put contract would expire worthless. The current analytical data (including greeks and implied greeks) suggest the current odds of that happening are 61%. Stock Options Channel will track those odds over time to see how they change, publishing a chart of those numbers on our website under the contract detail page for this contract . Should the contract expire worthless, the premium would represent a 12.50% return on the cash commitment, or 56.36% annualized - at Stock Options Channel we call this the YieldBoost .
Below is a chart showing the trailing twelve month trading history for Acadia Pharmaceuticals Inc, and highlighting in green where the $24.00 strike is located relative to that history: Turning to the calls side of the option chain, the call contract at the $25.00 strike price has a current bid of $3.30. If an investor was to purchase shares of ACAD stock at the current price level of $24.82/share, and then sell-to-open that call contract as a "covered call," they are committing to sell the stock at $25.00. Considering the call seller will also collect the premium, that would drive a total return (excluding dividends, if any) of 14.02% if the stock gets called away at the April 15th expiration (before broker commissions). Of course, a lot of upside could potentially be left on the table if ACAD shares really soar, which is why looking at the trailing twelve month trading history for Acadia Pharmaceuticals Inc, as well as studying the business fundamentals becomes important. Below is a chart showing ACAD's trailing twelve month trading history, with the $25.00 strike highlighted in red:
Considering the fact that the $25.00 strike represents an approximate 1% premium to the current trading price of the stock (in other words it is out-of-the-money by that percentage), there is also the possibility that the covered call contract would expire worthless, in which case the investor would keep both their shares of stock and the premium collected. The current analytical data (including greeks and implied greeks) suggest the current odds of that happening are 43%. On our website under the contract detail page for this contract , Stock Options Channel will track those odds over time to see how they change and publish a chart of those numbers (the trading history of the option contract will also be charted). Should the covered call contract expire worthless, the premium would represent a 13.30% boost of extra return to the investor, or 59.94% annualized, which we refer to as the YieldBoost .
The implied volatility in the put contract example is 89%, while the implied volatility in the call contract example is 86%. Meanwhile, we calculate the actual trailing twelve month volatility (considering the last 251 trading day closing values as well as today's price of $24.82) to be 64%. For more put and call options contract ideas worth looking at, visit StockOptionsChannel.com.
Top YieldBoost Calls of Stocks with Recent Secondaries »
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Of course, a lot of upside could potentially be left on the table if ACAD shares really soar, which is why looking at the trailing twelve month trading history for Acadia Pharmaceuticals Inc, as well as studying the business fundamentals becomes important. Below is a chart showing ACAD's trailing twelve month trading history, with the $25.00 strike highlighted in red: Considering the fact that the $25.00 strike represents an approximate 1% premium to the current trading price of the stock (in other words it is out-of-the-money by that percentage), there is also the possibility that the covered call contract would expire worthless, in which case the investor would keep both their shares of stock and the premium collected. Investors in Acadia Pharmaceuticals Inc (Symbol: ACAD) saw new options become available today, for the April 15th expiration. | Below is a chart showing ACAD's trailing twelve month trading history, with the $25.00 strike highlighted in red: Considering the fact that the $25.00 strike represents an approximate 1% premium to the current trading price of the stock (in other words it is out-of-the-money by that percentage), there is also the possibility that the covered call contract would expire worthless, in which case the investor would keep both their shares of stock and the premium collected. Investors in Acadia Pharmaceuticals Inc (Symbol: ACAD) saw new options become available today, for the April 15th expiration. At Stock Options Channel , our YieldBoost formula has looked up and down the ACAD options chain for the new April 15th contracts and identified one put and one call contract of particular interest. | Below is a chart showing the trailing twelve month trading history for Acadia Pharmaceuticals Inc, and highlighting in green where the $24.00 strike is located relative to that history: Turning to the calls side of the option chain, the call contract at the $25.00 strike price has a current bid of $3.30. Below is a chart showing ACAD's trailing twelve month trading history, with the $25.00 strike highlighted in red: Considering the fact that the $25.00 strike represents an approximate 1% premium to the current trading price of the stock (in other words it is out-of-the-money by that percentage), there is also the possibility that the covered call contract would expire worthless, in which case the investor would keep both their shares of stock and the premium collected. Investors in Acadia Pharmaceuticals Inc (Symbol: ACAD) saw new options become available today, for the April 15th expiration. | At Stock Options Channel , our YieldBoost formula has looked up and down the ACAD options chain for the new April 15th contracts and identified one put and one call contract of particular interest. Below is a chart showing ACAD's trailing twelve month trading history, with the $25.00 strike highlighted in red: Considering the fact that the $25.00 strike represents an approximate 1% premium to the current trading price of the stock (in other words it is out-of-the-money by that percentage), there is also the possibility that the covered call contract would expire worthless, in which case the investor would keep both their shares of stock and the premium collected. Investors in Acadia Pharmaceuticals Inc (Symbol: ACAD) saw new options become available today, for the April 15th expiration. |
36240.0 | 2016-01-12 00:00:00 UTC | Baker Brothers Advisors buys ACADIA shares | ACAD | https://www.nasdaq.com/articles/baker-brothers-advisors-buys-acadia-shares-2016-01-12 | nan | nan | The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. |
36241.0 | 2016-01-07 00:00:00 UTC | Why Shares of ACADIA Pharmaceuticals Inc. Fell off a Cliff | ACAD | https://www.nasdaq.com/articles/why-shares-acadia-pharmaceuticals-inc-fell-cliff-2016-01-07 | nan | nan | What: Investors in ACADIA Pharmaceuticals , a biopharmaceutical company focused on neurological and central nervous system disorders, are having a rough day as the stock fell by more than 12% earlier this morning (although shares have since recovered to down about 2.5% at the time of publication) after news broke that it will be raising capital via a common stock offering.
So what: The San Diego-based company announced today that it will be raising up to $345 million of fresh capital by selling shares of its common stock in a secondary public offering. The press release did not offer details about what it plans to do with the new capital.
The market appears to have been taken off guard by this news and is selling off shares hard as a result.
Now what: I am a bit surprised to see the company looking to raise capital today, so I understand why the market is reacting so negatively to the news. With more than $240 million in cash on its books as of the third quarter, it's not like it's hurting for cash, so why raise more now?
After all, biotech stocks are off to a rough start for the year as the SPDR S&P Biotech ETF , an exchange-traded fund that holds a collection of biotech stocks, has sold off by more than 6% since the calendar hit Jan. 1. With biotech valuations down so much, it might not be the best time to raise capital.
In addition, the company is set to hear from the Food and Drug Administration about its pending application for Nuplazid, its potential treatment for Parkinson's disease psychosis, on May 1, 2016. If the FDA gives Nuplazid the green light, then ACADIA's stock price could increase, so why would it want to raise capital ahead of that potential catalyst? Is the company simply hedging its bets or is it anticipating bad news from the FDA?
Only time will tell if this capital raise is happening at a favorable price or not, but given the sell-off of the SPDR S&P Biotech ETF since the start of the year, it's hard to blame the market for assuming the worst.
The next billion-dollar iSecret
The world's biggest tech company forgot to show you something at its recent event, but a few Wall Street analysts and the Fool didn't miss a beat: There's a small company that's powering their brand-new gadgets and the coming revolution in technology. And we think its stock price has nearly unlimited room to run for early in-the-know investors! To be one of them, just click here .
The article Why Shares of ACADIA Pharmaceuticals Inc. Fell off a Cliff originally appeared on Fool.com.
Brian Feroldi has no position in any stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. Try any of our Foolish newsletter services free for 30 days . We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy .
Copyright © 1995 - 2016 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy .
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | What: Investors in ACADIA Pharmaceuticals , a biopharmaceutical company focused on neurological and central nervous system disorders, are having a rough day as the stock fell by more than 12% earlier this morning (although shares have since recovered to down about 2.5% at the time of publication) after news broke that it will be raising capital via a common stock offering. If the FDA gives Nuplazid the green light, then ACADIA's stock price could increase, so why would it want to raise capital ahead of that potential catalyst? The article Why Shares of ACADIA Pharmaceuticals Inc. Fell off a Cliff originally appeared on Fool.com. | The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. What: Investors in ACADIA Pharmaceuticals , a biopharmaceutical company focused on neurological and central nervous system disorders, are having a rough day as the stock fell by more than 12% earlier this morning (although shares have since recovered to down about 2.5% at the time of publication) after news broke that it will be raising capital via a common stock offering. If the FDA gives Nuplazid the green light, then ACADIA's stock price could increase, so why would it want to raise capital ahead of that potential catalyst? | What: Investors in ACADIA Pharmaceuticals , a biopharmaceutical company focused on neurological and central nervous system disorders, are having a rough day as the stock fell by more than 12% earlier this morning (although shares have since recovered to down about 2.5% at the time of publication) after news broke that it will be raising capital via a common stock offering. If the FDA gives Nuplazid the green light, then ACADIA's stock price could increase, so why would it want to raise capital ahead of that potential catalyst? The article Why Shares of ACADIA Pharmaceuticals Inc. Fell off a Cliff originally appeared on Fool.com. | What: Investors in ACADIA Pharmaceuticals , a biopharmaceutical company focused on neurological and central nervous system disorders, are having a rough day as the stock fell by more than 12% earlier this morning (although shares have since recovered to down about 2.5% at the time of publication) after news broke that it will be raising capital via a common stock offering. If the FDA gives Nuplazid the green light, then ACADIA's stock price could increase, so why would it want to raise capital ahead of that potential catalyst? The article Why Shares of ACADIA Pharmaceuticals Inc. Fell off a Cliff originally appeared on Fool.com. |
36242.0 | 2015-11-16 00:00:00 UTC | Interesting ACAD Put And Call Options For January 2018 | ACAD | https://www.nasdaq.com/articles/interesting-acad-put-and-call-options-january-2018-2015-11-16 | nan | nan | Investors in Acadia Pharmaceuticals Inc (Symbol: ACAD) saw new options become available today, for the January 2018 expiration. One of the key data points that goes into the price an option buyer is willing to pay, is the time value, so with 795 days until expiration the newly available contracts represent a potential opportunity for sellers of puts or calls to achieve a higher premium than would be available for the contracts with a closer expiration. At Stock Options Channel , our YieldBoost formula has looked up and down the ACAD options chain for the new January 2018 contracts and identified one put and one call contract of particular interest.
The put contract at the $33.00 strike price has a current bid of $10.00. If an investor was to sell-to-open that put contract, they are committing to purchase the stock at $33.00, but will also collect the premium, putting the cost basis of the shares at $23.00 (before broker commissions). To an investor already interested in purchasing shares of ACAD, that could represent an attractive alternative to paying $34.24/share today.
Because the $33.00 strike represents an approximate 4% discount to the current trading price of the stock (in other words it is out-of-the-money by that percentage), there is also the possibility that the put contract would expire worthless. The current analytical data (including greeks and implied greeks) suggest the current odds of that happening are 70%. Stock Options Channel will track those odds over time to see how they change, publishing a chart of those numbers on our website under the contract detail page for this contract . Should the contract expire worthless, the premium would represent a 30.30% return on the cash commitment, or 13.91% annualized - at Stock Options Channel we call this the YieldBoost .
Below is a chart showing the trailing twelve month trading history for Acadia Pharmaceuticals Inc, and highlighting in green where the $33.00 strike is located relative to that history: Turning to the calls side of the option chain, the call contract at the $40.00 strike price has a current bid of $10.50. If an investor was to purchase shares of ACAD stock at the current price level of $34.24/share, and then sell-to-open that call contract as a "covered call," they are committing to sell the stock at $40.00. Considering the call seller will also collect the premium, that would drive a total return (excluding dividends, if any) of 47.49% if the stock gets called away at the January 2018 expiration (before broker commissions). Of course, a lot of upside could potentially be left on the table if ACAD shares really soar, which is why looking at the trailing twelve month trading history for Acadia Pharmaceuticals Inc, as well as studying the business fundamentals becomes important. Below is a chart showing ACAD's trailing twelve month trading history, with the $40.00 strike highlighted in red:
Considering the fact that the $40.00 strike represents an approximate 17% premium to the current trading price of the stock (in other words it is out-of-the-money by that percentage), there is also the possibility that the covered call contract would expire worthless, in which case the investor would keep both their shares of stock and the premium collected. The current analytical data (including greeks and implied greeks) suggest the current odds of that happening are 35%. On our website under the contract detail page for this contract , Stock Options Channel will track those odds over time to see how they change and publish a chart of those numbers (the trading history of the option contract will also be charted). Should the covered call contract expire worthless, the premium would represent a 30.67% boost of extra return to the investor, or 14.08% annualized, which we refer to as the YieldBoost .
The implied volatility in the put contract example is 68%, while the implied volatility in the call contract example is 73%. Meanwhile, we calculate the actual trailing twelve month volatility (considering the last 251 trading day closing values as well as today's price of $34.24) to be 59%. For more put and call options contract ideas worth looking at, visit StockOptionsChannel.com.
Top YieldBoost Calls of the S&P 500 »
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Of course, a lot of upside could potentially be left on the table if ACAD shares really soar, which is why looking at the trailing twelve month trading history for Acadia Pharmaceuticals Inc, as well as studying the business fundamentals becomes important. Below is a chart showing ACAD's trailing twelve month trading history, with the $40.00 strike highlighted in red: Considering the fact that the $40.00 strike represents an approximate 17% premium to the current trading price of the stock (in other words it is out-of-the-money by that percentage), there is also the possibility that the covered call contract would expire worthless, in which case the investor would keep both their shares of stock and the premium collected. Investors in Acadia Pharmaceuticals Inc (Symbol: ACAD) saw new options become available today, for the January 2018 expiration. | Below is a chart showing ACAD's trailing twelve month trading history, with the $40.00 strike highlighted in red: Considering the fact that the $40.00 strike represents an approximate 17% premium to the current trading price of the stock (in other words it is out-of-the-money by that percentage), there is also the possibility that the covered call contract would expire worthless, in which case the investor would keep both their shares of stock and the premium collected. Investors in Acadia Pharmaceuticals Inc (Symbol: ACAD) saw new options become available today, for the January 2018 expiration. At Stock Options Channel , our YieldBoost formula has looked up and down the ACAD options chain for the new January 2018 contracts and identified one put and one call contract of particular interest. | Below is a chart showing the trailing twelve month trading history for Acadia Pharmaceuticals Inc, and highlighting in green where the $33.00 strike is located relative to that history: Turning to the calls side of the option chain, the call contract at the $40.00 strike price has a current bid of $10.50. Below is a chart showing ACAD's trailing twelve month trading history, with the $40.00 strike highlighted in red: Considering the fact that the $40.00 strike represents an approximate 17% premium to the current trading price of the stock (in other words it is out-of-the-money by that percentage), there is also the possibility that the covered call contract would expire worthless, in which case the investor would keep both their shares of stock and the premium collected. Investors in Acadia Pharmaceuticals Inc (Symbol: ACAD) saw new options become available today, for the January 2018 expiration. | At Stock Options Channel , our YieldBoost formula has looked up and down the ACAD options chain for the new January 2018 contracts and identified one put and one call contract of particular interest. Below is a chart showing ACAD's trailing twelve month trading history, with the $40.00 strike highlighted in red: Considering the fact that the $40.00 strike represents an approximate 17% premium to the current trading price of the stock (in other words it is out-of-the-money by that percentage), there is also the possibility that the covered call contract would expire worthless, in which case the investor would keep both their shares of stock and the premium collected. Investors in Acadia Pharmaceuticals Inc (Symbol: ACAD) saw new options become available today, for the January 2018 expiration. |
36243.0 | 2015-11-02 00:00:00 UTC | Health Care Sector Update for 11/02/2015: TTPH, ACAD, CTMX | ACAD | https://www.nasdaq.com/articles/health-care-sector-update-11022015-ttph-acad-ctmx-2015-11-02 | nan | nan | Top Health-care stocks:
JNJ: flat
PFE: +0.8%
ABT: -0.7%
MRK: flat
AMGN: +0.5%
Health-care shares were mixed in pre-market trade Monday.
In health-care stocks news, Tetraphase Pharmaceuticals ( TTPH ), a clinical-stage biopharmaceutical company, reported a Q3 net loss of $18 million, or $0.49 per share, compared to a net loss of $14.2 million, or $0.55 per share, for the same period in 2014.
Shares in the company were unchanged at $9.03 pre-bell. Over the past 52 weeks, the company has traded between $7.20 and $52.90.
ACADIA Pharmaceuticals ( ACAD ) were up by 7.7% to $37.50 in recent pre-market trade after the company announced that the Food and Drug Administration granted priority review status to its New Drug Application for NUPLAZID to treat psychosis associated with Parkinson's disease.
Shares in the company have traded between $26.57 and $51.99 over the past 52 weeks.
And CytomX Therapeutics ( CTMX ) shares were initiated by Jeffferies & Co. with a buy rating and a price target set at $19.
The company's shares were unchanged at $10.40 pre-bell. Over the past 52 weeks, the company has traded between $9.01 and $17.02.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
Copyright (C) 2016 MTNewswires.com. All rights reserved. Unauthorized reproduction is strictly prohibited.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | ACADIA Pharmaceuticals ( ACAD ) were up by 7.7% to $37.50 in recent pre-market trade after the company announced that the Food and Drug Administration granted priority review status to its New Drug Application for NUPLAZID to treat psychosis associated with Parkinson's disease. In health-care stocks news, Tetraphase Pharmaceuticals ( TTPH ), a clinical-stage biopharmaceutical company, reported a Q3 net loss of $18 million, or $0.49 per share, compared to a net loss of $14.2 million, or $0.55 per share, for the same period in 2014. And CytomX Therapeutics ( CTMX ) shares were initiated by Jeffferies & Co. with a buy rating and a price target set at $19. | The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. ACADIA Pharmaceuticals ( ACAD ) were up by 7.7% to $37.50 in recent pre-market trade after the company announced that the Food and Drug Administration granted priority review status to its New Drug Application for NUPLAZID to treat psychosis associated with Parkinson's disease. In health-care stocks news, Tetraphase Pharmaceuticals ( TTPH ), a clinical-stage biopharmaceutical company, reported a Q3 net loss of $18 million, or $0.49 per share, compared to a net loss of $14.2 million, or $0.55 per share, for the same period in 2014. | ACADIA Pharmaceuticals ( ACAD ) were up by 7.7% to $37.50 in recent pre-market trade after the company announced that the Food and Drug Administration granted priority review status to its New Drug Application for NUPLAZID to treat psychosis associated with Parkinson's disease. In health-care stocks news, Tetraphase Pharmaceuticals ( TTPH ), a clinical-stage biopharmaceutical company, reported a Q3 net loss of $18 million, or $0.49 per share, compared to a net loss of $14.2 million, or $0.55 per share, for the same period in 2014. Shares in the company have traded between $26.57 and $51.99 over the past 52 weeks. | ACADIA Pharmaceuticals ( ACAD ) were up by 7.7% to $37.50 in recent pre-market trade after the company announced that the Food and Drug Administration granted priority review status to its New Drug Application for NUPLAZID to treat psychosis associated with Parkinson's disease. Top Health-care stocks: JNJ: flat Health-care shares were mixed in pre-market trade Monday. |
36244.0 | 2015-11-02 00:00:00 UTC | Why Acadia Pharmaceuticals Is Up Today | ACAD | https://www.nasdaq.com/articles/why-acadia-pharmaceuticals-today-2015-11-02 | nan | nan | What: Shares of Acadia Pharmaceuticals , a clinical-stage biopharmaceutical company focused on disorders of the central nervous system, were up more than 16% in late afternoon trading today on heavy volume after the company released good news related to its pending New Drug Application, or NDA, with the FDA.
So what: The company announced that its NDA filing for its drug Nuplazid, which was submitted earlier this year as a potential treatment for Parkinson's disease psychosis, has been accepted for priority review by the FDA. A priority review designation accelerates the timeline for review from 10 months to six months from the date of acceptance of filing, and thus a target action date of May 1, 2016 has been set.
Given the good news of a faster review timeline, investors in the company got excited today and bid up it shares accordingly.
Now what:
In clinical trials, Nuplazid was able to meet its primary and secondary efficacy endpoints in treating the disease, with no worsening of motor function. Based on the results, the FDA designated Nuplazid with the Breakthrough Therapy designation, so odds look favorable that it will be approved next year.
Given the huge potential for Nuplazid and the good news about the accelerated review, I certainly think the market was right to bid up shares today.
The next billion-dollar iSecret
The world's biggest tech company forgot to show you something at its recent event, but a few Wall Street analysts and the Fool didn't miss a beat: There's a small company that's powering their brand-new gadgets and the coming revolution in technology. And we think its stock price has nearly unlimited room to run for early, in-the-know investors! To be one of them, just click here .
The article Why Acadia Pharmaceuticals Is Up Today originally appeared on Fool.com.
Brian Feroldi has no position in any stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. Try any of our Foolish newsletter services free for 30 days . We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy .
Copyright © 1995 - 2015 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy .
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | What: Shares of Acadia Pharmaceuticals , a clinical-stage biopharmaceutical company focused on disorders of the central nervous system, were up more than 16% in late afternoon trading today on heavy volume after the company released good news related to its pending New Drug Application, or NDA, with the FDA. The article Why Acadia Pharmaceuticals Is Up Today originally appeared on Fool.com. So what: The company announced that its NDA filing for its drug Nuplazid, which was submitted earlier this year as a potential treatment for Parkinson's disease psychosis, has been accepted for priority review by the FDA. | What: Shares of Acadia Pharmaceuticals , a clinical-stage biopharmaceutical company focused on disorders of the central nervous system, were up more than 16% in late afternoon trading today on heavy volume after the company released good news related to its pending New Drug Application, or NDA, with the FDA. The article Why Acadia Pharmaceuticals Is Up Today originally appeared on Fool.com. A priority review designation accelerates the timeline for review from 10 months to six months from the date of acceptance of filing, and thus a target action date of May 1, 2016 has been set. | What: Shares of Acadia Pharmaceuticals , a clinical-stage biopharmaceutical company focused on disorders of the central nervous system, were up more than 16% in late afternoon trading today on heavy volume after the company released good news related to its pending New Drug Application, or NDA, with the FDA. The article Why Acadia Pharmaceuticals Is Up Today originally appeared on Fool.com. So what: The company announced that its NDA filing for its drug Nuplazid, which was submitted earlier this year as a potential treatment for Parkinson's disease psychosis, has been accepted for priority review by the FDA. | What: Shares of Acadia Pharmaceuticals , a clinical-stage biopharmaceutical company focused on disorders of the central nervous system, were up more than 16% in late afternoon trading today on heavy volume after the company released good news related to its pending New Drug Application, or NDA, with the FDA. The article Why Acadia Pharmaceuticals Is Up Today originally appeared on Fool.com. A priority review designation accelerates the timeline for review from 10 months to six months from the date of acceptance of filing, and thus a target action date of May 1, 2016 has been set. |
36245.0 | 2015-11-02 00:00:00 UTC | Noteworthy Monday Option Activity: LPLA, ACAD, ECOM | ACAD | https://www.nasdaq.com/articles/noteworthy-monday-option-activity-lpla-acad-ecom-2015-11-02 | nan | nan | Looking at options trading activity among components of the Russell 3000 index, there is noteworthy activity today in LPL Financial Holdings Inc. (Symbol: LPLA), where a total volume of 20,025 contracts has been traded thus far today, a contract volume which is representative of approximately 2.0 million underlying shares (given that every 1 contract represents 100 underlying shares). That number works out to 213.9% of LPLA's average daily trading volume over the past month, of 936,015 shares. Especially high volume was seen for the $42 strike put option expiring November 20, 2015 , with 10,003 contracts trading so far today, representing approximately 1.0 million underlying shares of LPLA. Below is a chart showing LPLA's trailing twelve month trading history, with the $42 strike highlighted in orange:
Acadia Pharmaceuticals Inc (Symbol: ACAD) options are showing a volume of 6,978 contracts thus far today. That number of contracts represents approximately 697,800 underlying shares, working out to a sizeable 63.9% of ACAD's average daily trading volume over the past month, of 1.1 million shares. Especially high volume was seen for the $38 strike put option expiring November 20, 2015 , with 1,026 contracts trading so far today, representing approximately 102,600 underlying shares of ACAD. Below is a chart showing ACAD's trailing twelve month trading history, with the $38 strike highlighted in orange:
And ChannelAdvisor Corp (Symbol: ECOM) saw options trading volume of 1,000 contracts, representing approximately 100,000 underlying shares or approximately 62.2% of ECOM's average daily trading volume over the past month, of 160,670 shares. Particularly high volume was seen for the $10 strike call option expiring December 18, 2015 , with 500 contracts trading so far today, representing approximately 50,000 underlying shares of ECOM. Below is a chart showing ECOM's trailing twelve month trading history, with the $10 strike highlighted in orange:
For the various different available expirations for LPLA options , ACAD options , or ECOM options , visit StockOptionsChannel.com.
Today's Most Active Call & Put Options of the S&P 500 »
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Especially high volume was seen for the $38 strike put option expiring November 20, 2015 , with 1,026 contracts trading so far today, representing approximately 102,600 underlying shares of ACAD. Below is a chart showing LPLA's trailing twelve month trading history, with the $42 strike highlighted in orange: Acadia Pharmaceuticals Inc (Symbol: ACAD) options are showing a volume of 6,978 contracts thus far today. That number of contracts represents approximately 697,800 underlying shares, working out to a sizeable 63.9% of ACAD's average daily trading volume over the past month, of 1.1 million shares. | Below is a chart showing LPLA's trailing twelve month trading history, with the $42 strike highlighted in orange: Acadia Pharmaceuticals Inc (Symbol: ACAD) options are showing a volume of 6,978 contracts thus far today. Below is a chart showing ACAD's trailing twelve month trading history, with the $38 strike highlighted in orange: And ChannelAdvisor Corp (Symbol: ECOM) saw options trading volume of 1,000 contracts, representing approximately 100,000 underlying shares or approximately 62.2% of ECOM's average daily trading volume over the past month, of 160,670 shares. That number of contracts represents approximately 697,800 underlying shares, working out to a sizeable 63.9% of ACAD's average daily trading volume over the past month, of 1.1 million shares. | Below is a chart showing ACAD's trailing twelve month trading history, with the $38 strike highlighted in orange: And ChannelAdvisor Corp (Symbol: ECOM) saw options trading volume of 1,000 contracts, representing approximately 100,000 underlying shares or approximately 62.2% of ECOM's average daily trading volume over the past month, of 160,670 shares. Below is a chart showing LPLA's trailing twelve month trading history, with the $42 strike highlighted in orange: Acadia Pharmaceuticals Inc (Symbol: ACAD) options are showing a volume of 6,978 contracts thus far today. That number of contracts represents approximately 697,800 underlying shares, working out to a sizeable 63.9% of ACAD's average daily trading volume over the past month, of 1.1 million shares. | Especially high volume was seen for the $38 strike put option expiring November 20, 2015 , with 1,026 contracts trading so far today, representing approximately 102,600 underlying shares of ACAD. Below is a chart showing ACAD's trailing twelve month trading history, with the $38 strike highlighted in orange: And ChannelAdvisor Corp (Symbol: ECOM) saw options trading volume of 1,000 contracts, representing approximately 100,000 underlying shares or approximately 62.2% of ECOM's average daily trading volume over the past month, of 160,670 shares. Below is a chart showing LPLA's trailing twelve month trading history, with the $42 strike highlighted in orange: Acadia Pharmaceuticals Inc (Symbol: ACAD) options are showing a volume of 6,978 contracts thus far today. |
36246.0 | 2015-09-28 00:00:00 UTC | Oversold Conditions For Acadia Pharmaceuticals (ACAD) | ACAD | https://www.nasdaq.com/articles/oversold-conditions-acadia-pharmaceuticals-acad-2015-09-28 | nan | nan | Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a technical analysis indicator called the Relative Strength Index, or RSI, which measures momentum on a scale of zero to 100. A stock is considered to be oversold if the RSI reading falls below 30.
In trading on Monday, shares of Acadia Pharmaceuticals Inc (Symbol: ACAD) entered into oversold territory, hitting an RSI reading of 29.1, after changing hands as low as $30.41 per share. By comparison, the current RSI reading of the S&P 500 ETF ( SPY ) is 33.7. A bullish investor could look at ACAD's 29.1 RSI reading today as a sign that the recent heavy selling is in the process of exhausting itself, and begin to look for entry point opportunities on the buy side. The chart below shows the one year performance of ACAD shares:
Looking at the chart above, ACAD's low point in its 52 week range is $22.04 per share, with $51.99 as the 52 week high point - that compares with a last trade of $31.83.
According to the ETF Finder at ETF Channel, ACAD makes up 1.79% of the PowerShares DWA Healthcare Momentum Portfolio ETF (Symbol: PTH) which is trading relatively unchanged on the day Monday.
Find out what 9 other oversold stocks you need to know about »
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | In trading on Monday, shares of Acadia Pharmaceuticals Inc (Symbol: ACAD) entered into oversold territory, hitting an RSI reading of 29.1, after changing hands as low as $30.41 per share. A bullish investor could look at ACAD's 29.1 RSI reading today as a sign that the recent heavy selling is in the process of exhausting itself, and begin to look for entry point opportunities on the buy side. The chart below shows the one year performance of ACAD shares: Looking at the chart above, ACAD's low point in its 52 week range is $22.04 per share, with $51.99 as the 52 week high point - that compares with a last trade of $31.83. | The chart below shows the one year performance of ACAD shares: Looking at the chart above, ACAD's low point in its 52 week range is $22.04 per share, with $51.99 as the 52 week high point - that compares with a last trade of $31.83. In trading on Monday, shares of Acadia Pharmaceuticals Inc (Symbol: ACAD) entered into oversold territory, hitting an RSI reading of 29.1, after changing hands as low as $30.41 per share. A bullish investor could look at ACAD's 29.1 RSI reading today as a sign that the recent heavy selling is in the process of exhausting itself, and begin to look for entry point opportunities on the buy side. | In trading on Monday, shares of Acadia Pharmaceuticals Inc (Symbol: ACAD) entered into oversold territory, hitting an RSI reading of 29.1, after changing hands as low as $30.41 per share. The chart below shows the one year performance of ACAD shares: Looking at the chart above, ACAD's low point in its 52 week range is $22.04 per share, with $51.99 as the 52 week high point - that compares with a last trade of $31.83. A bullish investor could look at ACAD's 29.1 RSI reading today as a sign that the recent heavy selling is in the process of exhausting itself, and begin to look for entry point opportunities on the buy side. | In trading on Monday, shares of Acadia Pharmaceuticals Inc (Symbol: ACAD) entered into oversold territory, hitting an RSI reading of 29.1, after changing hands as low as $30.41 per share. According to the ETF Finder at ETF Channel, ACAD makes up 1.79% of the PowerShares DWA Healthcare Momentum Portfolio ETF (Symbol: PTH) which is trading relatively unchanged on the day Monday. A bullish investor could look at ACAD's 29.1 RSI reading today as a sign that the recent heavy selling is in the process of exhausting itself, and begin to look for entry point opportunities on the buy side. |
36247.0 | 2015-09-25 00:00:00 UTC | 5 Sell-Ranked Biotechs That Fell More Than 5% Today | ACAD | https://www.nasdaq.com/articles/5-sell-ranked-biotechs-fell-more-5-today-2015-09-25 | nan | nan | Despite being one of the most successful sectors in the past few years where the markets produced substantial returns, the Biotech sector has been struggling as of late. Most investors probably have seen this industry in the news quite a bit, but they may not realize the effects of this industry's decline. The biotech industry has strong ties to the healthcare sector, one that many investors are tied to in one way or another in their portfolios.
Friday was an especially tough day for many biotech stocks, and below are 5 that suffered losses of at least 5% on the day.
Acadia Pharmaceuticals(ACAD)
Focuses on the discovery, development and commercialization of small molecule drugs for the treatment of central nervous system disorders is Acadia Pharmaceuticals. On Friday, the stock saw a decrease of -7.60%, closing the day at $34.15 per share. ACAD is currently a Zacks Rank #4 (Sell).
ANI Pharmaceuticals(ANIP)
ANI Pharmaceuticals engages in developing, manufacturing, and marketing branded and generic prescription pharmaceuticals. The company is currently a Zacks Rank #5 (Strong Sell) and on Friday suffered a decline of -6.47% as of market close.
Bluebird Bio Inc.(BLUE)
Bluebird Bio Inc is a biotech focused on the development, manufacture, and marketing of therapies for severe disorders. The company suffered a decline of -9.69% on Friday, and currently holds a Zacks Rank #4 (Sell).
Orexigen Therapeutics Inc.(OREX)
Orexigen Therapeutics Inc is a biopharmaceutical company focused on the development of pharmaceutical product candidates for the treatment of central nervous system disorders, including obesity. The company currently holds a Zacks Rank #4 (Sell). OREX had dropped -7.14% as of market close.
Alder Biopharmaceuticals(ALDR)
Alder Biopharmaceuticals currently holds a Zacks Rank #4 (Sell) and is a clinical-stage biopharmaceutical company that discovers, develops, and seeks to commercialize therapeutic antibodies. As of market close on Friday, the stock was down a substantial -9.25% to $33.86 a share.
Bottom Line
The biotech has had a rough time in the recent times, and at the moment it doesn't seem as though the end of this decline is in sight. It will be something to watch as this industry attempts to turn things around and finish out 2015 on a high note. Stay tuned to Zacks as we cover this industry as well as the popular healthcare industry that biotech's have strong ties to.
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report >>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
ACADIA PHARMA (ACAD): Free Stock Analysis Report
ANI PHARMACEUT (ANIP): Free Stock Analysis Report
BLUEBIRD BIO (BLUE): Free Stock Analysis Report
OREXIGEN THERAP (OREX): Free Stock Analysis Report
ALDER BIOPHARMA (ALDR): Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Acadia Pharmaceuticals(ACAD) Focuses on the discovery, development and commercialization of small molecule drugs for the treatment of central nervous system disorders is Acadia Pharmaceuticals. ACAD is currently a Zacks Rank #4 (Sell). Click to get this free report ACADIA PHARMA (ACAD): Free Stock Analysis Report ANI PHARMACEUT (ANIP): Free Stock Analysis Report BLUEBIRD BIO (BLUE): Free Stock Analysis Report OREXIGEN THERAP (OREX): Free Stock Analysis Report ALDER BIOPHARMA (ALDR): Free Stock Analysis Report To read this article on Zacks.com click here. | Click to get this free report ACADIA PHARMA (ACAD): Free Stock Analysis Report ANI PHARMACEUT (ANIP): Free Stock Analysis Report BLUEBIRD BIO (BLUE): Free Stock Analysis Report OREXIGEN THERAP (OREX): Free Stock Analysis Report ALDER BIOPHARMA (ALDR): Free Stock Analysis Report To read this article on Zacks.com click here. Acadia Pharmaceuticals(ACAD) Focuses on the discovery, development and commercialization of small molecule drugs for the treatment of central nervous system disorders is Acadia Pharmaceuticals. ACAD is currently a Zacks Rank #4 (Sell). | Click to get this free report ACADIA PHARMA (ACAD): Free Stock Analysis Report ANI PHARMACEUT (ANIP): Free Stock Analysis Report BLUEBIRD BIO (BLUE): Free Stock Analysis Report OREXIGEN THERAP (OREX): Free Stock Analysis Report ALDER BIOPHARMA (ALDR): Free Stock Analysis Report To read this article on Zacks.com click here. Acadia Pharmaceuticals(ACAD) Focuses on the discovery, development and commercialization of small molecule drugs for the treatment of central nervous system disorders is Acadia Pharmaceuticals. ACAD is currently a Zacks Rank #4 (Sell). | Acadia Pharmaceuticals(ACAD) Focuses on the discovery, development and commercialization of small molecule drugs for the treatment of central nervous system disorders is Acadia Pharmaceuticals. ACAD is currently a Zacks Rank #4 (Sell). Click to get this free report ACADIA PHARMA (ACAD): Free Stock Analysis Report ANI PHARMACEUT (ANIP): Free Stock Analysis Report BLUEBIRD BIO (BLUE): Free Stock Analysis Report OREXIGEN THERAP (OREX): Free Stock Analysis Report ALDER BIOPHARMA (ALDR): Free Stock Analysis Report To read this article on Zacks.com click here. |
36248.0 | 2015-09-10 00:00:00 UTC | The Zacks Analyst Blog Highlights: Amgen, Tetraphase, Geron, Alexion and ACADIA | ACAD | https://www.nasdaq.com/articles/the-zacks-analyst-blog-highlights%3A-amgen-tetraphase-geron-alexion-and-acadia-2015-09-10 | nan | nan | For Immediate Release
Chicago, IL - September 10, 2015 - Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include the Amgen ( AMGN ), Tetraphase ( TTPH ), Geron ( GERN ), Alexion ( ALXN ) and ACADIA ( ACAD ).
Today, Zacks is promoting its ''Buy'' stock recommendations. Get #1Stock of the Day pick for free .
Here are highlights from Wednesday's Analyst Blog:
Biotech Stock Roundup
The first biosimilar has finally arrived in the U.S. with Novartis' generic arm, Sandoz, launching its biosimilar version of Amgen's ( AMGN ) Neupogen. With Zarxio being the first biosimilar to launch in the U.S. market, investor focus will remain on its impact on Neupogen sales in the coming quarters. Meanwhile, Tetraphase ( TTPH ) suffered a huge setback with the company announcing disappointing late-stage data on its lead pipeline candidate.
Recap of the Week's Most Important Stories
1. Zarxio, the first FDA-approved biosimilar, was launched last week by Sandoz. Approved earlier this year in March, Zarxio is the biosimilar version of Amgen's blockbuster drug, Neupogen (filgrastim). While biosimilars have been available in the EU for quite a while, there was no regulatory pathway for biosimilars in the U.S.
However, this changed with the passing of The Biologics Price Competition and Innovation Act of 2009 (BPCI Act) as part of the Affordable Care Act that President Obama signed into law in Mar 2010. Biosimilars are expected to reduce healthcare costs and provide a large number of patients with access to much needed biologic treatments.
Meanwhile, Amgen continues to progress with its pipeline. The company, which recently gained FDA approval for its PCSK9 inhibitor, Repatha, filed a regulatory application in the EU last week for etelcalcetide. The company is looking to get etelcalcetide approved for the treatment of secondary hyperparathyroidism in adult patients with chronic kidney disease on hemodialysis therapy.
2. Tetraphase suffered a huge setback with its experimental antibiotic, eravacycline, failing to achieve the primary endpoint in a late stage study. Eravacycline failed to show statistical non-inferiority compared to levofloxacin in the study being conducted for the treatment of complicated urinary tract infections (cUTI). Shares were down significantly in pre-market trading .
3. Geron's ( GERN ) shares were up about 13% on data from two separate studies suggesting disease-modifying activity for the company's sole pipeline candidate, imetelstat, which is being evaluated for hematologic myeloid malignancies. This is encouraging news for Geron, which has had its share of hiccups related to the development of imetelstat. However, things started looking up for the company last year in November when it struck a deal with Johnson & Johnson's Janssen Biotech for the development and commercialization of imetelstat.
4. Alexion ( ALXN ), which gained EU approval recently for its ultra-rare metabolic disorder drug, Kanuma, is facing a delay in the U.S. The company said that the FDA has extended the PDUFA date for Kanuma by three months which means a response from the agency should now be out by Dec 8. Importantly, the FDA has not asked for additional clinical data (Read more: Alexion's Kanuma FDA Action Date Delayed by Three Months ).
5. ACADIA ( ACAD ) submitted a NDA seeking approval for its lead pipeline candidate, Nuplazid (pimavanserin). The company is looking to get Nuplazid approved for the treatment of psychosis associated with Parkinson's disease. Timely approval could very well make Nuplazid the first treatment to be approved for this indication. Of the one million people suffering from Parkinson's in the U.S., about 40% are estimated to suffer from Parkinson's disease psychosis, which is characterized by hallucinations and delusions. ACADIA is seeking priority review for its treatment, which has breakthrough therapy status.
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days.Click to get this free report >>
About Zacks Equity Research
Zacks Equity Research provides the best of quantitative and qualitative analysis to help investors know what stocks to buy and which to sell for the long-term.
Continuous coverage is provided for a universe of 1,150 publicly traded stocks. Our analysts are organized by industry which gives them keen insights to developments that affect company profits and stock performance. Recommendations and target prices are six-month time horizons.
Zacks "Profit from the Pros" e-mail newsletter provides highlights of the latest analysis from Zacks Equity Research. Subscribe to this free newsletter today . Find out What is happening in the stock market today on zacks.com.
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
AMGEN INC (AMGN): Free Stock Analysis Report
TETRAPHASE PHAR (TTPH): Free Stock Analysis Report
GERON CORP (GERN): Free Stock Analysis Report
ALEXION PHARMA (ALXN): Free Stock Analysis Report
ACADIA PHARMA (ACAD): Free Stock Analysis Report
To read this article on Zacks.com click here.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Stocks recently featured in the blog include the Amgen ( AMGN ), Tetraphase ( TTPH ), Geron ( GERN ), Alexion ( ALXN ) and ACADIA ( ACAD ). ACADIA ( ACAD ) submitted a NDA seeking approval for its lead pipeline candidate, Nuplazid (pimavanserin). ACADIA is seeking priority review for its treatment, which has breakthrough therapy status. | Stocks recently featured in the blog include the Amgen ( AMGN ), Tetraphase ( TTPH ), Geron ( GERN ), Alexion ( ALXN ) and ACADIA ( ACAD ). Click to get this free report AMGEN INC (AMGN): Free Stock Analysis Report TETRAPHASE PHAR (TTPH): Free Stock Analysis Report GERON CORP (GERN): Free Stock Analysis Report ALEXION PHARMA (ALXN): Free Stock Analysis Report ACADIA PHARMA (ACAD): Free Stock Analysis Report To read this article on Zacks.com click here. ACADIA ( ACAD ) submitted a NDA seeking approval for its lead pipeline candidate, Nuplazid (pimavanserin). | Click to get this free report AMGEN INC (AMGN): Free Stock Analysis Report TETRAPHASE PHAR (TTPH): Free Stock Analysis Report GERON CORP (GERN): Free Stock Analysis Report ALEXION PHARMA (ALXN): Free Stock Analysis Report ACADIA PHARMA (ACAD): Free Stock Analysis Report To read this article on Zacks.com click here. Stocks recently featured in the blog include the Amgen ( AMGN ), Tetraphase ( TTPH ), Geron ( GERN ), Alexion ( ALXN ) and ACADIA ( ACAD ). ACADIA ( ACAD ) submitted a NDA seeking approval for its lead pipeline candidate, Nuplazid (pimavanserin). | ACADIA ( ACAD ) submitted a NDA seeking approval for its lead pipeline candidate, Nuplazid (pimavanserin). Stocks recently featured in the blog include the Amgen ( AMGN ), Tetraphase ( TTPH ), Geron ( GERN ), Alexion ( ALXN ) and ACADIA ( ACAD ). ACADIA is seeking priority review for its treatment, which has breakthrough therapy status. |
36249.0 | 2015-09-03 00:00:00 UTC | Why Parkinson's Disease-Focused ACADIA Pharmaceuticals is Soaring Today | ACAD | https://www.nasdaq.com/articles/why-parkinsons-disease-focused-acadia-pharmaceuticals-soaring-today-2015-09-03 | nan | nan | What: Shares of ACADIA Pharmaceuticals , a clinical-stage biotech with a focus on neurological disorders, were up more than 12% at one point today (but have since settled down) after the company announced that it filed for FDA approval of its key compound.
So what: Acadia has officially submitted a New Drug Application, or NDA, to the FDA for approval of Nuplazid, which the company has studied as a potential treatment for Parkinson's Disease Psychosis. In clinical trials, Nuplazid was successful in meeting all of its primary and secondary endpoints, and the company believes that the drug offers hope to the millions of patients around the world who suffer from this awful disease.
Now what: Investors have been bidding up Acadia's stock for years now, and surprisingly enough the stock still managed to move higher during the summer despite the company announcing that they were delaying the submission of Nuplazid from the first half of the year to the second half, noting that they needed more time to properly prepare the company for commercialization.
I think investors were right to bid up the stock today as seeing Nuplazid officially pending FDA approval removes a small amount of uncertainly from the company's future, which always makes investors feel better about a company's prospects.
The FDA has already granted Nuplazid the much-coveted "breakthrough therapy" designation, and considering that patients who have Parkinson's Disease Psychosis currently have no real treatment options, sales estimates for Nuplazid look huge. Currently, analysts are expecting the drug to eventually reach more than $2 billion in peak sales.
Acadia has been an absolute dream stock for its long-term investors, and with its NDA submission officially behind it, it's no wonder that investors are excited today. If Nuplazid can successfully make its way through the FDA approval process, then it's highly likely that investors may continue to see huge gains in the company's stock.
The next billion-dollar iSecret
The world's biggest tech company forgot to show you something at its recent event, but a few Wall Street analysts and the Fool didn't miss a beat: There's a small company that's powering their brand-new gadgets and the coming revolution in technology. And we think its stock price has nearly unlimited room to run for early in-the-know investors! To be one of them, just click here .
The article Why Parkinson's Disease-Focused ACADIA Pharmaceuticals is Soaring Today originally appeared on Fool.com.
Brian Feroldi has no position in any stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. Try any of our Foolish newsletter services free for 30 days . We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy .
Copyright © 1995 - 2015 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy .
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | What: Shares of ACADIA Pharmaceuticals , a clinical-stage biotech with a focus on neurological disorders, were up more than 12% at one point today (but have since settled down) after the company announced that it filed for FDA approval of its key compound. So what: Acadia has officially submitted a New Drug Application, or NDA, to the FDA for approval of Nuplazid, which the company has studied as a potential treatment for Parkinson's Disease Psychosis. Now what: Investors have been bidding up Acadia's stock for years now, and surprisingly enough the stock still managed to move higher during the summer despite the company announcing that they were delaying the submission of Nuplazid from the first half of the year to the second half, noting that they needed more time to properly prepare the company for commercialization. | The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. What: Shares of ACADIA Pharmaceuticals , a clinical-stage biotech with a focus on neurological disorders, were up more than 12% at one point today (but have since settled down) after the company announced that it filed for FDA approval of its key compound. So what: Acadia has officially submitted a New Drug Application, or NDA, to the FDA for approval of Nuplazid, which the company has studied as a potential treatment for Parkinson's Disease Psychosis. | Now what: Investors have been bidding up Acadia's stock for years now, and surprisingly enough the stock still managed to move higher during the summer despite the company announcing that they were delaying the submission of Nuplazid from the first half of the year to the second half, noting that they needed more time to properly prepare the company for commercialization. What: Shares of ACADIA Pharmaceuticals , a clinical-stage biotech with a focus on neurological disorders, were up more than 12% at one point today (but have since settled down) after the company announced that it filed for FDA approval of its key compound. So what: Acadia has officially submitted a New Drug Application, or NDA, to the FDA for approval of Nuplazid, which the company has studied as a potential treatment for Parkinson's Disease Psychosis. | So what: Acadia has officially submitted a New Drug Application, or NDA, to the FDA for approval of Nuplazid, which the company has studied as a potential treatment for Parkinson's Disease Psychosis. What: Shares of ACADIA Pharmaceuticals , a clinical-stage biotech with a focus on neurological disorders, were up more than 12% at one point today (but have since settled down) after the company announced that it filed for FDA approval of its key compound. Now what: Investors have been bidding up Acadia's stock for years now, and surprisingly enough the stock still managed to move higher during the summer despite the company announcing that they were delaying the submission of Nuplazid from the first half of the year to the second half, noting that they needed more time to properly prepare the company for commercialization. |
36250.0 | 2015-08-20 00:00:00 UTC | Acadia Pharmaceuticals (ACAD) Shares Cross Below 200 DMA | ACAD | https://www.nasdaq.com/articles/acadia-pharmaceuticals-acad-shares-cross-below-200-dma-2015-08-20 | nan | nan | In trading on Thursday, shares of Acadia Pharmaceuticals Inc (Symbol: ACAD) crossed below their 200 day moving average of $36.50, changing hands as low as $35.96 per share. Acadia Pharmaceuticals Inc shares are currently trading down about 5.6% on the day. The chart below shows the one year performance of ACAD shares, versus its 200 day moving average:
Looking at the chart above, ACAD's low point in its 52 week range is $21.84 per share, with $51.99 as the 52 week high point - that compares with a last trade of $35.99.
According to the ETF Finder at ETF Channel, ACAD makes up 1.82% of the PowerShares DWA Healthcare Momentum Portfolio ETF (Symbol: PTH) which is trading lower by about 4.8% on the day Thursday.
Click here to find out which 9 other stocks recently crossed below their 200 day moving average »
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | In trading on Thursday, shares of Acadia Pharmaceuticals Inc (Symbol: ACAD) crossed below their 200 day moving average of $36.50, changing hands as low as $35.96 per share. The chart below shows the one year performance of ACAD shares, versus its 200 day moving average: Looking at the chart above, ACAD's low point in its 52 week range is $21.84 per share, with $51.99 as the 52 week high point - that compares with a last trade of $35.99. Acadia Pharmaceuticals Inc shares are currently trading down about 5.6% on the day. | In trading on Thursday, shares of Acadia Pharmaceuticals Inc (Symbol: ACAD) crossed below their 200 day moving average of $36.50, changing hands as low as $35.96 per share. The chart below shows the one year performance of ACAD shares, versus its 200 day moving average: Looking at the chart above, ACAD's low point in its 52 week range is $21.84 per share, with $51.99 as the 52 week high point - that compares with a last trade of $35.99. Acadia Pharmaceuticals Inc shares are currently trading down about 5.6% on the day. | In trading on Thursday, shares of Acadia Pharmaceuticals Inc (Symbol: ACAD) crossed below their 200 day moving average of $36.50, changing hands as low as $35.96 per share. The chart below shows the one year performance of ACAD shares, versus its 200 day moving average: Looking at the chart above, ACAD's low point in its 52 week range is $21.84 per share, with $51.99 as the 52 week high point - that compares with a last trade of $35.99. Acadia Pharmaceuticals Inc shares are currently trading down about 5.6% on the day. | In trading on Thursday, shares of Acadia Pharmaceuticals Inc (Symbol: ACAD) crossed below their 200 day moving average of $36.50, changing hands as low as $35.96 per share. According to the ETF Finder at ETF Channel, ACAD makes up 1.82% of the PowerShares DWA Healthcare Momentum Portfolio ETF (Symbol: PTH) which is trading lower by about 4.8% on the day Thursday. Acadia Pharmaceuticals Inc shares are currently trading down about 5.6% on the day. |
36251.0 | 2015-08-14 00:00:00 UTC | Why ACADIA Pharmaceuticals (ACAD) Could Be Positioned for a Slump | ACAD | https://www.nasdaq.com/articles/why-acadia-pharmaceuticals-acad-could-be-positioned-for-a-slump-2015-08-14 | nan | nan | Similar to wise buying decisions, exiting certain underperformers at the right time helps maximize portfolio returns. Selling off losers can be difficult, but if both the share price and estimates are falling, it could be time to get rid of the security before more losses hit your portfolio.
One such stock that you may want to consider dropping is ACADIA Pharmaceuticals Inc. ( ACAD ), which has witnessed a significant price decline in the past four weeks, and it has seen negative earnings estimate revisions for the current quarter and the current year. A Zacks Rank #4 (Sell) further confirms weakness in ACAD.
A key reason for this move has been the negative trend in earnings estimate revisions. For the full year, we have seen 3 estimates moving down in the past 30 days, compared with no upward revisions. This trend has caused the consensus estimate to trend lower, going from a loss of $1.35 a share a month ago to its current level of a loss of $1.49.
Also, for the current quarter, ACADIA Pharmaceuticals has seen 3 downward estimate revisions versus no revisions in the opposite direction, dragging the consensus estimate down to a loss of 39 cents a share from a loss of 33 cents over the past 30 days.
The stock also has seen some pretty dismal trading lately, as the share price has dropped 19.6% in the past month.
So it may not be a good decision to keep this stock in your portfolio anymore, at least if you don't have a long time horizon to wait.
If you are still interested in the Medicine - Biomed/Genetics sector, you may instead consider a better-ranked stock - Gilead Sciences Inc. ( GILD ). The stock currently holds a Zacks Rank #1 (Strong Buy) and may be better selection at this time.
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days . Click to get this free report >>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
ACADIA PHARMA (ACAD): Free Stock Analysis Report
GILEAD SCIENCES (GILD): Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | One such stock that you may want to consider dropping is ACADIA Pharmaceuticals Inc. ( ACAD ), which has witnessed a significant price decline in the past four weeks, and it has seen negative earnings estimate revisions for the current quarter and the current year. A Zacks Rank #4 (Sell) further confirms weakness in ACAD. Also, for the current quarter, ACADIA Pharmaceuticals has seen 3 downward estimate revisions versus no revisions in the opposite direction, dragging the consensus estimate down to a loss of 39 cents a share from a loss of 33 cents over the past 30 days. | One such stock that you may want to consider dropping is ACADIA Pharmaceuticals Inc. ( ACAD ), which has witnessed a significant price decline in the past four weeks, and it has seen negative earnings estimate revisions for the current quarter and the current year. Click to get this free report ACADIA PHARMA (ACAD): Free Stock Analysis Report GILEAD SCIENCES (GILD): Free Stock Analysis Report To read this article on Zacks.com click here. A Zacks Rank #4 (Sell) further confirms weakness in ACAD. | One such stock that you may want to consider dropping is ACADIA Pharmaceuticals Inc. ( ACAD ), which has witnessed a significant price decline in the past four weeks, and it has seen negative earnings estimate revisions for the current quarter and the current year. Also, for the current quarter, ACADIA Pharmaceuticals has seen 3 downward estimate revisions versus no revisions in the opposite direction, dragging the consensus estimate down to a loss of 39 cents a share from a loss of 33 cents over the past 30 days. Click to get this free report ACADIA PHARMA (ACAD): Free Stock Analysis Report GILEAD SCIENCES (GILD): Free Stock Analysis Report To read this article on Zacks.com click here. | One such stock that you may want to consider dropping is ACADIA Pharmaceuticals Inc. ( ACAD ), which has witnessed a significant price decline in the past four weeks, and it has seen negative earnings estimate revisions for the current quarter and the current year. A Zacks Rank #4 (Sell) further confirms weakness in ACAD. Also, for the current quarter, ACADIA Pharmaceuticals has seen 3 downward estimate revisions versus no revisions in the opposite direction, dragging the consensus estimate down to a loss of 39 cents a share from a loss of 33 cents over the past 30 days. |
36252.0 | 2015-08-12 00:00:00 UTC | 3 Small-Cap Biopharma Stocks I'd Never Short | ACAD | https://www.nasdaq.com/articles/3-small-cap-biopharma-stocks-id-never-short-2015-08-12 | nan | nan | Short-sellers frequently targets small-cap biopharmas because their stocks can crumble in spectacular fashion when things don't go their way on the clinical or regulatory fronts. In fact, you'd be hard pressed to find more than a handful of small to mid-sized biopharmas that haven't attracted short-sellers in droves this year.
Despite this somewhat brutal example, shorts have still poured into some of Acadia's more promising contemporaries such as Bellicum Pharmaceuticals , Exelixis , and Sarepta Therapeutics . Even if I could ignore the questionable morality of shorting stocks working on life-saving diseases, I still wouldn't dream of shorting these three stocks. Here's why.
Bellicum might leapfrog its competitors in the CAR-T space
Bellicum is lagging behind its peers, including Juno Therapeutics and Kite Pharma , in the CAR-T space for blood cancers and solid tumors. But its novel approach toward developing the next generation of CAR-T products could enable it to one day dominate this multibillion-dollar market.
In a nutshell, CAR-Ts have produced some promising early stage results in a host of blood cancers, but they've also been linked to several serious -- and even deadly -- adverse events. Bellicum is hoping to lower the potential for serious adverse events through its CaspaCIDe safety switch inserted in its CAR-T products. This molecular switch can be triggered by infusing a small-molecule called rimiducid into patients exhibiting signs of toxicity, thereby causing the cells to undergo programmed cell death.
In another stroke of genius, Bellicum developed a second molecule switch designed to "amp up" the therapeutic response in the presence of tumor cells, giving the company a relatively unique ability to modulate the activity of its CAR-T constructs in vivo .
Short-sellers appear to be unimpressed by Bellicum's platform, however, gobbling up 13% of the float at last count. With the company set to begin human trials in the first half of 2016, I wouldn't be surprised if they begin moving to the sidelines. After all, there has been a ton of high-dollar licensing activity in this space of late, and Bellicum is probably going to follow suit in this regard.
Exelixis is soaring after its flagship drug breaks through in kidney cancer
Exelixis got a much-needed boost last month, after its main value driver, Cometriq, reported strong late-stage results as a second-line treatment in kidney cancer. Specifically, Cometriq met its primary endpoint of improving progression-free survival for patients with renal-cell carcinoma, or kidney cancer, compared with those receiving Novartis ' Afinitor (everolimus). Even though this positive trial result should put Cometriq on track toward taking a big slice out of Afinitor's $400 million-plus in sales moving forward, shorts haven't exactly backed off, with a nearly a quarter of the float being short, per the latest figures.
Source: Exelixis.
With Exelixis and its partner Roche widely expected to receive good news from the FDA in November for their experimental metastatic melanoma combo therapy of cobimetinib and Zelboraf, and the drugmaker shoring up its cash position with a recent $135 million offering, I think the future looks particularly bright for this small-cap biopharma. Overall, Exelixis is shaping up into an attractive takeover target after these key clinical and business developments, putting shorts into a rather precarious, high-risk position moving forward.
Sarepta's stock could soar with a regulatory approval for its experimental DMD drug
Sarepta's shares have already climbed by a staggering 139% this year, after the company announced that the FDA agreed to review its exon-skipping Duchenne muscular dystrophy, or DMD, drug, eteplirsen. Shorts, though, still hold a massive position in the stock, with over 35% of the float being sold short. As a reminder, eteplirsen's regulatory pathway has been hindered by the fact that Sarepta has only completed a midstage study that included a grand total of 12 patients.
While there's a good chance that the FDA could still decide to reject the application outright or issue a Complete Response Letter following a formal review, the obvious risk for short-sellers is that eteplirsen's limited data turn out to be enough to convince the agency that its benefits outweigh the risks for a disease that is always fatal. Perhaps the biggest issue that should be keeping short-sellers up at night is that an eteplirsen approval may validate Sarepta's remaining DMD pipeline that seeks to treat upwards of 80% of this patient population -- meaning that its DMD platform has the potential to rake in billions in sales.
Are any of these three stocks compelling buys now?
Although I wouldn't be caught shorting any of these small-cap biopharmas because of their explosive upside potential, Exelixis is perhaps the only clear-cut buyout of the group. Exelixis already has an approved product on the market in Cometriq, and it's finally starting to blossom into a viable oncology company with the drug's positive top-line results in kidney cancer. Bellicum and Sarepta, by contrast, are probably best viewed as intriguing watchlist candidates because of the speculative nature of their upcoming catalysts.
The next billion-dollar iSecret
The world's biggest tech company forgot to show you something at its recent event, but a few Wall Street analysts and the Fool didn't miss a beat: There's a small company that's powering their brand-new gadgets and the coming revolution in technology. And we think its stock price has nearly unlimited room to run for early in-the-know investors! To be one of them, just click here .
The article 3 Small-Cap Biopharma Stocks I'd Never Short originally appeared on Fool.com.
George Budwell has no position in any stocks mentioned. The Motley Fool recommends Exelixis and Juno Therapeutics. Try any of our Foolish newsletter services free for 30 days . We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy .
Copyright © 1995 - 2015 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy .
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Despite this somewhat brutal example, shorts have still poured into some of Acadia's more promising contemporaries such as Bellicum Pharmaceuticals , Exelixis , and Sarepta Therapeutics . In another stroke of genius, Bellicum developed a second molecule switch designed to "amp up" the therapeutic response in the presence of tumor cells, giving the company a relatively unique ability to modulate the activity of its CAR-T constructs in vivo . Specifically, Cometriq met its primary endpoint of improving progression-free survival for patients with renal-cell carcinoma, or kidney cancer, compared with those receiving Novartis ' Afinitor (everolimus). | Despite this somewhat brutal example, shorts have still poured into some of Acadia's more promising contemporaries such as Bellicum Pharmaceuticals , Exelixis , and Sarepta Therapeutics . Even though this positive trial result should put Cometriq on track toward taking a big slice out of Afinitor's $400 million-plus in sales moving forward, shorts haven't exactly backed off, with a nearly a quarter of the float being short, per the latest figures. Sarepta's stock could soar with a regulatory approval for its experimental DMD drug Sarepta's shares have already climbed by a staggering 139% this year, after the company announced that the FDA agreed to review its exon-skipping Duchenne muscular dystrophy, or DMD, drug, eteplirsen. | Despite this somewhat brutal example, shorts have still poured into some of Acadia's more promising contemporaries such as Bellicum Pharmaceuticals , Exelixis , and Sarepta Therapeutics . Bellicum might leapfrog its competitors in the CAR-T space Bellicum is lagging behind its peers, including Juno Therapeutics and Kite Pharma , in the CAR-T space for blood cancers and solid tumors. Even though this positive trial result should put Cometriq on track toward taking a big slice out of Afinitor's $400 million-plus in sales moving forward, shorts haven't exactly backed off, with a nearly a quarter of the float being short, per the latest figures. | Despite this somewhat brutal example, shorts have still poured into some of Acadia's more promising contemporaries such as Bellicum Pharmaceuticals , Exelixis , and Sarepta Therapeutics . Bellicum might leapfrog its competitors in the CAR-T space Bellicum is lagging behind its peers, including Juno Therapeutics and Kite Pharma , in the CAR-T space for blood cancers and solid tumors. Shorts, though, still hold a massive position in the stock, with over 35% of the float being sold short. |
36253.0 | 2015-08-07 00:00:00 UTC | Acadia Pharmaceuticals Becomes Oversold (ACAD) | ACAD | https://www.nasdaq.com/articles/acadia-pharmaceuticals-becomes-oversold-acad-2015-08-07 | nan | nan | Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a technical analysis indicator called the Relative Strength Index, or RSI, which measures momentum on a scale of zero to 100. A stock is considered to be oversold if the RSI reading falls below 30.
In trading on Friday, shares of Acadia Pharmaceuticals Inc (Symbol: ACAD) entered into oversold territory, hitting an RSI reading of 29.0, after changing hands as low as $39.01 per share. By comparison, the current RSI reading of the S&P 500 ETF ( SPY ) is 39.0. A bullish investor could look at ACAD's 29.0 RSI reading today as a sign that the recent heavy selling is in the process of exhausting itself, and begin to look for entry point opportunities on the buy side. The chart below shows the one year performance of ACAD shares:
Looking at the chart above, ACAD's low point in its 52 week range is $19.90 per share, with $51.99 as the 52 week high point - that compares with a last trade of $39.12.
According to the ETF Finder at ETF Channel, ACAD makes up 1.96% of the PowerShares DWA Healthcare Momentum Portfolio ETF (Symbol: PTH) which is trading lower by about 3.1% on the day Friday.
Find out what 9 other oversold stocks you need to know about »
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | In trading on Friday, shares of Acadia Pharmaceuticals Inc (Symbol: ACAD) entered into oversold territory, hitting an RSI reading of 29.0, after changing hands as low as $39.01 per share. A bullish investor could look at ACAD's 29.0 RSI reading today as a sign that the recent heavy selling is in the process of exhausting itself, and begin to look for entry point opportunities on the buy side. The chart below shows the one year performance of ACAD shares: Looking at the chart above, ACAD's low point in its 52 week range is $19.90 per share, with $51.99 as the 52 week high point - that compares with a last trade of $39.12. | The chart below shows the one year performance of ACAD shares: Looking at the chart above, ACAD's low point in its 52 week range is $19.90 per share, with $51.99 as the 52 week high point - that compares with a last trade of $39.12. In trading on Friday, shares of Acadia Pharmaceuticals Inc (Symbol: ACAD) entered into oversold territory, hitting an RSI reading of 29.0, after changing hands as low as $39.01 per share. A bullish investor could look at ACAD's 29.0 RSI reading today as a sign that the recent heavy selling is in the process of exhausting itself, and begin to look for entry point opportunities on the buy side. | In trading on Friday, shares of Acadia Pharmaceuticals Inc (Symbol: ACAD) entered into oversold territory, hitting an RSI reading of 29.0, after changing hands as low as $39.01 per share. The chart below shows the one year performance of ACAD shares: Looking at the chart above, ACAD's low point in its 52 week range is $19.90 per share, with $51.99 as the 52 week high point - that compares with a last trade of $39.12. A bullish investor could look at ACAD's 29.0 RSI reading today as a sign that the recent heavy selling is in the process of exhausting itself, and begin to look for entry point opportunities on the buy side. | In trading on Friday, shares of Acadia Pharmaceuticals Inc (Symbol: ACAD) entered into oversold territory, hitting an RSI reading of 29.0, after changing hands as low as $39.01 per share. According to the ETF Finder at ETF Channel, ACAD makes up 1.96% of the PowerShares DWA Healthcare Momentum Portfolio ETF (Symbol: PTH) which is trading lower by about 3.1% on the day Friday. A bullish investor could look at ACAD's 29.0 RSI reading today as a sign that the recent heavy selling is in the process of exhausting itself, and begin to look for entry point opportunities on the buy side. |
36254.0 | 2015-08-07 00:00:00 UTC | Why ACADIA Pharmaceuticals Inc. is Dropping Today | ACAD | https://www.nasdaq.com/articles/why-acadia-pharmaceuticals-inc-dropping-today-2015-08-07 | nan | nan | What:
So what: Expense continued to rise at the company as it prepares for its first New Drug Application, or NDA, submission to the FDA for its lead compound Nuplazid, which is designed to treat Parkinson's disease psychosis.
Net loss for the quarter came in at $39.4 million, which was up significantly from the $21.5 million net loss reported during the same time last year. On a per share basis the net loss was $0.39, which was worse than the $0.33 that analysts were expecting.
These results caused a few analysts to revise their ratings today, as Piper Jaffray downgraded the stock to 'neutral' with a price target of $48, while Needham reiterated its 'buy' recommendation and increased its price target to $49. This activity appears to be the main reason for the stocks strong movement today.
Now what: During the call management confirmed that its NDA submission is ready to go, but that it will not happen until its manufacturing quality systems are firmly in place. The company reaffirmed that it is still planning to submit the NDA in the second half of the year, and stated that the company is making good progress as it prepares itself for a commercial launch.
Acadia's stock has been on a stellar run for quite some time, and has surpisingly kept its upwards trajectory going even after management announced that its NDA submission would be delayed until the second half of the year. However, Wall Street's patience for the stock appears to be finally wearing thin, causing today's price action.
Nuplazid still appears to hold huge commercial potential and insiders still hold a significant amount of stock . While waiting for the company to file its NDA continues to require patience, I think it's good that the company wants to ensure it has its ducks in a row before it makes the leap to become a commercial organization. If you were bullish on Acadia's stock before today's announcement, I see no reason to change your position.
The next billion-dollar iSecret
The world's biggest tech company forgot to show you something at its recent event, but a few Wall Street analysts and the Fool didn't miss a beat: There's a small company that's powering their brand-new gadgets and the coming revolution in technology. And we think its stock price has nearly unlimited room to run for early in-the-know investors! To be one of them, just click here .
The article Why ACADIA Pharmaceuticals Inc. is Dropping Today originally appeared on Fool.com.
Brian Feroldi has no position in any stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. Try any of our Foolish newsletter services free for 30 days . We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy .
Copyright © 1995 - 2015 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy .
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Acadia's stock has been on a stellar run for quite some time, and has surpisingly kept its upwards trajectory going even after management announced that its NDA submission would be delayed until the second half of the year. If you were bullish on Acadia's stock before today's announcement, I see no reason to change your position. The article Why ACADIA Pharmaceuticals Inc. is Dropping Today originally appeared on Fool.com. | The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. Acadia's stock has been on a stellar run for quite some time, and has surpisingly kept its upwards trajectory going even after management announced that its NDA submission would be delayed until the second half of the year. If you were bullish on Acadia's stock before today's announcement, I see no reason to change your position. | Acadia's stock has been on a stellar run for quite some time, and has surpisingly kept its upwards trajectory going even after management announced that its NDA submission would be delayed until the second half of the year. If you were bullish on Acadia's stock before today's announcement, I see no reason to change your position. The article Why ACADIA Pharmaceuticals Inc. is Dropping Today originally appeared on Fool.com. | Acadia's stock has been on a stellar run for quite some time, and has surpisingly kept its upwards trajectory going even after management announced that its NDA submission would be delayed until the second half of the year. If you were bullish on Acadia's stock before today's announcement, I see no reason to change your position. The article Why ACADIA Pharmaceuticals Inc. is Dropping Today originally appeared on Fool.com. |
36255.0 | 2015-07-24 00:00:00 UTC | XLF, UBIO: Big ETF Inflows | ACAD | https://www.nasdaq.com/articles/xlf-ubio-big-etf-inflows-2015-07-24 | nan | nan | Comparing units outstanding versus one week ago at the coverage universe of ETFs at ETF Channel, the biggest inflow was seen in the Financial Select Sector SPDR Fund ( XLF ), which added 27,800,000 units, or a 3.5% increase week over week. Among the largest underlying components of XLF, in morning trading today Wells Fargo & Company ( WFC ) is down about 0.3%, and Berkshire Hathaway Class B (BRK.B) is lower by about 0.1%.
And on a percentage change basis, the ETF with the biggest increase in inflows was the ProShares UltraPro Nasdaq Biotechnology ( UBIO ), which added 350,000 units, for a 38.9% increase in outstanding units. Among the largest underlying components of UBIO, in morning trading today Acadia Pharmaceuticals ( ACAD ) is up about 0.2%, and Acceleron Pharma ( XLRN ) is lower by about 0.9%.
VIDEO: XLF, UBIO: Big ETF Inflows
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Among the largest underlying components of UBIO, in morning trading today Acadia Pharmaceuticals ( ACAD ) is up about 0.2%, and Acceleron Pharma ( XLRN ) is lower by about 0.9%. Among the largest underlying components of XLF, in morning trading today Wells Fargo & Company ( WFC ) is down about 0.3%, and Berkshire Hathaway Class B (BRK.B) is lower by about 0.1%. And on a percentage change basis, the ETF with the biggest increase in inflows was the ProShares UltraPro Nasdaq Biotechnology ( UBIO ), which added 350,000 units, for a 38.9% increase in outstanding units. | Among the largest underlying components of UBIO, in morning trading today Acadia Pharmaceuticals ( ACAD ) is up about 0.2%, and Acceleron Pharma ( XLRN ) is lower by about 0.9%. Among the largest underlying components of XLF, in morning trading today Wells Fargo & Company ( WFC ) is down about 0.3%, and Berkshire Hathaway Class B (BRK.B) is lower by about 0.1%. VIDEO: XLF, UBIO: Big ETF Inflows The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Among the largest underlying components of UBIO, in morning trading today Acadia Pharmaceuticals ( ACAD ) is up about 0.2%, and Acceleron Pharma ( XLRN ) is lower by about 0.9%. Comparing units outstanding versus one week ago at the coverage universe of ETFs at ETF Channel, the biggest inflow was seen in the Financial Select Sector SPDR Fund ( XLF ), which added 27,800,000 units, or a 3.5% increase week over week. And on a percentage change basis, the ETF with the biggest increase in inflows was the ProShares UltraPro Nasdaq Biotechnology ( UBIO ), which added 350,000 units, for a 38.9% increase in outstanding units. | Among the largest underlying components of UBIO, in morning trading today Acadia Pharmaceuticals ( ACAD ) is up about 0.2%, and Acceleron Pharma ( XLRN ) is lower by about 0.9%. Comparing units outstanding versus one week ago at the coverage universe of ETFs at ETF Channel, the biggest inflow was seen in the Financial Select Sector SPDR Fund ( XLF ), which added 27,800,000 units, or a 3.5% increase week over week. Among the largest underlying components of XLF, in morning trading today Wells Fargo & Company ( WFC ) is down about 0.3%, and Berkshire Hathaway Class B (BRK.B) is lower by about 0.1%. |
36256.0 | 2015-07-22 00:00:00 UTC | Commit To Buy Acadia Pharmaceuticals At $32, Earn 13.8% Using Options | ACAD | https://www.nasdaq.com/articles/commit-buy-acadia-pharmaceuticals-32-earn-138-using-options-2015-07-22 | nan | nan | Investors considering a purchase of Acadia Pharmaceuticals Inc (Symbol: ACAD) stock, but tentative about paying the going market price of $49.37/share, might benefit from considering selling puts among the alternative strategies at their disposal. One interesting put contract in particular, is the January 2017 put at the $32 strike, which has a bid at the time of this writing of $4.40. Collecting that bid as the premium represents a 13.8% return against the $32 commitment, or a 9.2% annualized rate of return (at Stock Options Channel we call this the YieldBoost ).
Selling a put does not give an investor access to ACAD's upside potential the way owning shares would, because the put seller only ends up owning shares in the scenario where the contract is exercised. And the person on the other side of the contract would only benefit from exercising at the $32 strike if doing so produced a better outcome than selling at the going market price. ( Do options carry counterparty risk? This and six other common options myths debunked ). So unless Acadia Pharmaceuticals Inc sees its shares fall 35.2% and the contract is exercised (resulting in a cost basis of $27.60 per share before broker commissions, subtracting the $4.40 from $32), the only upside to the put seller is from collecting that premium for the 9.2% annualized rate of return.
Below is a chart showing the trailing twelve month trading history for Acadia Pharmaceuticals Inc, and highlighting in green where the $32 strike is located relative to that history:
The chart above, and the stock's historical volatility, can be a helpful guide in combination with fundamental analysis to judge whether selling the January 2017 put at the $32 strike for the 9.2% annualized rate of return represents good reward for the risks. We calculate the trailing twelve month volatility for Acadia Pharmaceuticals Inc (considering the last 252 trading day closing values as well as today's price of $49.37) to be 50%. For other put options contract ideas at the various different available expirations, visit the ACAD Stock Options page of StockOptionsChannel.com.
Top YieldBoost Puts of the S&P 500 »
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Investors considering a purchase of Acadia Pharmaceuticals Inc (Symbol: ACAD) stock, but tentative about paying the going market price of $49.37/share, might benefit from considering selling puts among the alternative strategies at their disposal. Below is a chart showing the trailing twelve month trading history for Acadia Pharmaceuticals Inc, and highlighting in green where the $32 strike is located relative to that history: The chart above, and the stock's historical volatility, can be a helpful guide in combination with fundamental analysis to judge whether selling the January 2017 put at the $32 strike for the 9.2% annualized rate of return represents good reward for the risks. We calculate the trailing twelve month volatility for Acadia Pharmaceuticals Inc (considering the last 252 trading day closing values as well as today's price of $49.37) to be 50%. | Selling a put does not give an investor access to ACAD's upside potential the way owning shares would, because the put seller only ends up owning shares in the scenario where the contract is exercised. Below is a chart showing the trailing twelve month trading history for Acadia Pharmaceuticals Inc, and highlighting in green where the $32 strike is located relative to that history: The chart above, and the stock's historical volatility, can be a helpful guide in combination with fundamental analysis to judge whether selling the January 2017 put at the $32 strike for the 9.2% annualized rate of return represents good reward for the risks. We calculate the trailing twelve month volatility for Acadia Pharmaceuticals Inc (considering the last 252 trading day closing values as well as today's price of $49.37) to be 50%. | Selling a put does not give an investor access to ACAD's upside potential the way owning shares would, because the put seller only ends up owning shares in the scenario where the contract is exercised. So unless Acadia Pharmaceuticals Inc sees its shares fall 35.2% and the contract is exercised (resulting in a cost basis of $27.60 per share before broker commissions, subtracting the $4.40 from $32), the only upside to the put seller is from collecting that premium for the 9.2% annualized rate of return. Below is a chart showing the trailing twelve month trading history for Acadia Pharmaceuticals Inc, and highlighting in green where the $32 strike is located relative to that history: The chart above, and the stock's historical volatility, can be a helpful guide in combination with fundamental analysis to judge whether selling the January 2017 put at the $32 strike for the 9.2% annualized rate of return represents good reward for the risks. | Investors considering a purchase of Acadia Pharmaceuticals Inc (Symbol: ACAD) stock, but tentative about paying the going market price of $49.37/share, might benefit from considering selling puts among the alternative strategies at their disposal. Below is a chart showing the trailing twelve month trading history for Acadia Pharmaceuticals Inc, and highlighting in green where the $32 strike is located relative to that history: The chart above, and the stock's historical volatility, can be a helpful guide in combination with fundamental analysis to judge whether selling the January 2017 put at the $32 strike for the 9.2% annualized rate of return represents good reward for the risks. For other put options contract ideas at the various different available expirations, visit the ACAD Stock Options page of StockOptionsChannel.com. |
36257.0 | 2015-07-21 00:00:00 UTC | Notable ETF Outflow Detected - BIB, ACAD, XLRN, ACRX | ACAD | https://www.nasdaq.com/articles/notable-etf-outflow-detected-bib-acad-xlrn-acrx-2015-07-21 | nan | nan | Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel , one standout is the ProShares Ultra Nasdaq Biotechnology (Symbol: BIB) where we have detected an approximate $31.4 million dollar outflow -- that's a 2.9% decrease week over week (from 10,350,000 to 10,050,000). Among the largest underlying components of BIB, in trading today Acadia Pharmaceuticals Inc (Symbol: ACAD) is off about 2.5%, Acceleron Pharma, Inc. (Symbol: XLRN) is off about 1.9%, and AcelRx Pharmaceuticals Inc (Symbol: ACRX) is up by about 0.9%. For a complete list of holdings, visit the BIB Holdings page » The chart below shows the one year price performance of BIB, versus its 200 day moving average:
Looking at the chart above, BIB's low point in its 52 week range is $83.38 per share, with $189.74 as the 52 week high point - that compares with a last trade of $102.70. Comparing the most recent share price to the 200 day moving average can also be a useful technical analysis technique -- learn more about the 200 day moving average » .
Exchange traded funds (ETFs) trade just like stocks, but instead of ''shares'' investors are actually buying and selling ''units''. These ''units'' can be traded back and forth just like stocks, but can also be created or destroyed to accommodate investor demand. Each week we monitor the week-over-week change in shares outstanding data, to keep a lookout for those ETFs experiencing notable inflows (many new units created) or outflows (many old units destroyed). Creation of new units will mean the underlying holdings of the ETF need to be purchased, while destruction of units involves selling underlying holdings, so large flows can also impact the individual components held within ETFs.
Click here to find out which 9 other ETFs experienced notable outflows »
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Among the largest underlying components of BIB, in trading today Acadia Pharmaceuticals Inc (Symbol: ACAD) is off about 2.5%, Acceleron Pharma, Inc. (Symbol: XLRN) is off about 1.9%, and AcelRx Pharmaceuticals Inc (Symbol: ACRX) is up by about 0.9%. Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel , one standout is the ProShares Ultra Nasdaq Biotechnology (Symbol: BIB) where we have detected an approximate $31.4 million dollar outflow -- that's a 2.9% decrease week over week (from 10,350,000 to 10,050,000). These ''units'' can be traded back and forth just like stocks, but can also be created or destroyed to accommodate investor demand. | Among the largest underlying components of BIB, in trading today Acadia Pharmaceuticals Inc (Symbol: ACAD) is off about 2.5%, Acceleron Pharma, Inc. (Symbol: XLRN) is off about 1.9%, and AcelRx Pharmaceuticals Inc (Symbol: ACRX) is up by about 0.9%. For a complete list of holdings, visit the BIB Holdings page » The chart below shows the one year price performance of BIB, versus its 200 day moving average: Looking at the chart above, BIB's low point in its 52 week range is $83.38 per share, with $189.74 as the 52 week high point - that compares with a last trade of $102.70. Each week we monitor the week-over-week change in shares outstanding data, to keep a lookout for those ETFs experiencing notable inflows (many new units created) or outflows (many old units destroyed). | Among the largest underlying components of BIB, in trading today Acadia Pharmaceuticals Inc (Symbol: ACAD) is off about 2.5%, Acceleron Pharma, Inc. (Symbol: XLRN) is off about 1.9%, and AcelRx Pharmaceuticals Inc (Symbol: ACRX) is up by about 0.9%. Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel , one standout is the ProShares Ultra Nasdaq Biotechnology (Symbol: BIB) where we have detected an approximate $31.4 million dollar outflow -- that's a 2.9% decrease week over week (from 10,350,000 to 10,050,000). For a complete list of holdings, visit the BIB Holdings page » The chart below shows the one year price performance of BIB, versus its 200 day moving average: Looking at the chart above, BIB's low point in its 52 week range is $83.38 per share, with $189.74 as the 52 week high point - that compares with a last trade of $102.70. | Among the largest underlying components of BIB, in trading today Acadia Pharmaceuticals Inc (Symbol: ACAD) is off about 2.5%, Acceleron Pharma, Inc. (Symbol: XLRN) is off about 1.9%, and AcelRx Pharmaceuticals Inc (Symbol: ACRX) is up by about 0.9%. Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel , one standout is the ProShares Ultra Nasdaq Biotechnology (Symbol: BIB) where we have detected an approximate $31.4 million dollar outflow -- that's a 2.9% decrease week over week (from 10,350,000 to 10,050,000). For a complete list of holdings, visit the BIB Holdings page » The chart below shows the one year price performance of BIB, versus its 200 day moving average: Looking at the chart above, BIB's low point in its 52 week range is $83.38 per share, with $189.74 as the 52 week high point - that compares with a last trade of $102.70. |
36258.0 | 2015-06-30 00:00:00 UTC | Andreas Halvorsen Increases Stake in Esperion Therapeutics | ACAD | https://www.nasdaq.com/articles/andreas-halvorsen-increases-stake-esperion-therapeutics-2015-06-30 | nan | nan | Andreas Halvorsen ( Trades , Portfolio )'s hedge fund Viking Global Investors increased its stake in pharmaceutical company Esperion Therapeutics ( ESPR ) by 875.1% on June 18, GuruFocus Real Time Picks reported Monday.
Founded in 2008, Esperion makes treatments for heart disease patients who experience intolerable side effects from existing drugs. Halvorsen holds 1,335,101 shares of the company, a 5.9% stake, after the increase. He began the position in the first quarter with 136,919 shares.
David Einhorn Undervalued Stocks
David Einhorn Top Growth Companies
David Einhorn High Yield stocks
Martin Whitman Undervalued Stocks
Martin Whitman Top Growth Companies
Martin Whitman High Yield stocks
Third Avenue Value Fund Undervalued Stocks
Third Avenue Value Fund Top Growth Companies
Third Avenue Value Fund High Yield stocks
John Griffin Undervalued Stocks
John Griffin Top Growth Companies
John Griffin High Yield stocks
Andreas Halvorsen Undervalued Stocks
Andreas Halvorsen Top Growth Companies
Andreas Halvorsen High Yield stocks
Esperion's share price rose more than 406% over the past 12 months as one of its treatments, ETC-1002, advanced toward FDA approval with plans to reach Phase 3 development before year end. Two other drugs are in its pipeline in preclinical stage.
The company ended the first quarter with $322.7 million in cash on its balance sheet, up from $141.6 million at the end of 2014. Esperion estimated that its cash reserves would enable it to operate through 2018 and the anticipated approval of ETC-1002. The company also carried $5.0 million in outstanding debt.
With a $1.86 billion market cap, Esperion has a P/B ratio of 5.55.
Halvorsen bought one biotechnology stock in addition to Esperion in the first quarter, ProQR Therapeutics NV ( PRQR ). He sold out of three other positions in the sector: Shire PLC ( SHPG ), ACADIA Pharmaceuticals Inc. ( ACAD ) and Alexion Pharmaceuticals Inc. ( ALXN ). Two more remained in his portfolio: Receptos INc. ( RCPT ) and Vertex Pharmaceuticals Inc. (VRTX).
For more stock trades of gurus in real time, visit GuruFocus' Real Time Picks , a Premium Feature. Not a Premium Member of GuruFocus? Try it free for 7 days here .
About GuruFocus: GuruFocus.com tracks the stocks picks and portfolio holdings of the world's best investors. This value investing site offers stock screeners and valuation tools. And publishes daily articles tracking the latest moves of the world's best investors. GuruFocus also provides promising stock ideas in 3 monthly newsletters sent to Premium Members .
This article first appeared on GuruFocus .
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | He sold out of three other positions in the sector: Shire PLC ( SHPG ), ACADIA Pharmaceuticals Inc. ( ACAD ) and Alexion Pharmaceuticals Inc. ( ALXN ). Andreas Halvorsen ( Trades , Portfolio )'s hedge fund Viking Global Investors increased its stake in pharmaceutical company Esperion Therapeutics ( ESPR ) by 875.1% on June 18, GuruFocus Real Time Picks reported Monday. Founded in 2008, Esperion makes treatments for heart disease patients who experience intolerable side effects from existing drugs. | He sold out of three other positions in the sector: Shire PLC ( SHPG ), ACADIA Pharmaceuticals Inc. ( ACAD ) and Alexion Pharmaceuticals Inc. ( ALXN ). Andreas Halvorsen ( Trades , Portfolio )'s hedge fund Viking Global Investors increased its stake in pharmaceutical company Esperion Therapeutics ( ESPR ) by 875.1% on June 18, GuruFocus Real Time Picks reported Monday. David Einhorn Undervalued Stocks David Einhorn Top Growth Companies David Einhorn High Yield stocks Martin Whitman Undervalued Stocks Martin Whitman Top Growth Companies Martin Whitman High Yield stocks Third Avenue Value Fund Undervalued Stocks Third Avenue Value Fund Top Growth Companies Third Avenue Value Fund High Yield stocks John Griffin Undervalued Stocks John Griffin Top Growth Companies John Griffin High Yield stocks Andreas Halvorsen Undervalued Stocks Andreas Halvorsen Top Growth Companies Andreas Halvorsen High Yield stocks Esperion's share price rose more than 406% over the past 12 months as one of its treatments, ETC-1002, advanced toward FDA approval with plans to reach Phase 3 development before year end. | He sold out of three other positions in the sector: Shire PLC ( SHPG ), ACADIA Pharmaceuticals Inc. ( ACAD ) and Alexion Pharmaceuticals Inc. ( ALXN ). Andreas Halvorsen ( Trades , Portfolio )'s hedge fund Viking Global Investors increased its stake in pharmaceutical company Esperion Therapeutics ( ESPR ) by 875.1% on June 18, GuruFocus Real Time Picks reported Monday. David Einhorn Undervalued Stocks David Einhorn Top Growth Companies David Einhorn High Yield stocks Martin Whitman Undervalued Stocks Martin Whitman Top Growth Companies Martin Whitman High Yield stocks Third Avenue Value Fund Undervalued Stocks Third Avenue Value Fund Top Growth Companies Third Avenue Value Fund High Yield stocks John Griffin Undervalued Stocks John Griffin Top Growth Companies John Griffin High Yield stocks Andreas Halvorsen Undervalued Stocks Andreas Halvorsen Top Growth Companies Andreas Halvorsen High Yield stocks Esperion's share price rose more than 406% over the past 12 months as one of its treatments, ETC-1002, advanced toward FDA approval with plans to reach Phase 3 development before year end. | He sold out of three other positions in the sector: Shire PLC ( SHPG ), ACADIA Pharmaceuticals Inc. ( ACAD ) and Alexion Pharmaceuticals Inc. ( ALXN ). Andreas Halvorsen ( Trades , Portfolio )'s hedge fund Viking Global Investors increased its stake in pharmaceutical company Esperion Therapeutics ( ESPR ) by 875.1% on June 18, GuruFocus Real Time Picks reported Monday. He began the position in the first quarter with 136,919 shares. |
36259.0 | 2015-06-30 00:00:00 UTC | Pabrai Funds 2014 Investor Meeting Notes | ACAD | https://www.nasdaq.com/articles/pabrai-funds-2014-investor-meeting-notes-2015-06-30 | nan | nan | Pabrai Investment Funds Annual Meeting Notes - 2014
- September 21, 2014
Fund Facts :
Mohnish Pabrai ( Trades , Portfolio ) is the principle investor and is a classic value investor in the tradition of Warren Buffett (Trades, Portfolio) and Charlie Munger (Trades, Portfolio)
Martin Whitman Undervalued Stocks
Martin Whitman Top Growth Companies
Martin Whitman High Yield stocks
Third Avenue Value Fund Undervalued Stocks
Third Avenue Value Fund Top Growth Companies
Third Avenue Value Fund High Yield stocks
John Griffin Undervalued Stocks
John Griffin Top Growth Companies
John Griffin High Yield stocks
Andreas Halvorsen Undervalued Stocks
Andreas Halvorsen Top Growth Companies
Andreas Halvorsen High Yield stocks
Mohnish Pabrai Undervalued Stocks
Mohnish Pabrai Top Growth Companies
Mohnish Pabrai High Yield stocks
Pabrai Funds ( PF1 through 4 ) have a combined capital of $690 Million under management
Inception : 2000
Value Proposition :
No leverage / no margin / no short positions
No management fees, only performance fees. ( typical expense ratio of Pabrai funds are between 0.04% to 0.08% )
Pabrai family is the second-largest investor.
Dhandho Holdings :
Founded in Q4 2013
Raised $152.4 Million
Setup as a SPAC ( Special purpose acquisition vehicle )
Flexible vehicle - Ability to buy and hold fully owned subsidiaries for long term and portfolio of stocks
Time limit (sunset) to invest funds raised from investors in proposed investment (Stone Trust Insurance )
Headquartered in Porte Rico - for tax benefits
First acquisition : Stone Trust Insurance
Proposed date for IPO : 2015
Stone Trust Insurance - quick facts :
Mutual insurance company with 5000+ policy holders
Primarily into workers comp insurance
Serving five starts in U.S in 2014 ( expected to expand to ten or fifteen stats in ten years )
Earned $70 million in annual premium ( compared to $20 million in premiums in 2009 and $10 million in premiums 2004 )
Expect combined ratio of 95 or lower over long term
Dandho Holdings will infuse a capital of $30 million after acquiring Stone Trust Insurance for $35 million
Dhandho + Stone Trust Advantage :
Dhandho's cash surplus and backing will allow Stone Trust Insurance to grow without capital constraints.
Boost's Stone Trust's credit rating from B+ to A- post acquisition
Single investor ( Mohnish Pabrai (Trades, Portfolio) himself ) managing investments for Stone Trust ( Clone of Buffet's model for Berkshire )
Environment where the focus is on under writing discipline and not growth
Dhandho will provide a non-institutional environment, which is important for success in insurance business
( Q ) Why did you invest in Chesapeake Energy and what were your reasons to exit ?
Historically based on an energy equivalent basis, crude oil and natural gas prices should have a 6 to 1 ratio . However in the recent years the price of oil typically had traded 8-12x that of natural gas due to a combination of rising domestic production from unconventional shale gas and regulation of natural gas export from U.S. depressing price levels and fear premium for the global crude oil prices .
Chesapeake Energy 's stock price had hit a low under the leadership of Aubrey McClendon due to unsustainable expansion and spending. Aubrey ran into financial and ethical trouble and was ousted by the board of directors
Chesapeake Energy was going through a change in management with the appointment of Doug Lawler as CEO and election of Carl Icon and Lou Simpson (Trades, Portfolio) to the board. Doug Lawler had started to bring spending discipline and focus the company on it's core business.
My expectations and assumptions when I invested in Chesapeake Energy were :
continue reading: http://bitsbusiness.com/investing-2/pabrai-investment-funds-annual-meeting-notes-2014/
About GuruFocus: GuruFocus.com tracks the stocks picks and portfolio holdings of the world's best investors. This value investing site offers stock screeners and valuation tools. And publishes daily articles tracking the latest moves of the world's best investors. GuruFocus also provides promising stock ideas in 3 monthly newsletters sent to Premium Members .
This article first appeared on GuruFocus .
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Boost's Stone Trust's credit rating from B+ to A- post acquisition Single investor ( Mohnish Pabrai (Trades, Portfolio) himself ) managing investments for Stone Trust ( Clone of Buffet's model for Berkshire ) Environment where the focus is on under writing discipline and not growth Dhandho will provide a non-institutional environment, which is important for success in insurance business ( Q ) Why did you invest in Chesapeake Energy and what were your reasons to exit ? Chesapeake Energy 's stock price had hit a low under the leadership of Aubrey McClendon due to unsustainable expansion and spending. My expectations and assumptions when I invested in Chesapeake Energy were : continue reading: http://bitsbusiness.com/investing-2/pabrai-investment-funds-annual-meeting-notes-2014/ About GuruFocus: GuruFocus.com tracks the stocks picks and portfolio holdings of the world's best investors. | Pabrai Investment Funds Annual Meeting Notes - 2014 - September 21, 2014 Fund Facts : Mohnish Pabrai ( Trades , Portfolio ) is the principle investor and is a classic value investor in the tradition of Warren Buffett (Trades, Portfolio) and Charlie Munger (Trades, Portfolio) Martin Whitman Undervalued Stocks Martin Whitman Top Growth Companies Martin Whitman High Yield stocks Third Avenue Value Fund Undervalued Stocks Third Avenue Value Fund Top Growth Companies Third Avenue Value Fund High Yield stocks John Griffin Undervalued Stocks John Griffin Top Growth Companies John Griffin High Yield stocks Andreas Halvorsen Undervalued Stocks Andreas Halvorsen Top Growth Companies Andreas Halvorsen High Yield stocks Mohnish Pabrai Undervalued Stocks Mohnish Pabrai Top Growth Companies Mohnish Pabrai High Yield stocks Pabrai Funds ( PF1 through 4 ) have a combined capital of $690 Million under management Inception : 2000 Value Proposition : No leverage / no margin / no short positions No management fees, only performance fees. Dhandho Holdings : Founded in Q4 2013 Raised $152.4 Million Setup as a SPAC ( Special purpose acquisition vehicle ) Flexible vehicle - Ability to buy and hold fully owned subsidiaries for long term and portfolio of stocks Time limit (sunset) to invest funds raised from investors in proposed investment (Stone Trust Insurance ) Headquartered in Porte Rico - for tax benefits First acquisition : Stone Trust Insurance Proposed date for IPO : 2015 Stone Trust Insurance - quick facts : Mutual insurance company with 5000+ policy holders Primarily into workers comp insurance Serving five starts in U.S in 2014 ( expected to expand to ten or fifteen stats in ten years ) Earned $70 million in annual premium ( compared to $20 million in premiums in 2009 and $10 million in premiums 2004 ) Expect combined ratio of 95 or lower over long term Dandho Holdings will infuse a capital of $30 million after acquiring Stone Trust Insurance for $35 million Dhandho + Stone Trust Advantage : Dhandho's cash surplus and backing will allow Stone Trust Insurance to grow without capital constraints. Boost's Stone Trust's credit rating from B+ to A- post acquisition Single investor ( Mohnish Pabrai (Trades, Portfolio) himself ) managing investments for Stone Trust ( Clone of Buffet's model for Berkshire ) Environment where the focus is on under writing discipline and not growth Dhandho will provide a non-institutional environment, which is important for success in insurance business ( Q ) Why did you invest in Chesapeake Energy and what were your reasons to exit ? | Pabrai Investment Funds Annual Meeting Notes - 2014 - September 21, 2014 Fund Facts : Mohnish Pabrai ( Trades , Portfolio ) is the principle investor and is a classic value investor in the tradition of Warren Buffett (Trades, Portfolio) and Charlie Munger (Trades, Portfolio) Martin Whitman Undervalued Stocks Martin Whitman Top Growth Companies Martin Whitman High Yield stocks Third Avenue Value Fund Undervalued Stocks Third Avenue Value Fund Top Growth Companies Third Avenue Value Fund High Yield stocks John Griffin Undervalued Stocks John Griffin Top Growth Companies John Griffin High Yield stocks Andreas Halvorsen Undervalued Stocks Andreas Halvorsen Top Growth Companies Andreas Halvorsen High Yield stocks Mohnish Pabrai Undervalued Stocks Mohnish Pabrai Top Growth Companies Mohnish Pabrai High Yield stocks Pabrai Funds ( PF1 through 4 ) have a combined capital of $690 Million under management Inception : 2000 Value Proposition : No leverage / no margin / no short positions No management fees, only performance fees. Dhandho Holdings : Founded in Q4 2013 Raised $152.4 Million Setup as a SPAC ( Special purpose acquisition vehicle ) Flexible vehicle - Ability to buy and hold fully owned subsidiaries for long term and portfolio of stocks Time limit (sunset) to invest funds raised from investors in proposed investment (Stone Trust Insurance ) Headquartered in Porte Rico - for tax benefits First acquisition : Stone Trust Insurance Proposed date for IPO : 2015 Stone Trust Insurance - quick facts : Mutual insurance company with 5000+ policy holders Primarily into workers comp insurance Serving five starts in U.S in 2014 ( expected to expand to ten or fifteen stats in ten years ) Earned $70 million in annual premium ( compared to $20 million in premiums in 2009 and $10 million in premiums 2004 ) Expect combined ratio of 95 or lower over long term Dandho Holdings will infuse a capital of $30 million after acquiring Stone Trust Insurance for $35 million Dhandho + Stone Trust Advantage : Dhandho's cash surplus and backing will allow Stone Trust Insurance to grow without capital constraints. Boost's Stone Trust's credit rating from B+ to A- post acquisition Single investor ( Mohnish Pabrai (Trades, Portfolio) himself ) managing investments for Stone Trust ( Clone of Buffet's model for Berkshire ) Environment where the focus is on under writing discipline and not growth Dhandho will provide a non-institutional environment, which is important for success in insurance business ( Q ) Why did you invest in Chesapeake Energy and what were your reasons to exit ? | Boost's Stone Trust's credit rating from B+ to A- post acquisition Single investor ( Mohnish Pabrai (Trades, Portfolio) himself ) managing investments for Stone Trust ( Clone of Buffet's model for Berkshire ) Environment where the focus is on under writing discipline and not growth Dhandho will provide a non-institutional environment, which is important for success in insurance business ( Q ) Why did you invest in Chesapeake Energy and what were your reasons to exit ? However in the recent years the price of oil typically had traded 8-12x that of natural gas due to a combination of rising domestic production from unconventional shale gas and regulation of natural gas export from U.S. depressing price levels and fear premium for the global crude oil prices . This article first appeared on GuruFocus . |
36260.0 | 2015-05-26 00:00:00 UTC | The Zacks Analyst Blog Highlights: Johnson & Johnson, AstraZeneca, ACADIA Pharmaceuticals, Actavis and Alkermes - Press Releases | ACAD | https://www.nasdaq.com/articles/the-zacks-analyst-blog-highlights%3A-johnson-johnson-astrazeneca-acadia-pharmaceuticals | nan | nan | For Immediate Release
Chicago, IL - May 26, 2015 - Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include the Johnson & Johnson ( JNJ ), AstraZeneca plc ( AZN ), ACADIA Pharmaceuticals Inc. ( ACAD ), Actavis plc ( ACT ) and Alkermes plc ( ALKS ).
Today, Zacks is promoting its ''Buy'' stock recommendations. Get #1Stock of the Day pick for free .
Here are highlights from Friday's Analyst Blog:
3 Stocks Poised to Grow in Schizophrenia Market
Schizophrenia is a chronic neurological brain disorder which adversely affects a patient's ability to think clearly. The symptoms are broadly categorized as positive and negative. While positive symptoms include hallucinations, delusions and suspiciousness, negative symptoms include social withdrawal, lack of motivation and reduced emotional reactivity. Patients also suffer from lack of concentration and memory problems.
Although symptoms associated with the disease generally start appearing between 16 to 30 years, they become pronounced at a later age. Genetic, environment and different brain chemistry and structure are the primary causes identified over the years for the same. Most patients have multiple relapses which fuel clinical progression. Syd Barrett (a founding member of rock band Pink Floyd) and noted painter Vincent van Gogh are among countless others who were believed to have suffered from schizophrenia.
While presently there is no cure for schizophrenia, antipsychotic drugs are generally used for the management of its symptoms. These drugs are classified as standard antipsychotics and atypical antipsychotics.
Atypical antipsychotics are a new class of drugs that boast of fewer side effects than conventional ones. Currently, the schizophrenia market is pretty crowded with quite a few established players and a couple of upcoming players. The situation is further intensified given the large unmet medical need for new therapies that have reduced side effects and improved efficacy profiles.
Leading drugs in this market include Johnson & Johnson's ( JNJ ) Risperdal and AstraZeneca plc's ( AZN ) Seroquel XR (an extended release formulation of quetiapine fumarate), among others.
Meanwhile, ACADIA Pharmaceuticals Inc. ( ACAD ) is evaluating its lead candidate Nuplazid (pimavanserin) for the treatment of schizophrenia. The company has successfully completed a phase II trial on Nuplazid as a co-therapy for schizophrenia. It also plans to evaluate the candidate as a stand-alone maintenance therapy in between acute psychotic episodes in a phase II study on schizophrenia.
With about 30 million people across the world estimated to be suffering from schizophrenia, the commercial opportunity in this market is immense.
Our 3 Picks for the Schizophrenia Market
Although picking the correct stocks from so many options could be a daunting task, our proprietary methodology makes it fairly simple. One way to narrow down the list of choices is by looking at stocks that carry a favorable Zacks Rank - Zacks Rank #1 (Strong Buy), #2 (Buy) or #3 (Hold).
We help you identify three players in the schizophrenia market which are poised for growth:
New Brunswick, NJ-based Johnson & Johnson focuses on the development, manufacturing and marketing of pharmaceutical, medical and consumer-related healthcare products. The company is already well-established in the schizophrenia market armed with Invega Sustenna and Risperdal Consta. The recent FDA approval of Invega Trinza should strengthen its position further in this market. Invega Trinza is the first and only schizophrenia medication that needs to be dosed just four times in a year. The stock currently carries a Zacks Rank #3 (Hold).
Dublin, Ireland-based Actavis plc ( ACT ) is a specialty pharmaceutical company engaged in the development, manufacturing, marketing, sale and distribution of generic, branded generic, brand, biosimilar and over-the-counter (OTC) pharmaceutical products. Actavis is evaluating cariprazine for the treatment of bipolar schizophrenia. The stock currently carries a Zacks Rank #3 (Hold).
Dublin, Ireland-based Alkermes plc ( ALKS ) was formed following the Sep 2011 merger between Waltham, MA-based Alkermes, Inc. and Elan Drug Technologies. Alkermes' aripiprazole lauroxil, a once-monthly formulation for the treatment of schizophrenia, is currently under review in the U.S. with a response expected by Aug 22, 2015. Aripiprazole lauroxil is designed to have multiple dosing options and will have to be administered in a ready-to-use, pre-filled product format.
The company is also evaluating oral atypical antipsychotic candidate ALKS 3831 for schizophrenia (currently in phase II). ALKS 3831 is composed of samidorphan in combination with Zyprexa. The company also earns royalty on Invega Sustenna and Risperdal Consta from Johnson & Johnson. The stock currently carries a Zacks Rank #3 (Hold).
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days.Click to get this free report >>
About Zacks Equity Research
Zacks Equity Research provides the best of quantitative and qualitative analysis to help investors know what stocks to buy and which to sell for the long-term.
Continuous coverage is provided for a universe of 1,150 publicly traded stocks. Our analysts are organized by industry which gives them keen insights to developments that affect company profits and stock performance. Recommendations and target prices are six-month time horizons.
Zacks "Profit from the Pros" e-mail newsletter provides highlights of the latest analysis from Zacks Equity Research. Subscribe to this free newsletter today .
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
JOHNSON & JOHNS (JNJ): Free Stock Analysis Report
ASTRAZENECA PLC (AZN): Free Stock Analysis Report
ACADIA PHARMA (ACAD): Free Stock Analysis Report
ACTAVIS PLC (ACT): Free Stock Analysis Report
ALKERMES INC (ALKS): Free Stock Analysis Report
To read this article on Zacks.com click here.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Stocks recently featured in the blog include the Johnson & Johnson ( JNJ ), AstraZeneca plc ( AZN ), ACADIA Pharmaceuticals Inc. ( ACAD ), Actavis plc ( ACT ) and Alkermes plc ( ALKS ). Meanwhile, ACADIA Pharmaceuticals Inc. ( ACAD ) is evaluating its lead candidate Nuplazid (pimavanserin) for the treatment of schizophrenia. Click to get this free report JOHNSON & JOHNS (JNJ): Free Stock Analysis Report ASTRAZENECA PLC (AZN): Free Stock Analysis Report ACADIA PHARMA (ACAD): Free Stock Analysis Report ACTAVIS PLC (ACT): Free Stock Analysis Report ALKERMES INC (ALKS): Free Stock Analysis Report To read this article on Zacks.com click here. | Stocks recently featured in the blog include the Johnson & Johnson ( JNJ ), AstraZeneca plc ( AZN ), ACADIA Pharmaceuticals Inc. ( ACAD ), Actavis plc ( ACT ) and Alkermes plc ( ALKS ). Click to get this free report JOHNSON & JOHNS (JNJ): Free Stock Analysis Report ASTRAZENECA PLC (AZN): Free Stock Analysis Report ACADIA PHARMA (ACAD): Free Stock Analysis Report ACTAVIS PLC (ACT): Free Stock Analysis Report ALKERMES INC (ALKS): Free Stock Analysis Report To read this article on Zacks.com click here. Meanwhile, ACADIA Pharmaceuticals Inc. ( ACAD ) is evaluating its lead candidate Nuplazid (pimavanserin) for the treatment of schizophrenia. | Stocks recently featured in the blog include the Johnson & Johnson ( JNJ ), AstraZeneca plc ( AZN ), ACADIA Pharmaceuticals Inc. ( ACAD ), Actavis plc ( ACT ) and Alkermes plc ( ALKS ). Click to get this free report JOHNSON & JOHNS (JNJ): Free Stock Analysis Report ASTRAZENECA PLC (AZN): Free Stock Analysis Report ACADIA PHARMA (ACAD): Free Stock Analysis Report ACTAVIS PLC (ACT): Free Stock Analysis Report ALKERMES INC (ALKS): Free Stock Analysis Report To read this article on Zacks.com click here. Meanwhile, ACADIA Pharmaceuticals Inc. ( ACAD ) is evaluating its lead candidate Nuplazid (pimavanserin) for the treatment of schizophrenia. | Stocks recently featured in the blog include the Johnson & Johnson ( JNJ ), AstraZeneca plc ( AZN ), ACADIA Pharmaceuticals Inc. ( ACAD ), Actavis plc ( ACT ) and Alkermes plc ( ALKS ). Meanwhile, ACADIA Pharmaceuticals Inc. ( ACAD ) is evaluating its lead candidate Nuplazid (pimavanserin) for the treatment of schizophrenia. Click to get this free report JOHNSON & JOHNS (JNJ): Free Stock Analysis Report ASTRAZENECA PLC (AZN): Free Stock Analysis Report ACADIA PHARMA (ACAD): Free Stock Analysis Report ACTAVIS PLC (ACT): Free Stock Analysis Report ALKERMES INC (ALKS): Free Stock Analysis Report To read this article on Zacks.com click here. |
36261.0 | 2015-05-11 00:00:00 UTC | Acadia Pharmaceuticals Moves Up In Market Cap Rank, Passing QEP Resources | ACAD | https://www.nasdaq.com/articles/acadia-pharmaceuticals-moves-market-cap-rank-passing-qep-resources-2015-05-11 | nan | nan | In the latest look at stocks ordered by largest market capitalization, Russell 3000 component Acadia Pharmaceuticals Inc (Symbol: ACAD) was identified as having a larger market cap than the smaller end of the S&P 500, for example QEP Resources Inc (Symbol: QEP), according to The Online Investor .
Market capitalization is an important data point for investors to keep an eye on, for various reasons. The most basic reason is that it gives a true comparison of the value attributed by the stock market to a given company's stock. Many beginning investors look at one stock trading at $10 and another trading at $20 and mistakenly think the latter company is worth twice as much - that of course is a completely meaningless comparison without knowing how many shares of each company exist. But comparing market capitalization (factoring in those share counts) creates a true "apples-to-apples" comparison of the value of two stocks. In the case of Acadia Pharmaceuticals Inc (Symbol: ACAD), the market cap is now $3.85B, versus QEP Resources Inc (Symbol: QEP) at $3.61B.
Below is a three month price history chart comparing the stock performance of ACAD vs. QEP:
Another reason market capitalization is important is where it places a company in terms of its size tier in relation to peers - much like the way a mid-size sedan is typically compared to other mid-size sedans (and not SUV's). This can have a direct impact on which indices will include the stock, and which mutual funds and ETFs are willing to own the stock. For instance, a mutual fund that is focused solely on Large Cap stocks may for example only be interested in those companies sized $10 billion or larger. Another illustrative example is the S&P MidCap index which essentially takes the S&P 500 index and "tosses out" the biggest 100 companies so as to focus solely on the 400 smaller "up-and-comers" (which in the right environment can outperform their larger rivals). And ETFs that directly follow an index like the S&P 500 will only own the underlying component of that index, selling companies that lose their status as an S&P 500 company, and buying companies when they are added to the index. So a company's market cap, especially in relation to other companies, carries great importance, and for this reason we at TheOnlineInvestor.com find value to putting together these looks at comparative market capitalization daily.
At the closing bell, ACAD is up about 1.1%, while QEP is trading flat on the day Monday.
The 20 Largest U.S. Companies By Market Capitalization »
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Below is a three month price history chart comparing the stock performance of ACAD vs. QEP: Another reason market capitalization is important is where it places a company in terms of its size tier in relation to peers - much like the way a mid-size sedan is typically compared to other mid-size sedans (and not SUV's). In the latest look at stocks ordered by largest market capitalization, Russell 3000 component Acadia Pharmaceuticals Inc (Symbol: ACAD) was identified as having a larger market cap than the smaller end of the S&P 500, for example QEP Resources Inc (Symbol: QEP), according to The Online Investor . In the case of Acadia Pharmaceuticals Inc (Symbol: ACAD), the market cap is now $3.85B, versus QEP Resources Inc (Symbol: QEP) at $3.61B. | In the latest look at stocks ordered by largest market capitalization, Russell 3000 component Acadia Pharmaceuticals Inc (Symbol: ACAD) was identified as having a larger market cap than the smaller end of the S&P 500, for example QEP Resources Inc (Symbol: QEP), according to The Online Investor . In the case of Acadia Pharmaceuticals Inc (Symbol: ACAD), the market cap is now $3.85B, versus QEP Resources Inc (Symbol: QEP) at $3.61B. Below is a three month price history chart comparing the stock performance of ACAD vs. QEP: Another reason market capitalization is important is where it places a company in terms of its size tier in relation to peers - much like the way a mid-size sedan is typically compared to other mid-size sedans (and not SUV's). | In the latest look at stocks ordered by largest market capitalization, Russell 3000 component Acadia Pharmaceuticals Inc (Symbol: ACAD) was identified as having a larger market cap than the smaller end of the S&P 500, for example QEP Resources Inc (Symbol: QEP), according to The Online Investor . Below is a three month price history chart comparing the stock performance of ACAD vs. QEP: Another reason market capitalization is important is where it places a company in terms of its size tier in relation to peers - much like the way a mid-size sedan is typically compared to other mid-size sedans (and not SUV's). In the case of Acadia Pharmaceuticals Inc (Symbol: ACAD), the market cap is now $3.85B, versus QEP Resources Inc (Symbol: QEP) at $3.61B. | In the case of Acadia Pharmaceuticals Inc (Symbol: ACAD), the market cap is now $3.85B, versus QEP Resources Inc (Symbol: QEP) at $3.61B. In the latest look at stocks ordered by largest market capitalization, Russell 3000 component Acadia Pharmaceuticals Inc (Symbol: ACAD) was identified as having a larger market cap than the smaller end of the S&P 500, for example QEP Resources Inc (Symbol: QEP), according to The Online Investor . Below is a three month price history chart comparing the stock performance of ACAD vs. QEP: Another reason market capitalization is important is where it places a company in terms of its size tier in relation to peers - much like the way a mid-size sedan is typically compared to other mid-size sedans (and not SUV's). |
36262.0 | 2015-04-16 00:00:00 UTC | Health Care Sector Update for 04/16/2015: ACAD, RCPT, HZNP | ACAD | https://www.nasdaq.com/articles/health-care-sector-update-04162015-acad-rcpt-hznp-2015-04-16 | nan | nan | Top Health-care stocks:
JNJ: flat
PFE: flat
ABT: flat
MRK: flat
AMGN: flat
Health-care shares were mainly flat in pre-market trade Thursday.
In health-care stocks news, ACADIA Pharmaceuticals ( ACAD ) shares were initiated by Leerink Partners with outperform rating and $48 price target.
Shares in the company were unchanged at $37.50 during pre-market trading . Over the past 52 weeks, the company has traded between $17.15 and $46.48.
Meanwhile Receptos ( RCPT ), a biopharmaceutical company, said its Phase 2 trial of ozanimod in ulcerative colitis met all efficacy endpoints with statistical significance in patients on the 1 mg dose of ozanimod after 32 weeks of treatment.
Shares in the company were up 3.0% at $163 during pre-market trading. Over the past 52 weeks, the company has traded between $24.53 and $203.25.
And Horizon Pharma ( HZNP ) said late Wednesday it has priced its public offering of 15.4 million ordinary shares at $28.25 per share for an expected net proceeds of $413.1 million.
The biopharmaceutical company has also granted the underwriters a 30-day option to purchase up to 2.3 million shares.
Shares in the company were 2.5% lower at $28.76 during pre-market trading. Over the past 52 weeks, the company has traded between $7.85 and $30.15.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
Copyright (C) 2016 MTNewswires.com. All rights reserved. Unauthorized reproduction is strictly prohibited.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | In health-care stocks news, ACADIA Pharmaceuticals ( ACAD ) shares were initiated by Leerink Partners with outperform rating and $48 price target. Meanwhile Receptos ( RCPT ), a biopharmaceutical company, said its Phase 2 trial of ozanimod in ulcerative colitis met all efficacy endpoints with statistical significance in patients on the 1 mg dose of ozanimod after 32 weeks of treatment. The biopharmaceutical company has also granted the underwriters a 30-day option to purchase up to 2.3 million shares. | The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. In health-care stocks news, ACADIA Pharmaceuticals ( ACAD ) shares were initiated by Leerink Partners with outperform rating and $48 price target. Top Health-care stocks: JNJ: flat PFE: flat ABT: flat MRK: flat AMGN: flat Health-care shares were mainly flat in pre-market trade Thursday. | In health-care stocks news, ACADIA Pharmaceuticals ( ACAD ) shares were initiated by Leerink Partners with outperform rating and $48 price target. Top Health-care stocks: JNJ: flat PFE: flat ABT: flat MRK: flat AMGN: flat Health-care shares were mainly flat in pre-market trade Thursday. Shares in the company were unchanged at $37.50 during pre-market trading . | In health-care stocks news, ACADIA Pharmaceuticals ( ACAD ) shares were initiated by Leerink Partners with outperform rating and $48 price target. Meanwhile Receptos ( RCPT ), a biopharmaceutical company, said its Phase 2 trial of ozanimod in ulcerative colitis met all efficacy endpoints with statistical significance in patients on the 1 mg dose of ozanimod after 32 weeks of treatment. Shares in the company were up 3.0% at $163 during pre-market trading. |
36263.0 | 2015-04-08 00:00:00 UTC | Should AbbVie, Inc. Buy Acadia Pharmaceuticals to Help Fight Parkinson's Disease? | ACAD | https://www.nasdaq.com/articles/should-abbvie-inc-buy-acadia-pharmaceuticals-help-fight-parkinsons-disease-2015-04-08 | nan | nan | The healthcare sector is unquestionably going through a period of major consolidation. And with dozens of additional blockbuster drugs scheduled to lose patent protection soon, this trend will probably continue for the foreseeable future.
AbbVie is one name in particular that's been aggressively pursuing major deals ahead of the patent expiration for its lead anti-inflammatory drug Humira. Specifically, the company was initially courting Irish biopharma Shire before backing out, and later cut a massive $21 billion deal for cancer drugmaker Pharmacyclics .
Given that this buyout won't entirely solve AbbVie's problems stemming from the loss of exclusivity for Humira, we're likely to see the drugmaker go after another, albeit much smaller, biopharma in the near term. Indeed, the company's management admitted in a recent investor conference call that they are considering a second acquisition.
So, this raises the question: Which small or mid-cap biopharma should AbbVie consider?
A great strategic fit
Acadia Pharmaceuticals is developing a selective serotonin inverse agonist, Nuplazid (pimavanserin), indicated for Alzheimer's (ADP) and Parkinson's disease psychosis (PDP), as well as schizophrenia.
This small-molecule drug previously reported strong late-stage results for its most advanced indication, PDP, back in 2012, garnering Fast Track status with the Food and Drug Administration in the process.
Despite fairly robust results for PDP and having Fast Track status, Acadia has been unable to push the drug into a regulatory review with the FDA. While some of these delays have been due to the need for additional supportive studies to wrap up first, the bulk of it appears to be Acadia's inexperience at handling a regulatory submission and preparing for a drug's subsequent commercialization.
Perhaps as a direct consequence of these issues, we witnessed the company's longtime CEO Uli Hacksell abruptly retire last month, even relinquishing his seat on the Board. This is certainly a big reason Acadia may wish to simply sell itself to a big pharma at this juncture.
Source: Flickr via Matthew Anderson.
For AbbVie's part, the pharma giant would gain a key asset that is expected to generate upwards of $3 billion in sales for its first indication alone, which would dovetail with the company's growing neuroscience franchise.
Specifically, Nuplazid should conceivably create important marketing synergies with AbbVie's newly-approved intestinal gel Duopa, used to alleviate involuntary motor fluctuations in people with advanced Parkinson's disease. Fleshing this idea out further, AbbVie could take advantage of its sales force for Duopa, and their experience with this particular patient population, to help bring Nuplazid to market in a more efficient manner than Acadia could do by itself -- assuming the drug is ultimately approved by the FDA.
On a final note, Nuplazid would fit nicely with AbbVie's desire to build out an Alzheimer's disease franchise, giving it another strong clinical candidate for this unmet medical need.
Can this buyout scenario turn into reality?
While there are some obvious synergies between AbbVie and Acadia's clinical pipelines, the hard truth is that most buyouts come out of left field. So, this deal may actually make too much sense for it to come to fruition in the whacky world of biopharma.
But if AbbVie did see the light, the first hurdle would be Acadia's asking price. What we've seen over the last 12 months or so has been a 30%-40% premium as the going rate in healthcare buyouts in general. That would put Acadia roughly into the $4.5 billion range, which might simply be too rich for AbbVie after its monstrous deal for Pharmacyclics. Then again, this merger should create comparatively more value for shareholders than the Pharmacyclics deal that won't add to earnings until at least 2017.
All told, Acadia will probably end up interesting some big pharma as Nuplazid nears a formal regulatory submission. And a new CEO may see fit to put the company up for sale, given the biopharma's inherent weaknesses at maximizing the potential returns on this novel asset. Indeed, Acadia selling itself appears to be beneficial to both the more than 1 million Parkinson's disease patients afflicted with this devastating disease -- and shareholders alike.
That's a win-win in my book, and a great reason I think these two companies should put their heads together in the fight against Parkinson's and Alzheimer's diseases.
This $19 trillion industry could destroy the Internet
One bleeding-edge technology is about to put the World Wide Web to bed. And if you act right away, it could make you wildly rich. Experts are calling it the single largest business opportunity in the history of capitalism, The Economist is calling it "transformative," but you'll probably just call it "how I made my millions." Don't be too late to the party -- click here for one stock to own when the Web goes dark.
The article Should AbbVie, Inc. Buy Acadia Pharmaceuticals to Help Fight Parkinson's Disease? originally appeared on Fool.com.
George Budwell owns shares of AbbVie. The Motley Fool has no position in any of the stocks mentioned. Try any of our Foolish newsletter services free for 30 days . We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy .
Copyright © 1995 - 2015 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy .
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | A great strategic fit Acadia Pharmaceuticals is developing a selective serotonin inverse agonist, Nuplazid (pimavanserin), indicated for Alzheimer's (ADP) and Parkinson's disease psychosis (PDP), as well as schizophrenia. Fleshing this idea out further, AbbVie could take advantage of its sales force for Duopa, and their experience with this particular patient population, to help bring Nuplazid to market in a more efficient manner than Acadia could do by itself -- assuming the drug is ultimately approved by the FDA. Despite fairly robust results for PDP and having Fast Track status, Acadia has been unable to push the drug into a regulatory review with the FDA. | Despite fairly robust results for PDP and having Fast Track status, Acadia has been unable to push the drug into a regulatory review with the FDA. Indeed, Acadia selling itself appears to be beneficial to both the more than 1 million Parkinson's disease patients afflicted with this devastating disease -- and shareholders alike. A great strategic fit Acadia Pharmaceuticals is developing a selective serotonin inverse agonist, Nuplazid (pimavanserin), indicated for Alzheimer's (ADP) and Parkinson's disease psychosis (PDP), as well as schizophrenia. | Fleshing this idea out further, AbbVie could take advantage of its sales force for Duopa, and their experience with this particular patient population, to help bring Nuplazid to market in a more efficient manner than Acadia could do by itself -- assuming the drug is ultimately approved by the FDA. That would put Acadia roughly into the $4.5 billion range, which might simply be too rich for AbbVie after its monstrous deal for Pharmacyclics. Indeed, Acadia selling itself appears to be beneficial to both the more than 1 million Parkinson's disease patients afflicted with this devastating disease -- and shareholders alike. | A great strategic fit Acadia Pharmaceuticals is developing a selective serotonin inverse agonist, Nuplazid (pimavanserin), indicated for Alzheimer's (ADP) and Parkinson's disease psychosis (PDP), as well as schizophrenia. Despite fairly robust results for PDP and having Fast Track status, Acadia has been unable to push the drug into a regulatory review with the FDA. While some of these delays have been due to the need for additional supportive studies to wrap up first, the bulk of it appears to be Acadia's inexperience at handling a regulatory submission and preparing for a drug's subsequent commercialization. |
36264.0 | 2015-03-30 00:00:00 UTC | Healthcare Merger Monday: These 3 Stocks Could Be Healthcare's Next Buyout Targets | ACAD | https://www.nasdaq.com/articles/healthcare-merger-monday-these-3-stocks-could-be-healthcares-next-buyout-targets-2015-03 | nan | nan | The investment bankers were busy this weekend with four healthcare industry acquisitions announced today. Teva Pharmaceuticals is buying Auspex Pharmaceuticals for $3.5 billion, Horizon Pharma picked up Hyperion Therapeutics for $1.1 billion, Cellular Dynamics was purchased by Fujifilm -- just a $307 million deal, but more than a 100% premium on Friday's close -- and in the pharmacy benefit management space, UnitedHealth Group bought Catamaran for $12.8 billion.
Which company might be acquired next? Read on to see why our team of healthcare experts think Esperion Therapeutics (NASDAQ: ESPR), BioMarin Pharmaceuticals (NASDAQ: BMRN), and Acadia Pharmaceuticals (NASDAQ: ACAD) could be next on the auction block.
Todd Campbell : First, let me state that investors shouldn't buy shares in a company just because they think a suitor could emerge. Instead, they should focus on buying companies like Esperion Therapeutics because of their potential as a stand-alone company and then consider an acquisition as an unlikely, yet welcome, outcome.
Esperion's ETC-1002, a cholesterol-busting medicine, just put up impressive mid-stage trial results showing that combining it with statins can significantly reduce cholesterol levels in patients. If those results are duplicated in to-be-held phase 3 trials, then Esperion could have a multibillion-dollar blockbuster therapy on its hands.
Express Scripts estimates that 71 million Americans have high cholesterol, and since tens of millions of patients already take statins, ETC-1002 could become a big seller someday. Just how big is uncertain, but Esperion's co-founder is Roger Newton, the co-inventor of the wildly successful Lipitor.
Indeed, Lipitor was the world's biggest-selling drug of all time, notching $125 billion in sales prior to losing patent protection. ETC-1002 isn't likely to be that successful, but it could certainly have blockbuster potential. Analysts think PCSK9 cholesterol fighters making their way through the FDA approval process could rake in $2 billion a year, or more. With a billion-dollar opportunity like that ahead of it, I wouldn't be shocked if a large drugmaker makes a bid for Esperion -- especially if the upcoming phase 3 trials pan out.
Brian Orelli: I'll second Todd's assertion that you shouldn't buy a company simply because it might get acquired. That's a pretty poor investment thesis, especially since there's usually a lot going on behind closed doors that investors aren't privy to: What premium on the current price is management willing to accept? Does confidential information the company shares with potential acquires make it more or less attractive?
Take BioMarin Pharmaceuticals, for instance. The biotech has been rumored to be a takeover target for years since BioMarin specializes in orphan drugs, a specialty pharma has an appetite for. While the company remains independent for reasons no one outside of BioMarin's management really knows, it's still a solid company, and investors have been rewarded nevertheless.
With the company approaching profitability , BioMarin still looks like an attractive bolt-on acquisition for a pharma looking to add a few already-approved drugs and a decent pipeline.
There's one caveat here, though. BioMarin recently acquired Prosensa for its Duchenne Muscular Dystrophy drug, drisapersen, which isn't approved yet and has a bit of a checkered past, having failed a phase 3 trial. Potential acquirers are likely to wait until the biotech is able to gain FDA or EU approval to sell drisapersen before acquiring BioMarin, because the likelihood of approval is hard to quantify.
Alternatively, an acquirer might offer BioMarin's shareholders a "contingent value rights" that pays them more after the acquisition if drisapersen is approved, which is actually the mechanism that allowed BioMarin to acquire Prosensa.
George Budwell : Acadia Pharmaceuticals has repeatedly been the subject of the buyout rumor mill ever since it reported stellar late-stage results for its experimental Parkinson's disease psychosis drug Nuplazid (pimavanserin) over two years ago. And the underlying reasons for these lingering rumors are easy to understand.
First off, this devastating disease has no real treatment options beyond supportive care, meaning Nuplazid wouldn't face any meaningful competition upon its commercial launch. Experts thus have the drug's peak sales pegged at nearly $3 billion a year.
And with a market cap of about $3.3 billion at present, Acadia appears to be fairly valued in light of Nuplazid's value proposition, giving any buyer a good bit of upside potential going forward.
So, which big pharma might be lurking in the shadows? My money is on AbbVie . AbbVie already has an important new Parkinson's disease drug in Duopa -- so a buyout of Acadia would significantly strengthen the drugmaker's position in this vastly under-served market.
This $19 trillion industry could destroy the Internet
One bleeding-edge technology is about to put the World Wide Web to bed. And if you act right away, it could make you wildly rich. Experts are calling it the single largest business opportunity in the history of capitalism, The Economist is calling it "transformative," but you'll probably just call it "how I made my millions." Don't be too late to the party -- click here for one stock to own when the Web goes dark.
The article Healthcare Merger Monday: These 3 Stocks Could Be Healthcare's Next Buyout Targets originally appeared on Fool.com.
Brian Orelli has no position in any stocks mentioned. George Budwell owns shares of AbbVie. Todd Campbell owns shares of BioMarin Pharmaceutical. The Motley Fool recommends BioMarin Pharmaceutical, Catamaran, Express Scripts, Teva Pharmaceutical Industries, and UnitedHealth. The Motley Fool owns shares of Catamaran and Express Scripts.Try any of our Foolish newsletter services free for 30 days . We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy .
Copyright © 1995 - 2015 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy .
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | George Budwell : Acadia Pharmaceuticals has repeatedly been the subject of the buyout rumor mill ever since it reported stellar late-stage results for its experimental Parkinson's disease psychosis drug Nuplazid (pimavanserin) over two years ago. Read on to see why our team of healthcare experts think Esperion Therapeutics (NASDAQ: ESPR), BioMarin Pharmaceuticals (NASDAQ: BMRN), and Acadia Pharmaceuticals (NASDAQ: ACAD) could be next on the auction block. And with a market cap of about $3.3 billion at present, Acadia appears to be fairly valued in light of Nuplazid's value proposition, giving any buyer a good bit of upside potential going forward. | Read on to see why our team of healthcare experts think Esperion Therapeutics (NASDAQ: ESPR), BioMarin Pharmaceuticals (NASDAQ: BMRN), and Acadia Pharmaceuticals (NASDAQ: ACAD) could be next on the auction block. George Budwell : Acadia Pharmaceuticals has repeatedly been the subject of the buyout rumor mill ever since it reported stellar late-stage results for its experimental Parkinson's disease psychosis drug Nuplazid (pimavanserin) over two years ago. And with a market cap of about $3.3 billion at present, Acadia appears to be fairly valued in light of Nuplazid's value proposition, giving any buyer a good bit of upside potential going forward. | Read on to see why our team of healthcare experts think Esperion Therapeutics (NASDAQ: ESPR), BioMarin Pharmaceuticals (NASDAQ: BMRN), and Acadia Pharmaceuticals (NASDAQ: ACAD) could be next on the auction block. George Budwell : Acadia Pharmaceuticals has repeatedly been the subject of the buyout rumor mill ever since it reported stellar late-stage results for its experimental Parkinson's disease psychosis drug Nuplazid (pimavanserin) over two years ago. And with a market cap of about $3.3 billion at present, Acadia appears to be fairly valued in light of Nuplazid's value proposition, giving any buyer a good bit of upside potential going forward. | Read on to see why our team of healthcare experts think Esperion Therapeutics (NASDAQ: ESPR), BioMarin Pharmaceuticals (NASDAQ: BMRN), and Acadia Pharmaceuticals (NASDAQ: ACAD) could be next on the auction block. George Budwell : Acadia Pharmaceuticals has repeatedly been the subject of the buyout rumor mill ever since it reported stellar late-stage results for its experimental Parkinson's disease psychosis drug Nuplazid (pimavanserin) over two years ago. And with a market cap of about $3.3 billion at present, Acadia appears to be fairly valued in light of Nuplazid's value proposition, giving any buyer a good bit of upside potential going forward. |
36265.0 | 2015-03-29 00:00:00 UTC | 1 Clinical-Stage Biotech Stock That Could Make You Into a Millionaire | ACAD | https://www.nasdaq.com/articles/1-clinical-stage-biotech-stock-could-make-you-millionaire-2015-03-29 | nan | nan | Biotech stocks have the ability to absolutely crush it in short order, turning even small investments into respectable sums of money. Investors that caught lightning in a bottle with Acadia Pharmaceuticals prior to the company releasing pivotal late-stage data for its Parkinson's disease psychosis drug, for example, could have easily turned $10,000 into a whopping $128,000 in less than three years:
On the flip side, this industry is littered with tragic stories of cratering share prices after poor clinical trial results or regulatory outcomes. The lesson is that many biotechs -- especially those existing purely in the realm of clinical-stage entities -- are often all-or-nothing types of investments, making them only suited for investors with an extremely high risk tolerance.
For that rare breed out there, I think the tiny gene-therapy company Celladon is a name that should be on your watchlist right now.
Cutting to the chase, Celladon is set to release top-line data for the midstage trial , CUPID-2, in late April. This purpose of this trial is to test if the company's flagship gene therapy, Mydicar, can reduce the rate at which patients are rehospitalized for heart related problems over a 12-month period, compared to individuals on placebo.
I'm keenly watching this stock heading into this data release because its value proposition is perhaps unprecedented, although its risks are equally as heart-pounding. Here's why.
Celladon is going after a widespread disease with no real treatment options
The limited successes of gene therapies to date have been confined to the area of rare diseases, with few to no treatment options. Indeed, bluebird bio 's gene-therapy Lentiglobin is indicated for a rare blood disorder.
Celladon, by contrast, is going after much bigger game, namely heart disease. Patients afflicted with the various forms of the disease have no good options treatment-wise, resulting in a high rate of hospital readmissions and mortality. According to the American Heart Association, for example, a staggering 387,000 people die from heart disease every year.
The burden on the American healthcare system is also enormous, with direct and indirect costs exceeding $320 billion annually.
So, a drug or therapy that could significantly lower the rate of hospitalizations for heart disease patients would be a huge step forward for medicine, and a welcome relief to the healthcare system in general. And that's what Mydicar aims to do -- giving it a commercial potential that is simply mind-boggling.
Mydicar's value proposition in a nutshell
Mydicar is presently in clinical testing for systolic heart failure. If CUPID-2's results are positive, Celladon plans on launching a follow-on trial aimed at patients afflicted with diastolic heart failure. Combined, these two indications would give Mydicar a target patient population of roughly 700,000 individuals.
Although Celladon fully plans on going after a much broader array of indications, we can use some fairly standard pricing and reimbursement figures for these initial target populations to illustrate Mydicar's potential.
Assuming a 35% penetration rate at peak and an average price tag of $29,500 per treatment (averaged across the EU and U.S. populations), Mydicar should top $7 billion in annual sales. What's really eye-popping is that some experts are estimating peak sales for these two indications could actually top $10 billion.
Turning our focus to how Mydicar's commercial potential could impact Celladon's shares, let's limit our focus to systolic heart failure (the most advanced condition), where the therapy is still projected to generate around $3.5 billion a year in peak sales.
Applying a conservative multiple of 5, we arrive at a forward-looking market cap of $17.5 billion for this single indication. All else being equal, that would yield a share price of around $735.
Putting this into context, Celladon's share price is presently trading at around $21, meaning that a $30,000 investment in this speculative stock could, if everything alights perfectly for the company, lead to a million dollar return. In the same breath, a negative result come April would turn that same $30,000 into mere lunch money -- and that lunch would probably come from a fast food joint.
So, why doesn't Celladon's market cap reflect Mydicar's value proposition?
The answer to this glaring question is simple: Mr. Market firmly believes that CUPID-2 will fail. And given the troubling history of gene therapies in general, there are ample reasons to believe the market is indeed correct in its assessment.
By the same token, the market took almost exactly the same position with Acadia predata release, with the biotech's shares scraping along at $3 to $4 per share. And bluebird bio's were struggling as well ahead of the data release for Lentiglobin, before ultimately jumping by more than 300%. Of course, these companies are few and far between, and the biotech industry is littered with companies that haven't been so lucky.
Clinical trial results are nothing if not unpredictable, but a positive turnout here could lead to one of the biggest rallies in the wild biotech arena yet. Stay tuned!
This $19 trillion industry could destroy the Internet
One bleeding-edge technology is about to put the World Wide Web to bed. And if you act right away, it could make you wildly rich. Experts are calling it the single largest business opportunity in the history of capitalism... The Economist is calling it "transformative"... But you'll probably just call it "how I made my millions." Don't be too late to the party -- click here for one stock to own when the Web goes dark.
The article 1 Clinical-Stage Biotech Stock That Could Make You Into a Millionaire originally appeared on Fool.com.
George Budwell has no position in any stocks mentioned. The Motley Fool recommends Bluebird Bio. Try any of our Foolish newsletter services free for 30 days . We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy .
Copyright © 1995 - 2015 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy .
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Investors that caught lightning in a bottle with Acadia Pharmaceuticals prior to the company releasing pivotal late-stage data for its Parkinson's disease psychosis drug, for example, could have easily turned $10,000 into a whopping $128,000 in less than three years: On the flip side, this industry is littered with tragic stories of cratering share prices after poor clinical trial results or regulatory outcomes. By the same token, the market took almost exactly the same position with Acadia predata release, with the biotech's shares scraping along at $3 to $4 per share. This purpose of this trial is to test if the company's flagship gene therapy, Mydicar, can reduce the rate at which patients are rehospitalized for heart related problems over a 12-month period, compared to individuals on placebo. | Investors that caught lightning in a bottle with Acadia Pharmaceuticals prior to the company releasing pivotal late-stage data for its Parkinson's disease psychosis drug, for example, could have easily turned $10,000 into a whopping $128,000 in less than three years: On the flip side, this industry is littered with tragic stories of cratering share prices after poor clinical trial results or regulatory outcomes. By the same token, the market took almost exactly the same position with Acadia predata release, with the biotech's shares scraping along at $3 to $4 per share. Mydicar's value proposition in a nutshell Mydicar is presently in clinical testing for systolic heart failure. | Investors that caught lightning in a bottle with Acadia Pharmaceuticals prior to the company releasing pivotal late-stage data for its Parkinson's disease psychosis drug, for example, could have easily turned $10,000 into a whopping $128,000 in less than three years: On the flip side, this industry is littered with tragic stories of cratering share prices after poor clinical trial results or regulatory outcomes. By the same token, the market took almost exactly the same position with Acadia predata release, with the biotech's shares scraping along at $3 to $4 per share. Turning our focus to how Mydicar's commercial potential could impact Celladon's shares, let's limit our focus to systolic heart failure (the most advanced condition), where the therapy is still projected to generate around $3.5 billion a year in peak sales. | Investors that caught lightning in a bottle with Acadia Pharmaceuticals prior to the company releasing pivotal late-stage data for its Parkinson's disease psychosis drug, for example, could have easily turned $10,000 into a whopping $128,000 in less than three years: On the flip side, this industry is littered with tragic stories of cratering share prices after poor clinical trial results or regulatory outcomes. By the same token, the market took almost exactly the same position with Acadia predata release, with the biotech's shares scraping along at $3 to $4 per share. If CUPID-2's results are positive, Celladon plans on launching a follow-on trial aimed at patients afflicted with diastolic heart failure. |
36266.0 | 2015-03-27 00:00:00 UTC | First Week of May 15th Options Trading For Acadia Pharmaceuticals (ACAD) | ACAD | https://www.nasdaq.com/articles/first-week-may-15th-options-trading-acadia-pharmaceuticals-acad-2015-03-27 | nan | nan | Investors in Acadia Pharmaceuticals Inc (Symbol: ACAD) saw new options become available this week, for the May 15th expiration. At Stock Options Channel , our YieldBoost formula has looked up and down the ACAD options chain for the new May 15th contracts and identified one put and one call contract of particular interest.
The put contract at the $30.00 strike price has a current bid of $1.95. If an investor was to sell-to-open that put contract, they are committing to purchase the stock at $30.00, but will also collect the premium, putting the cost basis of the shares at $28.05 (before broker commissions). To an investor already interested in purchasing shares of ACAD, that could represent an attractive alternative to paying $30.78/share today.
Because the $30.00 strike represents an approximate 3% discount to the current trading price of the stock (in other words it is out-of-the-money by that percentage), there is also the possibility that the put contract would expire worthless. The current analytical data (including greeks and implied greeks) suggest the current odds of that happening are 59%. Stock Options Channel will track those odds over time to see how they change, publishing a chart of those numbers on our website under the contract detail page for this contract . Should the contract expire worthless, the premium would represent a 6.50% return on the cash commitment, or 48.42% annualized - at Stock Options Channel we call this the YieldBoost .
Below is a chart showing the trailing twelve month trading history for Acadia Pharmaceuticals Inc, and highlighting in green where the $30.00 strike is located relative to that history:
Turning to the calls side of the option chain, the call contract at the $31.00 strike price has a current bid of $2.20. If an investor was to purchase shares of ACAD stock at the current price level of $30.78/share, and then sell-to-open that call contract as a "covered call," they are committing to sell the stock at $31.00. Considering the call seller will also collect the premium, that would drive a total return (excluding dividends, if any) of 7.86% if the stock gets called away at the May 15th expiration (before broker commissions). Of course, a lot of upside could potentially be left on the table if ACAD shares really soar, which is why looking at the trailing twelve month trading history for Acadia Pharmaceuticals Inc, as well as studying the business fundamentals becomes important. Below is a chart showing ACAD's trailing twelve month trading history, with the $31.00 strike highlighted in red:
Considering the fact that the $31.00 strike represents an approximate 1% premium to the current trading price of the stock (in other words it is out-of-the-money by that percentage), there is also the possibility that the covered call contract would expire worthless, in which case the investor would keep both their shares of stock and the premium collected. The current analytical data (including greeks and implied greeks) suggest the current odds of that happening are 47%. On our website under the contract detail page for this contract , Stock Options Channel will track those odds over time to see how they change and publish a chart of those numbers (the trading history of the option contract will also be charted). Should the covered call contract expire worthless, the premium would represent a 7.15% boost of extra return to the investor, or 53.24% annualized, which we refer to as the YieldBoost .
The implied volatility in the put contract example is 56%, while the implied volatility in the call contract example is 57%. Meanwhile, we calculate the actual trailing twelve month volatility (considering the last 253 trading day closing values as well as today's price of $30.78) to be 54%. For more put and call options contract ideas worth looking at, visit StockOptionsChannel.com.
Top YieldBoost Calls of the S&P 500 »
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Of course, a lot of upside could potentially be left on the table if ACAD shares really soar, which is why looking at the trailing twelve month trading history for Acadia Pharmaceuticals Inc, as well as studying the business fundamentals becomes important. Below is a chart showing ACAD's trailing twelve month trading history, with the $31.00 strike highlighted in red: Considering the fact that the $31.00 strike represents an approximate 1% premium to the current trading price of the stock (in other words it is out-of-the-money by that percentage), there is also the possibility that the covered call contract would expire worthless, in which case the investor would keep both their shares of stock and the premium collected. Investors in Acadia Pharmaceuticals Inc (Symbol: ACAD) saw new options become available this week, for the May 15th expiration. | Below is a chart showing ACAD's trailing twelve month trading history, with the $31.00 strike highlighted in red: Considering the fact that the $31.00 strike represents an approximate 1% premium to the current trading price of the stock (in other words it is out-of-the-money by that percentage), there is also the possibility that the covered call contract would expire worthless, in which case the investor would keep both their shares of stock and the premium collected. Investors in Acadia Pharmaceuticals Inc (Symbol: ACAD) saw new options become available this week, for the May 15th expiration. At Stock Options Channel , our YieldBoost formula has looked up and down the ACAD options chain for the new May 15th contracts and identified one put and one call contract of particular interest. | Below is a chart showing the trailing twelve month trading history for Acadia Pharmaceuticals Inc, and highlighting in green where the $30.00 strike is located relative to that history: Turning to the calls side of the option chain, the call contract at the $31.00 strike price has a current bid of $2.20. Below is a chart showing ACAD's trailing twelve month trading history, with the $31.00 strike highlighted in red: Considering the fact that the $31.00 strike represents an approximate 1% premium to the current trading price of the stock (in other words it is out-of-the-money by that percentage), there is also the possibility that the covered call contract would expire worthless, in which case the investor would keep both their shares of stock and the premium collected. Investors in Acadia Pharmaceuticals Inc (Symbol: ACAD) saw new options become available this week, for the May 15th expiration. | At Stock Options Channel , our YieldBoost formula has looked up and down the ACAD options chain for the new May 15th contracts and identified one put and one call contract of particular interest. Below is a chart showing ACAD's trailing twelve month trading history, with the $31.00 strike highlighted in red: Considering the fact that the $31.00 strike represents an approximate 1% premium to the current trading price of the stock (in other words it is out-of-the-money by that percentage), there is also the possibility that the covered call contract would expire worthless, in which case the investor would keep both their shares of stock and the premium collected. Investors in Acadia Pharmaceuticals Inc (Symbol: ACAD) saw new options become available this week, for the May 15th expiration. |
36267.0 | 2015-03-19 00:00:00 UTC | The Zacks Analyst Blog Highlights: Amgen, Regeneron, Nektar, ACADIA and Pharmacyclics - Press Releases | ACAD | https://www.nasdaq.com/articles/the-zacks-analyst-blog-highlights%3A-amgen-regeneron-nektar-acadia-and-pharmacyclics-press | nan | nan | For Immediate Release
Chicago, IL - March 19, 2015 - Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include the Amgen ( AMGN - Free Report ), Regeneron ( REGN - Free Report ), Nektar ( NKTR - Free Report ), ACADIA ( ACAD - Free Report ) and Pharmacyclics ( PCYC - Free Report ).
Today, Zacks is promoting its ''Buy'' stock recommendations. Get #1Stock of the Day pick for free .
Here are highlights from Wednesday's Analyst Blog:
Biotech Stock Roundup
Last week, companies like Amgen ( AMGN - Free Report ) and Regeneron ( REGN - Free Report ) were present at the American College of Cardiology's (ACC) Annual Scientific Session with data on their PCSK9 inhibitors. Meanwhile, Nektar ( NKTR - Free Report ) came out with some disappointing late-stage data on its experimental cancer treatment and ACADIA ( ACAD - Free Report ) is facing yet another delay in the regulatory filing for its Parkinson's treatment.
Recap of the Week's Most Important Stories
1. Nektar came out with disappointing late-stage data on one of its most advanced pipeline candidates - NKTR-102. Top-line results from the phase III BEACON study in advanced breast cancer patients showed that NKTR-102 failed to achieve the primary endpoint of overall survival. Secondary endpoints like objective response rate (ORR) and progression-free survival (PFS) also did not achieve statistical significance in the study. Although Nektar did report improvements in certain patient subgroups, shares were down in pre-market trading .
2. Amgen presented promising long-term data on its PCSK9 inhibitor, evolocumab, at the recently held annual meeting of the ACC. Evolocumab consistently reduced LDL-C or "bad" cholesterol over a one-year period and lowered the rate of cardiovascular events when added to standard of care (Read more: Amgen Presents Encouraging PCSK9 Inhibitor Repatha Data ). Evolocumab is currently under regulatory review with the FDA expected to respond by Aug 27.
However, Regeneron and Sanofi are also looking to get their PCSK9 inhibitor, Praluent, approved and could get a head start over Amgen as the FDA action date for their candidate is Jul 24. Regeneron and Sanofi also came out with their own set of promising long-term data (18-month) on Praluent (Read more: Regeneron/Sanofi's PCSK9 Drug Praluent Data Published ).
3. There was some good news on the development front for Pharmacyclics ( PCYC - Free Report ) with an Independent Data Monitoring Committee recommending that a late-stage study evaluating Imbruvica in chronic lymphocytic leukemia or small lymphocytic lymphoma patients should be unblinded. The recommendation was based on clinically meaningful and statistically significant treatment benefit observed in the Imbruvica arm (Read more: Pharmacyclics' Imbruvica Encourages in a Phase III Study ).
4. ACADIA saw its shares tumbling on news regarding yet another delay in the NDA filing for its experimental Parkinson's disease treatment, Nuplazid. The company also announced the exit of its CEO (Read more: ACADIA Down on Nuplazid NDA Delay and CEO Resignation ).
Today, Zacks is promoting its ''Buy'' stock recommendations. Get #1Stock of the Day pick for free .
About Zacks Equity Research
Zacks Equity Research provides the best of quantitative and qualitative analysis to help investors know what stocks to buy and which to sell for the long-term.
Continuous coverage is provided for a universe of 1,150 publicly traded stocks. Our analysts are organized by industry which gives them keen insights to developments that affect company profits and stock performance. Recommendations and target prices are six-month time horizons.
Zacks "Profit from the Pros" e-mail newsletter provides highlights of the latest analysis from Zacks Equity Research. Subscribe to this free newsletter today .
About Zacks
Zacks.com is a property of Zacks Investment Research, Inc., which was formed in 1978. The later formation of the Zacks Rank, a proprietary stock picking system; continues to outperform the market by nearly a 3 to 1 margin. The best way to unlock the profitable stock recommendations and market insights of Zacks Investment Research is through our free daily email newsletter; Profit from the Pros. In short, it's your steady flow of Profitable ideas GUARANTEED to be worth your time! Register for your free subscription to Profit from the Pros .
Get the full Report on AMGN - FREE
Get the full Report on REGN - FREE
Get the full Report on NKTR - FREE
Get the full Report on ACAD - FREE
Get the full Report on PCYC - FREE
Follow us on Twitter: http://twitter.com/zacksresearch
Join us on Facebook: http://www.facebook.com/home.php#/pages/Zacks-Investment-Research/57553657748?ref=ts
Zacks Investment Research is under common control with affiliated entities (including a broker-dealer and an investment adviser), which may engage in transactions involving the foregoing securities for the clients of such affiliates.
Media Contact
Zacks Investment Research
800-767-3771 ext. 9339
support@zacks.com
http://www.zacks.com
Past performance is no guarantee of future results. Inherent in any investment is the potential for loss. This material is being provided for informational purposes only and nothing herein constitutes investment, legal, accounting or tax advice, or a recommendation to buy, sell or hold a security. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. It should not be assumed that any investments in securities, companies, sectors or markets identified and described were or will be profitable. All information is current as of the date of herein and is subject to change without notice. Any views or opinions expressed may not reflect those of the firm as a whole. Zacks Investment Research does not engage in investment banking, market making or asset management activities of any securities. These returns are from hypothetical portfolios consisting of stocks with Zacks Rank = 1 that were rebalanced monthly with zero transaction costs. These are not the returns of actual portfolios of stocks. The S&P 500 is an unmanaged index. Visit http://www.zacks.com/performance for information about the performance numbers displayed in this press release.
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
AMGEN INC (AMGN): Free Stock Analysis Report
REGENERON PHARM (REGN): Free Stock Analysis Report
ACADIA PHARMA (ACAD): Free Stock Analysis Report
PHARMACYCLICS (PCYC): Free Stock Analysis Report
To read this article on Zacks.com click here.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Stocks recently featured in the blog include the Amgen ( AMGN - Free Report ), Regeneron ( REGN - Free Report ), Nektar ( NKTR - Free Report ), ACADIA ( ACAD - Free Report ) and Pharmacyclics ( PCYC - Free Report ). Meanwhile, Nektar ( NKTR - Free Report ) came out with some disappointing late-stage data on its experimental cancer treatment and ACADIA ( ACAD - Free Report ) is facing yet another delay in the regulatory filing for its Parkinson's treatment. ACADIA saw its shares tumbling on news regarding yet another delay in the NDA filing for its experimental Parkinson's disease treatment, Nuplazid. | Stocks recently featured in the blog include the Amgen ( AMGN - Free Report ), Regeneron ( REGN - Free Report ), Nektar ( NKTR - Free Report ), ACADIA ( ACAD - Free Report ) and Pharmacyclics ( PCYC - Free Report ). Get the full Report on AMGN - FREE Get the full Report on REGN - FREE Get the full Report on NKTR - FREE Get the full Report on ACAD - FREE Get the full Report on PCYC - FREE Follow us on Twitter: http://twitter.com/zacksresearch Join us on Facebook: http://www.facebook.com/home.php#/pages/Zacks-Investment-Research/57553657748?ref=ts Zacks Investment Research is under common control with affiliated entities (including a broker-dealer and an investment adviser), which may engage in transactions involving the foregoing securities for the clients of such affiliates. Click to get this free report AMGEN INC (AMGN): Free Stock Analysis Report REGENERON PHARM (REGN): Free Stock Analysis Report ACADIA PHARMA (ACAD): Free Stock Analysis Report PHARMACYCLICS (PCYC): Free Stock Analysis Report To read this article on Zacks.com click here. | Stocks recently featured in the blog include the Amgen ( AMGN - Free Report ), Regeneron ( REGN - Free Report ), Nektar ( NKTR - Free Report ), ACADIA ( ACAD - Free Report ) and Pharmacyclics ( PCYC - Free Report ). Get the full Report on AMGN - FREE Get the full Report on REGN - FREE Get the full Report on NKTR - FREE Get the full Report on ACAD - FREE Get the full Report on PCYC - FREE Follow us on Twitter: http://twitter.com/zacksresearch Join us on Facebook: http://www.facebook.com/home.php#/pages/Zacks-Investment-Research/57553657748?ref=ts Zacks Investment Research is under common control with affiliated entities (including a broker-dealer and an investment adviser), which may engage in transactions involving the foregoing securities for the clients of such affiliates. Click to get this free report AMGEN INC (AMGN): Free Stock Analysis Report REGENERON PHARM (REGN): Free Stock Analysis Report ACADIA PHARMA (ACAD): Free Stock Analysis Report PHARMACYCLICS (PCYC): Free Stock Analysis Report To read this article on Zacks.com click here. | Stocks recently featured in the blog include the Amgen ( AMGN - Free Report ), Regeneron ( REGN - Free Report ), Nektar ( NKTR - Free Report ), ACADIA ( ACAD - Free Report ) and Pharmacyclics ( PCYC - Free Report ). Meanwhile, Nektar ( NKTR - Free Report ) came out with some disappointing late-stage data on its experimental cancer treatment and ACADIA ( ACAD - Free Report ) is facing yet another delay in the regulatory filing for its Parkinson's treatment. ACADIA saw its shares tumbling on news regarding yet another delay in the NDA filing for its experimental Parkinson's disease treatment, Nuplazid. |
36268.0 | 2015-03-19 00:00:00 UTC | This Exciting Biotech Isn't Built to Last | ACAD | https://www.nasdaq.com/articles/exciting-biotech-isnt-built-last-2015-03-19 | nan | nan | If you're not an investor in Acadia, you could brush off this chart and be glad you dodged a bullet. But not so fast. Inside Acadia's boom-to-bust cycle are some practical lessons that could be applied to coming stock picks, particularly biotechs, and provide you a better chance of finding a company built to last.
There is one thing even more important than taking off: landing.
A company can really take off when it gets a candidate drug successfully through clinical trials, but it still has a very dangerous maneuver ahead of it: commercialization. Acadia provides a good example of how tricky this can get, because last week wasn't the first time it put Nuplazid's NDA on hold. Four months ago, the biotech also delayed its NDA, with Acadia's management saying the company hadn't yet prepared its FDA pitch.
This time, Acadia's acting CEO, Steve Davis, who replaced previous CEO Uli Hacksell after his sudden retirement earlier this month, said: "We have concluded that additional time is needed to complete the readiness of our commercial manufacturing systems. We are working expeditiously to ensure that our systems are robust and ready for FDA review and commercial launch."
As Motley Fool biotech writer George Budwell pointed out , Nuplazid reported strong late-stage clinical trial results way back in 2012. Since then, Acadia has had over two years to work out the kinks and hasn't been able to do so. That's a whopping red flag that this company isn't built to last.
The company's words would have you believe that there's nothing to be concerned about; Davis affirmed, "We remain confident in the safety and efficacy package supporting the NDA of Nuplazid."
But here's the thing. Acadia's management can insist all it wants that this new delay is not the result of any interaction with the FDA, or of a problem with this dug. However, management's claims have to be considered in light of the its prior insistence (before the previous NDA delay) that everything with the drug's regulatory submissions were on track.
And look at how that ended.
So what's afoot? For a company to take this long to file an NDA is extremely unusual. While the company could have some recently discovered concerns with the drug, that seems unlikely. Nuplazid had a breakthrough designation from the FDA, which makes it highly probable that the clinical data is good enough for an FDA approval.
Taking the next steps
Acadia's previous CEO was with the company for over 16 years, presiding over its growth from a start-up to a full-fledged biotech. Haskell's success at getting things done in the clinic led to huge gains for this stock. When Nuplazid achieved its primary endpoint of a phase 3 study, shares spiked 145% to $5.64. Acadia has also two clinical collaborations with Allergan on a promising phase 2 chronic pain drug, as well as a phase 1 glaucoma therapy.
But the skills required to get a drug into and through the clinic are different from the skills required to get it through commercialization. That's particularly true with a potential blockbuster like Nuplazid, since the FDA will require evidence that this company can manufacture the drug in sufficient quantity to meet demand.
According to the National Institute of Neurological Disorders, at least a half million people in the U.S. suffer from Parkinson's disease. Psychosis tied to the disease can strike as many as one in five Parkinson's patients. Guaranteeing a sufficient supply of Nuplazid is thus a tall order, and having a safe and effective commercial manufacturing procedure in place is essential before the FDA will grant approval.
Acadia has badly needed to find a third-party manufacturing or marketing partner for several years. Despite that, probably because it fears signing away a future revenue stream, the company has repeatedly said it prefers to market Nuplazid alone. For example, in a presentation at the Oppenheimer Healthcare Conference , Hacksell said the company wanted to use "the commercial phases of Nuplazid to form the foundation for a successful neurology company in the U.S., and perhaps also outside the U.S." In case his meaning wasn't clear enough, he added, "We want to commercialize Nuplazid ourselves in the U.S." Outside the U.S., he conceded, "We may or may not partner."
During the presentation, Hacksell focused a great deal on Nuplazid's potential. While his pride in the drug is understandable, I couldn't help thinking of one of my favorite installments of the comic strip Peanuts. In his wonderfully understated manner, cartoonist Charles Schultz had Linus say, "There is no heavier burden than having great potential."
Many small- to mid-size biotechs fall into this trap. The scientists and entrepreneurs who build these companies are highly skilled in assessing the clinical value of their product. But a drug launch is its own complex, resource-intensive process requiring a large headcount experienced in regulatory issues, market access, marketing, sales, medical affairs, communications, distribution -- you get the idea.
Occasionally, refusing to out-license to a pharmaceutical partner, or seek a collaborator, works out. But it usually extends the launch time dangerously. It also puts significant fixed costs on the books at a time when financial flexibility is greatly needed.
In the very worst cases, great and needed drugs remain where Acadia's drug is -- stuck. In Nuplazid's case, Parkinson's psychosis is a completely unmet medical need. Right now, the drug could be helping patients cope with a very difficult neurodegenerative disorder, and it has other potential applications as well, including Alzheimer's psychosis and psychiatry areas such as schizophrenia and bipolar mania.
Delays can't always be avoided with drug commercialization, but it's how delays are handled that makes the difference. Acadia has done two bailouts now, and it has yet to communicate to investors how it plans to get Nuplazid to market. Nor has it indicated how it is going to get its own house strategically in order -- meaning that, at the very least, it needs to put resources into finding a new CEO with commercialization experience.
Acadia has produced a drug for a needed indication, but it appears to lack the ability to take the strategic actions necessary to move to the next level. In terms of the company's investors, having this amount of difficultly getting together a regulatory review doesn't bode well for Nuplazid's future commercialization.
But here's the broader lesson to learn: Biotechs achieve greatness with exuberance, not with excuses, and with leaders who don't try to retain full control when it's not in the best interests of the company's future. It's best to avoid these companies that are simply not built to last.
This coming blockbuster will make every biotech jealous
The best biotech investors consistently energize their portfolios by adding companies that are built to last. Let me cut right to the chase. If you liked this article, keep reading to find a product in development that could revolutionize not just how we treat a common chronic illness, but potentially the entire health industry. Analysts are already licking their chops at the sales potential. If you hope to outsmart Wall Street and realize multi-bagger returns you will need to get in early -- check out The Motley Fool's new free report on the dream-team responsible for this coming blockbuster. CLICK HERE NOW .
The article This Exciting Biotech Isn't Built to Last originally appeared on Fool.com.
Cheryl Swanson has no position in any stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. Try any of our Foolish newsletter services free for 30 days . We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy .
Copyright © 1995 - 2015 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy .
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Inside Acadia's boom-to-bust cycle are some practical lessons that could be applied to coming stock picks, particularly biotechs, and provide you a better chance of finding a company built to last. If you're not an investor in Acadia, you could brush off this chart and be glad you dodged a bullet. Acadia provides a good example of how tricky this can get, because last week wasn't the first time it put Nuplazid's NDA on hold. | In the very worst cases, great and needed drugs remain where Acadia's drug is -- stuck. If you're not an investor in Acadia, you could brush off this chart and be glad you dodged a bullet. Inside Acadia's boom-to-bust cycle are some practical lessons that could be applied to coming stock picks, particularly biotechs, and provide you a better chance of finding a company built to last. | Four months ago, the biotech also delayed its NDA, with Acadia's management saying the company hadn't yet prepared its FDA pitch. If you're not an investor in Acadia, you could brush off this chart and be glad you dodged a bullet. Inside Acadia's boom-to-bust cycle are some practical lessons that could be applied to coming stock picks, particularly biotechs, and provide you a better chance of finding a company built to last. | Four months ago, the biotech also delayed its NDA, with Acadia's management saying the company hadn't yet prepared its FDA pitch. If you're not an investor in Acadia, you could brush off this chart and be glad you dodged a bullet. Inside Acadia's boom-to-bust cycle are some practical lessons that could be applied to coming stock picks, particularly biotechs, and provide you a better chance of finding a company built to last. |
36269.0 | 2015-03-13 00:00:00 UTC | ACADIA Down on Nuplazid NDA Delay and CEO Resignation - Analyst Blog | ACAD | https://www.nasdaq.com/articles/acadia-down-on-nuplazid-nda-delay-and-ceo-resignation-analyst-blog-2015-03-13 | nan | nan | Shares of ACADIA PharmaceuticalsACAD plunged 22.2% after the company announced that its planned new drug application (NDA) on pipeline candidate Nuplazid has been delayed and that its Chief Executive Officer (CEO) has retired and resigned from the company's board.
Following an assessment of its manufacturing quality systems and procedures, ACADIA Pharmaceuticals now plans to submit its NDA on Nuplazid in the second half of 2015, delayed from the previous plan of submission in the first quarter of 2015. We remind investors that this is the second delay in NDA submission by the company.
In Nov 2014, the company had said that it will submit its NDA in the first quarter of 2015 as compared to the previous plan of submission by 2014-end.
The candidate is being evaluated for the treatment of Parkinson's disease psychosis in the second half of 2015.
The company attributed the delay to the additional time required to complete the preparation of systems to support commercial-scale manufacturing and supply in order to facilitate the FDA's review.
ACADIA Pharmaceuticals reinstated that the postponement is not due to a change in the candidate's clinical or safety profile or the result of any interaction with or request for information from the FDA. We note that the candidate enjoys Breakthrough Therapy designation in the U.S.
Concurrently, ACADIA Pharmaceuticals announced the resignation of CEO Uli Hacksell from the board of directors.
Our Take
ACADIA Pharmaceuticals (ACAD) currently carries a Zacks Rank #4 (Sell). A consecutive delay in NDA submission for Nuplazid along with the stepping down of the CEO has clouded growth prospects of the candidate.
We note that Nuplazid is the lead candidate at ACADIA Pharmaceuticals. Hence, the delay in NDA submission is a major setback for the company as well. Earlier in the week, there have been takeover rumors for ACADIA Pharmaceuticals leading to a surge in shares of the company.
We expect investor focus on further updates from the company on the NDA submission.
Some better-ranked stocks in the health care sector include Mallinckrodt public limited company MNK , Actavis plc ACT , and Impax Laboratories Inc. IPXL . All these stocks hold a Zacks Rank #2 (Buy).
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
ACADIA PHARMA (ACAD): Free Stock Analysis Report
IMPAX LABORATRS (IPXL): Free Stock Analysis Report
MALLINCKRODT PL (MNK): Free Stock Analysis Report
ACTAVIS PLC (ACT): Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | We note that the candidate enjoys Breakthrough Therapy designation in the U.S. Concurrently, ACADIA Pharmaceuticals announced the resignation of CEO Uli Hacksell from the board of directors. Shares of ACADIA PharmaceuticalsACAD plunged 22.2% after the company announced that its planned new drug application (NDA) on pipeline candidate Nuplazid has been delayed and that its Chief Executive Officer (CEO) has retired and resigned from the company's board. Following an assessment of its manufacturing quality systems and procedures, ACADIA Pharmaceuticals now plans to submit its NDA on Nuplazid in the second half of 2015, delayed from the previous plan of submission in the first quarter of 2015. | Following an assessment of its manufacturing quality systems and procedures, ACADIA Pharmaceuticals now plans to submit its NDA on Nuplazid in the second half of 2015, delayed from the previous plan of submission in the first quarter of 2015. Click to get this free report ACADIA PHARMA (ACAD): Free Stock Analysis Report IMPAX LABORATRS (IPXL): Free Stock Analysis Report MALLINCKRODT PL (MNK): Free Stock Analysis Report ACTAVIS PLC (ACT): Free Stock Analysis Report To read this article on Zacks.com click here. Shares of ACADIA PharmaceuticalsACAD plunged 22.2% after the company announced that its planned new drug application (NDA) on pipeline candidate Nuplazid has been delayed and that its Chief Executive Officer (CEO) has retired and resigned from the company's board. | Shares of ACADIA PharmaceuticalsACAD plunged 22.2% after the company announced that its planned new drug application (NDA) on pipeline candidate Nuplazid has been delayed and that its Chief Executive Officer (CEO) has retired and resigned from the company's board. Following an assessment of its manufacturing quality systems and procedures, ACADIA Pharmaceuticals now plans to submit its NDA on Nuplazid in the second half of 2015, delayed from the previous plan of submission in the first quarter of 2015. Click to get this free report ACADIA PHARMA (ACAD): Free Stock Analysis Report IMPAX LABORATRS (IPXL): Free Stock Analysis Report MALLINCKRODT PL (MNK): Free Stock Analysis Report ACTAVIS PLC (ACT): Free Stock Analysis Report To read this article on Zacks.com click here. | Shares of ACADIA PharmaceuticalsACAD plunged 22.2% after the company announced that its planned new drug application (NDA) on pipeline candidate Nuplazid has been delayed and that its Chief Executive Officer (CEO) has retired and resigned from the company's board. Following an assessment of its manufacturing quality systems and procedures, ACADIA Pharmaceuticals now plans to submit its NDA on Nuplazid in the second half of 2015, delayed from the previous plan of submission in the first quarter of 2015. We note that Nuplazid is the lead candidate at ACADIA Pharmaceuticals. |
36270.0 | 2015-03-12 00:00:00 UTC | Why Acadia Pharmaceuticals Inc. Stock Crashed | ACAD | https://www.nasdaq.com/articles/why-acadia-pharmaceuticals-inc-stock-crashed-2015-03-12 | nan | nan | Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis.
What : Shares of the clinical-stage drugmaker Acadia Pharmaceuticals dropped by over 20% on extremely high volume today. The culprits behind this major downward move are twofold. First, the company announced that it will delay the New Drug Application for its experimental Parkinson's disease psychosis drug nuplazid (pimavanserin) from this quarter to sometime in the second half of the year, citing issues with their ability to manufacture the drug on a commercial scale for the setback.
Perhaps even more concerning, Acadia's longtime CEO Uli Hacksell decided to retire and is stepping down from the board as well. The company's CFO Steve Davis will take over as CEO on an interim basis.
So what : Nuplazid reported strong late-stage results all the way back in 2012. But, despite the drug being granted Breakthrough Therapy status by the Food and Drug Administration, Acadia has been unable to get a regulatory application in front of the agency to review.
In short, they've had over two years to iron out the kinks and simply haven't been able to do so. So even though Acadia's remaining executives tried to downplay the CEO's sudden departure as nothing more than a personal decision, these two events appear to be coupled in investors' minds today.
Now what : Acadia's experimental Parkinson's disease psychosis drug is widely believed to have blockbuster potential, causing shares to soar over the last few years. Nonetheless, nuplazid's regulatory filing has been repeatedly postponed for various reasons, and the CEO's retirement during the most pivotal point in the company's life to date brings up a lot of questions. You may want to exercise caution with this biotech right now -- at least until the smoke clears from these latest events.
This coming blockbuster will make every biotech jealous
The best biotech investors consistently reap gigantic profits by recognizing true potential earlier and more accurately than anyone else. Let me cut right to the chase. There is a product in development that could revolutionize not just how we treat a common chronic illness, but potentially the entire health industry. Analysts are already licking their chops at the sales potential. If you hope to outsmart Wall Street and realize multi-bagger returns you will need to get in early -- check out The Motley Fool's new free report on the dream-team responsible for this game-changing blockbuster. CLICK HERE NOW .
The article Why Acadia Pharmaceuticals Inc. Stock Crashed originally appeared on Fool.com.
George Budwell has no position in any stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. Try any of our Foolish newsletter services free for 30 days . We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy .
Copyright © 1995 - 2015 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy .
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | So even though Acadia's remaining executives tried to downplay the CEO's sudden departure as nothing more than a personal decision, these two events appear to be coupled in investors' minds today. What : Shares of the clinical-stage drugmaker Acadia Pharmaceuticals dropped by over 20% on extremely high volume today. Perhaps even more concerning, Acadia's longtime CEO Uli Hacksell decided to retire and is stepping down from the board as well. | Now what : Acadia's experimental Parkinson's disease psychosis drug is widely believed to have blockbuster potential, causing shares to soar over the last few years. What : Shares of the clinical-stage drugmaker Acadia Pharmaceuticals dropped by over 20% on extremely high volume today. Perhaps even more concerning, Acadia's longtime CEO Uli Hacksell decided to retire and is stepping down from the board as well. | Now what : Acadia's experimental Parkinson's disease psychosis drug is widely believed to have blockbuster potential, causing shares to soar over the last few years. What : Shares of the clinical-stage drugmaker Acadia Pharmaceuticals dropped by over 20% on extremely high volume today. Perhaps even more concerning, Acadia's longtime CEO Uli Hacksell decided to retire and is stepping down from the board as well. | What : Shares of the clinical-stage drugmaker Acadia Pharmaceuticals dropped by over 20% on extremely high volume today. Perhaps even more concerning, Acadia's longtime CEO Uli Hacksell decided to retire and is stepping down from the board as well. But, despite the drug being granted Breakthrough Therapy status by the Food and Drug Administration, Acadia has been unable to get a regulatory application in front of the agency to review. |
36271.0 | 2015-03-12 00:00:00 UTC | US Futures Point Higher Amid Lower-Than-Expected Jobless Claims; Retail Sales Disappoint | ACAD | https://www.nasdaq.com/articles/us-futures-point-higher-amid-lower-expected-jobless-claims-retail-sales-disappoint-2015-03 | nan | nan | U.S. stock futures were higher Thursday as jobless claims and retail sales provided mixed signals about the economy by beating and missing expectations, respectively.
Weekly jobless claims in the week ended March 7 fell 36,000 to 289,000 compared to the expected 309,000 claims and also below the lower end of the consensus range compiled by Econoday between 292,000 and 320,000. Claims in the week ended Feb. 28 were revised upwards to 325,000 from 320,000.
Retail sales in February fell 0.6% compared to the expected 0.3% gain and a 0.8% drop in January. The consensus range was between a decline of 0.1% and a gain of 0.5%. Meanwhile, export prices in February fell 0.1% as expected while January export prices were revised to have declined 1.9% from initially reported a 2.0% decline. Import prices rose 0.4% in February compared to the 0.2% expected gain while January was revised to have declined 3.1% from the initially reported 2.8%
In equities, Acadia Pharmaceuticals ( ACAD ) dropped 21% in recent pre-market trade after delaying submission of the new drug application for its Parkinson's disease psychosis treatment Nuplazid till the second half of 2015 instead of in Q1, as previously planned. Meanwhile, CEO Uli Hacksell resigned effective immediately. CFO Steve Davis was appointed interim CEO.
Lumber Liquidators ( LL ) meanwhile traded higher by 5.6% after trying to allay concerns about the safety of its products, according to a presentation that will be given at a call later Thursday. The retailer of hardwood flooring said it "stands by every single plank of wood and laminate we sell," in response to a CBS 60 minutes report that claimed formaldehyde levels in its laminate flooring were unsafe. Lumber Liquidators also gave a Q1 guidance for sales that was well below analyst estimates.
U.S. PRE-MARKET INDICATORS
-Dow Jones Industrial up 0.41%
-S&P 500 futures up 0.37%
-Nasdaq 100 futures up 0.20%
GLOBAL SENTIMENT
Nikkei up 1.43%
Hang Seng up 0.34%
Shanghai Composite up 1.93%
FTSE-100 up 0.94%
DAX-30 down 0.30%
PRE-MARKET SECTOR WATCH
(+/-) Large cap tech: mixed
(+) Chip stocks: unchanged to higher
(+) Software stocks: unchanged to higher
(+/-) Hardware stocks: mixed
(+) Internet stocks: higher
(+/-) Drug stocks: mixed
(+) Financial stocks: higher
(+/-) Retail stocks: unchanged
(+/-) Industrial stocks: mixed
(+/-) Airlines: unchanged to higher
(+) Autos: higher
UPSIDE MOVERS
(+) C (+3.6%) Fed doesn't object to Capital plan; hikes dividend, plans $7.8 billion buyback
(+) AMRN (+16.0%) HC Wainwright upgrades to buy vs neutral
(+) DG (+2.5%) Q4 earnings meet views, sales shy
(+) BABA (+0.5%) Reportedly invests $200 million in Snapchat
(+) JASO (+7.1%) Q4 beats Street view
(+) LIVE (+8.8%) Forecasts higher profit margins
DOWNSIDE MOVERS
(-) INTC (-3.8%) Cuts Q1 revenue guidance
(-) CUR (-2.4%) Announces results from ALS treatment study
(-) CYBR (-6.4%) Prices secondary share sale
(-) INGN (-17.0%) Postpones release of Q4 due to accounting audit
(-) HPQ (-2.2%) Barclays downgrades to equalweightv vs. overweight; cut PT to $35
(-) BOX (-17.5%) Posts wider-than-expected Q4 net loss
(-) VRA (-1.0%) Telsey Advisory cuts price target
(-) TTPH (-1.0%) Prices 4.3 million share sale at $35 each
(-) QIWI (-8.1%) Q4 EPS misses views
(-) BVX (-16.7%) Prices 4.8-million-share-sale at 20% discount
(-) LOGI (-2.2%) JP Morgan downgrades to underweight vs neutral
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
Copyright (C) 2016 MTNewswires.com. All rights reserved. Unauthorized reproduction is strictly prohibited.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Import prices rose 0.4% in February compared to the 0.2% expected gain while January was revised to have declined 3.1% from the initially reported 2.8% In equities, Acadia Pharmaceuticals ( ACAD ) dropped 21% in recent pre-market trade after delaying submission of the new drug application for its Parkinson's disease psychosis treatment Nuplazid till the second half of 2015 instead of in Q1, as previously planned. U.S. stock futures were higher Thursday as jobless claims and retail sales provided mixed signals about the economy by beating and missing expectations, respectively. (+) C (+3.6%) Fed doesn't object to Capital plan; hikes dividend, plans $7.8 billion buyback (+) AMRN (+16.0%) HC Wainwright upgrades to buy vs neutral (+) DG (+2.5%) Q4 earnings meet views, sales shy (+) BABA (+0.5%) Reportedly invests $200 million in Snapchat (+) JASO (+7.1%) Q4 beats Street view (+) LIVE (+8.8%) Forecasts higher profit margins | Import prices rose 0.4% in February compared to the 0.2% expected gain while January was revised to have declined 3.1% from the initially reported 2.8% In equities, Acadia Pharmaceuticals ( ACAD ) dropped 21% in recent pre-market trade after delaying submission of the new drug application for its Parkinson's disease psychosis treatment Nuplazid till the second half of 2015 instead of in Q1, as previously planned. U.S. stock futures were higher Thursday as jobless claims and retail sales provided mixed signals about the economy by beating and missing expectations, respectively. Meanwhile, export prices in February fell 0.1% as expected while January export prices were revised to have declined 1.9% from initially reported a 2.0% decline. | Import prices rose 0.4% in February compared to the 0.2% expected gain while January was revised to have declined 3.1% from the initially reported 2.8% In equities, Acadia Pharmaceuticals ( ACAD ) dropped 21% in recent pre-market trade after delaying submission of the new drug application for its Parkinson's disease psychosis treatment Nuplazid till the second half of 2015 instead of in Q1, as previously planned. (+/-) Large cap tech: mixed (+) Chip stocks: unchanged to higher (+) Software stocks: unchanged to higher (+/-) Hardware stocks: mixed (+) Internet stocks: higher (+/-) Drug stocks: mixed (+) Financial stocks: higher (+/-) Retail stocks: unchanged (+/-) Industrial stocks: mixed (+/-) Airlines: unchanged to higher (+) Autos: higher (-) INTC (-3.8%) Cuts Q1 revenue guidance (-) CUR (-2.4%) Announces results from ALS treatment study (-) CYBR (-6.4%) Prices secondary share sale (-) INGN (-17.0%) Postpones release of Q4 due to accounting audit (-) HPQ (-2.2%) Barclays downgrades to equalweightv vs. overweight; cut PT to $35 (-) BOX (-17.5%) Posts wider-than-expected Q4 net loss (-) VRA (-1.0%) Telsey Advisory cuts price target (-) TTPH (-1.0%) Prices 4.3 million share sale at $35 each (-) QIWI (-8.1%) Q4 EPS misses views (-) BVX (-16.7%) Prices 4.8-million-share-sale at 20% discount (-) LOGI (-2.2%) JP Morgan downgrades to underweight vs neutral The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Import prices rose 0.4% in February compared to the 0.2% expected gain while January was revised to have declined 3.1% from the initially reported 2.8% In equities, Acadia Pharmaceuticals ( ACAD ) dropped 21% in recent pre-market trade after delaying submission of the new drug application for its Parkinson's disease psychosis treatment Nuplazid till the second half of 2015 instead of in Q1, as previously planned. U.S. stock futures were higher Thursday as jobless claims and retail sales provided mixed signals about the economy by beating and missing expectations, respectively. Weekly jobless claims in the week ended March 7 fell 36,000 to 289,000 compared to the expected 309,000 claims and also below the lower end of the consensus range compiled by Econoday between 292,000 and 320,000. |
36272.0 | 2015-03-12 00:00:00 UTC | Correction: US Futures Higher Ahead of Weekly Jobless Claims Data, Retail Sales | ACAD | https://www.nasdaq.com/articles/correction-us-futures-higher-ahead-weekly-jobless-claims-data-retail-sales-2015-03-12 | nan | nan | (Corrects the movement of the Dow Jones Industrial Average and the Nasdaq 100 as higher, not lower)
U.S. stock futures were higher Thursday as markets waited for data on jobless claims and retail sales that could provide further incentive for the U.S. Federal Reserve to raise interest rates.
At 8:30 a.m. E.T. data are expected to show that jobless claims in the week ended March 7 were 309,000, down from 320,000 the preceding week. The consensus range is for claims between 292,000 and 320,000, according to data compiled by Econoday.
Retail sales in February, also out at 8:30 a.m., are expected to have gained 0.3% from a 0.8% drop in January. The consensus range is between a decline of 0.1% and a gain of 0.5%. Meanwhile, export prices in February are seen down 0.1% compared to a 2.0% decline in January while import prices are seen higher 0.2% compared to a 2.8% decline in January.
In equities, Acadia Pharmaceuticals ( ACAD ) dropped 22% in recent pre-market trade after delaying submission of the new drug application for its Parkinson's disease psychosis treatment Nuplazid till the second half of 2015 instead of in Q1, as previously planned. Meanwhile, CEO Uli Hacksell resigned effective immediately. CFO Steve Davis was appointed interim CEO.
Lumber Liquidators ( LL ) meanwhile traded higher by 3% after trying to allay concerns about the safety of its products, according to a presentation that will be given at a call later Thursday. The retailer of hardwood flooring said it "stands by every single plank of wood and laminate we sell," in response to a CBS 60 minutes report that claimed formaldehyde levels in its laminate flooring were unsafe. Lumber Liquidators also gave a Q1 guidance for sales that was well below analyst estimates.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
Copyright (C) 2016 MTNewswires.com. All rights reserved. Unauthorized reproduction is strictly prohibited.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | In equities, Acadia Pharmaceuticals ( ACAD ) dropped 22% in recent pre-market trade after delaying submission of the new drug application for its Parkinson's disease psychosis treatment Nuplazid till the second half of 2015 instead of in Q1, as previously planned. (Corrects the movement of the Dow Jones Industrial Average and the Nasdaq 100 as higher, not lower) U.S. stock futures were higher Thursday as markets waited for data on jobless claims and retail sales that could provide further incentive for the U.S. Federal Reserve to raise interest rates. Lumber Liquidators ( LL ) meanwhile traded higher by 3% after trying to allay concerns about the safety of its products, according to a presentation that will be given at a call later Thursday. | The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. In equities, Acadia Pharmaceuticals ( ACAD ) dropped 22% in recent pre-market trade after delaying submission of the new drug application for its Parkinson's disease psychosis treatment Nuplazid till the second half of 2015 instead of in Q1, as previously planned. Meanwhile, export prices in February are seen down 0.1% compared to a 2.0% decline in January while import prices are seen higher 0.2% compared to a 2.8% decline in January. | In equities, Acadia Pharmaceuticals ( ACAD ) dropped 22% in recent pre-market trade after delaying submission of the new drug application for its Parkinson's disease psychosis treatment Nuplazid till the second half of 2015 instead of in Q1, as previously planned. (Corrects the movement of the Dow Jones Industrial Average and the Nasdaq 100 as higher, not lower) U.S. stock futures were higher Thursday as markets waited for data on jobless claims and retail sales that could provide further incentive for the U.S. Federal Reserve to raise interest rates. Meanwhile, export prices in February are seen down 0.1% compared to a 2.0% decline in January while import prices are seen higher 0.2% compared to a 2.8% decline in January. | In equities, Acadia Pharmaceuticals ( ACAD ) dropped 22% in recent pre-market trade after delaying submission of the new drug application for its Parkinson's disease psychosis treatment Nuplazid till the second half of 2015 instead of in Q1, as previously planned. (Corrects the movement of the Dow Jones Industrial Average and the Nasdaq 100 as higher, not lower) U.S. stock futures were higher Thursday as markets waited for data on jobless claims and retail sales that could provide further incentive for the U.S. Federal Reserve to raise interest rates. Retail sales in February, also out at 8:30 a.m., are expected to have gained 0.3% from a 0.8% drop in January. |
36273.0 | 2015-03-12 00:00:00 UTC | Pre-Market Most Active for Mar 12, 2015 : BAC, LL, ACAD, HSBC, EQM, CYBR, C, AAPL, QQQ, KO, AMRN, TVIX | ACAD | https://www.nasdaq.com/articles/pre-market-most-active-mar-12-2015-bac-ll-acad-hsbc-eqm-cybr-c-aapl-qqq-ko-amrn-tvix-2015 | nan | nan | The NASDAQ 100 Pre-Market Indicator is up 9.56 to 4,314.94. The total Pre-Market volume is currently 2,615,534 shares traded.
The following are the most active stocks for the pre-market session :
Bank of America Corporation ( BAC ) is unchanged at $16.11, with 1,541,491 shares traded. BAC's current last sale is 84.79% of the target price of $19.
Lumber Liquidators Holdings, Inc ( LL ) is +1.37 at $34.10, with 831,128 shares traded. LL's current last sale is 63.74% of the target price of $53.5.
ACADIA Pharmaceuticals Inc. ( ACAD ) is -10.26 at $34.50, with 498,950 shares traded. As reported in the last short interest update the days to cover for ACAD is 11.766846; this calculation is based on the average trading volume of the stock.
HSBC Holdings plc ( HSBC ) is unchanged at $42.05, with 489,523 shares traded., following a 52-week high recorded in prior regular session.
EQT Midstream Partners, LP ( EQM ) is -1.07 at $75.23, with 419,155 shares traded. As reported by Zacks, the current mean recommendation for EQM is in the "buy range".
CyberArk Software Ltd. ( CYBR ) is -3.12 at $52.48, with 375,178 shares traded. CYBR's current last sale is 104.96% of the target price of $50.
Citigroup Inc. ( C ) is +1.77 at $54.10, with 286,724 shares traded. As reported by Zacks, the current mean recommendation for C is in the "buy range".
Apple Inc. ( AAPL ) is +0.32 at $122.56, with 262,903 shares traded. Over the last four weeks they have had 3 up revisions for the earnings forecast, for the fiscal quarter ending Sep 2015. The consensus EPS forecast is $1.74. As reported by Zacks, the current mean recommendation for AAPL is in the "buy range".
PowerShares QQQ Trust, Series 1 ( QQQ ) is +0.38 at $105.49, with 246,575 shares traded. This represents a 26.67% increase from its 52 Week Low.
Coca-Cola Company (The) ( KO ) is +0.33 at $40.10, with 238,634 shares traded. KO's current last sale is 89.11% of the target price of $45.
Amarin Corporation PLC ( AMRN ) is +0.36 at $2.30, with 188,775 shares traded. AMRN's current last sale is 83.64% of the target price of $2.75.
VelocityShares Daily 2x VIX Short Term ETN ( TVIX ) is -0.07 at $2.15, with 173,275 shares traded. This represents a 9.14% increase from its 52 Week Low.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | As reported in the last short interest update the days to cover for ACAD is 11.766846; this calculation is based on the average trading volume of the stock. ACADIA Pharmaceuticals Inc. ( ACAD ) is -10.26 at $34.50, with 498,950 shares traded. The following are the most active stocks for the pre-market session : Bank of America Corporation ( BAC ) is unchanged at $16.11, with 1,541,491 shares traded. | ACADIA Pharmaceuticals Inc. ( ACAD ) is -10.26 at $34.50, with 498,950 shares traded. As reported in the last short interest update the days to cover for ACAD is 11.766846; this calculation is based on the average trading volume of the stock. The total Pre-Market volume is currently 2,615,534 shares traded. | ACADIA Pharmaceuticals Inc. ( ACAD ) is -10.26 at $34.50, with 498,950 shares traded. As reported in the last short interest update the days to cover for ACAD is 11.766846; this calculation is based on the average trading volume of the stock. The total Pre-Market volume is currently 2,615,534 shares traded. | ACADIA Pharmaceuticals Inc. ( ACAD ) is -10.26 at $34.50, with 498,950 shares traded. As reported in the last short interest update the days to cover for ACAD is 11.766846; this calculation is based on the average trading volume of the stock. As reported by Zacks, the current mean recommendation for EQM is in the "buy range". |
36274.0 | 2015-03-12 00:00:00 UTC | US Futures Mixed Ahead of Weekly Jobless Claims Data, Retail Sales | ACAD | https://www.nasdaq.com/articles/us-futures-mixed-ahead-weekly-jobless-claims-data-retail-sales-2015-03-12 | nan | nan | U.S. stock futures were mixed Thursday, with the Dow Jones Industrial Average and Nasdaq 100 lower and the S&P 500 higher, as markets waited for data on jobless claims and retail sales that could provide further incentive for the U.S. Federal Reserve to raise interest rates.
At 8:30 a.m. E.T. data are expected to show that jobless claims in the week ended March 7 were 309,000, down from 320,000 the preceding week. The consensus range is for claims between 292,000 and 320,000, according to data compiled by Econoday.
Retail sales in February, also out at 8:30 a.m., are expected to have gained 0.3% from a 0.8% drop in January. The consensus range is between a decline of 0.1% and a gain of 0.5%. Meanwhile, export prices in February are seen down 0.1% compared to a 2.0% decline in January while import prices are seen higher 0.2% compared to a 2.8% decline in January.
In equities, Acadia Pharmaceuticals ( ACAD ) dropped 22% in recent pre-market trade after delaying submission of the new drug application for its Parkinson's disease psychosis treatment Nuplazid till the second half of 2015 instead of in Q1, as previously planned. Meanwhile, CEO Uli Hacksell resigned effective immediately. CFO Steve Davis was appointed interim CEO.
Lumber Liquidators ( LL ) meanwhile traded higher by 3% after trying to allay concerns about the safety of its products, according to a presentation that will be given at a call later Thursday. The retailer of hardwood flooring said it "stands by every single plank of wood and laminate we sell," in response to a CBS 60 minutes report that claimed formaldehyde levels in its laminate flooring were unsafe. Lumber Liquidators also gave a Q1 guidance for sales that was well below analyst estimates.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
Copyright (C) 2016 MTNewswires.com. All rights reserved. Unauthorized reproduction is strictly prohibited.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | In equities, Acadia Pharmaceuticals ( ACAD ) dropped 22% in recent pre-market trade after delaying submission of the new drug application for its Parkinson's disease psychosis treatment Nuplazid till the second half of 2015 instead of in Q1, as previously planned. U.S. stock futures were mixed Thursday, with the Dow Jones Industrial Average and Nasdaq 100 lower and the S&P 500 higher, as markets waited for data on jobless claims and retail sales that could provide further incentive for the U.S. Federal Reserve to raise interest rates. Lumber Liquidators ( LL ) meanwhile traded higher by 3% after trying to allay concerns about the safety of its products, according to a presentation that will be given at a call later Thursday. | The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. In equities, Acadia Pharmaceuticals ( ACAD ) dropped 22% in recent pre-market trade after delaying submission of the new drug application for its Parkinson's disease psychosis treatment Nuplazid till the second half of 2015 instead of in Q1, as previously planned. Meanwhile, export prices in February are seen down 0.1% compared to a 2.0% decline in January while import prices are seen higher 0.2% compared to a 2.8% decline in January. | In equities, Acadia Pharmaceuticals ( ACAD ) dropped 22% in recent pre-market trade after delaying submission of the new drug application for its Parkinson's disease psychosis treatment Nuplazid till the second half of 2015 instead of in Q1, as previously planned. U.S. stock futures were mixed Thursday, with the Dow Jones Industrial Average and Nasdaq 100 lower and the S&P 500 higher, as markets waited for data on jobless claims and retail sales that could provide further incentive for the U.S. Federal Reserve to raise interest rates. Meanwhile, export prices in February are seen down 0.1% compared to a 2.0% decline in January while import prices are seen higher 0.2% compared to a 2.8% decline in January. | In equities, Acadia Pharmaceuticals ( ACAD ) dropped 22% in recent pre-market trade after delaying submission of the new drug application for its Parkinson's disease psychosis treatment Nuplazid till the second half of 2015 instead of in Q1, as previously planned. U.S. stock futures were mixed Thursday, with the Dow Jones Industrial Average and Nasdaq 100 lower and the S&P 500 higher, as markets waited for data on jobless claims and retail sales that could provide further incentive for the U.S. Federal Reserve to raise interest rates. data are expected to show that jobless claims in the week ended March 7 were 309,000, down from 320,000 the preceding week. |
36275.0 | 2015-03-11 00:00:00 UTC | After Hours Most Active for Mar 11, 2015 : SWKS, MSFT, MMS, FB, BAC, PETM, ACAD, HPQ, INTC, CRC, EVHC, HTZ | ACAD | https://www.nasdaq.com/articles/after-hours-most-active-mar-11-2015-swks-msft-mms-fb-bac-petm-acad-hpq-intc-crc-evhc-htz | nan | nan | The NASDAQ 100 After Hours Indicator is up 2.28 to 4,307.66. The total After hours volume is currently 60,462,884 shares traded.
The following are the most active stocks for the after hours session :
Skyworks Solutions, Inc. ( SWKS ) is -0.01 at $92.19, with 23,946,498 shares traded. As reported by Zacks, the current mean recommendation for SWKS is in the "buy range".
Microsoft Corporation ( MSFT ) is -0.01 at $41.97, with 3,727,943 shares traded. MSFT's current last sale is 83.94% of the target price of $50.
Maximus, Inc. ( MMS ) is unchanged at $62.75, with 3,496,954 shares traded. As reported by Zacks, the current mean recommendation for MMS is in the "buy range".
Facebook, Inc. ( FB ) is -0.01 at $77.56, with 3,062,476 shares traded. As reported by Zacks, the current mean recommendation for FB is in the "buy range".
Bank of America Corporation ( BAC ) is -0.2 at $15.91, with 2,219,156 shares traded. BAC's current last sale is 83.74% of the target price of $19.
PetSmart, Inc ( PETM ) is +0.01 at $82.99, with 1,941,421 shares traded. Over the last four weeks they have had 3 up revisions for the earnings forecast, for the fiscal quarter ending Jan 2016. The consensus EPS forecast is $1.57. PETM's current last sale is 101.83% of the target price of $81.5.
ACADIA Pharmaceuticals Inc. ( ACAD ) is -9.91 at $34.85, with 1,818,170 shares traded. As reported in the last short interest update the days to cover for ACAD is 11.766846; this calculation is based on the average trading volume of the stock.
Hewlett-Packard Company ( HPQ ) is unchanged at $32.61, with 1,760,992 shares traded. As reported by Zacks, the current mean recommendation for HPQ is in the "buy range".
Intel Corporation ( INTC ) is -0.01 at $32.32, with 1,553,832 shares traded. INTC's current last sale is 85.05% of the target price of $38.
California Resources Corporation ( CRC ) is unchanged at $7.10, with 1,450,527 shares traded. CRC's current last sale is 67.62% of the target price of $10.5.
Envision Healthcare Holdings, Inc. ( EVHC ) is -0.257 at $36.26, with 1,388,176 shares traded. Over the last four weeks they have had 3 up revisions for the earnings forecast, for the fiscal quarter ending Mar 2015. The consensus EPS forecast is $0.27. As reported by Zacks, the current mean recommendation for EVHC is in the "buy range".
Hertz Global Holdings, Inc ( HTZ ) is unchanged at $21.53, with 886,819 shares traded.HTZ is scheduled to provide an earnings report on 3/17/2015, for the fiscal quarter ending Dec2014. The consensus earnings per share forecast is 0.03 per share, which represents a 26 percent increase over the EPS one Year Ago
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | As reported in the last short interest update the days to cover for ACAD is 11.766846; this calculation is based on the average trading volume of the stock. ACADIA Pharmaceuticals Inc. ( ACAD ) is -9.91 at $34.85, with 1,818,170 shares traded. The following are the most active stocks for the after hours session : Skyworks Solutions, Inc. ( SWKS ) is -0.01 at $92.19, with 23,946,498 shares traded. | ACADIA Pharmaceuticals Inc. ( ACAD ) is -9.91 at $34.85, with 1,818,170 shares traded. As reported in the last short interest update the days to cover for ACAD is 11.766846; this calculation is based on the average trading volume of the stock. The total After hours volume is currently 60,462,884 shares traded. | ACADIA Pharmaceuticals Inc. ( ACAD ) is -9.91 at $34.85, with 1,818,170 shares traded. As reported in the last short interest update the days to cover for ACAD is 11.766846; this calculation is based on the average trading volume of the stock. California Resources Corporation ( CRC ) is unchanged at $7.10, with 1,450,527 shares traded. | ACADIA Pharmaceuticals Inc. ( ACAD ) is -9.91 at $34.85, with 1,818,170 shares traded. As reported in the last short interest update the days to cover for ACAD is 11.766846; this calculation is based on the average trading volume of the stock. As reported by Zacks, the current mean recommendation for FB is in the "buy range". |
36276.0 | 2015-02-25 00:00:00 UTC | Is a Surprise Coming for ACADIA Pharmaceuticals (ACAD) This Earnings Season? - Tale of the Tape | ACAD | https://www.nasdaq.com/articles/is-a-surprise-coming-for-acadia-pharmaceuticals-acad-this-earnings-season-tale-of-the-tape | nan | nan | Investors are always looking for stocks that are poised to beat at earnings season and ACADIA Pharmaceuticals Inc. ( ACAD ) may be one such company. The firm has earnings coming up pretty soon, and events are shaping up quite nicely for their report.
That is because ACADIA Pharmaceuticals is seeing favorable earnings estimate revision activity as of late, which is generally a precursor to an earnings beat. After all, analysts raising estimates right before earnings-with the most up-to-date information possible-is a pretty good indicator of some favorable trends underneath the surface for ACAD in this report.
In fact, the Most Accurate Estimate for the current quarter is currently at a loss of 25 cents per share for ACAD, compared to a broader Zacks Consensus Estimate of a loss of 26 cents per share. This suggests that analysts have very recently bumped up their estimates for ACAD, giving the stock a Zacks Earnings ESP of 3.85% heading into earnings season.
Why is this Important?
A positive reading for the Zacks Earnings ESP has proven to be very powerful in producing both positive surprises, and outperforming the market. Our recent 10 year backtest shows that stocks that have a positive Earnings ESP and a Zacks Rank #3 (Hold) or better show a positive surprise nearly 70% of the time, and have returned over 28% on average in annual returns (see more Top Earnings ESP stocks here ).
Given that ACAD has a Zacks Rank #2 (Buy) and an ESP in positive territory, investors might want to consider this stock ahead of earnings. Clearly, recent earnings estimate revisions suggest that good things are ahead for ACADIA Pharmaceuticals, and that a beat might be in the cards for the upcoming report.
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report >>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
ACADIA PHARMA (ACAD): Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | After all, analysts raising estimates right before earnings-with the most up-to-date information possible-is a pretty good indicator of some favorable trends underneath the surface for ACAD in this report. Given that ACAD has a Zacks Rank #2 (Buy) and an ESP in positive territory, investors might want to consider this stock ahead of earnings. Clearly, recent earnings estimate revisions suggest that good things are ahead for ACADIA Pharmaceuticals, and that a beat might be in the cards for the upcoming report. | Clearly, recent earnings estimate revisions suggest that good things are ahead for ACADIA Pharmaceuticals, and that a beat might be in the cards for the upcoming report. Click to get this free report ACADIA PHARMA (ACAD): Free Stock Analysis Report To read this article on Zacks.com click here. Investors are always looking for stocks that are poised to beat at earnings season and ACADIA Pharmaceuticals Inc. ( ACAD ) may be one such company. | This suggests that analysts have very recently bumped up their estimates for ACAD, giving the stock a Zacks Earnings ESP of 3.85% heading into earnings season. Given that ACAD has a Zacks Rank #2 (Buy) and an ESP in positive territory, investors might want to consider this stock ahead of earnings. Investors are always looking for stocks that are poised to beat at earnings season and ACADIA Pharmaceuticals Inc. ( ACAD ) may be one such company. | Given that ACAD has a Zacks Rank #2 (Buy) and an ESP in positive territory, investors might want to consider this stock ahead of earnings. Investors are always looking for stocks that are poised to beat at earnings season and ACADIA Pharmaceuticals Inc. ( ACAD ) may be one such company. That is because ACADIA Pharmaceuticals is seeing favorable earnings estimate revision activity as of late, which is generally a precursor to an earnings beat. |
36277.0 | 2015-02-24 00:00:00 UTC | Will Allscripts (MDRX) Surprise Earnings Estimates in Q4? - Analyst Blog | ACAD | https://www.nasdaq.com/articles/will-allscripts-mdrx-surprise-earnings-estimates-in-q4-analyst-blog-2015-02-24 | nan | nan | Allscripts Healthcare Solutions Inc. ( MDRX ) is set to report fourth-quarter fiscal 2014 results on Feb 26. Last quarter, Allscripts reported earnings of 2 cents per share, which missed the Zacks Consensus Estimate by 3 cents.
Let's see how things are shaping up prior to this announcement.
Factors Likely to Influence this Quarter
Allscripts is increasingly gaining popularity among hospitals and healthcare systems on the back of its Sunrise Electronic Health Record (EHR) platform - a comprehensive suite of fully integrated population health capabilities comprising inpatient, ambulatory, emergency care and surgical care solutions.
We note that Allscripts continues to benefit from the HITECH Act, as reflected by the significant number of client admissions registered during the year and additional related orders for its EHR products. In the first nine months of 2014, Allscripts added more than 550 new clients for its EHR and related solutions.
Allscripts has a leading market share in both inpatient and ambulatory settings. We believe that the company's strong market position is a significant competitive advantage, which will enhance its growth prospects in the long run.
Earnings Whispers?
Our proven model does not conclusively show that Allscripts is likely to beat earnings this quarter. That is because a stock needs to have both a positive Earnings ESP and a Zacks Rank #1, 2 or 3 for this to happen. That is not the case here as you will see below.
Zacks ESP : Allscripts currently has an Earnings ESP of 0.00%. This is because both the Most Accurate estimate and the Zacks Consensus Estimate stand at 6 cents.
Zacks Rank : Allscripts has a Zacks Rank #2 (Buy) which increases the predictive power of ESP. However, the company's ESP of 0.00% makes surprise prediction difficult.
On the other hand, we caution against stocks with Zacks Rank #4 and 5 (Sell-rated stocks) going into the earnings announcement, especially when the company is seeing negative estimate revisions.
Stocks to Consider
Here are some companies you may want to consider as our model shows they have the right combination of elements to post an earnings beat this quarter:
Impax Laboratories ( IPXL ) with an Earnings ESP of +27.27% and a Zacks Rank #1 (Strong Buy).
ACADIA Pharmaceuticals ( ACAD ) with an Earnings ESP of +3.85% and a Zacks Rank #2.
Hyperion Therapeutics ( HPTX ) with an Earnings ESP of +15.38% and a Zacks Rank #2.
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
ALLSCRIPTS HLTH (MDRX): Free Stock Analysis Report
IMPAX LABORATRS (IPXL): Free Stock Analysis Report
HYPERION THERAP (HPTX): Free Stock Analysis Report
ACADIA PHARMA (ACAD): Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | ACADIA Pharmaceuticals ( ACAD ) with an Earnings ESP of +3.85% and a Zacks Rank #2. Click to get this free report ALLSCRIPTS HLTH (MDRX): Free Stock Analysis Report IMPAX LABORATRS (IPXL): Free Stock Analysis Report HYPERION THERAP (HPTX): Free Stock Analysis Report ACADIA PHARMA (ACAD): Free Stock Analysis Report To read this article on Zacks.com click here. Factors Likely to Influence this Quarter Allscripts is increasingly gaining popularity among hospitals and healthcare systems on the back of its Sunrise Electronic Health Record (EHR) platform - a comprehensive suite of fully integrated population health capabilities comprising inpatient, ambulatory, emergency care and surgical care solutions. | Click to get this free report ALLSCRIPTS HLTH (MDRX): Free Stock Analysis Report IMPAX LABORATRS (IPXL): Free Stock Analysis Report HYPERION THERAP (HPTX): Free Stock Analysis Report ACADIA PHARMA (ACAD): Free Stock Analysis Report To read this article on Zacks.com click here. ACADIA Pharmaceuticals ( ACAD ) with an Earnings ESP of +3.85% and a Zacks Rank #2. Last quarter, Allscripts reported earnings of 2 cents per share, which missed the Zacks Consensus Estimate by 3 cents. | Click to get this free report ALLSCRIPTS HLTH (MDRX): Free Stock Analysis Report IMPAX LABORATRS (IPXL): Free Stock Analysis Report HYPERION THERAP (HPTX): Free Stock Analysis Report ACADIA PHARMA (ACAD): Free Stock Analysis Report To read this article on Zacks.com click here. ACADIA Pharmaceuticals ( ACAD ) with an Earnings ESP of +3.85% and a Zacks Rank #2. Zacks Rank : Allscripts has a Zacks Rank #2 (Buy) which increases the predictive power of ESP. | ACADIA Pharmaceuticals ( ACAD ) with an Earnings ESP of +3.85% and a Zacks Rank #2. Click to get this free report ALLSCRIPTS HLTH (MDRX): Free Stock Analysis Report IMPAX LABORATRS (IPXL): Free Stock Analysis Report HYPERION THERAP (HPTX): Free Stock Analysis Report ACADIA PHARMA (ACAD): Free Stock Analysis Report To read this article on Zacks.com click here. That is because a stock needs to have both a positive Earnings ESP and a Zacks Rank #1, 2 or 3 for this to happen. |
36278.0 | 2015-02-24 00:00:00 UTC | Merrimack Pharmaceuticals (MACK): A Miss this Earnings? - Analyst Blog | ACAD | https://www.nasdaq.com/articles/merrimack-pharmaceuticals-mack%3A-a-miss-this-earnings-analyst-blog-2015-02-24 | nan | nan | Merrimack Pharmaceuticals, Inc. ( MACK ) is slated to report fourth-quarter 2014 results on Feb 26, 2015.
The company missed estimates last quarter. On an average, Merrimack Pharma beat estimates in three of the last four trailing quarters with a negative earnings surprise of 93.70%. Let's see how things are shaping up for this announcement.
Factors Influencing this Quarter
Being a development-stage biopharmaceutical company, Merrimack Pharma has not generated product revenue so far. In such a scenario, investor focus should remain on pipeline updates.
On its third-quarter call, Merrimack Pharma announced a revised timeline for submitting a new drug application for its most advanced candidate, MM-398 (metastatic pancreatic cancer). Since the company was asked by the FDA to improve an analytic assay for liposome product quality on the basis of a refined release specification, Merrimack Pharma is expected to file for the drug by the end of first-quarter or early second-quarter 2015 (previously expected to be submitted by the end of 2014).
We expect the company to throw light on the candidate's development status on its fourth-quarter call.
Apart from metastatic pancreatic cancer, MM-398 is being evaluated for the treatment of colorectal cancer (phase II), glioma (phase I) and pediatric solid tumors (phase I). Moreover, Merrimack Pharma has a number of early- and mid-stage oncology candidates in its pipeline - MM-121, MM-111, MM-302, MM-151 and MM-141. Updates on these candidates are also expected.
Although we expect Merrimack Pharma to benefit from its Sep 2014 collaboration with Baxter International ( BAX ) for the development of MM-398, we believe the company will continue to face an increase in its R&D expenditure.
What Our Model Indicates
Our proven model does not conclusively show that Merrimack Pharma is likely to beat earnings this quarter. That is because a stock needs to have both a positive Earnings ESP and a Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 (Hold) to be able to beat earnings. That is not the case here as you will see below.
Zacks ESP : The Earnings ESP, which represents the difference between the Most Accurate estimate and the Zacks Consensus Estimate, is 0.00% since the Most Accurate estimate is in line with the Zacks Consensus Estimate of a loss of 23 cents.
Zacks Rank : Merrimack Pharma carries a Zacks Rank #3. Though a Zacks Rank #1, 2 or 3 increases the predictive power of ESP, the company's ESP of 0.00% makes a surprise prediction difficult.
However, we caution against stocks with Zacks Ranks #4 and 5 (Sell-rated stocks) going into the earnings announcement, especially when the company is seeing negative estimate revisions.
Stocks That Warrant a Look
Here are some companies you may want to consider as our model shows that these have the right combination of elements to post an earnings beat this quarter:
ACADIA Pharmaceuticals Inc. ( ACAD ) has an Earnings ESP of +3.85% and carries a Zacks Rank #2. The company is scheduled to release its fourth-quarter 2014 results on Feb 26.
Amarin Corporation plc ( AMRN ) has an Earnings ESP of +14.29% and carries a Zacks Rank #2. The company is scheduled to release its fourth-quarter 2014 results on Mar 3.
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
BAXTER INTL (BAX): Free Stock Analysis Report
MERRIMACK PHAR (MACK): Free Stock Analysis Report
AMARIN CORP PLC (AMRN): Free Stock Analysis Report
ACADIA PHARMA (ACAD): Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Stocks That Warrant a Look Here are some companies you may want to consider as our model shows that these have the right combination of elements to post an earnings beat this quarter: ACADIA Pharmaceuticals Inc. ( ACAD ) has an Earnings ESP of +3.85% and carries a Zacks Rank #2. Click to get this free report BAXTER INTL (BAX): Free Stock Analysis Report MERRIMACK PHAR (MACK): Free Stock Analysis Report AMARIN CORP PLC (AMRN): Free Stock Analysis Report ACADIA PHARMA (ACAD): Free Stock Analysis Report To read this article on Zacks.com click here. Factors Influencing this Quarter Being a development-stage biopharmaceutical company, Merrimack Pharma has not generated product revenue so far. | Stocks That Warrant a Look Here are some companies you may want to consider as our model shows that these have the right combination of elements to post an earnings beat this quarter: ACADIA Pharmaceuticals Inc. ( ACAD ) has an Earnings ESP of +3.85% and carries a Zacks Rank #2. Click to get this free report BAXTER INTL (BAX): Free Stock Analysis Report MERRIMACK PHAR (MACK): Free Stock Analysis Report AMARIN CORP PLC (AMRN): Free Stock Analysis Report ACADIA PHARMA (ACAD): Free Stock Analysis Report To read this article on Zacks.com click here. Zacks Rank : Merrimack Pharma carries a Zacks Rank #3. | Stocks That Warrant a Look Here are some companies you may want to consider as our model shows that these have the right combination of elements to post an earnings beat this quarter: ACADIA Pharmaceuticals Inc. ( ACAD ) has an Earnings ESP of +3.85% and carries a Zacks Rank #2. Click to get this free report BAXTER INTL (BAX): Free Stock Analysis Report MERRIMACK PHAR (MACK): Free Stock Analysis Report AMARIN CORP PLC (AMRN): Free Stock Analysis Report ACADIA PHARMA (ACAD): Free Stock Analysis Report To read this article on Zacks.com click here. Zacks ESP : The Earnings ESP, which represents the difference between the Most Accurate estimate and the Zacks Consensus Estimate, is 0.00% since the Most Accurate estimate is in line with the Zacks Consensus Estimate of a loss of 23 cents. | Stocks That Warrant a Look Here are some companies you may want to consider as our model shows that these have the right combination of elements to post an earnings beat this quarter: ACADIA Pharmaceuticals Inc. ( ACAD ) has an Earnings ESP of +3.85% and carries a Zacks Rank #2. Click to get this free report BAXTER INTL (BAX): Free Stock Analysis Report MERRIMACK PHAR (MACK): Free Stock Analysis Report AMARIN CORP PLC (AMRN): Free Stock Analysis Report ACADIA PHARMA (ACAD): Free Stock Analysis Report To read this article on Zacks.com click here. On its third-quarter call, Merrimack Pharma announced a revised timeline for submitting a new drug application for its most advanced candidate, MM-398 (metastatic pancreatic cancer). |
36279.0 | 2015-02-24 00:00:00 UTC | Will Aegerion (AEGR) Miss Earnings Estimates This Season? - Analyst Blog | ACAD | https://www.nasdaq.com/articles/will-aegerion-aegr-miss-earnings-estimates-this-season-analyst-blog-2015-02-24 | nan | nan | Aegerion Pharmaceuticals, Inc. ( AEGR ) is slated to report fourth-quarter 2014 results on Feb 26, 2015.
Aegerion beat estimates in three of the last four trailing quarters, maintaining an average positive earnings surprise of 12.62%. Let's see how things are shaping up for this announcement.
Factors Influencing Fourth-Quarter and 2014 Results
Although Juxtapid should remain the primary growth driver with sales force expansion leading to increased commercial reach in the U.S., Aegerion may continue to experience issues in Brazil. Longer-than-expected turnaround times between price quotation and order at the federal level as well as delays in the receipt of orders from the government due to ongoing investigation of a possible violation of Brazilian anti-corruption laws related to the prescriptions written could affect sales.
Additionally, reimbursement issues could impact Juxtapid's performance. The company said on its third-quarter call that it might receive reimbursement approvals in key European countries in the first half of 2015. Updates regarding this issue are expected on the fourth-quarter call.
Moreover, 2015 is expected to be a pivotal year for Aegerion in determining the growth trajectory of Juxtapid, particularly in the context of the prospective approval of some PCSK9 therapies like Repatha and Praluent. Juxtapid being the only marketed product at Aegerion, investor focus will remain on the development of other PCSK9 therapies.
For the fourth quarter of 2014, Aegerion expects net product sales in the range of $49.3 million to $51.3 million. The current Zacks Consensus Estimate is $52 million. For 2014, the company expects preliminary net product sales in the range of $156 million to $158 million reflecting almost 220% growth over 2013 net product sales.
What Our Model Indicates
Our proven model does not conclusively show that Aegerion is likely to beat earnings this quarter. That is because a stock needs to have both a positive Earnings ESP and a Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 (Hold) to be able to beat earnings. That is not the case here as you will see below.
Zacks ESP: The Earnings ESP, which represents the difference between the Most Accurate estimate and the Zacks Consensus Estimate, is -220.00% since the Most Accurate estimate stands at a loss of 6 cents, while the Zacks Consensus Estimate is 5 cents.
Zacks Rank : Although Aegerion's Zacks Rank #3 increases the predictive power of ESP, we need to have a positive ESP to be confident of an earnings beat.
However, we caution against stocks with Zacks Ranks #4 and 5 (Sell-rated stocks) going into the earnings announcement, especially when the company is seeing negative estimate revisions.
Stocks That Warrant a Look
Here are some companies you may want to consider as our model shows that these have the right combination of elements to post an earnings beat this quarter:
Sarepta Therapeutics, Inc. ( SRPT ) has an Earnings ESP of +14.46% and carries a Zacks Rank #3. The company is scheduled to release its fourth-quarter 2014 results on Feb 26, 2015.
ACADIA Pharmaceuticals Inc. ( ACAD ) has an Earnings ESP of +3.85% and carries a Zacks Rank #2. The company is scheduled to release its fourth-quarter 2014 results on Feb 26, 2015.
Amarin Corporation plc ( AMRN ) has an Earnings ESP of +14.29% and carries a Zacks Rank #2. The company is scheduled to release its fourth-quarter 2014 results on Mar 3, 2015.
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
AEGERION PHARMA (AEGR): Free Stock Analysis Report
SAREPTA THERAP (SRPT): Free Stock Analysis Report
AMARIN CORP PLC (AMRN): Free Stock Analysis Report
ACADIA PHARMA (ACAD): Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | ACADIA Pharmaceuticals Inc. ( ACAD ) has an Earnings ESP of +3.85% and carries a Zacks Rank #2. Click to get this free report AEGERION PHARMA (AEGR): Free Stock Analysis Report SAREPTA THERAP (SRPT): Free Stock Analysis Report AMARIN CORP PLC (AMRN): Free Stock Analysis Report ACADIA PHARMA (ACAD): Free Stock Analysis Report To read this article on Zacks.com click here. Factors Influencing Fourth-Quarter and 2014 Results Although Juxtapid should remain the primary growth driver with sales force expansion leading to increased commercial reach in the U.S., Aegerion may continue to experience issues in Brazil. | Click to get this free report AEGERION PHARMA (AEGR): Free Stock Analysis Report SAREPTA THERAP (SRPT): Free Stock Analysis Report AMARIN CORP PLC (AMRN): Free Stock Analysis Report ACADIA PHARMA (ACAD): Free Stock Analysis Report To read this article on Zacks.com click here. ACADIA Pharmaceuticals Inc. ( ACAD ) has an Earnings ESP of +3.85% and carries a Zacks Rank #2. For 2014, the company expects preliminary net product sales in the range of $156 million to $158 million reflecting almost 220% growth over 2013 net product sales. | Click to get this free report AEGERION PHARMA (AEGR): Free Stock Analysis Report SAREPTA THERAP (SRPT): Free Stock Analysis Report AMARIN CORP PLC (AMRN): Free Stock Analysis Report ACADIA PHARMA (ACAD): Free Stock Analysis Report To read this article on Zacks.com click here. ACADIA Pharmaceuticals Inc. ( ACAD ) has an Earnings ESP of +3.85% and carries a Zacks Rank #2. Zacks ESP: The Earnings ESP, which represents the difference between the Most Accurate estimate and the Zacks Consensus Estimate, is -220.00% since the Most Accurate estimate stands at a loss of 6 cents, while the Zacks Consensus Estimate is 5 cents. | ACADIA Pharmaceuticals Inc. ( ACAD ) has an Earnings ESP of +3.85% and carries a Zacks Rank #2. Click to get this free report AEGERION PHARMA (AEGR): Free Stock Analysis Report SAREPTA THERAP (SRPT): Free Stock Analysis Report AMARIN CORP PLC (AMRN): Free Stock Analysis Report ACADIA PHARMA (ACAD): Free Stock Analysis Report To read this article on Zacks.com click here. Updates regarding this issue are expected on the fourth-quarter call. |
36280.0 | 2015-02-23 00:00:00 UTC | Will DexCom (DXCM) Loss Better Estimates this Earnings? - Analyst Blog | ACAD | https://www.nasdaq.com/articles/will-dexcom-dxcm-loss-better-estimates-this-earnings-analyst-blog-2015-02-23 | nan | nan | We expect DexCom Inc. ( DXCM ) to post a narrower-than-expected loss figure when it reports fourth quarter and full year 2014 results on Feb 25. However, in the last quarter, the company's loss of 8 cents per share was wider than the Zacks Consensus Estimate by 3 cents.
Let's see how things are shaping up for this announcement.
What is Driving the Better-than-Expected Earnings?
Last month, DexCom announced its preliminary fourth-quarter 2014 results. The company anticipates product revenues to surge an impressive 64% on a year-over-year basis to $84 million. DexCom is riding high on the back of a number of FDA approvals as well as a robust product pipeline.
Meanwhile, the company has received clearances from the FDA for G4 Platinum Continuous Glucose Monitoring (CGM) system and the CGM remote mobile communications device - DexCom SHARE. DexCom is also focused on introducing a steady stream of innovative products related to its sensor technology.
We believe DexCom will generate significant top-line growth on the back of strong performance by the G4 Platinum system coupled with other innovative product launches.
Why a Likely Positive Surprise?
Our proven model shows that DexCom is likely to post narrower loss because it has the right combination of two key ingredients.
Zacks ESP : DexCom's Earnings ESP stands at +66.67%. This is because the company's Most Accurate estimate stands at a loss of a penny, whereas the Zacks Consensus Estimate is pegged at a loss of 3 cents. A favorable Zacks ESP serves as a meaningful and leading indicator of a likely positive surprise.
Zacks Rank : DexCom currently has a Zacks Rank #3 (Hold). Note that stocks with Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 have a significantly higher chance of beating earnings estimates. Conversely, Sell-rated stocks (Zacks Rank #4 or 5) should never be considered going into an earnings announcement.
The combination of DexCom's Zacks Rank #3 and +66.67% ESP makes us reasonably confident of the company surpassing estimates this quarter.
Other Stocks to Consider
Here are some other companies you may want to consider as our model shows these have the right combination of elements to post an earnings beat this quarter:
Impax Laboratories ( IPXL ) has an earnings ESP of +27.27% and a Zacks Rank #1.
ACADIA Pharmaceuticals ( ACAD ) has an earnings ESP of +3.85% and a Zacks Rank #2.
Hyperion Therapeutics ( HPTX ) has an earnings ESP of +15.38% and a Zacks Rank #2.
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
DEXCOM INC (DXCM): Free Stock Analysis Report
IMPAX LABORATRS (IPXL): Free Stock Analysis Report
HYPERION THERAP (HPTX): Free Stock Analysis Report
ACADIA PHARMA (ACAD): Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | ACADIA Pharmaceuticals ( ACAD ) has an earnings ESP of +3.85% and a Zacks Rank #2. Click to get this free report DEXCOM INC (DXCM): Free Stock Analysis Report IMPAX LABORATRS (IPXL): Free Stock Analysis Report HYPERION THERAP (HPTX): Free Stock Analysis Report ACADIA PHARMA (ACAD): Free Stock Analysis Report To read this article on Zacks.com click here. We expect DexCom Inc. ( DXCM ) to post a narrower-than-expected loss figure when it reports fourth quarter and full year 2014 results on Feb 25. | Click to get this free report DEXCOM INC (DXCM): Free Stock Analysis Report IMPAX LABORATRS (IPXL): Free Stock Analysis Report HYPERION THERAP (HPTX): Free Stock Analysis Report ACADIA PHARMA (ACAD): Free Stock Analysis Report To read this article on Zacks.com click here. ACADIA Pharmaceuticals ( ACAD ) has an earnings ESP of +3.85% and a Zacks Rank #2. Zacks ESP : DexCom's Earnings ESP stands at +66.67%. | Click to get this free report DEXCOM INC (DXCM): Free Stock Analysis Report IMPAX LABORATRS (IPXL): Free Stock Analysis Report HYPERION THERAP (HPTX): Free Stock Analysis Report ACADIA PHARMA (ACAD): Free Stock Analysis Report To read this article on Zacks.com click here. ACADIA Pharmaceuticals ( ACAD ) has an earnings ESP of +3.85% and a Zacks Rank #2. Zacks Rank : DexCom currently has a Zacks Rank #3 (Hold). | ACADIA Pharmaceuticals ( ACAD ) has an earnings ESP of +3.85% and a Zacks Rank #2. Click to get this free report DEXCOM INC (DXCM): Free Stock Analysis Report IMPAX LABORATRS (IPXL): Free Stock Analysis Report HYPERION THERAP (HPTX): Free Stock Analysis Report ACADIA PHARMA (ACAD): Free Stock Analysis Report To read this article on Zacks.com click here. We believe DexCom will generate significant top-line growth on the back of strong performance by the G4 Platinum system coupled with other innovative product launches. |
36281.0 | 2015-02-23 00:00:00 UTC | Will Wright Medical (WMGI) Disappoint Earnings Again in Q4? - Analyst Blog | ACAD | https://www.nasdaq.com/articles/will-wright-medical-wmgi-disappoint-earnings-again-in-q4-analyst-blog-2015-02-23 | nan | nan | Wright Medical Group Inc. ( WMGI ) is set to report fourth-quarter 2014 results on Feb 25. Last quarter, the company posted loss of 35 cents per share, which was wider than the Zacks Consensus Estimate by a couple of cents. However, we note that the company has beat the Zacks Consensus Estimate by an average of 2.97% in the last four quarters.
Let's see how things are shaping up for this quarter.
Factors at Play
In Jan 2015, Wright Medical announced preliminary fourth-quarter 2014 results. The company expects revenues in the quarter to grow 23% (25% on a constant currency basis) on a year-over-year basis to $83.3 million.
The fourth-quarter estimates reflected a significant acceleration in the domestic foot and ankle business, which is expected to increase 39% year over year. The upside may be primarily attributed to an expansion in the product portfolio, made possible by significant product launches and acquired products.
On the other hand, global total ankle growth is likely to be 38% in the quarter primarily on the back of the ongoing launch of INFINITY total ankle replacement system.
Gross margin for the fourth quarter is estimated to be approximately 77%.
Earnings Whispers?
Our proven model does not conclusively show that Wright Medical is likely to beat earnings this quarter. That is because a stock needs to have both a positive Earnings ESP and a Zacks Rank of #1, 2 or at least 3 for this to happen. That is not the case here as you will see below.
Zacks ESP: Wright Medical currently has an Earnings ESP of -7.41%. This is because the Most Accurate estimate stands at a loss of 29 cents wider than the Zacks Consensus Estimate of a loss of 27 cents.
Zacks Rank: Wright Medical Group has a Zacks Rank #3 (Hold) which increases the predictive power of ESP; but when combined with a -7.41% ESP, it makes surprise prediction difficult.
We caution against stocks with Zacks Rank #4 and 5 (Sell-rated stocks) going into the earnings announcement, especially when the company is seeing negative estimate revisions momentum.
Stocks to Consider
Here are a few stocks worth considering that, as per our model, have the right combination of elements to post an earnings beat this quarter:
Impax Laboratories ( IPXL ) with an Earnings ESP of +27.27% and a Zacks Rank #1 (Strong Buy).
ACADIA Pharmaceuticals ( ACAD ) with an Earnings ESP of +3.85% and a Zacks Rank #2 (Buy).
Hyperion Therapeutics ( HPTX ) with an Earnings ESP of +15.38% and a Zacks Rank #2.
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
WRIGHT MEDICAL (WMGI): Free Stock Analysis Report
IMPAX LABORATRS (IPXL): Free Stock Analysis Report
HYPERION THERAP (HPTX): Free Stock Analysis Report
ACADIA PHARMA (ACAD): Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | ACADIA Pharmaceuticals ( ACAD ) with an Earnings ESP of +3.85% and a Zacks Rank #2 (Buy). Click to get this free report WRIGHT MEDICAL (WMGI): Free Stock Analysis Report IMPAX LABORATRS (IPXL): Free Stock Analysis Report HYPERION THERAP (HPTX): Free Stock Analysis Report ACADIA PHARMA (ACAD): Free Stock Analysis Report To read this article on Zacks.com click here. Wright Medical Group Inc. ( WMGI ) is set to report fourth-quarter 2014 results on Feb 25. | Click to get this free report WRIGHT MEDICAL (WMGI): Free Stock Analysis Report IMPAX LABORATRS (IPXL): Free Stock Analysis Report HYPERION THERAP (HPTX): Free Stock Analysis Report ACADIA PHARMA (ACAD): Free Stock Analysis Report To read this article on Zacks.com click here. ACADIA Pharmaceuticals ( ACAD ) with an Earnings ESP of +3.85% and a Zacks Rank #2 (Buy). Zacks Rank: Wright Medical Group has a Zacks Rank #3 (Hold) which increases the predictive power of ESP; but when combined with a -7.41% ESP, it makes surprise prediction difficult. | Click to get this free report WRIGHT MEDICAL (WMGI): Free Stock Analysis Report IMPAX LABORATRS (IPXL): Free Stock Analysis Report HYPERION THERAP (HPTX): Free Stock Analysis Report ACADIA PHARMA (ACAD): Free Stock Analysis Report To read this article on Zacks.com click here. ACADIA Pharmaceuticals ( ACAD ) with an Earnings ESP of +3.85% and a Zacks Rank #2 (Buy). Zacks Rank: Wright Medical Group has a Zacks Rank #3 (Hold) which increases the predictive power of ESP; but when combined with a -7.41% ESP, it makes surprise prediction difficult. | ACADIA Pharmaceuticals ( ACAD ) with an Earnings ESP of +3.85% and a Zacks Rank #2 (Buy). Click to get this free report WRIGHT MEDICAL (WMGI): Free Stock Analysis Report IMPAX LABORATRS (IPXL): Free Stock Analysis Report HYPERION THERAP (HPTX): Free Stock Analysis Report ACADIA PHARMA (ACAD): Free Stock Analysis Report To read this article on Zacks.com click here. However, we note that the company has beat the Zacks Consensus Estimate by an average of 2.97% in the last four quarters. |
36282.0 | 2015-02-20 00:00:00 UTC | Can Greatbatch (GB) Keep the Earnings Streak Alive in Q4? - Analyst Blog | ACAD | https://www.nasdaq.com/articles/can-greatbatch-gb-keep-the-earnings-streak-alive-in-q4-analyst-blog-2015-02-20 | nan | nan | We expect Greatbatch Inc. ( GB ) to beat earnings when the company reports its fourth quarter and full year 2014 financial numbers on Feb 24.
Last quarter, the company's earnings had surpassed the Zacks Consensus Estimate by 12.3%. Moreover, Greatbatch outpaced our estimates in three of the past four quarters, with an average earnings beat of 4.6%.
Let's see how things are shaping up for this announcement.
What is Driving the Better-than-Expected Earnings?
Greatbatch is focused on achieving growth through strategic investments, manufacturing efficiencies, operating cost curtailments. The company continues to invest heavily in research and development (R&D) in order to develop innovative medical devices, which will help Greatbatch gain a significant foothold in the competitive medical device market.
Greatbatch also boasts an encouraging product pipeline with the most notable product being Algovita spinal cord stimulator, designed for chronic pain treatment in the trunk and limbs. New products targeted for the vascular, CRM/neuromodulation and orthopedic markets are also expected to offer incremental revenue opportunities, going forward.
Why a Likely Positive Surprise?
Our proven model shows that Greatbatch is likely to beat earnings because it has the right combination of two key ingredients.
Zacks ESP : Greatbatch's Earnings ESP stands at +1.70%. This is because the company's Most Accurate estimate is poised at 60 cents, whereas the Zacks Consensus Estimate is pegged a tad lower at 59 cents. A favorable Zacks ESP serves as a meaningful and leading indicator of a likely positive earnings surprise.
Zacks Rank : Greatbatch currently has a Zacks Rank #3 (Hold). Note that stocks with Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 have a significantly higher chance of beating earnings estimates. Conversely, Sell-rated stocks (Zacks Rank #4 or 5) should never be considered going into an earnings announcement.
The combination of Greatbatch's Zacks Rank #3 and +1.70% ESP makes us reasonably confident of a positive earnings beat this quarter.
Other Stocks to Consider
Here are some other companies you may want to consider as our model shows these have the right combination of elements to post an earnings beat this quarter:
Impax Laboratories ( IPXL ) has an earnings ESP of +27.27% and a Zacks Rank #1.
ACADIA Pharmaceuticals ( ACAD ) has an earnings ESP of +3.85% and a Zacks Rank #2.
Hyperion Therapeutics ( HPTX ) has an earnings ESP of +15.38% and a Zacks Rank #2.
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
GREATBATCH INC (GB): Free Stock Analysis Report
IMPAX LABORATRS (IPXL): Free Stock Analysis Report
HYPERION THERAP (HPTX): Free Stock Analysis Report
ACADIA PHARMA (ACAD): Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | ACADIA Pharmaceuticals ( ACAD ) has an earnings ESP of +3.85% and a Zacks Rank #2. Click to get this free report GREATBATCH INC (GB): Free Stock Analysis Report IMPAX LABORATRS (IPXL): Free Stock Analysis Report HYPERION THERAP (HPTX): Free Stock Analysis Report ACADIA PHARMA (ACAD): Free Stock Analysis Report To read this article on Zacks.com click here. We expect Greatbatch Inc. ( GB ) to beat earnings when the company reports its fourth quarter and full year 2014 financial numbers on Feb 24. | Click to get this free report GREATBATCH INC (GB): Free Stock Analysis Report IMPAX LABORATRS (IPXL): Free Stock Analysis Report HYPERION THERAP (HPTX): Free Stock Analysis Report ACADIA PHARMA (ACAD): Free Stock Analysis Report To read this article on Zacks.com click here. ACADIA Pharmaceuticals ( ACAD ) has an earnings ESP of +3.85% and a Zacks Rank #2. Other Stocks to Consider Here are some other companies you may want to consider as our model shows these have the right combination of elements to post an earnings beat this quarter: Impax Laboratories ( IPXL ) has an earnings ESP of +27.27% and a Zacks Rank #1. | Click to get this free report GREATBATCH INC (GB): Free Stock Analysis Report IMPAX LABORATRS (IPXL): Free Stock Analysis Report HYPERION THERAP (HPTX): Free Stock Analysis Report ACADIA PHARMA (ACAD): Free Stock Analysis Report To read this article on Zacks.com click here. ACADIA Pharmaceuticals ( ACAD ) has an earnings ESP of +3.85% and a Zacks Rank #2. The combination of Greatbatch's Zacks Rank #3 and +1.70% ESP makes us reasonably confident of a positive earnings beat this quarter. | ACADIA Pharmaceuticals ( ACAD ) has an earnings ESP of +3.85% and a Zacks Rank #2. Click to get this free report GREATBATCH INC (GB): Free Stock Analysis Report IMPAX LABORATRS (IPXL): Free Stock Analysis Report HYPERION THERAP (HPTX): Free Stock Analysis Report ACADIA PHARMA (ACAD): Free Stock Analysis Report To read this article on Zacks.com click here. Zacks Rank : Greatbatch currently has a Zacks Rank #3 (Hold). |
36283.0 | 2015-02-19 00:00:00 UTC | Can the Uptrend Continue for ACADIA Pharmaceuticals (ACAD)? - Tale of the Tape | ACAD | https://www.nasdaq.com/articles/can-the-uptrend-continue-for-acadia-pharmaceuticals-acad-tale-of-the-tape-2015-02-19 | nan | nan | Investors certainly have to be happy with ACADIA Pharmaceuticals Inc. ( ACAD ) and its short term performance. After all, the stock has jumped by 5.8% in the past 4 weeks, and it is also above its 20 Day Simple Moving Average as well. This is certainly a good trend, but investors are probably asking themselves, can this positive trend continue for ACAD?
While we can never know for sure, it is pretty encouraging that estimates for ACAD have moved higher in the past few weeks, meaning that analyst sentiment is moving in the right way. Plus, the stock actually has a Zacks Rank #2 (Buy), so the recent move higher for this spotlighted company may definitely continue over the next few weeks.
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
ACADIA PHARMA (ACAD): Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Investors certainly have to be happy with ACADIA Pharmaceuticals Inc. ( ACAD ) and its short term performance. This is certainly a good trend, but investors are probably asking themselves, can this positive trend continue for ACAD? While we can never know for sure, it is pretty encouraging that estimates for ACAD have moved higher in the past few weeks, meaning that analyst sentiment is moving in the right way. | Click to get this free report ACADIA PHARMA (ACAD): Free Stock Analysis Report To read this article on Zacks.com click here. Investors certainly have to be happy with ACADIA Pharmaceuticals Inc. ( ACAD ) and its short term performance. This is certainly a good trend, but investors are probably asking themselves, can this positive trend continue for ACAD? | While we can never know for sure, it is pretty encouraging that estimates for ACAD have moved higher in the past few weeks, meaning that analyst sentiment is moving in the right way. Click to get this free report ACADIA PHARMA (ACAD): Free Stock Analysis Report To read this article on Zacks.com click here. Investors certainly have to be happy with ACADIA Pharmaceuticals Inc. ( ACAD ) and its short term performance. | Investors certainly have to be happy with ACADIA Pharmaceuticals Inc. ( ACAD ) and its short term performance. This is certainly a good trend, but investors are probably asking themselves, can this positive trend continue for ACAD? While we can never know for sure, it is pretty encouraging that estimates for ACAD have moved higher in the past few weeks, meaning that analyst sentiment is moving in the right way. |
36284.0 | 2015-02-18 00:00:00 UTC | Will Patterson Companies (PDCO) Earnings Disappoint in Q4? - Analyst Blog | ACAD | https://www.nasdaq.com/articles/will-patterson-companies-pdco-earnings-disappoint-in-q4-analyst-blog-2015-02-18 | nan | nan | Patterson Companies, Inc. ( PDCO ) is slated to release its third-quarter fiscal 2015 financial numbers after the closing bell on Feb 19.
Last time, Patterson Companies reported a decent fiscal second quarter, beating the Zacks Consensus Estimate on both lines. The dental and veterinary segments performed well, positively contributing to the company's business.
Moreover, over the trailing four quarters, the company has posted a positive average earnings surprise of 0.58%.
Let's see how things are shaping up for this announcement.
Factors to be Considered this Quarter
Over the past few quarters, core dental equipment sales have been improving substantially for Patterson Companies, on the back of partnerships with equipment manufacturers. We expect this trend to continue even in the third quarter. Although we are encouraged with this growth, it must be kept in mind that industry-wide growth has still not recovered to the levels before 2008.
We feel the strategic partnerships with Quality Systems and Abaxis will help improve the prospects of Patterson's dental and veterinary segment, respectively. At the same time, Patterson Companies continues to gain significant market share from their previous acquisition of NVS.
In addition, the company recently announced an agreement to acquire Holt Dental Supply. The takeover is expected to expand Patterson Dental's local reach while also enhancing its Midwest domination.
Patterson Companies medical business is poised to earn greater market share as market fundamentals slowly improve.
Patterson Companies reiterated its earnings per share (EPS) projection for fiscal 2015 at $2.20-$2.30. Management is optimistic that the second half of the fiscal will bring forth higher sales volume.
Earnings Whispers
Our proven model does not conclusively show that Patterson Companies is likely to beat the Zacks Consensus Estimate this quarter. This is because a stock needs to have both a positive Earnings ESP and a Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 (Hold) for this to happen. Unfortunately, that is not the case here as elaborated below.
Zacks ESP : Earnings ESP represents the difference between the Most Accurate estimate and the Zacks Consensus Estimate. This leads to an ESP of -1.70% for Patterson Companies as the Most Accurate estimate for earnings stands at 58 cents while the consensus estimate is pegged higher at 59 cents.
Zacks Rank : Patterson Companies has a Zacks Rank #3 which increases the predictive power of ESP. However, we need to have a positive ESP to be confident of an earnings surprise.
Note that we caution against stocks with Zacks Rank #4 or 5 (Sell-rated stocks) going into the earnings announcement, especially when the company is seeing negative estimate revisions.
Stocks to Consider
Here are some companies in the broader medical sector that you may consider instead as our model shows they have the right combination of elements to post an earnings beat this quarter.
BioTelemetry, Inc. ( BEAT ) has an earnings ESP of +20.00% and carries a Zacks Rank #1.
ACADIA Pharmaceuticals Inc. ( ACAD ) has an earnings ESP of +3.85% and carries a Zacks Rank #2.
Endo International plc ( ENDP ) has an earnings ESP of +0.89% and carries a Zacks Rank #2.
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
ENDO INTL PLC (ENDP): Free Stock Analysis Report
PATTERSON COS (PDCO): Free Stock Analysis Report
BIOTELEMETRY (BEAT): Free Stock Analysis Report
ACADIA PHARMA (ACAD): Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | ACADIA Pharmaceuticals Inc. ( ACAD ) has an earnings ESP of +3.85% and carries a Zacks Rank #2. Click to get this free report ENDO INTL PLC (ENDP): Free Stock Analysis Report PATTERSON COS (PDCO): Free Stock Analysis Report BIOTELEMETRY (BEAT): Free Stock Analysis Report ACADIA PHARMA (ACAD): Free Stock Analysis Report To read this article on Zacks.com click here. Patterson Companies, Inc. ( PDCO ) is slated to release its third-quarter fiscal 2015 financial numbers after the closing bell on Feb 19. | Click to get this free report ENDO INTL PLC (ENDP): Free Stock Analysis Report PATTERSON COS (PDCO): Free Stock Analysis Report BIOTELEMETRY (BEAT): Free Stock Analysis Report ACADIA PHARMA (ACAD): Free Stock Analysis Report To read this article on Zacks.com click here. ACADIA Pharmaceuticals Inc. ( ACAD ) has an earnings ESP of +3.85% and carries a Zacks Rank #2. Last time, Patterson Companies reported a decent fiscal second quarter, beating the Zacks Consensus Estimate on both lines. | Click to get this free report ENDO INTL PLC (ENDP): Free Stock Analysis Report PATTERSON COS (PDCO): Free Stock Analysis Report BIOTELEMETRY (BEAT): Free Stock Analysis Report ACADIA PHARMA (ACAD): Free Stock Analysis Report To read this article on Zacks.com click here. ACADIA Pharmaceuticals Inc. ( ACAD ) has an earnings ESP of +3.85% and carries a Zacks Rank #2. Earnings Whispers Our proven model does not conclusively show that Patterson Companies is likely to beat the Zacks Consensus Estimate this quarter. | ACADIA Pharmaceuticals Inc. ( ACAD ) has an earnings ESP of +3.85% and carries a Zacks Rank #2. Click to get this free report ENDO INTL PLC (ENDP): Free Stock Analysis Report PATTERSON COS (PDCO): Free Stock Analysis Report BIOTELEMETRY (BEAT): Free Stock Analysis Report ACADIA PHARMA (ACAD): Free Stock Analysis Report To read this article on Zacks.com click here. Last time, Patterson Companies reported a decent fiscal second quarter, beating the Zacks Consensus Estimate on both lines. |
36285.0 | 2015-02-17 00:00:00 UTC | Will Community Health Systems (CYH) Q4 Earnings Miss? - Analyst Blog | ACAD | https://www.nasdaq.com/articles/will-community-health-systems-cyh-q4-earnings-miss-analyst-blog-2015-02-17 | nan | nan | Community Health Systems, Inc. ( CYH ) is slated to release its fourth-quarter and full year 2014 financial numbers on Feb 19.
In the last reported quarter, the company's earnings topped the Zacks Consensus Estimate by an impressive 33.3%. Moreover, over the trailing four quarters, the company has posted a positive average earnings surprise of 37.6%.
Let's see how things are shaping up for this announcement.
Factors to be Considered this Quarter
Management is optimistic about the improving volume trend observed over the past three quarters of 2014 (a 530 basis point improvement since the first quarter) and expects this to continue in the fourth quarter as well.
Recently, the company has announced preliminary results for the fourth quarter and full year 2014.
Community Health Systems expects fourth-quarter net operating revenue of $4.9 billion, in line with the current Zacks Consensus Estimate. The estimated revenue figure represents stupendous 53% growth on a year-over-year basis.
Notably, during the fourth quarter, Community Health Systems recognized the recently approved California Medicaid supplemental program's revenues of $35 million and additional provider taxes associated with this program of $9 million.
Fourth-quarter adjusted EBITDA is estimated to grow 71% from the year-ago quarter to $785 million. For the full year, adjusted EBITDA is projected at roughly $2.78 billion, reflecting an increase of 49% year over year.
On the earnings front, Community Health Systems estimates fourth-quarter and full-year adjusted earnings at $1.23 and $3.29 per share, respectively. The fourth-quarter projection is in line with the Zacks Consensus Estimate while the same for the full year is higher than the comparable period's estimate of $3.25. Notably, the company reported earnings per share of 30 cents and $1.51 for the fourth quarter and full year-2013.
We feel that the company is poised to gain market traction from the acquisitions of Sharon Regional Medical Center, Natchez Regional Medical Center and Upstate Carolina Medical Center. Moreover, Community Health Systems expects to continue acquire Metro Health in the first half of 2015.
Community Health Systems also recently sold Carolina Pines, one of the HMA facilities which were required to sell as determined by the Federal Trade Commission (FTC) for approximately $70 million.
The company's physician practices are also engaging in outreach programs in order to increase patient access for preventive health services. The Medicare wellness initiatives have resulted in additional visits to the company's physicians' clinics. We feel Community Health Systems will continue to benefit from these initiatives.
Earnings Whispers
Our proven model does not conclusively show that Community Health Systems is likely to beat the Zacks Consensus Estimate this quarter. This is because a stock needs to have both a positive Earnings ESP and a Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 (Hold) for this to happen. Unfortunately, that is not the case here as elaborated below.
Zacks ESP : Earnings ESP represents the difference between the Most Accurate estimate and the Zacks Consensus Estimate. This leads to an ESP of -0.81% for the company. as while the Most Accurate estimate for earnings stands at $1.22, the consensus estimate is pegged higher at $1.23.
Zacks Rank : Community Health Systems has a Zacks Rank #3 which increases the predictive power of ESP. However, we need to have a positive ESP to be confident of an earnings surprise.
Note that we caution against stocks with Zacks Rank #4 or 5 (Sell-rated stocks) going into the earnings announcement, especially when the company is seeing negative estimate revisions.
Stocks to Consider
Here are some companies in the broader medical sector that you may consider instead as our model shows they have the right combination of elements to post an earnings beat this quarter.
BioTelemetry, Inc. ( BEAT ) has an earnings ESP of +20.00% and carries a Zacks Rank #1.
ACADIA Pharmaceuticals Inc. ( ACAD ) has an earnings ESP of +3.85% and carries a Zacks Rank #2.
Endo International plc ( ENDP ) has an earnings ESP of +0.89% and carries a Zacks Rank #2.
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
ENDO INTL PLC (ENDP): Free Stock Analysis Report
COMMNTY HLTH SY (CYH): Free Stock Analysis Report
BIOTELEMETRY (BEAT): Free Stock Analysis Report
ACADIA PHARMA (ACAD): Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | ACADIA Pharmaceuticals Inc. ( ACAD ) has an earnings ESP of +3.85% and carries a Zacks Rank #2. Click to get this free report ENDO INTL PLC (ENDP): Free Stock Analysis Report COMMNTY HLTH SY (CYH): Free Stock Analysis Report BIOTELEMETRY (BEAT): Free Stock Analysis Report ACADIA PHARMA (ACAD): Free Stock Analysis Report To read this article on Zacks.com click here. Community Health Systems expects fourth-quarter net operating revenue of $4.9 billion, in line with the current Zacks Consensus Estimate. | Click to get this free report ENDO INTL PLC (ENDP): Free Stock Analysis Report COMMNTY HLTH SY (CYH): Free Stock Analysis Report BIOTELEMETRY (BEAT): Free Stock Analysis Report ACADIA PHARMA (ACAD): Free Stock Analysis Report To read this article on Zacks.com click here. ACADIA Pharmaceuticals Inc. ( ACAD ) has an earnings ESP of +3.85% and carries a Zacks Rank #2. Community Health Systems expects fourth-quarter net operating revenue of $4.9 billion, in line with the current Zacks Consensus Estimate. | Click to get this free report ENDO INTL PLC (ENDP): Free Stock Analysis Report COMMNTY HLTH SY (CYH): Free Stock Analysis Report BIOTELEMETRY (BEAT): Free Stock Analysis Report ACADIA PHARMA (ACAD): Free Stock Analysis Report To read this article on Zacks.com click here. ACADIA Pharmaceuticals Inc. ( ACAD ) has an earnings ESP of +3.85% and carries a Zacks Rank #2. Earnings Whispers Our proven model does not conclusively show that Community Health Systems is likely to beat the Zacks Consensus Estimate this quarter. | ACADIA Pharmaceuticals Inc. ( ACAD ) has an earnings ESP of +3.85% and carries a Zacks Rank #2. Click to get this free report ENDO INTL PLC (ENDP): Free Stock Analysis Report COMMNTY HLTH SY (CYH): Free Stock Analysis Report BIOTELEMETRY (BEAT): Free Stock Analysis Report ACADIA PHARMA (ACAD): Free Stock Analysis Report To read this article on Zacks.com click here. Recently, the company has announced preliminary results for the fourth quarter and full year 2014. |
36286.0 | 2015-02-09 00:00:00 UTC | Will CVS Health's (CVS) Earnings Surprise this Season? - Analyst Blog | ACAD | https://www.nasdaq.com/articles/will-cvs-healths-cvs-earnings-surprise-this-season-analyst-blog-2015-02-09 | nan | nan | CVS Health Corporation ( CVS ) - formerly known as CVS Caremark - is scheduled to report its fourth-quarter and full year 2014 results before the opening bell on Feb 10. Last quarter, the company had posted a positive earnings surprise of 0.88% while the four-quarter trailing average beat is pegged at 0.41%. Let's see how things are shaping up prior to this announcement.
Factors at Play
Barring an unimpressive first quarter of 2014, CVS Health delivered two successive quarters of earnings and revenue beat in 2014. However, this being the first quarter that will see the full financial effect of the company's decision to exit the tobacco category, CVS expects profit growth in the fourth quarter to be somewhat lower than the sequentially previous numbers.
However, we are encouraged that based on 15 successful selling seasons; the company has invested incrementally in the next season to ensure a successful migration of new customers.
Over the quarters, the Pharmacy Services segment has been positively impacted by growth in specialty pharmacy and favorable purchasing economics while the Retail Pharmacy segment has benefited from increased sales and an improved margin rate, partially offset by incremental store operating costs associated with operating more number of stores.
In the fourth quarter, within the retail segment, CVS expects revenues to be up 0.25% to 1.75% year over year. Adjusted script comps are expected to increase in the range of 3.5% to 4.5% while total same store sales growth are projected to remain in the range of negative 1% to positive 0.5%. The company expects front store same store sales to reflect a negative impact of approximately 900 basis points relative to the tobacco exit in the fourth quarter.
On the bright side, the company expects expansion in retail gross margins in the fourth quarter driven by better purchasing economics which includes the quarterly payment from Cardinal Health as well as the exit from the tobacco business.
In the PBM segment, the company expects revenues to increase 16.75% to 18.25% with adjusted claims to remain between 270 million and 275 million. However, the company expects a significant decline in PBM gross margins during the fourth quarter due to price compression and drug mix.
Earnings Whispers?
Our proven model does not conclusively show that CVS Health is likely to beat earnings this quarter. This is because a stock needs to have both a positive Earnings ESP and a Zacks Rank #1, 2 or 3 for this to happen. That is, however, not the case here as you will see below.
Zacks ESP: CVS Health's earnings ESP is 0.00%, as both the Most Accurate estimate and the Zacks Consensus Estimate stand at $1.21.
Zacks Rank: CVS Caremark has a Zacks Rank #2 (Buy) which increases the predictive power of ESP. However, a 0.00% ESP makes surprise prediction difficult.
Note that we caution against stocks with Zacks Ranks #4 and 5 (Sell-rated stocks) going into the earnings announcement, especially when the company is seeing negative estimate revisions.
Stocks that Warrant a Look
Here are three companies you may want to consider as our model shows they have the right combination of elements to post an earnings beat this quarter:
ACADIA Pharmaceuticals Inc. ( ACAD ) has an earnings ESP of +3.85% and holds a Zacks Rank #2. ACADIA is expected to report fourth-quarter 2014 earnings on Feb 26.
Actavis plc ( ACT ) has an earnings ESP of +4.38% and carries a Zacks Rank #2. Actavis is scheduled to report fourth-quarter earnings on Feb 18.
DexCom, Inc. ( DXCM ) has an earnings ESP of +100% and retains a Zacks Rank #3 (Hold). DexCom is expected to report fourth-quarter earnings on Feb 19.
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
DEXCOM INC (DXCM): Free Stock Analysis Report
CVS HEALTH CORP (CVS): Free Stock Analysis Report
ACTAVIS PLC (ACT): Free Stock Analysis Report
ACADIA PHARMA (ACAD): Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Stocks that Warrant a Look Here are three companies you may want to consider as our model shows they have the right combination of elements to post an earnings beat this quarter: ACADIA Pharmaceuticals Inc. ( ACAD ) has an earnings ESP of +3.85% and holds a Zacks Rank #2. ACADIA is expected to report fourth-quarter 2014 earnings on Feb 26. Click to get this free report DEXCOM INC (DXCM): Free Stock Analysis Report CVS HEALTH CORP (CVS): Free Stock Analysis Report ACTAVIS PLC (ACT): Free Stock Analysis Report ACADIA PHARMA (ACAD): Free Stock Analysis Report To read this article on Zacks.com click here. | Stocks that Warrant a Look Here are three companies you may want to consider as our model shows they have the right combination of elements to post an earnings beat this quarter: ACADIA Pharmaceuticals Inc. ( ACAD ) has an earnings ESP of +3.85% and holds a Zacks Rank #2. Click to get this free report DEXCOM INC (DXCM): Free Stock Analysis Report CVS HEALTH CORP (CVS): Free Stock Analysis Report ACTAVIS PLC (ACT): Free Stock Analysis Report ACADIA PHARMA (ACAD): Free Stock Analysis Report To read this article on Zacks.com click here. ACADIA is expected to report fourth-quarter 2014 earnings on Feb 26. | Stocks that Warrant a Look Here are three companies you may want to consider as our model shows they have the right combination of elements to post an earnings beat this quarter: ACADIA Pharmaceuticals Inc. ( ACAD ) has an earnings ESP of +3.85% and holds a Zacks Rank #2. Click to get this free report DEXCOM INC (DXCM): Free Stock Analysis Report CVS HEALTH CORP (CVS): Free Stock Analysis Report ACTAVIS PLC (ACT): Free Stock Analysis Report ACADIA PHARMA (ACAD): Free Stock Analysis Report To read this article on Zacks.com click here. ACADIA is expected to report fourth-quarter 2014 earnings on Feb 26. | Stocks that Warrant a Look Here are three companies you may want to consider as our model shows they have the right combination of elements to post an earnings beat this quarter: ACADIA Pharmaceuticals Inc. ( ACAD ) has an earnings ESP of +3.85% and holds a Zacks Rank #2. ACADIA is expected to report fourth-quarter 2014 earnings on Feb 26. Click to get this free report DEXCOM INC (DXCM): Free Stock Analysis Report CVS HEALTH CORP (CVS): Free Stock Analysis Report ACTAVIS PLC (ACT): Free Stock Analysis Report ACADIA PHARMA (ACAD): Free Stock Analysis Report To read this article on Zacks.com click here. |
36287.0 | 2015-02-04 00:00:00 UTC | Myriad Genetics Q2 Earnings, Revenues Beat; Fall Y/Y - Analyst Blog | ACAD | https://www.nasdaq.com/articles/myriad-genetics-q2-earnings-revenues-beat-fall-y-y-analyst-blog-2015-02-04 | nan | nan | Myriad Genetics Inc. ( MYGN ) reported adjusted earnings per share (EPS) of 40 cents in the second quarter of fiscal 2015, down 39.4% from year-ago 66 cents but ahead of the Zacks Consensus Estimate by a nickel.
The year-on-year downside reflected the absence of the positive impact of celebrity publicity on profitability that was observed in the second quarter of fiscal 2014; dilution from the recent Crescendo acquisition and lower margin associated with the process of converting Myriad's hereditary cancer franchise to myRisk. Also, a rise in sample volume expenses associated with the company's new products that have not yet obtained full insurance reimbursement also contributed to this bottom-line deterioration.
Myriad Genetics Inc. - Earnings Surprise | FindTheBest
Revenues
In the second quarter, total revenue declined 9.6% year over year to $184.4 million. The top line, however, beat the Zacks Consensus Estimate of $183 million.
The year-over-year revenue decline was primarily attributable to the one-time revenue benefit that the company had gained from celebrity publicity in the second quarter of the prior year, and the timing of certain pharmaceutical and clinical services contracts. In addition, the reduction in Medicare reimbursement for Myriad's Hereditary Cancer test was also responsible for the downside. However, all these negatives were partially offset by the benefits from the Crescendo acquisition.
In the reported quarter, Myriad's Molecular diagnostic tests (97.2% of total revenue in the second quarter) recorded revenues of $179.1 million, down 8.7% year over year. Molecular diagnostic testing revenues are primarily derived from the Oncology unit (down 17.6% to $83.7 million) and the Preventive Care unit (down 10.6% to $84.6 million).
Pharmaceutical and clinical service revenues (accounting for the rest) in the second quarter were $5.2 million, down 34.2% year over year.
Revenues from Myriad's myRisk Hereditary Cancer surged 640% to $85.1 million from the year-ago equivalent of $11.5 million. In the reported quarter, a large percentage of Integrated BRACAnalysis tests were transitioned to myRisk, resulting in Integrated BRACAnalysis revenues of $72.5 million compared to $165.9 million in the prior-year quarter. The company also transitioned approximately one half of its COLARIS and COLARIS AP tests to myRisk, resulting in COLARIS and COLARIS AP revenues of $7.4 million compared to $15.6 million in the second quarter of fiscal 2014.
Margin Trends
Adjusted gross margin during the quarter contracted 770 basis points (bps) to 79.5%, primarily due to the costs associated with increased demand for Prolaris and myPath Melanoma tests.
Adjusted operating expenses spiked 16.1% to $110.2 million due to a 9.9% increase in adjusted selling, general and administrative (SG&A) expenses (to $85.3 million) and a 2.4% rise in research and development (R&D) expenses (to $17.4 million), primarily owing to the Crescendo acquisition.
As a result, adjusted operating margin contracted to 23.7% in the quarter from 40.8% in the same quarter last year.
Financial Position
Myriad exited the reported quarter with cash, cash equivalents and marketable securities of $207.4 million, compared with $270.6 million as of Jun 30, 2014. In the second quarter, Myriad reported cash flow from operations of $52.6 million, up 10.6% from the year ago equivalent of $47.5 million. Consequently, free cash flow from operations was $46.7 million, up from the year-ago tally of $44.7 million.
The company repurchased 1.7 million shares for $58 million during the quarter and was left with an authorization to buy back shares worth another $62 million.
Guidance
Myriad has lowered its guidance for fiscal 2015. The company now envisages revenues in the range of $730-$740 million, down from the prior range of $800−$820 million. The Zacks Consensus Estimate of $790 million lies way above the guidance.
Likewise, the company now expects adjusted EPS for the fiscal in the range of $1.50 to $1.55, down from the previously announced range of $1.90-$2.00. The current Zacks Consensus Estimate of $1.84 lies considerably above Myriad's guidance.
Management also provided its outlook for third-quarter fiscal 2015. The company expects adjusted earnings per share of 38 to 40 cents on total revenue of $180 to $185 million. Both the Zacks Consensus Estimate for revenues of $207 million and adjusted EPS of 55 cents lie above the respective guided ranges.
Our View
Although the company's results beat the Zacks Consensus Estimate on both the top and bottom line fronts, on a year-over-year basis, both the figures declined substantially. Besides, we are concerned about the guidance cut initiated by the company for fiscal 2015. Per management, a lag in obtaining private insurance coverage for Vectra DA; a delay in the timing of Medicare reimbursement for Prolaris; an increase in work-in-process; and the timing of certain contracts in the pharmaceutical and clinical services segment were the primary reasons responsible for the trimmed guidance on the company's part.
However, we are hopeful that none of these factors are expected to linger over the long run, as according to management's estimation, these are likely to be resolved soon.
Moreover, during the reported quarter, Myriad achieved a major milestone with its BRACAnalysis CDx test becoming the first FDA-approved, complex, laboratory-developed sequencing test. We believe, going forward, the company will be able to fetch higher profits banking on higher demand for this test.
Zacks Rank
Currently, Myriad holds a Zacks Rank #2 (Buy). Some other top-ranked med-biomed/generic stocks include Ophthotech Corporation ( OPHT ), Prothena Corporation plc ( PRTA ) and ACADIA Pharmaceuticals Inc. ( ACAD ). While Ophthotech and Prothena sport a Zacks Rank #1 (Strong Buy), ACADIA carries a Zacks Rank #2 (Buy).
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
MYRIAD GENETICS (MYGN): Free Stock Analysis Report
PROTHENA CP PLC (PRTA): Free Stock Analysis Report
ACADIA PHARMA (ACAD): Free Stock Analysis Report
OPHTHOTECH CORP (OPHT): Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Some other top-ranked med-biomed/generic stocks include Ophthotech Corporation ( OPHT ), Prothena Corporation plc ( PRTA ) and ACADIA Pharmaceuticals Inc. ( ACAD ). While Ophthotech and Prothena sport a Zacks Rank #1 (Strong Buy), ACADIA carries a Zacks Rank #2 (Buy). Click to get this free report MYRIAD GENETICS (MYGN): Free Stock Analysis Report PROTHENA CP PLC (PRTA): Free Stock Analysis Report ACADIA PHARMA (ACAD): Free Stock Analysis Report OPHTHOTECH CORP (OPHT): Free Stock Analysis Report To read this article on Zacks.com click here. | Some other top-ranked med-biomed/generic stocks include Ophthotech Corporation ( OPHT ), Prothena Corporation plc ( PRTA ) and ACADIA Pharmaceuticals Inc. ( ACAD ). Click to get this free report MYRIAD GENETICS (MYGN): Free Stock Analysis Report PROTHENA CP PLC (PRTA): Free Stock Analysis Report ACADIA PHARMA (ACAD): Free Stock Analysis Report OPHTHOTECH CORP (OPHT): Free Stock Analysis Report To read this article on Zacks.com click here. While Ophthotech and Prothena sport a Zacks Rank #1 (Strong Buy), ACADIA carries a Zacks Rank #2 (Buy). | Click to get this free report MYRIAD GENETICS (MYGN): Free Stock Analysis Report PROTHENA CP PLC (PRTA): Free Stock Analysis Report ACADIA PHARMA (ACAD): Free Stock Analysis Report OPHTHOTECH CORP (OPHT): Free Stock Analysis Report To read this article on Zacks.com click here. Some other top-ranked med-biomed/generic stocks include Ophthotech Corporation ( OPHT ), Prothena Corporation plc ( PRTA ) and ACADIA Pharmaceuticals Inc. ( ACAD ). While Ophthotech and Prothena sport a Zacks Rank #1 (Strong Buy), ACADIA carries a Zacks Rank #2 (Buy). | Some other top-ranked med-biomed/generic stocks include Ophthotech Corporation ( OPHT ), Prothena Corporation plc ( PRTA ) and ACADIA Pharmaceuticals Inc. ( ACAD ). While Ophthotech and Prothena sport a Zacks Rank #1 (Strong Buy), ACADIA carries a Zacks Rank #2 (Buy). Click to get this free report MYRIAD GENETICS (MYGN): Free Stock Analysis Report PROTHENA CP PLC (PRTA): Free Stock Analysis Report ACADIA PHARMA (ACAD): Free Stock Analysis Report OPHTHOTECH CORP (OPHT): Free Stock Analysis Report To read this article on Zacks.com click here. |
36288.0 | 2015-02-03 00:00:00 UTC | Acadia Pharmaceuticals Larger Than S&P 500 Component Denbury Resources | ACAD | https://www.nasdaq.com/articles/acadia-pharmaceuticals-larger-sp-500-component-denbury-resources-2015-02-03 | nan | nan | In the latest look at stocks ordered by largest market capitalization, Russell 3000 component Acadia Pharmaceuticals Inc (Symbol: ACAD) was identified as having a larger market cap than the smaller end of the S&P 500, for example Denbury Resources, Inc. (Symbol: DNR), according to The Online Investor .
Market capitalization is an important data point for investors to keep an eye on, for various reasons. The most basic reason is that it gives a true comparison of the value attributed by the stock market to a given company's stock. Many beginning investors look at one stock trading at $10 and another trading at $20 and mistakenly think the latter company is worth twice as much - that of course is a completely meaningless comparison without knowing how many shares of each company exist. But comparing market capitalization (factoring in those share counts) creates a true "apples-to-apples" comparison of the value of two stocks. In the case of Acadia Pharmaceuticals Inc (Symbol: ACAD), the market cap is now $3.17B, versus Denbury Resources, Inc. (Symbol: DNR) at $3.04B.
Below is a three month price history chart comparing the stock performance of ACAD vs. DNR:
Another reason market capitalization is important is where it places a company in terms of its size tier in relation to peers - much like the way a mid-size sedan is typically compared to other mid-size sedans (and not SUV's). This can have a direct impact on which indices will include the stock, and which mutual funds and ETFs are willing to own the stock. For instance, a mutual fund that is focused solely on Large Cap stocks may for example only be interested in those companies sized $10 billion or larger. Another illustrative example is the S&P MidCap index which essentially takes the S&P 500 index and "tosses out" the biggest 100 companies so as to focus solely on the 400 smaller "up-and-comers" (which in the right environment can outperform their larger rivals). And ETFs that directly follow an index like the S&P 500 will only own the underlying component of that index, selling companies that lose their status as an S&P 500 company, and buying companies when they are added to the index. So a company's market cap, especially in relation to other companies, carries great importance, and for this reason we at TheOnlineInvestor.com find value to putting together these looks at comparative market capitalization daily.
At the closing bell, ACAD is up about 2.1%, while DNR is up about 11.2% on the day Tuesday.
The 20 Largest U.S. Companies By Market Capitalization »
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Below is a three month price history chart comparing the stock performance of ACAD vs. DNR: Another reason market capitalization is important is where it places a company in terms of its size tier in relation to peers - much like the way a mid-size sedan is typically compared to other mid-size sedans (and not SUV's). In the latest look at stocks ordered by largest market capitalization, Russell 3000 component Acadia Pharmaceuticals Inc (Symbol: ACAD) was identified as having a larger market cap than the smaller end of the S&P 500, for example Denbury Resources, Inc. (Symbol: DNR), according to The Online Investor . In the case of Acadia Pharmaceuticals Inc (Symbol: ACAD), the market cap is now $3.17B, versus Denbury Resources, Inc. (Symbol: DNR) at $3.04B. | In the latest look at stocks ordered by largest market capitalization, Russell 3000 component Acadia Pharmaceuticals Inc (Symbol: ACAD) was identified as having a larger market cap than the smaller end of the S&P 500, for example Denbury Resources, Inc. (Symbol: DNR), according to The Online Investor . In the case of Acadia Pharmaceuticals Inc (Symbol: ACAD), the market cap is now $3.17B, versus Denbury Resources, Inc. (Symbol: DNR) at $3.04B. Below is a three month price history chart comparing the stock performance of ACAD vs. DNR: Another reason market capitalization is important is where it places a company in terms of its size tier in relation to peers - much like the way a mid-size sedan is typically compared to other mid-size sedans (and not SUV's). | In the latest look at stocks ordered by largest market capitalization, Russell 3000 component Acadia Pharmaceuticals Inc (Symbol: ACAD) was identified as having a larger market cap than the smaller end of the S&P 500, for example Denbury Resources, Inc. (Symbol: DNR), according to The Online Investor . Below is a three month price history chart comparing the stock performance of ACAD vs. DNR: Another reason market capitalization is important is where it places a company in terms of its size tier in relation to peers - much like the way a mid-size sedan is typically compared to other mid-size sedans (and not SUV's). In the case of Acadia Pharmaceuticals Inc (Symbol: ACAD), the market cap is now $3.17B, versus Denbury Resources, Inc. (Symbol: DNR) at $3.04B. | In the latest look at stocks ordered by largest market capitalization, Russell 3000 component Acadia Pharmaceuticals Inc (Symbol: ACAD) was identified as having a larger market cap than the smaller end of the S&P 500, for example Denbury Resources, Inc. (Symbol: DNR), according to The Online Investor . In the case of Acadia Pharmaceuticals Inc (Symbol: ACAD), the market cap is now $3.17B, versus Denbury Resources, Inc. (Symbol: DNR) at $3.04B. Below is a three month price history chart comparing the stock performance of ACAD vs. DNR: Another reason market capitalization is important is where it places a company in terms of its size tier in relation to peers - much like the way a mid-size sedan is typically compared to other mid-size sedans (and not SUV's). |
36289.0 | 2015-02-01 00:00:00 UTC | An $8 Billion Hedge Fund Bought This Extremely Risky Stock: Should You? | ACAD | https://www.nasdaq.com/articles/8-billion-hedge-fund-bought-extremely-risky-stock-should-you-2015-02-01 | nan | nan | The market activity of billionaire investors tends to attract a lot of attention because these billionaires are often perceived as having some kind of special insight into the direction of the broader market or individual stocks.
In the world of healthcare, the billionaire tandem of Julian and Felix Baker, collectively known as the Baker Brothers, are perhaps the most closely watched superinvestors because their hedge fund has repeatedly generated annual returns in excess of 100%. Moreover, they have shown a penchant for picking the next "home run" biotech stocks, such as Acadia Pharmaceuticals and Pharmacyclics , with both of these stocks exploding higher since the fund took a position:
Per the third-quarter 13F filings, we learned that the Baker Brothers have amassed a huge position -- more than 10 million shares -- in the orphan-drug maker Synageva BioPharma Corp. , making them the company's largest shareholders and Synageva the fund's fourth largest holding.
Given the Baker Brothers' stellar record of generating marketing-crushing returns and the considerable size of their stake in Synageva, should average investors consider buying this stock? Let's take a deeper look.
Synageva is looking to become a leader in the orphan-drug space
Drugs for rare diseases have gained favor in the pharmaceutical industry because they offer their manufacturers several key advantages over treatments for more common conditions, such as an extended period of market exclusivity, tax credits, faster review times, and even a waiver of some regulatory fees.
To top it off, most approved treatments for rare diseases to date have been biologics -- or therapies developed from biological organisms -- making them hard to copy via so-called generic biosimilars. The net result is a group of products that tend to enjoy a long shelf life and high profit margins, which is probably why most orphan-drug makers garner huge premiums in terms of their share price.
Synageva is looking to break into this space with its lead clinical candidate, sebelipase alfa (brand named Kanuma), an enzyme replacement therapy indicated for patients afflicted with the rare disease lysosomal acid lipase, or LAL, deficiency. So far, the company has filed regulatory applications in both the EU and the U.S., with possible approvals coming in the third or fourth quarters of this year.
Although the market size for Kanuma is still up in the air because the disease often goes undiagnosed or misdiagnosed, according to Synageva, the company noted in a recent investor presentation that most enzyme replacement therapies eventually generate several hundred million in annual revenues once the work of identifying patients has begun in earnest:
Synageva isn't without its risks
While Synageva looks like it's on the fast track toward following in the footsteps of rare-disease drugmakers such as BioMarin , the company's rapid ascent and limited revenue opportunities in the near term present some serious risks that should be carefully considered.
First, management is going to have to spend a tremendous amount of money on developing the LAL deficiency market after Kanuma's launch. In short, Kanuma won't be a major revenue source for the company anytime soon, and its launch will more than likely result in an increase in net losses.
Next up, the remainder of Synageva's clinical pipeline is extremely early stage:
What this means in a nutshell is Synageva is years away from becoming cash flow-positive, with most of its resources going into its clinical pipeline and the commercial launch of Kanuma. The company does have a strong balance sheet, with $797 million in cash and zero debt at last count. But its market cap of $4 billion clearly reflects the market's enthusiasm for orphan drugs, more than Synageva's fundamental outlook.
Foolish takeaways
A big part of the Baker Brothers' resounding success in the healthcare sector has been their ability to identify undervalued companies with long-tailed growth prospects. In many ways, Synageva fits this classic profile of a Baker Brothers pick -- i.e., the company is only now transitioning into a commercial operation in a space with a bright future in terms of revenue potential.
And if the truth be told, the same risks inherent in Synageva could have been applied to BioMarin as well, once upon a time. Now that BioMarin's business plan has unfolded more or less as planned, the result has been nothing short of spectacular for early investors who were willing to take on the risk:
By the same token, there's no guarantee that Synageva will turn out to be a leader in the orphan-drug space, and its present market cap, in light of its development stage, is off-putting, in my opinion. So I think average investors may want to take a pass on this stock for the time being. That said, it still looks like a good watch list candidate and a potential buy if its shares pull back in a significant way.
This coming blockbuster will make every biotech jealous
The best biotech investors consistently reap gigantic profits by recognizing true potential earlier and more accurately than anyone else. Let me cut right to the chase. There is a product in development that could revolutionize not just how we treat a common chronic illness, but potentially the entire health industry. Analysts are already licking their chops at the sales potential. If you hope to outsmart Wall Street and realize multi-bagger returns you will need to get in early -- check out The Motley Fool's new free report on the dream-team responsible for this game-changing blockbuster. CLICK HERE NOW .
The article An $8 Billion Hedge Fund Bought This Extremely Risky Stock: Should You? originally appeared on Fool.com.
George Budwell has no position in any stocks mentioned. The Motley Fool recommends BioMarin Pharmaceuticals. Try any of our Foolish newsletter services free for 30 days . We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy .
Copyright © 1995 - 2015 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy .
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Moreover, they have shown a penchant for picking the next "home run" biotech stocks, such as Acadia Pharmaceuticals and Pharmacyclics , with both of these stocks exploding higher since the fund took a position: Per the third-quarter 13F filings, we learned that the Baker Brothers have amassed a huge position -- more than 10 million shares -- in the orphan-drug maker Synageva BioPharma Corp. , making them the company's largest shareholders and Synageva the fund's fourth largest holding. Synageva is looking to become a leader in the orphan-drug space Drugs for rare diseases have gained favor in the pharmaceutical industry because they offer their manufacturers several key advantages over treatments for more common conditions, such as an extended period of market exclusivity, tax credits, faster review times, and even a waiver of some regulatory fees. The net result is a group of products that tend to enjoy a long shelf life and high profit margins, which is probably why most orphan-drug makers garner huge premiums in terms of their share price. | Moreover, they have shown a penchant for picking the next "home run" biotech stocks, such as Acadia Pharmaceuticals and Pharmacyclics , with both of these stocks exploding higher since the fund took a position: Per the third-quarter 13F filings, we learned that the Baker Brothers have amassed a huge position -- more than 10 million shares -- in the orphan-drug maker Synageva BioPharma Corp. , making them the company's largest shareholders and Synageva the fund's fourth largest holding. Although the market size for Kanuma is still up in the air because the disease often goes undiagnosed or misdiagnosed, according to Synageva, the company noted in a recent investor presentation that most enzyme replacement therapies eventually generate several hundred million in annual revenues once the work of identifying patients has begun in earnest: Synageva isn't without its risks While Synageva looks like it's on the fast track toward following in the footsteps of rare-disease drugmakers such as BioMarin , the company's rapid ascent and limited revenue opportunities in the near term present some serious risks that should be carefully considered. Next up, the remainder of Synageva's clinical pipeline is extremely early stage: What this means in a nutshell is Synageva is years away from becoming cash flow-positive, with most of its resources going into its clinical pipeline and the commercial launch of Kanuma. | Moreover, they have shown a penchant for picking the next "home run" biotech stocks, such as Acadia Pharmaceuticals and Pharmacyclics , with both of these stocks exploding higher since the fund took a position: Per the third-quarter 13F filings, we learned that the Baker Brothers have amassed a huge position -- more than 10 million shares -- in the orphan-drug maker Synageva BioPharma Corp. , making them the company's largest shareholders and Synageva the fund's fourth largest holding. Although the market size for Kanuma is still up in the air because the disease often goes undiagnosed or misdiagnosed, according to Synageva, the company noted in a recent investor presentation that most enzyme replacement therapies eventually generate several hundred million in annual revenues once the work of identifying patients has begun in earnest: Synageva isn't without its risks While Synageva looks like it's on the fast track toward following in the footsteps of rare-disease drugmakers such as BioMarin , the company's rapid ascent and limited revenue opportunities in the near term present some serious risks that should be carefully considered. Now that BioMarin's business plan has unfolded more or less as planned, the result has been nothing short of spectacular for early investors who were willing to take on the risk: By the same token, there's no guarantee that Synageva will turn out to be a leader in the orphan-drug space, and its present market cap, in light of its development stage, is off-putting, in my opinion. | Moreover, they have shown a penchant for picking the next "home run" biotech stocks, such as Acadia Pharmaceuticals and Pharmacyclics , with both of these stocks exploding higher since the fund took a position: Per the third-quarter 13F filings, we learned that the Baker Brothers have amassed a huge position -- more than 10 million shares -- in the orphan-drug maker Synageva BioPharma Corp. , making them the company's largest shareholders and Synageva the fund's fourth largest holding. Although the market size for Kanuma is still up in the air because the disease often goes undiagnosed or misdiagnosed, according to Synageva, the company noted in a recent investor presentation that most enzyme replacement therapies eventually generate several hundred million in annual revenues once the work of identifying patients has begun in earnest: Synageva isn't without its risks While Synageva looks like it's on the fast track toward following in the footsteps of rare-disease drugmakers such as BioMarin , the company's rapid ascent and limited revenue opportunities in the near term present some serious risks that should be carefully considered. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. |
36290.0 | 2015-01-23 00:00:00 UTC | First Week of September 18th Options Trading For Acadia Pharmaceuticals (ACAD) | ACAD | https://www.nasdaq.com/articles/first-week-september-18th-options-trading-acadia-pharmaceuticals-acad-2015-01-23 | nan | nan | Investors in Acadia Pharmaceuticals Inc (Symbol: ACAD) saw new options become available this week, for the September 18th expiration. One of the key inputs that goes into the price an option buyer is willing to pay, is the time value, so with 238 days until expiration the newly available contracts represent a possible opportunity for sellers of puts or calls to achieve a higher premium than would be available for the contracts with a closer expiration. At Stock Options Channel , our YieldBoost formula has looked up and down the ACAD options chain for the new September 18th contracts and identified one put and one call contract of particular interest.
The put contract at the $27.00 strike price has a current bid of $3.10. If an investor was to sell-to-open that put contract, they are committing to purchase the stock at $27.00, but will also collect the premium, putting the cost basis of the shares at $23.90 (before broker commissions). To an investor already interested in purchasing shares of ACAD, that could represent an attractive alternative to paying $31.44/share today.
Because the $27.00 strike represents an approximate 14% discount to the current trading price of the stock (in other words it is out-of-the-money by that percentage), there is also the possibility that the put contract would expire worthless. The current analytical data (including greeks and implied greeks) suggest the current odds of that happening are 71%. Stock Options Channel will track those odds over time to see how they change, publishing a chart of those numbers on our website under the contract detail page for this contract . Should the contract expire worthless, the premium would represent a 11.48% return on the cash commitment, or 17.61% annualized - at Stock Options Channel we call this the YieldBoost .
Below is a chart showing the trailing twelve month trading history for Acadia Pharmaceuticals Inc, and highlighting in green where the $27.00 strike is located relative to that history:
Turning to the calls side of the option chain, the call contract at the $33.00 strike price has a current bid of $5.30. If an investor was to purchase shares of ACAD stock at the current price level of $31.44/share, and then sell-to-open that call contract as a "covered call," they are committing to sell the stock at $33.00. Considering the call seller will also collect the premium, that would drive a total return (excluding dividends, if any) of 21.82% if the stock gets called away at the September 18th expiration (before broker commissions). Of course, a lot of upside could potentially be left on the table if ACAD shares really soar, which is why looking at the trailing twelve month trading history for Acadia Pharmaceuticals Inc, as well as studying the business fundamentals becomes important. Below is a chart showing ACAD's trailing twelve month trading history, with the $33.00 strike highlighted in red:
Considering the fact that the $33.00 strike represents an approximate 5% premium to the current trading price of the stock (in other words it is out-of-the-money by that percentage), there is also the possibility that the covered call contract would expire worthless, in which case the investor would keep both their shares of stock and the premium collected. The current analytical data (including greeks and implied greeks) suggest the current odds of that happening are 43%. On our website under the contract detail page for this contract , Stock Options Channel will track those odds over time to see how they change and publish a chart of those numbers (the trading history of the option contract will also be charted). Should the covered call contract expire worthless, the premium would represent a 16.86% boost of extra return to the investor, or 25.86% annualized, which we refer to as the YieldBoost .
The implied volatility in the put contract example is 70%, while the implied volatility in the call contract example is 65%. Meanwhile, we calculate the actual trailing twelve month volatility (considering the last 253 trading day closing values as well as today's price of $31.44) to be 52%. For more put and call options contract ideas worth looking at, visit StockOptionsChannel.com.
Top YieldBoost Calls of the S&P 500 »
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Of course, a lot of upside could potentially be left on the table if ACAD shares really soar, which is why looking at the trailing twelve month trading history for Acadia Pharmaceuticals Inc, as well as studying the business fundamentals becomes important. Below is a chart showing ACAD's trailing twelve month trading history, with the $33.00 strike highlighted in red: Considering the fact that the $33.00 strike represents an approximate 5% premium to the current trading price of the stock (in other words it is out-of-the-money by that percentage), there is also the possibility that the covered call contract would expire worthless, in which case the investor would keep both their shares of stock and the premium collected. Investors in Acadia Pharmaceuticals Inc (Symbol: ACAD) saw new options become available this week, for the September 18th expiration. | Below is a chart showing ACAD's trailing twelve month trading history, with the $33.00 strike highlighted in red: Considering the fact that the $33.00 strike represents an approximate 5% premium to the current trading price of the stock (in other words it is out-of-the-money by that percentage), there is also the possibility that the covered call contract would expire worthless, in which case the investor would keep both their shares of stock and the premium collected. Investors in Acadia Pharmaceuticals Inc (Symbol: ACAD) saw new options become available this week, for the September 18th expiration. At Stock Options Channel , our YieldBoost formula has looked up and down the ACAD options chain for the new September 18th contracts and identified one put and one call contract of particular interest. | Below is a chart showing the trailing twelve month trading history for Acadia Pharmaceuticals Inc, and highlighting in green where the $27.00 strike is located relative to that history: Turning to the calls side of the option chain, the call contract at the $33.00 strike price has a current bid of $5.30. Below is a chart showing ACAD's trailing twelve month trading history, with the $33.00 strike highlighted in red: Considering the fact that the $33.00 strike represents an approximate 5% premium to the current trading price of the stock (in other words it is out-of-the-money by that percentage), there is also the possibility that the covered call contract would expire worthless, in which case the investor would keep both their shares of stock and the premium collected. Investors in Acadia Pharmaceuticals Inc (Symbol: ACAD) saw new options become available this week, for the September 18th expiration. | At Stock Options Channel , our YieldBoost formula has looked up and down the ACAD options chain for the new September 18th contracts and identified one put and one call contract of particular interest. Below is a chart showing ACAD's trailing twelve month trading history, with the $33.00 strike highlighted in red: Considering the fact that the $33.00 strike represents an approximate 5% premium to the current trading price of the stock (in other words it is out-of-the-money by that percentage), there is also the possibility that the covered call contract would expire worthless, in which case the investor would keep both their shares of stock and the premium collected. Investors in Acadia Pharmaceuticals Inc (Symbol: ACAD) saw new options become available this week, for the September 18th expiration. |
36291.0 | 2014-11-10 00:00:00 UTC | After-Hours Earnings Report for November 10, 2014 : RAX, DEI, WWD, PRAA, NPSP, CIB, ACAD, ATW, ATLS, CZR, HK, ARP | ACAD | https://www.nasdaq.com/articles/after-hours-earnings-report-november-10-2014-rax-dei-wwd-praa-npsp-cib-acad-atw-atls-czr | nan | nan | The following companies are expected to report earnings after hours on 11/10/2014. Visit our Earnings Calendar for a full list of expected earnings releases.
Rackspace Hosting, Inc ( RAX ) is reporting for the quarter ending September 30, 2014. The internet services company's consensus earnings per share forecast from the 11 analysts that follow the stock is $0.16. This value represents a 45.45% increase compared to the same quarter last year. Zacks Investment Research reports that the 2014 Price to Earnings ratio for RAX is 55.87 vs. an industry ratio of 2.70, implying that they will have a higher earnings growth than their competitors in the same industry.
Douglas Emmett, Inc. ( DEI ) is reporting for the quarter ending September 30, 2014. The reit company's consensus earnings per share forecast from the 8 analysts that follow the stock is $0.39. This value represents a 5.41% increase compared to the same quarter last year. In the past year DEI has met analyst expectations once and beat the expectations the other three quarters. Zacks Investment Research reports that the 2014 Price to Earnings ratio for DEI is 17.97 vs. an industry ratio of 15.90, implying that they will have a higher earnings growth than their competitors in the same industry.
Woodward, Inc. ( WWD ) is reporting for the quarter ending September 30, 2014. The industrial company's consensus earnings per share forecast from the 5 analysts that follow the stock is $0.76. This value represents a no change for the same quarter last year. WWD missed the consensus earnings per share in the 4th calendar quarter of 2013 by -17.07%. Zacks Investment Research reports that the 2014 Price to Earnings ratio for WWD is 21.14 vs. an industry ratio of 11.70, implying that they will have a higher earnings growth than their competitors in the same industry.
PRA Group, Inc. ( PRAA ) is reporting for the quarter ending September 30, 2014. The financial services company's consensus earnings per share forecast from the 5 analysts that follow the stock is $1.11. This value represents a 4.72% increase compared to the same quarter last year. PRAA missed the consensus earnings per share in the 2nd calendar quarter of 2014 by -17.78%. The "days to cover" for this stock exceeds 15 days. Zacks Investment Research reports that the 2014 Price to Earnings ratio for PRAA is 15.94 vs. an industry ratio of 21.40.
NPS Pharmaceuticals, Inc. ( NPSP ) is reporting for the quarter ending September 30, 2014. The drug company's consensus earnings per share forecast from the 7 analysts that follow the stock is $0.01. This value represents a 200.00% increase compared to the same quarter last year. NPSP missed the consensus earnings per share in the 1st calendar quarter of 2014 by -50%. Zacks Investment Research reports that the 2014 Price to Earnings ratio for NPSP is 916.33 vs. an industry ratio of 8.20, implying that they will have a higher earnings growth than their competitors in the same industry.
BanColombia S.A. ( CIB ) is reporting for the quarter ending September 30, 2014. The bank (foreign) company's consensus earnings per share forecast from the 3 analysts that follow the stock is $1.09. This value represents a 36.25% increase compared to the same quarter last year. Zacks Investment Research reports that the 2014 Price to Earnings ratio for CIB is 12.77 vs. an industry ratio of 12.20, implying that they will have a higher earnings growth than their competitors in the same industry.
ACADIA Pharmaceuticals Inc. ( ACAD ) is reporting for the quarter ending September 30, 2014. The biomedical (gene) company's consensus earnings per share forecast from the 3 analysts that follow the stock is $-0.21. This value represents a 75.00% decrease compared to the same quarter last year. The last two quarters ACAD had negative earnings surprises; the latest report they missed by -29.41%. The "days to cover" for this stock exceeds 13 days. Zacks Investment Research reports that the 2014 Price to Earnings ratio for ACAD is -32.58 vs. an industry ratio of -6.60.
Atwood Oceanics, Inc. ( ATW ) is reporting for the quarter ending September 30, 2014. The oil & gas drilling company's consensus earnings per share forecast from the 10 analysts that follow the stock is $1.52. This value represents a 3.18% decrease compared to the same quarter last year. In the past year ATW has beat the expectations every quarter. The highest one was in the 2nd calendar quarter where they beat the consensus by 2.78%. Zacks Investment Research reports that the 2014 Price to Earnings ratio for ATW is 8.16 vs. an industry ratio of 8.00, implying that they will have a higher earnings growth than their competitors in the same industry.
Atlas Energy, L.P. ( ATLS ) is reporting for the quarter ending September 30, 2014. The oil (production/pipeline) company's consensus earnings per share forecast from the 2 analysts that follow the stock is $0.16. This value represents a 366.67% increase compared to the same quarter last year. Zacks Investment Research reports that the 2014 Price to Earnings ratio for ATLS is -35.54 vs. an industry ratio of 32.40.
Caesars Entertainment Corporation ( CZR ) is reporting for the quarter ending September 30, 2014. The gaming company's consensus earnings per share forecast from the 2 analysts that follow the stock is $-1.68. This value represents a 33.33% decrease compared to the same quarter last year. The "days to cover" for this stock exceeds 10 days. Zacks Investment Research reports that the 2014 Price to Earnings ratio for CZR is -1.28 vs. an industry ratio of 14.10.
Halcon Resources Corporation ( HK ) is reporting for the quarter ending September 30, 2014. The oil (us exp & production) company's consensus earnings per share forecast from the 9 analysts that follow the stock is $0.06. This value represents a 50.00% increase compared to the same quarter last year. Zacks Investment Research reports that the 2014 Price to Earnings ratio for HK is 16.20 vs. an industry ratio of 17.40.
Atlas Resource Partners, L.P. ( ARP ) is reporting for the quarter ending September 30, 2014. The oil (us exp & production) company's consensus earnings per share forecast from the 6 analysts that follow the stock is $-0.01. This value represents a 92.31% increase compared to the same quarter last year. Zacks Investment Research reports that the 2014 Price to Earnings ratio for ARP is -59.43 vs. an industry ratio of 17.40.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | ACADIA Pharmaceuticals Inc. ( ACAD ) is reporting for the quarter ending September 30, 2014. The last two quarters ACAD had negative earnings surprises; the latest report they missed by -29.41%. Zacks Investment Research reports that the 2014 Price to Earnings ratio for ACAD is -32.58 vs. an industry ratio of -6.60. | ACADIA Pharmaceuticals Inc. ( ACAD ) is reporting for the quarter ending September 30, 2014. The last two quarters ACAD had negative earnings surprises; the latest report they missed by -29.41%. Zacks Investment Research reports that the 2014 Price to Earnings ratio for ACAD is -32.58 vs. an industry ratio of -6.60. | ACADIA Pharmaceuticals Inc. ( ACAD ) is reporting for the quarter ending September 30, 2014. The last two quarters ACAD had negative earnings surprises; the latest report they missed by -29.41%. Zacks Investment Research reports that the 2014 Price to Earnings ratio for ACAD is -32.58 vs. an industry ratio of -6.60. | ACADIA Pharmaceuticals Inc. ( ACAD ) is reporting for the quarter ending September 30, 2014. The last two quarters ACAD had negative earnings surprises; the latest report they missed by -29.41%. Zacks Investment Research reports that the 2014 Price to Earnings ratio for ACAD is -32.58 vs. an industry ratio of -6.60. |
36292.0 | 2014-10-23 00:00:00 UTC | First Week of June 2015 Options Trading For Acadia Pharmaceuticals (ACAD) | ACAD | https://www.nasdaq.com/articles/first-week-june-2015-options-trading-acadia-pharmaceuticals-acad-2014-10-23 | nan | nan | Investors in Acadia Pharmaceuticals Inc (Symbol: ACAD) saw new options become available this week, for the June 2015 expiration. One of the key inputs that goes into the price an option buyer is willing to pay, is the time value, so with 239 days until expiration the newly available contracts represent a potential opportunity for sellers of puts or calls to achieve a higher premium than would be available for the contracts with a closer expiration. At Stock Options Channel , our YieldBoost formula has looked up and down the ACAD options chain for the new June 2015 contracts and identified one put and one call contract of particular interest.
The put contract at the $26.00 strike price has a current bid of $4.30. If an investor was to sell-to-open that put contract, they are committing to purchase the stock at $26.00, but will also collect the premium, putting the cost basis of the shares at $21.70 (before broker commissions). To an investor already interested in purchasing shares of ACAD, that could represent an attractive alternative to paying $26.37/share today.
Because the $26.00 strike represents an approximate 1% discount to the current trading price of the stock (in other words it is out-of-the-money by that percentage), there is also the possibility that the put contract would expire worthless. The current analytical data (including greeks and implied greeks) suggest the current odds of that happening are 62%. Stock Options Channel will track those odds over time to see how they change, publishing a chart of those numbers on our website under the contract detail page for this contract . Should the contract expire worthless, the premium would represent a 16.54% return on the cash commitment, or 25.26% annualized - at Stock Options Channel we call this the YieldBoost .
Below is a chart showing the trailing twelve month trading history for Acadia Pharmaceuticals Inc, and highlighting in green where the $26.00 strike is located relative to that history:
Considering the fact that the $27.00 strike represents an approximate 2% premium to the current trading price of the stock (in other words it is out-of-the-money by that percentage), there is also the possibility that the covered call contract would expire worthless, in which case the investor would keep both their shares of stock and the premium collected. The current analytical data (including greeks and implied greeks) suggest the current odds of that happening are 41%. On our website under the contract detail page for this contract , Stock Options Channel will track those odds over time to see how they change and publish a chart of those numbers (the trading history of the option contract will also be charted). Should the covered call contract expire worthless, the premium would represent a 17.06% boost of extra return to the investor, or 26.06% annualized, which we refer to as the YieldBoost .
The implied volatility in the put contract example is 73%, while the implied volatility in the call contract example is 66%. Meanwhile, we calculate the actual trailing twelve month volatility (considering the last 253 trading day closing values as well as today's price of $26.37) to be 54%. For more put and call options contract ideas worth looking at, visit StockOptionsChannel.com.
Top YieldBoost Calls of the S&P 500 »
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Below is a chart showing the trailing twelve month trading history for Acadia Pharmaceuticals Inc, and highlighting in green where the $26.00 strike is located relative to that history: Considering the fact that the $27.00 strike represents an approximate 2% premium to the current trading price of the stock (in other words it is out-of-the-money by that percentage), there is also the possibility that the covered call contract would expire worthless, in which case the investor would keep both their shares of stock and the premium collected. Investors in Acadia Pharmaceuticals Inc (Symbol: ACAD) saw new options become available this week, for the June 2015 expiration. At Stock Options Channel , our YieldBoost formula has looked up and down the ACAD options chain for the new June 2015 contracts and identified one put and one call contract of particular interest. | Investors in Acadia Pharmaceuticals Inc (Symbol: ACAD) saw new options become available this week, for the June 2015 expiration. At Stock Options Channel , our YieldBoost formula has looked up and down the ACAD options chain for the new June 2015 contracts and identified one put and one call contract of particular interest. To an investor already interested in purchasing shares of ACAD, that could represent an attractive alternative to paying $26.37/share today. | Below is a chart showing the trailing twelve month trading history for Acadia Pharmaceuticals Inc, and highlighting in green where the $26.00 strike is located relative to that history: Considering the fact that the $27.00 strike represents an approximate 2% premium to the current trading price of the stock (in other words it is out-of-the-money by that percentage), there is also the possibility that the covered call contract would expire worthless, in which case the investor would keep both their shares of stock and the premium collected. Investors in Acadia Pharmaceuticals Inc (Symbol: ACAD) saw new options become available this week, for the June 2015 expiration. At Stock Options Channel , our YieldBoost formula has looked up and down the ACAD options chain for the new June 2015 contracts and identified one put and one call contract of particular interest. | At Stock Options Channel , our YieldBoost formula has looked up and down the ACAD options chain for the new June 2015 contracts and identified one put and one call contract of particular interest. Below is a chart showing the trailing twelve month trading history for Acadia Pharmaceuticals Inc, and highlighting in green where the $26.00 strike is located relative to that history: Considering the fact that the $27.00 strike represents an approximate 2% premium to the current trading price of the stock (in other words it is out-of-the-money by that percentage), there is also the possibility that the covered call contract would expire worthless, in which case the investor would keep both their shares of stock and the premium collected. Investors in Acadia Pharmaceuticals Inc (Symbol: ACAD) saw new options become available this week, for the June 2015 expiration. |
36293.0 | 2014-10-20 00:00:00 UTC | 3 Stocks I'll Buy if the Market Crashes | ACAD | https://www.nasdaq.com/articles/3-stocks-ill-buy-if-market-crashes-2014-10-20 | nan | nan | After a monstrous bull run of late, the stock market finally started to pullback. The Nasdaq Biotechnology Index , for instance, fell by nearly 7% last week alone:
Even so, it's important to keep the magnitude of this week's drop in perspective. This leading biotech index is still up by 28% over the past year, and the correction among healthcare stocks in the second quarter has been far steeper than that:
As a value investor, I am always keen on buying my favorite stocks at discounted prices. Honestly, though, I haven't been buying much lately because prices have gotten ahead of fundamentals, in my view. And despite the drop across the board during the week, prices, to me, still appear to be on the high side.
With this in mind, I would strongly consider buying Acadia Pharmaceuticals , Gilead Sciences , and NPS Pharmaceuticals , if the market goes into a full blown crash. Here's why.
Acadia Pharmaceuticals has a mega blockbuster on its hands
For me to buy a stock as prices plummet, I have to be reasonably comfortable that the company's core business prospects are going to be strong over the long haul. Acadia fits that bill nicely, in my opinion.
My investing thesis in this stock centers around Acadia's experimental treatment for Parkinson's disease psychosis, or PDP, called Nuplazid (pimavanserin). This is a condition with really no treatment options beyond supportive care, which is why the Food and Drug Administration recently bestowed a "breakthrough therapy" designation upon Nuplazid. Acadia is planning to submit Nuplazid's New Drug Application to the FDA before year's end, putting it on track for a potential approval by mid-2015.
Given Nuplazid's strong late-stage trial results and the need for new therapies for PDP, I think the regulatory risk is minimal going forward, making this stock's value proposition worth checking out. Acadia presently sports a market cap of roughly $2.5 billion, yet experts believe Nuplazid could see peak sales in excess of $3 billion. While I am not a huge fan of speculating about forward P/E ratios based on experimental drugs, Nuplazid's huge commercial potential, compared to Acadia's market cap, has this stock at the top of my watch list.
Gilead Sciences is a no-brainer if prices continue to slide
Because of its record setting hepatitis C drug Sovaldi and its new teammate, Harvoni, Gilead should easily see its revenue double this year compared to 2013. And despite its share price climbing over 50% this year (it was higher before this pullback), industry experts have Gilead shares trading at a forward P/E ratio of a mere 10. While the likely approval of competing therapies may cut into Harvoni's commercial potential somewhat, Gilead also offers investors a handful of new HIV and cancer drugs to pick up any slack. In short, this stock looks like its only at the beginning of a long growth trajectory. Any further price dips would therefore make this stock a huge bargain, in my opinion.
Orphan drugmaker NPS Pharmaceuticals might have the highest upside
I am closely watching NPS Pharmaceuticals during this correction for two reasons. First, the upcoming target action date for the company's experimental long-term treatment of Hypoparathyroidism, Natpara, is close at hand (Oct. 24). Natpara's approval would give the company two commercially available orphan drugs, with Gattex for short bowel syndrome being the other.
These two drugs together are expected to generate about $500 million in peak sales for NPS. Although most orphan drugmakers trade at mind-boggling premiums, this scenario would have the stock trading at only five times peak sales at current levels. Moreover, this rough valuation doesn't factor in the company's other clinical prospects.
Secondly, Shire has reportedly been interested in buying NPS for some time, and may pursue a deal after AbbVie decided to reconsider its tender offer this week. Given Shire's history of buying orphan drugmakers and its desire to build out a rare disease portfolio, this is a deal that makes a lot of sense. The sticking point, to me, seems to be the massive premium NPS' board would likely want for the company.
All told, I don't think NPS shares are an outstanding bargain right now, but my interest would be peaked if shares moved south with the broader market.
Foolish wrap-up
The stock market hasn't crashed -- yet. So, I think it's a good idea to have a list of stocks to buy for the long-term in the event a crash does come to fruition. Because of their stellar growth potentials over the long-haul, I think Acadia, Gilead, and NPS are all worth a deeper look.
This coming blockbuster will make every biotech jealous
The best biotech investors consistently reap gigantic profits by recognizing true potential earlier and more accurately than anyone else. Let me cut right to the chase. There is a product in development that will revolutionize not just how we treat a common chronic illness, but potentially the entire health industry. Analysts are already licking their chops at the sales potential. In order to outsmart Wall Street and realize multi-bagger returns you will need The Motley Fool's new free report on the dream-team responsible for this game-changing blockbuster. CLICK HERE NOW .
The article 3 Stocks I'll Buy if the Market Crashes originally appeared on Fool.com.
George Budwell owns shares of NPS Pharmaceuticals. The Motley Fool recommends Gilead Sciences. The Motley Fool owns shares of Gilead Sciences. Try any of our Foolish newsletter services free for 30 days . We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy .
Copyright © 1995 - 2014 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy .
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Acadia Pharmaceuticals has a mega blockbuster on its hands For me to buy a stock as prices plummet, I have to be reasonably comfortable that the company's core business prospects are going to be strong over the long haul. With this in mind, I would strongly consider buying Acadia Pharmaceuticals , Gilead Sciences , and NPS Pharmaceuticals , if the market goes into a full blown crash. Acadia fits that bill nicely, in my opinion. | With this in mind, I would strongly consider buying Acadia Pharmaceuticals , Gilead Sciences , and NPS Pharmaceuticals , if the market goes into a full blown crash. While I am not a huge fan of speculating about forward P/E ratios based on experimental drugs, Nuplazid's huge commercial potential, compared to Acadia's market cap, has this stock at the top of my watch list. Acadia Pharmaceuticals has a mega blockbuster on its hands For me to buy a stock as prices plummet, I have to be reasonably comfortable that the company's core business prospects are going to be strong over the long haul. | With this in mind, I would strongly consider buying Acadia Pharmaceuticals , Gilead Sciences , and NPS Pharmaceuticals , if the market goes into a full blown crash. Acadia Pharmaceuticals has a mega blockbuster on its hands For me to buy a stock as prices plummet, I have to be reasonably comfortable that the company's core business prospects are going to be strong over the long haul. While I am not a huge fan of speculating about forward P/E ratios based on experimental drugs, Nuplazid's huge commercial potential, compared to Acadia's market cap, has this stock at the top of my watch list. | With this in mind, I would strongly consider buying Acadia Pharmaceuticals , Gilead Sciences , and NPS Pharmaceuticals , if the market goes into a full blown crash. Acadia Pharmaceuticals has a mega blockbuster on its hands For me to buy a stock as prices plummet, I have to be reasonably comfortable that the company's core business prospects are going to be strong over the long haul. Acadia fits that bill nicely, in my opinion. |
36294.0 | 2014-07-01 00:00:00 UTC | ACAD Makes Bullish Cross Above Critical Moving Average | ACAD | https://www.nasdaq.com/articles/acad-makes-bullish-cross-above-critical-moving-average-2014-07-01 | nan | nan | In trading on Tuesday, shares of Acadia Pharmaceuticals Inc (Symbol: ACAD) crossed above their 200 day moving average of $23.33, changing hands as high as $23.35 per share. Acadia Pharmaceuticals Inc shares are currently trading up about 3.2% on the day. The chart below shows the one year performance of ACAD shares, versus its 200 day moving average:
Looking at the chart above, ACAD's low point in its 52 week range is $15.64 per share, with $32.00 as the 52 week high point - that compares with a last trade of $23.38.
According to the ETF Finder at ETF Channel, ACAD makes up 5.13% of the PowerShares DWA Healthcare Momentum Portfolio ETF (Symbol: PTH) which is trading higher by about 1.4% on the day Tuesday.
Click here to find out which 9 other stocks recently crossed above their 200 day moving average »
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | In trading on Tuesday, shares of Acadia Pharmaceuticals Inc (Symbol: ACAD) crossed above their 200 day moving average of $23.33, changing hands as high as $23.35 per share. The chart below shows the one year performance of ACAD shares, versus its 200 day moving average: Looking at the chart above, ACAD's low point in its 52 week range is $15.64 per share, with $32.00 as the 52 week high point - that compares with a last trade of $23.38. Acadia Pharmaceuticals Inc shares are currently trading up about 3.2% on the day. | In trading on Tuesday, shares of Acadia Pharmaceuticals Inc (Symbol: ACAD) crossed above their 200 day moving average of $23.33, changing hands as high as $23.35 per share. The chart below shows the one year performance of ACAD shares, versus its 200 day moving average: Looking at the chart above, ACAD's low point in its 52 week range is $15.64 per share, with $32.00 as the 52 week high point - that compares with a last trade of $23.38. Acadia Pharmaceuticals Inc shares are currently trading up about 3.2% on the day. | In trading on Tuesday, shares of Acadia Pharmaceuticals Inc (Symbol: ACAD) crossed above their 200 day moving average of $23.33, changing hands as high as $23.35 per share. The chart below shows the one year performance of ACAD shares, versus its 200 day moving average: Looking at the chart above, ACAD's low point in its 52 week range is $15.64 per share, with $32.00 as the 52 week high point - that compares with a last trade of $23.38. Acadia Pharmaceuticals Inc shares are currently trading up about 3.2% on the day. | In trading on Tuesday, shares of Acadia Pharmaceuticals Inc (Symbol: ACAD) crossed above their 200 day moving average of $23.33, changing hands as high as $23.35 per share. According to the ETF Finder at ETF Channel, ACAD makes up 5.13% of the PowerShares DWA Healthcare Momentum Portfolio ETF (Symbol: PTH) which is trading higher by about 1.4% on the day Tuesday. Acadia Pharmaceuticals Inc shares are currently trading up about 3.2% on the day. |
36295.0 | 2014-06-27 00:00:00 UTC | Friday's ETF Movers: FNX, XBI | ACAD | https://www.nasdaq.com/articles/fridays-etf-movers-fnx-xbi-2014-06-27 | nan | nan | In trading on Friday, the First Trust Mid Cap Core AlphaDEX Fund ETF ( FNX ) is outperforming other ETFs, up about 0.6% on the day. Components of that ETF showing particular strength include shares of Health Net ( HNT ), up about 3.7% and shares of Trinity Industries ( TRN ), up about 3.3% on the day.
And underperforming other ETFs today is the SPDR S&P Biotech ETF ( XBI ), down about 0.8% in Friday afternoon trading. Among components of that ETF with the weakest showing on Friday were shares of Acadia Pharmaceuticals ( ACAD ), lower by about 3.9%, and shares of Alnylam Pharmaceuticals (ALNY), lower by about 3.8% on the day.
VIDEO: Friday's ETF Movers: FNX, XBI
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Among components of that ETF with the weakest showing on Friday were shares of Acadia Pharmaceuticals ( ACAD ), lower by about 3.9%, and shares of Alnylam Pharmaceuticals (ALNY), lower by about 3.8% on the day. Components of that ETF showing particular strength include shares of Health Net ( HNT ), up about 3.7% and shares of Trinity Industries ( TRN ), up about 3.3% on the day. VIDEO: Friday's ETF Movers: FNX, XBI The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Among components of that ETF with the weakest showing on Friday were shares of Acadia Pharmaceuticals ( ACAD ), lower by about 3.9%, and shares of Alnylam Pharmaceuticals (ALNY), lower by about 3.8% on the day. VIDEO: Friday's ETF Movers: FNX, XBI The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Among components of that ETF with the weakest showing on Friday were shares of Acadia Pharmaceuticals ( ACAD ), lower by about 3.9%, and shares of Alnylam Pharmaceuticals (ALNY), lower by about 3.8% on the day. In trading on Friday, the First Trust Mid Cap Core AlphaDEX Fund ETF ( FNX ) is outperforming other ETFs, up about 0.6% on the day. VIDEO: Friday's ETF Movers: FNX, XBI The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Among components of that ETF with the weakest showing on Friday were shares of Acadia Pharmaceuticals ( ACAD ), lower by about 3.9%, and shares of Alnylam Pharmaceuticals (ALNY), lower by about 3.8% on the day. In trading on Friday, the First Trust Mid Cap Core AlphaDEX Fund ETF ( FNX ) is outperforming other ETFs, up about 0.6% on the day. Components of that ETF showing particular strength include shares of Health Net ( HNT ), up about 3.7% and shares of Trinity Industries ( TRN ), up about 3.3% on the day. |
36296.0 | 2014-06-02 00:00:00 UTC | ImmunoCellular Plans To Move ICT-107 Forward Into Phase III Trials Based On New Sub-Group Analysis Presented At ASCO | ACAD | https://www.nasdaq.com/articles/immunocellular-plans-move-ict-107-forward-phase-iii-trials-based-new-sub-group-analysis | nan | nan | By Smith On Stocks :
Investment Overview
ImmunoCellular ( IMUC ) presented an update on thePhase II results of ICT-107 in glioblastoma multiforme or GBM at ASCO in which the authors concluded that pre-specified analyses of MGMT and HLA subgroups (I'll try to explain this later) demonstrated meaningful clinical improvements for ICT-107 patients.The company went on to say that it believes these new findings form the basis for planning aPhase III trial. It plans to discuss its registration strategy with European and US regulators in 3Q, 2014. There is a good possibility of aPhase III study beginning in 1H, 2015. Topline results from this trial could be available in late 2018 or 2019 by my estimates.
This note lays out some initial thoughts on this new data to help investors decide if this is a sound decision; however, mine is not the last word and there is more to be learned from the data. IMUC has suggested that results in two sub-groups prospectively identified in this trial could be the basis for regulatory approval ifPhase II results hold up in a largerPhase III trial and I concur. These sub-groups are HLA-A2 positive unmethylated MGMT patients who I estimate are 18% of the broad GBM population and HLA-A2 positive methylated MGMT patients who are 13% of the broad GBM population.
There will be a great deal of discussion about this data and whether it is indeed the basis for going forward with aPhase III trial. ThePhase II trial failed to reach its primary endpoint of median overall survival in the broad GBM population. Some investors will accuse IMUC of data dredging to come up with positive results in sub-groups although IMUC states they were prospectively defined in the statistical analysis. Also, the sub-groups were so small that with one exception, the data, which has encouraged IMUC is based on numerical trends in progression free survival and overall survival and not statistical significance.
I think that IMUC will elect to go forward with aPhase III trial and regulatory agencies will concur. I think that it could begin enrolling patients in 1H, 2015, and we could probably see topline data in late 2018 or 2019. The gating factor on undertaking thePhase III will likely be the ability of IMUC to attract enough capital to begin the trial and this may not be easy. Also, there could be concern about the ability to enroll patients as it is likely that Bristol-Myers Squibb's ( BMY ) nivolumab and Merck's ( MRK ) similar drug lambrolizumab, will be startingPhase II trials in GBM and there will be fierce competition to enroll patients.
Although I view the data as positive, I am not moving to a Buy on the stock and have a neutral opinion. The long time to toplinePhase III results, financing uncertainties and potentially an intense competition for enrolling GBM patients are issues that are just too daunting. On a more general basis, I find these results encouraging and add further evidence that dendritic cell cancer vaccines have clinical benefit in at least sub-groups of the glioblastoma patient base.
Investment Background
ImmunoCellular and its dendritic cell cancer vaccine ICT-107 were written off as failures in December of 2013 after thePhase II trial in newly diagnosed glioblastoma failed to reach statistical significance on the endpoint of overall survival. However, failure in a clinical trial does not always mean that the drug is ineffective. Trial design can sometimes be the cause of a trial failure that can be corrected and lead to success in subsequent trials.
The recent experience with Acadia Pharmaceutical's ( ACAD ) pimavanserin is an example of this. TwoPhase III attempts failed which caused the stock after the second failure to drop to $0.67 in November 2011. Then a well-designedPhase III trial based on knowledge gained from the two previous trials resulted in a successful outcome and the stock is currently trading at $20.65. I would caution that the Acadia example is far from the norm. However, it does show that it is possible to use information gained in a failed trial to design a new trial that goes on to be successful.
There is and should be appropriate investor skepticism when a trial fails. This means that management's hypothesis for how the drug works or how active it is in a disease state is wrong and a new hypothesis must be formed. Also, biotechnology managements have so much vested in a developmental drug that they are very reluctant to give up on it because of emotional or financial reasons (they could lose their jobs); they will often perpetuate development of a drug that ultimately is doomed to fail. It is always a hard judgment for investors to make on whether there is a reasonable basis for continuing development of the drug following disappointing trial results.
One important issue for me in considering whether IMUC should pursue aPhase III trial is that I think thePhase II trial of ICT-107, was incorrectly presented by previous management as a potential registrational trial. It was suggested that it might even be stopped at an interim analysis for efficacy. As a result, expectations were extremely high that the trial would reach its primary endpoint of overall survival and a BLA would be filed. The trial more properly should have been presented as an exploratory trial that was intended to provide a signal of biological activity and to gather information needed to plan for aPhase III trial. Had it been represented in this context, investors might well have deemedPhase II results as encouraging or successful. By the way, this is how current management presented thePhase II trial.
I think that there has been a strong consensus view of investors that ICT-107 has failed and any plan of management to do aPhase III trial would be a hopeless, quixotic adventure that would only waste shareholders' money, what little remains. It will be a very difficult challenge forThe company to raise this amount of money or even the money needed to begin aPhase III or attract a partner to help in the conduct of the trial. There is a very serious financial risk.
Sub-Groups Examined
IMUC believes that the data that it has shown in methylated and unmethylated HLA-A2 positive patients is exciting and defines two target populations for aPhase III trial. In order to provide some perspective, let me briefly describe what HLA-A2 positive and methylation of the MGMT gene refers to.
The Importance of the MGMT Gene
The class of chemotherapy drugs called alkylating agents treats cancer by damaging the DNA of cancer cells and blocking their ability to replicate. This is the mode of action of temozolomide, which is part of the standard of care for treating newly diagnosed glioblastoma. The MGMT gene encodes a DNA repair enzyme that can block the activity of alkylating agents such as temozolamide.
If the MGMT gene is active, the damage caused by temozolomide is rapidly repaired. In glioblastoma, the MGMT gene can be inactivated by methylation of its promoter region, which controls gene expression. If the MGMT gene is methylated and thereby inactivated, there is a better response to temozolomide because the tumor has no means to repair the DNA damage. Hence MGMT methylation is a favorable prognostic factor for glioblastoma in the setting of radiation and temozolomide.
The importance of methylated MGMT is shown by looking at trials in which temozolomide was used as part of standard of care. Patients with methylated MGMT had median overall survival of about 22 months and the unmethylated MGMT group had median overall survival of 13 months. Methylated MGMT conveys a very significant advantage for survival. According to IMUC, about 1/3 to 1/2 (I am using the average 42% for some subsequent calculations) of GBM patients have methylated MGMT.
ImmunoCellular recorded the MGMT status of 90% or more of patients in thePhase II trial of ICT-107.
HLA Status
Histocompatibility is a term that is used in organ transplantation to describe the ability of a donor's tissue or organ to be accepted by a recipient (to be matched). There is a group of genes present in all animals called the major histocompatibility complex (( MHC )); in humans this is referred to as human leukocyte antigens ((HLA)). The more HLA proteins shared between a donor and recipient, the better the potential outcome of the transplantation.
Human leukocyte antigens are proteins located on the surface of white blood cells and other tissues in the body. Their central role is to recognize the difference from "self" tissue and antigens displayed to the immune system from foreign invaders such as bacteria, viruses and parasites and launch an immune response. Differences can trigger an immune response against antigens. In the case of ICT-107, the human is the recipient of dendritic cells loaded with six peptides that mimic tumor antigens. Because of this, ICT-107 is only histocompatible with certain HLA types. This product design makes ICT-107 only compatible with patients with HLA-A1 and HLA-A2 proteins on their white blood cells. Without this match antibodies will be formed to attack and destroy the dendritic cells of ICT-107.
What Percentage of the Glioblastoma Population are Comprised of Unmethylated and Methylated HLA-A2 Patients?
IMUC issued a press release in December 2013 on the topline results of thePhase II trial and now an update on those results. In those releases, the company did not explicitly state the size breakdowns of the HLA-A2 positive unmethylated and methylated patient groups, which would be nice to know. However, it did give enough information to estimate these numbers so that we can come up with rough estimates. My estimates are summarized in the following table:
Here is the information provided in the press releases that I used to make the estimates shown in the above table:
· There were 81 patients on ICT + SOC in the trial and 43 on SOC.
· IMUC says that HLA-A2 patients are about twice as prevalent in the general population as HLA-A1 patients. I am using a 62%/32% breakdown of HLA-A2 to HLA-A1.
· IMUC says that 1/2 to 2/3 of patients have unmethylated MGMT. I am using a ratio of 58%/42% for unmethylated/methylated MGMT status.
· I am assuming that 50% of the overall number of glioblastoma multiforme populations is either HLA-A1 or HLA-A2 positive. In the trial, 278 patients had to be screened to obtain 124 patients (45% of those screened) for randomization. Most of the 55% screened but not randomized, were due to not being HLA-A1 or HLA-A2 positive. I assume that 50% of the GBM populations are HLA-A1 or HLA-A2 positive.
The number of patients who were on ICT-107 plus SOC that were HLA-A2 positive and had unmethylated MGMT can be calculated with the formula:
(number of patients treated with ICT-107 plus SOC) x (percentage of HLA-A2 patients in the trial) x (percentage of unmethylated patients). In numerical terms this is 81 x 62% x 58% or 29 patients.
The number of HLA-A2 positive methylated patients on ICT 107 + SOC is 81 x 62% x 42% or 21 patients.
The number of HLA-A1 positive unmethylated patients on ICT + SOC is 81 x 38% x 58% or 18 patients.
The number of HLA-A1 positive methylated patients on ICT + SOC is 81 x 38% x 42% or 13 patients.
Assuming that the SOC groups break down the same way we can calculate the breakdowns by multiplying the number of ICT + 107 patients by the ratio of 43/81 to find the number of patients on SOC in each sub-group.
Finally, I calculate how prevalent these sub-groups are in the general glioblastoma population by multiplying each group by 50%.
I realize that I am throwing around a lot of numbers that can be confusing. However, this reflects the way that IMUC presented the data. They did not show the above breakdowns but just gave approximate information. I suspect that in the future they will present these breakdowns but for the present I have had to go through these mathematical gymnastics in order to get a perspective on the sub-groups they are talking about in which they presented data.
Sub-Groups Analyses Are Based on Per Protocol Patients
Further exasperating those of us who would like more precision, the data reported on sub-groups was based on per protocol treatment. There were 124 patients randomized in the trial, which is called the intent to treat or ITT population.The company reported on 117 per protocol or PP patients, which were defined as patients who received at least 4 injections. With such small numbers, the difference in ITT and PP patients might be noticeable but I have no way of estimating this. In doing this, IMUC may be presenting the results in a more favorable light as regulatory judgments are made on ITT results. Encouraging data was presented on two sub-groups: methylated HLA-A2 positive and unmethylated HLA-A2 positive patients. Here are the results from the press release.
The Sub-Group of HLA-A2 Positive Patients with Unmethylated MGMT
In the per-protocol ((PP)) analysis of data from HLA-A2 patients with unmethylated MGMT (SmithOnStocks estimates there were 29 patients on ICT 107 plus SOC in this group and 15 on SOC):
· The control and treated median OS times were 11.8 and 15.8 months, respectively, indicating about a 4-month or 33% numeric survival increase for treated patients (HR=0.612, log-rank p-value=0.175);
· The median PFS times for control and treated patients were 6.0 and 10.5 months, respectively, indicating about a 4.5-month or 75% numeric PFS increase for treated patients (HR=0.758, log-rank p-value=0.442);
· There were also signs of a potential long-term survival benefit for ICT-107-treated patients, with 21% of treated patients still alive compared to only 7% of controls. By SmithOnStocks estimates 23 of 29 patients died on ICT 107 plus SOC as compared to 14 of 15 on SOC.
This group was too small to expect to achieve statistical significance, but the numerical trend in overall survival and progression free survival were numerically better for ICT plus SOC patients. I am not sure how to read that OS was shorter at 4.0 months than PFS at 4.5 months since death constitutes progression and OS should be expected to be longer than OS. There must be some quirk due to small numbers, but this is puzzling on the surface.
That OS and PFS trend in the same direction and thereby support each other is encouraging. In oncology, a 4.0 month improvement in OS is generally considered a significant advance in an aggressive cancer like GBM. These results if replicated in a largerPhase III trial could be the basis for regulatory approval. By my estimates, this sub-group accounts for 18% of the overall GBM population.
The Sub-Group of HLA-A2 Positive Patients with Methylated MGMT
In the PP analysis of data from HLA-A2 patients with methylated MGMT (SmithOnStocks estimates there were 21 patients on ICT 107 plus SOC in this group and 11 on SOC):
· The control and treated groups had still not reached median survival times as of the time of data analysis, with the majority of patients still alive (65% of treated compared to 57% of control patients; SmithOnStocks estimates that 7 of 21 patients on ICT 107 plus SOC died as compared to 5 of 11 on SOC.
· However, the median PFS times for control and treated patients were 8.5 and 24.1 months, respectively, indicating about a 15.6-month or 184% statistically significant PFS increase for treated patients (HR=0.259, log-rank p-value=0.005).
This data shows the dramatic effect of methylated MGMT in prolonging longer PFS and presumably longer OS in the ICT plus SOC and SOC groups. That PFS reached statistical significance in this sub-group, which I estimate as 21 patients on ICT plus SOC versus 11 on SOC is impressive.
The effect of methylation is very much brought out by comparing the deaths and death rates in the unmethylated and methylated groups.
I would expect that if these results could be duplicated in a largerPhase III trial that it would be the basis for regulatory approval. This HLA-A2 positive methylated MGMT group is roughly 13% of the GBM population.
Regulatory Pathways
The company plans to have an end ofPhase II meeting with the FDA at the end of summer to discuss the design of aPhase III trial. In Europe, there will be advice meetings with regulators from the UK, Germany and Netherlands to discuss the possible design of aPhase III. They will be meeting with the EMA in 2H, 2014 to discuss the possible design of aPhase III trial based on information learned from thePhase II.
The endpoint of the trial will be overall survival. They could start planning thePhase III trials late this year and begin the trial in early 2015. There might be a reason to delay the start of thePhase III if they see something inPhase II that justifies waiting for more data to present to the regulators.
Financial Issues
The company had a cash burn of $2.6 million in 1Q, 2014 and ended the quarter with $25 million of cash. The balance of the year could see a comparable cash burn so that the IMUC could end the year with $17 to $18 million.
ThePhase III trial could not start before 2015. The design of the trial has not yet been determined, but a possibility is that it could be 300 to 500 patients and could cost $30 to $50 million and take about four years to complete. This will be dependent on the design of the trial.
Disclosure: I am long BMY. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it. I have no business relationship with any company whose stock is mentioned in this article.
See also iKang: Benefiting From The Rising Private Healthcare Market In China on seekingalpha.com
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | The recent experience with Acadia Pharmaceutical's ( ACAD ) pimavanserin is an example of this. I would caution that the Acadia example is far from the norm. By Smith On Stocks : Investment Overview ImmunoCellular ( IMUC ) presented an update on thePhase II results of ICT-107 in glioblastoma multiforme or GBM at ASCO in which the authors concluded that pre-specified analyses of MGMT and HLA subgroups (I'll try to explain this later) demonstrated meaningful clinical improvements for ICT-107 patients.The company went on to say that it believes these new findings form the basis for planning aPhase III trial. | The recent experience with Acadia Pharmaceutical's ( ACAD ) pimavanserin is an example of this. I would caution that the Acadia example is far from the norm. The Sub-Group of HLA-A2 Positive Patients with Unmethylated MGMT In the per-protocol ((PP)) analysis of data from HLA-A2 patients with unmethylated MGMT (SmithOnStocks estimates there were 29 patients on ICT 107 plus SOC in this group and 15 on SOC): · The control and treated median OS times were 11.8 and 15.8 months, respectively, indicating about a 4-month or 33% numeric survival increase for treated patients (HR=0.612, log-rank p-value=0.175); · The median PFS times for control and treated patients were 6.0 and 10.5 months, respectively, indicating about a 4.5-month or 75% numeric PFS increase for treated patients (HR=0.758, log-rank p-value=0.442); · There were also signs of a potential long-term survival benefit for ICT-107-treated patients, with 21% of treated patients still alive compared to only 7% of controls. | The recent experience with Acadia Pharmaceutical's ( ACAD ) pimavanserin is an example of this. I would caution that the Acadia example is far from the norm. The number of patients who were on ICT-107 plus SOC that were HLA-A2 positive and had unmethylated MGMT can be calculated with the formula: (number of patients treated with ICT-107 plus SOC) x (percentage of HLA-A2 patients in the trial) x (percentage of unmethylated patients). | The recent experience with Acadia Pharmaceutical's ( ACAD ) pimavanserin is an example of this. I would caution that the Acadia example is far from the norm. Investment Background ImmunoCellular and its dendritic cell cancer vaccine ICT-107 were written off as failures in December of 2013 after thePhase II trial in newly diagnosed glioblastoma failed to reach statistical significance on the endpoint of overall survival. |
36297.0 | 2014-02-24 00:00:00 UTC | ACADIA Pharmaceuticals (ACAD) Jumps: Stock Rises 17.3% - Tale of the Tape | ACAD | https://www.nasdaq.com/articles/acadia-pharmaceuticals-acad-jumps%3A-stock-rises-17.3-tale-of-the-tape-2014-02-24 | nan | nan | ACADIA Pharmaceuticals Inc. ( ACAD ) was a big mover last session, as the company saw its shares rise by over 17% on the day. The move came on solid volume too with far more shares changing hands than in a normal session. This continues the recent uptrend of the company as the stock has now gained almost 32% since Feb 5.
This biotechnology company has seen no estimate revision over the past 30 days and its Zacks Consensus Estimate remained unchanged over the same time frame. The recent price action is encouraging though, so make sure to keep a close watch on this firm in the near future.
ACADIA Pharmaceuticals currently has a Zacks Rank #2 (Buy) while its Earnings ESP is 0.00%.
Some stocks in the basic materials sector looking equally good include Alexion Pharmaceuticals, Inc. ( ALXN ), Biogen Idec Inc. ( BIIB ) and Emergent BioSolutions, Inc. ( EBS ). All these stocks hold a Zacks Rank #1 (Strong Buy).
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report >>
ACADIA PHARMA (ACAD): Get Free Report
ALEXION PHARMA (ALXN): Free Stock Analysis Report
BIOGEN IDEC INC (BIIB): Free Stock Analysis Report
EMERGENT BIOSOL (EBS): Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | ACADIA Pharmaceuticals Inc. ( ACAD ) was a big mover last session, as the company saw its shares rise by over 17% on the day. ACADIA Pharmaceuticals currently has a Zacks Rank #2 (Buy) while its Earnings ESP is 0.00%. Click to get this free report >> ACADIA PHARMA (ACAD): Get Free Report ALEXION PHARMA (ALXN): Free Stock Analysis Report BIOGEN IDEC INC (BIIB): Free Stock Analysis Report EMERGENT BIOSOL (EBS): Free Stock Analysis Report To read this article on Zacks.com click here. | Click to get this free report >> ACADIA PHARMA (ACAD): Get Free Report ALEXION PHARMA (ALXN): Free Stock Analysis Report BIOGEN IDEC INC (BIIB): Free Stock Analysis Report EMERGENT BIOSOL (EBS): Free Stock Analysis Report To read this article on Zacks.com click here. ACADIA Pharmaceuticals Inc. ( ACAD ) was a big mover last session, as the company saw its shares rise by over 17% on the day. ACADIA Pharmaceuticals currently has a Zacks Rank #2 (Buy) while its Earnings ESP is 0.00%. | Click to get this free report >> ACADIA PHARMA (ACAD): Get Free Report ALEXION PHARMA (ALXN): Free Stock Analysis Report BIOGEN IDEC INC (BIIB): Free Stock Analysis Report EMERGENT BIOSOL (EBS): Free Stock Analysis Report To read this article on Zacks.com click here. ACADIA Pharmaceuticals Inc. ( ACAD ) was a big mover last session, as the company saw its shares rise by over 17% on the day. ACADIA Pharmaceuticals currently has a Zacks Rank #2 (Buy) while its Earnings ESP is 0.00%. | ACADIA Pharmaceuticals Inc. ( ACAD ) was a big mover last session, as the company saw its shares rise by over 17% on the day. ACADIA Pharmaceuticals currently has a Zacks Rank #2 (Buy) while its Earnings ESP is 0.00%. Click to get this free report >> ACADIA PHARMA (ACAD): Get Free Report ALEXION PHARMA (ALXN): Free Stock Analysis Report BIOGEN IDEC INC (BIIB): Free Stock Analysis Report EMERGENT BIOSOL (EBS): Free Stock Analysis Report To read this article on Zacks.com click here. |
36298.0 | 2014-02-21 00:00:00 UTC | Friday's ETF Movers: XBI, GDXJ | ACAD | https://www.nasdaq.com/articles/fridays-etf-movers-xbi-gdxj-2014-02-21 | nan | nan | In trading on Friday, the SPDR S&P Biotech ETF ( XBI ) is outperforming other ETFs, up about 2.8% on the day. Components of that ETF showing particular strength include shares of Isis Pharmaceuticals ( ISIS ), up about 18.4% and shares of Acadia Pharmaceuticals ( ACAD ), up about 13.6% on the day.
And underperforming other ETFs today is the Junior Gold Miners ETF ( GDXJ ), down about 1.9% in Friday afternoon trading. Among components of that ETF with the weakest showing on Friday were shares of Gabriel Resources (GBU.CA), lower by about 6.4%, and shares of Great Panther Silver ( GPL ), lower by about 6.2% on the day.
VIDEO: Friday's ETF Movers: XBI, GDXJ
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Components of that ETF showing particular strength include shares of Isis Pharmaceuticals ( ISIS ), up about 18.4% and shares of Acadia Pharmaceuticals ( ACAD ), up about 13.6% on the day. Among components of that ETF with the weakest showing on Friday were shares of Gabriel Resources (GBU.CA), lower by about 6.4%, and shares of Great Panther Silver ( GPL ), lower by about 6.2% on the day. VIDEO: Friday's ETF Movers: XBI, GDXJ The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Components of that ETF showing particular strength include shares of Isis Pharmaceuticals ( ISIS ), up about 18.4% and shares of Acadia Pharmaceuticals ( ACAD ), up about 13.6% on the day. VIDEO: Friday's ETF Movers: XBI, GDXJ The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Components of that ETF showing particular strength include shares of Isis Pharmaceuticals ( ISIS ), up about 18.4% and shares of Acadia Pharmaceuticals ( ACAD ), up about 13.6% on the day. Among components of that ETF with the weakest showing on Friday were shares of Gabriel Resources (GBU.CA), lower by about 6.4%, and shares of Great Panther Silver ( GPL ), lower by about 6.2% on the day. VIDEO: Friday's ETF Movers: XBI, GDXJ The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Components of that ETF showing particular strength include shares of Isis Pharmaceuticals ( ISIS ), up about 18.4% and shares of Acadia Pharmaceuticals ( ACAD ), up about 13.6% on the day. In trading on Friday, the SPDR S&P Biotech ETF ( XBI ) is outperforming other ETFs, up about 2.8% on the day. And underperforming other ETFs today is the Junior Gold Miners ETF ( GDXJ ), down about 1.9% in Friday afternoon trading. |
36299.0 | 2014-01-20 00:00:00 UTC | Upside in biotech, cloud, materials? | ACAD | https://www.nasdaq.com/articles/upside-biotech-cloud-materials-2014-01-20 | nan | nan | Biotech, cloud computing and bulk materials could be winners as 2014 unfolds.
optionMONSTER's researchLAB market-analysis tool has shown emerging strength in those industries as investors look for new opportunities amid the ongoing bull market. Of the three, only biotech outperformed the broader market last year.
Large-cap biotechnology and pharmaceutical names have been strong for a long time, but investors are now turning to a new roster of smaller companies with strong growth prospects.
Acadia Pharmaceuticals, for instance, lit up researchLAB's momentum meter in late 2012 and then rallied more than 400 percent through early October. It's pulled back more recently and may be ready to run again as it makes higher lows along its 100-day moving average. Management plans to seek approval of its pimavanserin drug for the treatment of Parkinson's disease psychosis later this year, so there are no major events on the calendar soon. Given its longer-term uptrend and strength in the broader space, ACAD looks interesting around its current $24 level. The June 26 calls for $4 or better, with a 50 percent stop loss, are one way to play it, as well.
BioMarin Pharmaceutical also has a deep pipeline and got a boost after Deutsche Bank raised its price target last week. The stock has been consolidating over the longer run and may be getting ready for the next push higher after finding support above its 50-day moving average. The July 75 calls for $7.50 or better, also with a 50 percent stop, are one way to play it.
Smaller names showing bullish price action recently include Pacific Biosciences and Supernus Pharmaceuticals. Neither have great option liquidity so shares would make more sense in those.
Cloud computing has been dead in the water following a strong run in 2009 and 2010. Much of the weakness resulted from belt-tightening by government agencies, but enterprise spending appears to be making a comeback. We've recently seen strong price action in NetApp, F5 Networks, Cavium Networks, and Teradata, to name a few. Given the improving economy, the ongoing secular shift toward cloud computing and these companies' long-term underperformance, now could be the time for them to play catch-up.
Bulk materials include suppliers of crushed stone, like Vulcan Materials and Martin Marietta, plus cement giant Cemex. Of those three, only CX has kept up with the S&P 500 over the last year, but they've all delivered at least twice the performance of the broader market in the last three months. Once again, the story is an improving economy and the new catalyst of domestic energy production. VMC had bullish call buying in December and CX followed this month. All three of these stocks remain trapped in their long-term ranges, and it's probably no more than a matter of time before they break back to levels from before the 2008 crash.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
Copyright © 2010 OptionMonster® Holdings, Inc. All Rights Reserved.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Acadia Pharmaceuticals, for instance, lit up researchLAB's momentum meter in late 2012 and then rallied more than 400 percent through early October. Given its longer-term uptrend and strength in the broader space, ACAD looks interesting around its current $24 level. optionMONSTER's researchLAB market-analysis tool has shown emerging strength in those industries as investors look for new opportunities amid the ongoing bull market. | Acadia Pharmaceuticals, for instance, lit up researchLAB's momentum meter in late 2012 and then rallied more than 400 percent through early October. Given its longer-term uptrend and strength in the broader space, ACAD looks interesting around its current $24 level. Biotech, cloud computing and bulk materials could be winners as 2014 unfolds. | Acadia Pharmaceuticals, for instance, lit up researchLAB's momentum meter in late 2012 and then rallied more than 400 percent through early October. Given its longer-term uptrend and strength in the broader space, ACAD looks interesting around its current $24 level. Large-cap biotechnology and pharmaceutical names have been strong for a long time, but investors are now turning to a new roster of smaller companies with strong growth prospects. | Acadia Pharmaceuticals, for instance, lit up researchLAB's momentum meter in late 2012 and then rallied more than 400 percent through early October. Given its longer-term uptrend and strength in the broader space, ACAD looks interesting around its current $24 level. Biotech, cloud computing and bulk materials could be winners as 2014 unfolds. |
Subsets and Splits
No community queries yet
The top public SQL queries from the community will appear here once available.